Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level by Moore, Corey Benjamin
 
 
 
 
 
 
 
 
 
 
 
 
 
Evidence of HIV-1 Adaptation to HLA-
Restricted Immune Responses at a Population 
Level 
 
 
 
 
Corey Benjamin Moore 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This thesis is presented for the degree of Doctor of Philosophy of  
Murdoch University, 2002 
 
I declare that this thesis is my own account of my research and contains as its main 
content work that has not previously been submitted for a degree at any tertiary 
education institution. 
 
 
 
Corey Benjamin Moore 
1 January 2003 
Abstract 
 
Selection of HIV-1 variants resistant to antiretroviral therapy is well documented. 
However, the selection in vivo of HIV-1 mutant species that can escape host immune 
system HLA class I restricted cytotoxic T-lymphocyte responses has, to date, only been 
documented in a few individuals and its clinical importance is not well understood. This 
thesis analyses the observed diversity of the HIV-1 reverse transcriptase protein in a 
well characterised, stable, HLA-diverse cohort of HIV-1 infected patients with over two 
thousand patient-years of observation. The results show that HIV-1 polymorphism is 
selected within functional constraints and is associated with specific HLA class I 
alleles. Furthermore, these associations significantly cluster along the sequence and tend 
to occur within known corresponding HLA-restricted epitopes. Absence of 
polymorphism is also HLA-specific and more often seen with common HLA alleles. 
Knowledge of HLA-specific viral polymorphisms can be used to model an individual’s 
viral load from their HLA type and viral sequence. These results suggest that cytotoxic 
T-lymphocyte escape mutation in HIV-1 is critical to the host at an individual and 
population level as well as to short and long term viral evolution. This work provides 
new insights into viral-host interactions and has clinical implications for 
individualisation of HIV-1 therapy and vaccine design. 
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Chapter 1 Introduction 
This thesis focuses on interactions between human immunodeficiency virus type 1 
(HIV-1) and controlling cell-mediated immune responses. The outcome of which 
determine the rate of progression of untreated HIV-1 infection in the human host. As 
the presentation of HIV-1 antigens to this immunological system is mediated by highly 
polymorphic class I histocompatibility leukocyte antigens (HLA), much work – 
theoretical, in vitro, in vivo and retrospective – has focused on HLA polymorphisms and 
their effects on HIV-1 progression. There are surprisingly few published studies, 
however, on the effect of differences in the virus on progression, possibly reflecting a 
common belief that the virus is reasonably conserved and that variation is stochastic. In 
this thesis, the hypothesis that the progression of HIV-1 infection is influenced by a 
dynamic interaction between the host and virus is examined. In this interaction, the 
ability of the host to recognise specific HIV-1 antigens, and subsequently to bind and 
present them to immune cells, is shaped primarily by HLA polymorphism; which 
therefore provides an immunological environment that is relatively specific to the 
individual. This provides a set of constraints to HIV-1 infection, in which a selective 
advantage is given to viral populations that are poorly recognised by the immune 
system. Hence, it is predicted that HIV-1 genetic variation is driven, at least in part, by 
host HLA polymorphism, and is therefore adaptive rather than stochastic in nature. 
Further, the need to conserve HIV-1 structure and function (to maintain ‘viral fitness’) 
provides an opposing selective pressure that limits viral adaptation. In this way, the 
adaptation of HIV-1 is determined in part by the strength and breadth of the HLA-
restricted immune response, as well as by the genetic barrier to escape and the 
compromises in viral fitness that the virus must make to successfully adapt to this 
environment. Chapter 1 Introduction  2 
Selection of viral mutations associated with escape from antiviral cytotoxic T-
lymphocyte (CTL) responses have been described in humans with acute and chronic 
HIV-1 infection,
1 and rhesus macaques infected with simian immunodeficiency virus 
(SIV)
2,3 and challenged with simian-human immunodeficiency virus (SHIV) after 
vaccination.
4 However, the full extent and impact of CTL escape mutations on HIV-1 
evolution has yet to be determined. CTL escape mutations occur at critical sites within 
HLA-restricted CTL epitopes where an amino acid substitution may abrogate epitope-
HLA binding, reduce T-cell receptor recognition or generate antagonistic CTL 
responses.
1 Mutations affecting proteasome cleavage sites flanking CTL epitopes may 
also disrupt cellular processing of the epitope.
5 
This thesis describes a population-based approach to identify putative CTL escape 
mutations. It is believed by some that part of the genetic diversity in HIV-1 is driven 
largely by CTL recognition and killing of infected cells. Hence, as CTL epitopes are 
HLA-restricted, polymorphisms that are selected within an individual host would be 
‘characteristic’ for specific HLA class I alleles across an HLA-diverse host population. 
We speculate that such polymorphisms would be particularly evident in viral genes 
encoding internal proteins such as HIV-1 reverse transcriptase (RT), which is highly 
expressed in virions
6 and immunogenic in the early response to HIV-1.
7,8 Therefore, this 
thesis examines the relationship between HIV-1 RT sequence polymorphisms, known 
functional constraints and HLA genotypes in 473 participants of the Western Australian 
HIV Cohort Study.
9 
For the studies described in this thesis, a customised software program (EpiPop) was 
designed and developed to perform the analyses (see EpiPop user manual, page 313 of 
Appendices).
10 This program is directly linked to the cohort database (see WA HIV 
Cohort Study database user manual, page 331 of Appendices)
11 to allow analysis of the Chapter 1 Introduction     
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latest information on the patients in the cohort. This program also provides a platform 
for distributed analysis over several computers of the computationally intensive data 
manipulation and statistics. 
Chapter 2 presents a comprehensive literature review of the interactions between HIV-1 
and the human cell-mediated immune responses. Several studies have examined the 
effect of the immune system on disease progression while others have investigated the 
influence of viral changes on the course of disease. However, it is surprising to note that 
despite the large amount of resources spent in the global effort to understand HIV-1, 
knowledge of the interaction of host genetic polymorphism and viral adaptation, and the 
influence of this on disease progression, has been speculative and based on in vitro 
studies or in vivo studies of a few individuals. Throughout this review footnotes are 
included to indicate the relevance of the literature to the hypotheses tested in this thesis 
and to where the results from later chapters fit with the literature.  
Chapter 3 (Study group and general methods, page 97) defines the cohort of patients 
that is studied and the laboratory methods used to generate the data for later chapters. 
Chapter 4 (Determining the population consensus sequence, page 105) defines and 
justifies the use of the HIV-1 reference sequence determined from the cohort that is 
used in the studies in subsequent chapters. In Chapter 5 (Functional constraints of HIV-
1 reverse transcriptase, page 111), the hypothesis that functionally and structurally 
critical residues in HIV-1 are conserved is tested.  
Chapter 6 (Determining putative escape mutation sites in HIV-1 reverse transcriptase, 
page 119) is the pivotal chapter in this thesis. It describes the method for identifying 
putative HLA escape mutation sites, and the results generated by applying this method 
to the cohort. Subsequent chapters use these results to validate this approach by using 
further statistical and independent biological information from other studies; and to Chapter 1 Introduction  4 
determine the implications of polymorphism in this cohort on HIV-1 at the population 
and individual levels. 
Several HLA-restricted CTL epitopes have been defined in HIV-1. A method for 
determining if the putative escape mutations identified in Chapter 6 occur more often 
than by chance within known epitopes with the same HLA specificity is presented in 
Chapter 7 (Correlation between putative escape mutation sites and known HLA-
restricted CTL epitopes, page 137). Chapter 8 (Clustering of putative escape mutations 
sites, page 143) tests the hypothesis speculated by some and shown in very limited 
studies by others
3,12,13 that HLA escape can be achieved through more than one 
mutation within or flanking CTL epitopes.  
The human proteasome is a molecule in the HLA class I presentation pathway that 
digests intracellular proteins into peptides that are later loaded on to HLA class I 
molecules.
14,15 It has been shown to have very little polymorphism between individuals 
but exhibits some specificity in the peptides it creates.
16-18 Partial escape from the 
processing of peptides by the proteasome would represent escape that could reduce the 
presentation of several epitopes, and hence may be more beneficial than escape from a 
single HLA-restricted epitope at a population level. Evidence for this type of escape is 
tested in Chapter 9 (Putative escape mutation sites flanking known HLA-restricted CTL 
epitopes, page 149). 
HLA molecules are known to exhibit bias in the peptides they bind.
19 This bias can be 
easily seen by looking at HLA motifs. These denote the most common amino acids that 
are found at each position in peptides that have bound to HLA molecules. In Chapter 10 
(Determining putative HLA-restricted CTL epitopes from the putative escape mutation 
sites and HLA binding motifs, page 157) HLA motifs are used to attempt to define Chapter 1 Introduction     
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putative HLA-restricted CTL epitopes from the putative escape mutations identified in 
Chapter 6.  
Many of the studies on associations with HIV-1 disease are hampered by the problem of 
multiple comparisons. This is a valid criticism of the study in Chapter 6 as several 
covariates and many amino acid positions are analysed. The most common approach to 
adjust for multiple comparisons is to multiply every P-value by the number of tests 
performed (the Bonferroni correction). In most cases this approach is overly 
conservative as often tests are not independent, and many true associations are often lost 
by using it. In Chapter 11 (Adjustment for multiple comparisons, page 171) a method 
for estimating the effective number of independent tests is calculated and those results 
from Chapter 6 that withstand this correction are identified. Chapter 12 (Overall test of 
significance, page 179) also tackles the problem of multiple comparisons, but in a 
different, and perhaps more traditional mathematical way. In this chapter, a single test 
for HLA associated polymorphism across all HLA and all positions in the region of 
HIV-1 analysed is presented.  
Some authors have speculated that the common HLA alleles in a population influence 
the consensus virus found in that population.
20,21 Indeed this appears to be the case in 
other viruses,
22-25 but it has not been shown in HIV-1. While the majority of 
polymorphism in the different HIV-1 clades appears to be due to founder effects,
26 we 
test that the common HLA alleles in our cohort are correlated with the putative escape 
mutations found in the consensus sequence of our population and present it in Chapter 
13 (Population evolution of HIV-1, page 183). 
It is generally believed that the frequency and linkage of polymorphisms in the peptide-
binding region of HLA molecules have been selected in the human population by past 
and existing pathogens because they express different epitopes with different Chapter 1 Introduction  6 
affinities.
27-40 Our HLA associations with polymorphisms in Chapter 6 were based on 
broad serological groupings of HLA alleles. We hypothesise that determining the HLA 
molecular subtype of these broad alleles improves the associations with polymorphisms. 
Chapter 14 (HLA molecular subtyping: improving the strength of associations and 
biological importance, page 191) tests this for two broad HLA groups where the 
molecular subtypes are determined.  
HIV-1 viral diversity has been observed to increase over the course of disease.
13,41-48 
However it is unclear how much of this is induced by CTL pressure and how much is 
due to genetic drift. In Chapter 15 (Longitudinal analysis of putative escape mutation 
sites, page 205) we compare the amounts of polymorphism at the putative HLA 
mutation sites identified in Chapter 6 in those individuals with the corresponding HLA 
and those without. 
Escape from HLA restricted CTL epitopes has been associated with HIV-1 disease 
progression in a few individuals
12,13,49-51 and in SIV in animal models.
2,3 In Chapter 16 
(Putative escape mutations and viral load: clinical implications, page 211) we test the 
hypothesis that at a population level those individuals with a polymorphism at an HLA-
corresponding putative escape mutation site have higher viral loads. In addition, the 
combined effect of all putatively defined escape polymorphisms on viral load is tested. 
Chapter 17 (General discussion, page 227) concludes the thesis with a general 
discussion of the results and directions for future work in extending the methods 
presented in this thesis to the entire HIV-1 genome and other pathogens. The 
implications and applicability of these results to patient management and monitoring, 
and vaccine design are also discussed. 
In summary, this thesis tests for the existance of HLA associated viral polymorphism at 
a population level, with supporting and independent biological data by applying Chapter 1 Introduction     
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mathematical computational approaches designed to mirror evolutionary selective 
pressures and clinical importance with viral load. 
Some of the work presented in this thesis was published in: Moore CB, John M, James 
IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-
restricted immune responses at a population level. Science  2002;296:1439-43. 
Supplementary material is published online at 
http://www.sciencemag.org/cgi/content/full/296/5572/1439/DC1. An editorial by 
Andrew McMichael and Paul Klenerman of this publication also appeared in the same 
issue of Science, and a review based on our findings was published in The New England 
Journal of Medicine. Copies of these articles may be found in Appendices (see page 
354).  
Chapter 2 Literature review
Introduction and scope 
To provide a background for the consideration of viral-host interactions in HIV-1 
infection, and their potential impact on HIV-1 progression and clinical disease, the 
relevant literature will be reviewed in six parts. First, the genetic organisation of the 
HIV-1 virus, its lifecycle, and the structure and function of the proteins it encodes are 
reviewed. Second, the HLA class I immune system presentation pathway is reviewed. 
This section concentrates on the role of the individual’s molecular variation as a 
determinant of intracellular peptide presentation. Thirdly, a review of clinical studies 
that have shown associations between host genetic factors and progression of (or 
protection from) HIV-1 disease is presented; focusing on those associations found with 
HLA class I polymorphisms. The fourth section reviews the effect of HIV-1 infection 
on the human class I and class II pathways throughout disease. The viral mechanisms – 
both generic and specific – to avoid immune recognition by these pathways are also 
reviewed.  
Antiretroviral therapies can reduce the plasma HIV-1 viral load to undetectable levels 
and hence apply a strong pressure on the virus. Their mode of action and effect on viral 
evolution is discussed. This fifth section also reviews the effect of the reduced 
availability of HIV-1 antigen on the immune system; the next generation of anti-viral 
therapies being considered, researched and developed; and current ideas on viral 
eradication using standard treatments and possible future treatments. The final section 
reviews the current understanding of the role of pathogens in shaping the evolution of Chapter 2 Literature review  10 
the HLA. This is contrasted with the more rapid evolution of HIV-1 to selective 
pressures exerted by the human host. 
The human immunodeficiency virus - type 1 
Genetics 
The genetic structure of the HIV-1 genome was first reported in 1984
54 – just three 
years after the first reports of autoimmune deficiency syndrome (AIDS)
55 and one year 
after the HIV-1 was found to be the causative agent of AIDS.
56 It is believed that the 
major types of HIV [HIV-type 2 (HIV-2), HIV-1 and its major subtypes] originated 
from separate transmissions of SIV from other primates.
57 The HIV-1 genome varies 
between nine and 10kb and its organisation is shown in Figure 2.1. 
                                                 
i Copyright © The Regents of the University of California. 
 
Figure 2.1. The HIV-1 genome.  
Panel A. Each rectangle represents a gene and the long terminal repeats (LTR) from the reference 
sequence HXB2CG. The start and stop nucleotide position of each gene is shown in the top left and 
bottom left corner of each rectangle, respectively. The gene name is shown within the rectangle or 
midway between rectangles where genes are encoded by two separated regions. The coding frame for 
each gene is shown vertically. Panel B. The gag, pol, and env genes encode multiple proteins. These are 
cleaved from the translated precursor gene product. Panel C. The protein p51 is produced by cleaving 
the p15 (RNase) from the p66 protein. p51 proteins join with p66 proteins to form the functional reverse 
transcriptase heterodimer (see Figure 2.11). Adapted from references 52
i and 53. The human immunodeficiency virus - type 1  
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HIV-1 is a retrovirus and belongs to the lentivirus family. Retroviruses replicate their 
ribonucleic acid (RNA) genome via deoxyribonucleic acid (DNA) intermediates using 
their reverse transcriptase protein. This is the reverse of the replication sequence of 
most organisms, in which genomic DNA forms the template for RNA transcription. 
HIV-1 contains ten genes, of which the pol, gag and env genes are common to all 
lentiviruses. The remaining seven genes can be categorised into four groups based on 
their function. Tat, rev, vpr and nef regulate the virus lifecycle. Vif and nef alter viral 
infectivity. Vpu aids in particle maturation. Tev has no known function and its actual 
existence is debatable.  
                                                 
ii Copyright © International Medical Press. 
 
 
Figure 2.2. The HIV-1 virion.  
The HIV-1 virion has a diameter of approximately 100 nm. Its outer envelope is formed from the host 
cell’s membrane (which can include surface molecules, including HLA, from the host cell) and the 
viral envelope glycoproteins, gp120 and gp41. Inside the virion are the internal structural capsid and 
core proteins p17, p24, p7 and p6. These surround two copies of the single-stranded RNA genome and 
multiple copies of the reverse transcriptase molecules. Taken from reference 53.
ii Chapter 2 Literature review  12 
Lifecycle 
The HIV-1 virion is spherical in shape with a lipid bilayer exterior that surrounds the 
core proteins and two single strand viral RNA genomes contained within an icosahedral 
capsid. The envelope glycoproteins gp41 and gp120 protrude through the bilayer and 
are visible to antibodies (see Figure 2.2). HIV-1 virions typically enter cells through 
interactions between these glycoproteins and the cell-surface molecules CD4 and one of 
seven chemokine coreceptors. This interaction results in a conformational change in the 
envelope proteins and results in the virion’s and cell’s lipid bilayers merging (see 
Figure 2.15, page 25).
59 This exposes the interior of the virion, and the core proteins and 
two RNA genomes are released into the cell. The matrix proteins then assist in 
transporting these to the nucleus. At the same time, the reverse transcriptase protein 
creates a DNA copy of its RNA genome with the assistance of the tat protein. This 
DNA copy is integrated into the host cell’s DNA by the integrase and vpr proteins.
60 
After the host cell transcribes the viral DNA to proviral RNA and later into proteins, the 
rev protein assists in the transportation of the viral products from the nucleus to the 
cytoplasm where the protease protein cleaves the HIV-1 precursor proteins into their 
functional parts. Following this, the nucleocapsid and p6 proteins assemble the viral 
RNA and proteins into virions (see Figure 2.3). After assembly, the virions ‘bud’ from 
the cell, with the assistance of the vpu protein (see Figure 2.4).
61  
After a virion infects a cell, the regulatory proteins are the first to be expressed. These 
include tat, nef and vpr.
62 These genes interfere with the HLA class I and II pathways, 
alter the amount of virus that is available to these pathways (see nef, page 27; and vpu, 
page 28) and are able to maintain latent infection (see tat, page 26).
63 These early 
expressed genes are less commonly recognised by CTL than the later expressed proteins The human immunodeficiency virus - type 1  
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(such as gag and RT).
64-66 However, immune recognition has been observed, thus 
allowing the possibility for CTL 
killing of latently infected cells.
64,67-
69  
In active cells, production of new 
virions usually occurs within 24 
hours of infection
62,71,72 which is 
usually several hours after viral 
peptides are presented in HLA class 
                                                 
iii Reprinted from: Behrman AJ. Priorities in HIV prevention. Science  2001;291:45. Copyright 2001 
American Association for the Advancement of Science. 
 
Figure 2.3. Lifecycle of HIV-1.  
Taken from reference 58. 
 
Figure 2.4. Virions of HIV-1 budding from a CD4+ T-cell. 
Taken from reference 70.
iii 
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I and II molecules (see Figure 2.5).
73 The HIV-1 virion has a limited half-life of about 
six hours.
72 This is because gp120 proteins dissociate from the viral envelope
74,75 
resulting in lipid membrane deterioration,
76 deterioration of the p24 core proteins 
encasing the viral RNA,
77 and loss of RNA polymerase activity.
6,78,79 Table 2.1 
summarises the viral and cellular dynamics of HIV-1. Figure 2.6 and Figure 2.7 show 
the half-life of cells infected by HIV-1 and the lifecycle of production and infection, 
respectively. 
 
Table 2.1. Viral and cellular dynamics of HIV-1. 
Total HIV-1 production  10.3x10
9 virions per day
53 
Average duration of HIV-1 lifecycle in vivo 1.2-1.5  days
53,80 
Percentage of virus produced by recently infected cells  99%
53 
Number of generations per year  240-300
53,80 
Half-lives:  
  Productively infected cells  1-2 days
72,81,82 
  Virion in the blood  ≤6 hours
72 
  Stability of unintegrated HIV-1 DNA in resting 
CD4+ T-cells 
Uncertain
83-86 
  Extracellular virions attached to follicular dendritic 
cells 
1
st phase: 1.7 days 
2
nd phase: 14 days
87 
  Infected macrophages  Maybe 14 days
82,83 
  Uninfected macrophages  14 days
88 
  Post-integrated resting CD4+ T-cells  6 – 48 months
89-91 
                                                 
iv From the Annual Review of Immunology, Volume 15, ©1997 by Annual Reviews, 
http://www.annualreviews.org. 
 
Figure 2.5. HIV-1 cell infection and killing.  
After infection (time-point A), it may take four to five hours until HIV-1 peptides are presented on the 
cell surface. New virions may be released within 24 hours of infection. Cytopathicity may occur between 
one and two days. An efficient CTL response can kill infected cells before viral release (at time-point B). 
A weaker CTL response at time-point C will reduce the viral production. A response at time point D, 
after cell death, will have no effect. Adapted from reference 50.
iv The human immunodeficiency virus - type 1  
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Historically, HIV-1 strains 
have been grouped into two 
categories depending on the 
types of cells the virus can 
infect. Macrophage tropic 
(M-tropic) strains were first 
described to infect 
macrophages and CD4+ T-
cells, and T-cell tropic (T-
tropic) strains were described to infect CD4+ T-cells and not macrophages (see Figure 
2.8). T-tropic strains have the characteristic of amassing many CD4+ T-cells and 
creating large localised centres of infected cells and were also called syncytium-
inducing (SI) strains. Because M-tropic strains did not exhibit this characteristic, they 
were called non-syncytium inducing (NSI). More recently it has been observed that M-
                                                 
v Copyright © 1998 by Cell Press. 
vi From: Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 Dynamics in Vivo: 
Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time. Science 1996;271:1582-6. 
Copyright 1996 American Association for the Advancement of Science. 
 
Figure 2.6. Half-lives of HIV-1 in cellular and extracellular 
compartments. 
Taken from reference 83.
v  
Figure 2.7. Schematic of the kinetics of HIV-1 in known compartments in vivo. 
Taken from reference 92.
vi Chapter 2 Literature review  16 
tropic strains usually use the 
chemokine receptor CCR5 as a 
coreceptor for cell entry, while T-
tropic strains usually use the 
chemokine receptor CXCR4. 
Strains exhibiting these 
specificities are called R5 and X4 
strains respectively. However, the 
rules for chemokine receptor usage 
and tropism are not simple.
93,94 
Some strains can infect cells using 
either the CCR5 or CXCR4 
coreceptors (these are known as 
‘dual strains’ or R5X4 strains), and 
some can use other chemokine 
receptors.
95-99 Furthermore, not all NSI strains can infect macrophages,
100 not all CCR5-
using strains can infect macrophages,
101,102 some SI strains can infect macrophages 
(which do not express CXCR4),
100 and SIV uses CCR5 regardless of T- or  M-tropism, 
or SI or NSI strain.
103 
M-tropic strains of HIV-1 are primarily selected for during transmission. Individuals 
that do not express functional CCR5 are rarely infected by HIV-1, as M-tropic strains 
usually use the CCR5 coreceptor for cell entry.
98,105,106 After infection, these strains 
remain present during the asymptomatic phase of infection. Later in the course of 
                                                 
vii From: Stewart G (ed). Managing HIV. MJA 1997; :-. ©Copyright 1997. The Medical Journal of 
Australia – reproduced with permission. 
 
 
 
Figure 2.8. HIV-1 tropism and coreceptor usage for cell 
entry.  
Panel A: M-tropic strains of HIV-1 are able to infect 
macrophages and T cells by using the expressed coreceptor 
CCR5. T-tropic strains use the CXCR4 as the coreceptors 
for cell entry. Macrophages do not express CXCR4, but T 
cells do. Panel B. Individuals that do not express CCR5, due 
to a polymorphism that makes it nonfunctional, cannot be 
infected by M-tropic strains. As the M-tropic strain is the 
strain that is most commonly transmitted, individuals 
without functional CCR5 molecules are protected from 
infection. Taken from reference 104.
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infection, the more virulent T-tropic 
strains become more prevalent (see 
Figure 2.9). It is not fully 
understood how HIV-1 evolves 
from being M-tropic to T-tropic, 
but it has been shown that only two 
amino acids need to be changed in 
the envelope glycoproteins of M-
tropic strains so they can use the 
CXCR4 molecule for cell entry. 
Hence, viral mutation from M-
tropic to T-tropic strains, possibly through a dual-tropic virus, is believed to be the 
mechanism for the viral tropism switch. It is not clear if the tropism switch is a cause or 
consequence of immune deficiency, but is probably the latter, where the more infectious 
T-tropic strains have the advantage over M-tropic strains in the presence of a weakened 
immune system.
107 This is supported by the observations that T-tropic strains can infect 
cells in vitro; the switch from M-tropism to T-tropism only requires two amino acid 
changes; T-tropic strains only exist late in the symptomatic phase of disease; M-tropic 
variants appear to be required for both sexual and blood-borne transmission;
108 and no 
correlation has been shown between tropism and fitness in vitro.
109 
Both resting and activated CD4+ T-cells express CCR5 and CXCR4 with CCR5 
expressed more so on activated T-cells and CXCR4 more highly expressed on naïve T-
cells.
111-115 Macrophage expression of chemokine receptors depends on the state of 
cellular differentiation and activation,
116-118 but CXCR4 is never expressed on 
macrophages.
119,120 HIV-1 can enter resting CD4+ T-cells, but integration of the viral 
genome into the host cell is blocked. Hence, resting CD4+ T-cells provide a pool of 
 
Figure 2.9. HIV-1 phenotypes throughout infection.  
R5 HIV-1 variants (using the CCR5 co-receptor), are 
usually non-syncytium inducing (NSI) and M-tropic, 
dominant throughout asymptomatic infection. X4 HIV-1 
variants (using the CXCR4 co-receptor), are usually 
syncytium inducing (SI) and T-tropic, increase around the 
time of the burst in viral load and weakening immune 
system seen before AIDS. Adapted from references 59
iv and 
110. Chapter 2 Literature review  18 
(pre-integration) latently infected cells. Activated CD4+ T-cells are more commonly 
infected, and integration of the viral genome into the host cell’s DNA is not blocked. If 
activated CD4+ T-cells are infected and survive long enough to revert back to the 
resting state, they provide a stable pool of (post-integration) latently infected cells (see 
Figure 2.10).
83  
Protein structure and functions 
HIV-1 pol gene 
The pol gene encodes for the viral proteins protease (p10), reverse transcriptase (RT; 
p66/p51) and integrase (p32). Pol and gag are synthesised together with their sequences 
overlapping by 208 nucleotides. Pol is translated in a different open reading frame to 
gag. The cis-acting sequence (ttttttag), at the start of pol (and at the 3’ end of, and 
within gag), form part of a stem that causes ribosomal slippage and a –1 frame shift in 
translation.
121,122 The pol product is first cleaved from the gag-pol precursor by the viral 
 
Figure 2.10. Cellular dynamics of HIV-1 infection in CD4+ T cells. 
Horizontal arrows represent successive steps in the HIV-1 lifecycle. Vertical arrows represent transitions 
between resting (small) and activated (large) T-cells. HIV-1 can only infect activated CD4+ T-cells, and 
resting T-cells with sufficient amounts of CCR5. Infected resting T-cells represent a pool of latent (pre-
integration) virus as HIV-1 does not replicate in these cells. Some infected T-cells live long enough to go 
back to a resting state and hence provide a latent reservoir of (resting memory CD4+ T cells with) post-
integrated HIV-1. Taken from reference 83.
v  
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protease. Then the 
protease cleaves the 
protease, RT and 
integrase proteins (see 
Figure 2.11). The ratio 
of gag to pol genes is 
about 20 to one.
123 Pol 
is the most conserved 
(that is, least 
polymorphic) gene among sequenced HIV-1 isolates.
7,52,54,124-129;viii 
Reverse transcriptase protein 
Structure 
HIV-1 RT is an asymmetric dimer composed of two polypeptide chains of 66 kDa (p66, 
560 amino acids) and 51 kDA (p51, 440 amino acids).
126 Both subunits are encoded by 
the same sequence in the pol gene. p66 contains five domains – a palm, fingers, thumb, 
connection and RNase H domain. p55 is derived from p66 in a process mediated by 
HIV-1 protease that removes the RNase H domain.
130 The remaining four subunits in 
p51 are also referred to as palm, fingers, thumb and connection subunits, although the 
two domains fold to have different conformations, with the catalytic sites of the p66 
subunit buried and not active in the p51 subunit (see Figure 2.12).
131 The resulting 
                                                 
viii In the short region of pol sequenced in our cohort (amino acids 20 to 227; which includes the catalytic 
binding site of RT), some amino acids are highly polymorphic (up to 60% of individuals having a 
different amino acid compared to the most common amino acid), while others do not differ between 
individuals. Furthermore, no two individuals in our cohort have the same sequence (see Chapter 5, Figure 
5.2, Figure 6.3, Figure 14.3 and Figure 14.4). 
 
 
 
  
Figure 2.11. HIV-1 RT and its precursor proteins. 
The HIV-1 pol gene encodes three proteins. 1. These are cleaved from the 
pol precursor by the viral protease protein. 2. Reverse transcriptase is a 
heterodimer and consists of 2 subunits, p66 and p51. 3. p51 is produced 
from the p66 subunit.  Taken from reference 53. Chapter 2 Literature review  20 
heterodimer has only one active site, one RNase H active site and one transfer RNA 
(tRNA) binding site.
132-134 
Despite HIV-RT being structurally similar to other DNA/RNA viral RTs, there are only 
a few sequence similarities.
131 Most notably the YMDD sequence (residues 183 to 186) 
of the catalytic site is very highly conserved in HIV-RT and other DNA/RNA RTs.
135 
Other highly conserved residues are 91 to 119 (within the palm subdomain), 151 to 157 
(within the palm subdomain), and residues 120 to 150 (within the fingers 
subdomain).
136;ix  
                                                 
ix The amount of polymorphism before antiretroviral treatment in our cohort was least polymorphic at the 
catalytic site (183 to 186) and residues 151 to 157 (polymorphism frequency less than 0.5 percent at all 
residues). At the other regions defined as being highly conserved, there was polymorphism frequency of 
up to 38 percent at some residues. Many residues outside of these regions had little polymorphism (see 
Chapter 5 and Figure 5.2). The amount of polymorphism at these sites increased between serial sequences 
within individuals. In addition, drug pressures increased polymorphism at some of these sites; most 
notably the lamivudine, didanosine, zalcitabine and abacavir induced M184V/I increased from a 
frequency of zero percent in the population prior to treatment to 10 percent in the most recent sequence 
(see Chapter 15 and Figure 6.3). 
 
 
Figure 2.12. Structure of the HIV-1 RT subunits. 
The two subunits of HIV-1 (p66 and p51) are shown in panels A and B respectively. Helical regions are 
represented as tubes and are lettered, and β strands are represented as arrows and are numbered. The 
analogy of p66 to the right hand is shown, and the domains are labelled accordingly. The p66 and p51 
subunits have different conformations, despite sharing the same sequence. The RNase H domain of p66 is 
not shown. The genome regions coding each of the domains are shown in panel C. Taken from reference 
131.  
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A cleft large enough to accommodate an 
RNA-DNA hybrid exists between the 
RNase H and the pol active sites of p66.
131 
The single-stranded template (RNA or 
DNA) comes in from the top left of this 
cleft (as shown in Figure 2.13) and the 
duplex product emerges from the bottom 
right.
131 The p51 subunit lacks a DNA 
binding groove and a functional 
polymerase active site.
136 
Function 
The HIV-1 RT is a DNA polymerase that can use either an RNA or DNA template to 
synthesise a DNA copy.
137-139 The virus uses its RT to copy its genome by first 
synthesising a DNA copy of its RNA genome. This creates an RNA-DNA complex, 
which is cleaved by the RT’s RNase H to leave a single stranded DNA copy.
123,140 RT 
uses this single stranded DNA copy to make a second DNA strand (proviral DNA).
107 
The end result is a double-stranded DNA copy of the viral genome that is later 
integrated into the host genome.  
 
HIV-1 RT has a high error rate of around 3.4x10
-5 errors per base.
141-145 Other DNA 
polymerases in the lentiviruses family also have high error rates.
142,146-148 However, 
HIV-1 RT’s ability to continue elongation beyond nucleotide mismatches appears 
greater.
142,146,148 The lack of proofreading, because of the absence of editing 3’-5’ 
exonuclease activity, also contributes to relatively high error rates.
107,131 Errors due to 
host cell DNA-dependent DNA polymerase that replicates the integrated provirus, and 
  
Figure 2.13. Schematic of HIV-1 RT creating an 
RNA-DNA hybrid from an RNA template. 
Taken from reference 131.  Chapter 2 Literature review  22 
cellular RNA polymerase II that transcribes the integrated viral DNA into RNA, may 
also contribute to the error rate.
107 
HIV-1 RT’s high conservation is believed to be because of its essential function in viral 
replication.
149,150 The functions of many regions and residues in HIV-RT and other RTs 
have been determined using mutagenesis analysis. These analyses create or use natural 
variants of RTs to determine the effect of mutation on the RNA-dependent DNA 
polymerase, DNA-dependent DNA polymerase and RNase H activities, as well as the 
stability of the protein in forming the mature heterodimeric protein.
136,151,152 Critical 
residues for DNA polymerisation are 110, 185 and 186 in HIV-1 RT,
153 and have been 
confirmed to be catalytically important in mutagenesis studies.
136,152 Residues 107, 198 
and 191 are important in hydrogen bonding in protein stability;
152 residues 74, 110, 115, 
116, 151, 184 and 185 help define the polymerisation complex;
154 residues 94, 96, 113, 
114, 115, 116, 119, 151 appear to be important for RNase H activity;
136 and the residues 
443, 473 and 498 are the catalytic residues of RNase H.
126;x External residues are less 
residue-specific and more polymorphic.
155,156;xi 
The RNase H activity of lentiviruses exhibits bias in degrading different nucleotide 
mismatches, resulting in HIV-1, as well as many other lentiviruses, having a high 
composition of adenine (around 34 percent) compared to other retroviruses (around 22 
to 30 percent).
137 A high rate of guanine (G) to adenine (A) mutations has been termed 
hypermutation. For HIV-1 the hypermutation is more biased for the dinucleotides GG 
and GA than other dinucleotides. Of these two dinucleotides, the GA to AA 
                                                 
x No individual in our cohort had a polymorphism at residues 94, 96, 116, 119, 184, 185, 191 and 198 
prior to antiretroviral therapy. Residues 107, 113, 114, 151 and 186 had a polymorphism frequency of 
less than 0.5 percent. Residues 74, 110 and 115 had polymorphism frequencies less than 1.5 percent. 
These compared to a mean polymorphism frequency of 3.84 percent. The remaining residues 443, 473 
and 498 were not sequenced in our cohort (see Chapter 5 and Figure 5.2). 
xi We also observed more polymorphism in external residues compared to other residues with known 
function (see Chapter 5, Figure 5.1 and Figure 5.2). The human immunodeficiency virus - type 1  
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dinucleotide transition is more common.
157;xii HIV-1 RT’s high error rate may be due to 
imbalances in intracellular pool concentration of nucleosides, which may be due to 
HIV-1’s high copy rate of its adenine rich genome.
157 
Protease protein 
Protease’s function is to cleave the 
gag-pol precursors into their 
functional products. It does this by 
recognising cleavage sites along the 
sequence.
58 These cleavage site 
sequences along the gag-pol 
precursor are diverse and protease 
can tolerate a number of changes 
within them.
160 Mutations within the 
protease or cleavage site sequences 
can cause different amounts of final 
product to be produced.
161 Of the 99 amino acids that encode the protease protein, 
almost half can tolerate mutation,
155,156 with some affecting function more than 
others.
161 However, mutations in the cleavage sequence sites (located outside the 
sequence coding the protease protein) can compensate for the loss of function in 
protease.
162 Protease also has a role in breaking up the virion capsid after cell entry.
163 
The structure of protease is shown in Figure 2.14. 
                                                 
xii Our pre-treatment population consensus sequence differed from the HXB2CG clade B reference 
sequence by four nucleotides. Three of these four differences were an A replacing a G, the other encoded 
a different amino acid that could not have been achieved by a G to A polymorphism. Of the three G to A 
polymorphisms, two were an AA replacing a GA dinucleotide. 
 
Figure 2.14. Ribbon model of the tertiary structure of 
HIV-1 protease homodimer. 
One domain (labelled 1) is coloured blue with its N-
terminal amino acid coloured pink (N1) and its C-terminal 
amino acid (C1) coloured cyan. The other domain 
(labelled 2) is coloured green with its N-terminal amino 
acid (N2) coloured red and its C-terminal amino (C2) acid 
coloured yellow. Adapted from reference 158 using the 
software package RasMol.
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Integrase protein 
Integrase is responsible for integrating the DNA copy of the viral genome into the host 
nucleus. This is accomplished by a number of cutting and joining procedures. First 
integrase removes two nucleotides from the 3’ ends of the viral DNA. Next integrase 
makes cuts, five nucleotides apart, in the host cell’s DNA and joins the viral 3’ ends to 
the host’s 5’ ends. The joining of the 5’ ends of the viral DNA and the 3’ ends of the 
host DNA is done by host DNA repair mechanisms.
53 Only a single copy of the viral 
genome is integrated into the host cell’s DNA. As most mutations in HIV-1 occur by 
HIV-1 RT in copying its genome prior to integration, all viral products from the same 
cell have the same mutations.
164 The location of integration in the host genome varies 
but does not appear to be totally stochastic.
165  
Integrase has three domains, however the functions of these are not well characterised. 
One domain can bind viral and host DNA. Another appears to be responsible for the 
reactions of integration. The third may have some function that involves interaction 
with nucleic acids.
53 
Envelope gene 
The envelope (env) gene encodes for the two glycoproteins, gp120 and gp41. The 
precursor to these proteins is the glycoprotein gp160. The final products are cleaved by 
cellular proteases. The gp41 protein is attached to the viral membrane on the HIV-1 
virion while gp120 is attached to the outer surface of the virion through non-covalent 
interactions with gp41 (see Figure 2.2, page 11).
166 
HIV-1 enters cells through interactions between the viral glycoproteins gp120 and gp41, 
and molecules on the target cell’s surface (see Figure 2.15).
75,167,168 Firstly, gp120 
interacts with CD4 and a coreceptor (usually the chemokine CCR5 or CXCR4). This The human immunodeficiency virus - type 1  
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exposes gp41 which then 
interacts with the cellular surface 
and reconforms to pull the virion 
closer to the cell so their 
membranes can fuse. The need 
for a conformational change may 
have evolved to avoid 
recognition of the conserved 
receptor and co-receptor binding 
sites that are concealed and covered by loops of variable sequence and non-antigenic 
carbohydrates.
169,170 As a result, the conserved binding sites are not commonly 
recognised by antibodies.
171 
gp120 varies between viral isolates and appears to be important for cellular tropism. As 
an external protein, gp120 is also the target for neutralising antibodies.
168,172 The lipid 
bilayer of HIV-1 virions originates from the cell from which the virion budded and may 
contain cell surface molecules from that cell. 
Group-specific antigen gene 
All lentiviruses encode a group-specific antigen (gag) gene. In HIV-1, gag encodes for 
the core nucleocapsid polypeptides capsid (ribonucleic or p24), nucleocapsid (p7), and 
the structural proteins matrix (p17) and p6. These proteins are cleaved from the 
precursor protein, p55, by the HIV-1 protease. Gag is a relatively conserved gene, in 
that the number of natural variations found in its sequence is small compared to other 
genes. Each HIV-1 virion contains about 1200 p24 molecules.
6 
 
Figure 2.15. Mechanism for coreceptor function in HIV-1. 
Upon binding of gp120 to CD4, gp120 undergoes a 
conformational change. This allows gp120 to bind to the 
coreceptor, and triggers gp41 to undergo a conformational 
change that leads to the fusion of gp41 and the cell membrane. 
Taken from reference 104.
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Matrix protein 
The matrix protein has two characterised functions. First, it stabilises the virion by 
binding to the inner surface of the virion lipid bilayer. Second, it assists in the transport 
of the viral genome to the host cell’s nucleus using a signal (amino acid sequences 
called INS elements) that is recognised by the human cellular nuclear import 
machinery.
173 These signals may also help keep the HIV-1 mRNA in the nucleus.
174 
Capsid protein 
Capsid proteins form the conical core of viral particles. They also interact with the 
precursor protein, p55, to prevent the cellular protein cyclophilin A, which also interacts 
with p55, inhibiting viral replication.
175-177  
Nucleocapsid protein 
Nucleocapsid recognises a specific structure in the viral RNA genome and thereby 
incorporates them into virions.
178 Like other gag proteins, p7 has more than one 
function, mainly to facilitate reverse transcription.
179 
p6 protein 
p6 helps incorporate vpr into virions.
180 
Accessory genes and proteins 
Tat 
Tat is expressed early in the HIV-1 lifecycle. It encodes a protein that promotes the 
production of HIV-1 RNA/DNA translation. It does this by binding to an RNA element, 
                                                                                                                                               
xiii From: Stewart G (ed). Managing HIV. MJA 1997; :-. ©Copyright 1997. The Medical Journal of 
Australia – reproduced with permission. 
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called TAR, found at the 5’ end of the genome [in the 5’ long terminal repeat (LTR)], 
that stimulates transcription of the genome.
62,63,181-184 Tat can control HIV-1 protein 
expression, possibly allowing the virus to be latent or produce high levels of proteins. 
Tat may also be involved in activating and downregulating various cytokines and 
chemokines
185-189 and has been shown to inhibit the peptidase activity and formation of 
the human proteasome complex.
190 
Rev 
Rev is necessary for the expression of intermediate to late proteins.
62,184 Rev binds to 
viral RNA in the cellular nucleus at rev-responsive elements (RRE) and transports them 
to the cytoplasm.
191-199  
Nef 
Nef proteins are highly expressed on the host cell’s surface and are one of the first viral 
proteins to be produced at detectable levels after infection.
200-202 A study of nef 
defective and nef competent HIV-1 strains has shown that nef increases proviral DNA 
synthesis.
203 Nef also downregulates the cell surface expression of the HLA class Ia 
molecules HLA-A and HLA-B (but not HLA-C)
204-207 and CD4.
208 Mutational analyses 
have shown that the mechanisms by which nef achieves increased proviral DNA 
synthesis and downregulation of host genes are different.
209 The effect of class I 
downregulation by nef has been measured in in vitro studies, where a 20 to 50 percent 
reduction in class I levels was found following HIV-1 cell infection.
206,210-212 Nef also 
appears to delay the expression of HLA class I molecules.
213 The effect of nef on 
disease progression has been seen in individuals infected with nef defective virus. These 
individuals have a substantial decrease in HIV-1 disease progression.
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Vpr 
Vpr assists in localising the preintegration complex in the nucleus.
217 Vpr also blocks 
cell division
218 and may have other functions including replication and error 
avoidance.
219-221 Vpr defective virus has a four fold increase in the viral replication error 
rate.
219 
Vpu 
Vpu reduces the amount of functional CD4 molecules by binding with them in the 
endoplasmic reticulum.
222 As well as reducing the cell surface expression of CD4 
molecules, this also reduces the amount of intracellular env-CD4 complexes.
61 An in 
vitro study of a non-functional vpu HIV-1 variant showed that the variant has a reduced 
ability to release progeny virions from the cell surface.
61 
Vif 
Vif is necessary for regulating the production of virions from peripheral blood 
lymphocytes, macrophages and certain other cells
223 and may act by blocking an 
antiviral factor within CD4+ T-cells.
224  I t  a l s o  a p p e a r s  t o  aid in the synthesis of 
proviral DNA.
225  
Tev 
This protein has no known function in HIV-1. Host immune defences     
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Host immune defences 
HLA Class I presentation 
The primary role of class I molecules is to present short sequences of amino acids 
(peptides) from antigen inside a cell to CD8+ CTL.
40 Peptides derived from both the 
individual (self peptides) and from intracellular pathogens (non-self peptides) are 
presented. Presentation of self-peptides allows the immune system to monitor for 
possible downregulation of the class I pathway.
226-231 Class I molecules can also mark 
malignant cells by the presentation of peptides derived from neo-antigens (novel 
antigens). Presentation of peptides derived from intracellular pathogens, such as viruses 
and some intracellular bacteria, mark the cell as being infected. 
The class I pathway plays a major role in controlling and eradicating tumours and 
intracellular pathogens.
232-241 While there are over 20 class I genes, the classical class I 
(or class Ia) genes; HLA-A, HLA-B and HLA-C; are the most important class I genes in 
this immune response.
242 Class I genes differ in regulation and cell surface expression, 
and have evolved specialisations.
27,28,40 For example, HLA-A, HLA-B and HLA-C 
present short peptides from degraded intracellular proteins to T-cell receptors (TCRs) 
on CTLs for immune surveillance. HLA-C interacts with natural killer (NK) cells to 
inhibit the cytotoxic activity of CTLs and thus protect target cells.
207,243 Other class I 
genes (including HLA-E and HLA-G) are important in pregnancy.
244,245;xiv 
Proteins within the cell are degraded by the proteasome complex (a large multi catalytic 
protease) into short peptides.
14,15 Some proteins are also degraded by soluble enzymes 
                                                 
xiv In this thesis we examine association between HLA-A and HLA-B and viral polymorphism and HIV-1 
viral load. Chapter 2 Literature review  30 
in the cytosol to form peptides.
246 These peptides are delivered into the endoplasmic 
reticulum (ER) via TAP-dependent transporters.
247,248 The transport complex is a 
heterodimer composed of TAP-1 (transporter associated with antigen presentation type 
1) and TAP-2 polypeptides. There, an HLA class I α-β2m complex folds around the 
peptide to form a trimer. If transportation and folding is successful, the trimer is 
released from TAP-1 and transported to the cell surface (see Figure 2.16). 
Figure 2.16. The HLA class I and II pathways.  
Panel A shows the pathway of endogenous antigen delivery to class I HLA molecules. Proteins in the 
cytosol are degraded by proteasomes into peptides. In virally infected cells, these include viral proteins. 
Selected peptides are transported into the endoplasmic reticulum where they are loaded on to class I 
molecules. The HLA-peptide complex is transported to the cell surface for expression. Panel B shows the 
pathway of exogenous antigen delivery to class II HLA molecules. Foreign and self proteins from outside 
the cell are taken up into the cell by endocytosis and enclosed in an endosome. Class II molecules, 
synthesized in the endoplasmic reticulum are exported into vesicles which combine with endosomes to 
form an HLA class II compartment. The extracellular-derived proteins are degraded into peptides by 
enzymes. These peptides are loaded on to class II molecules using HLA-DM molecules. The HLA-
peptide complexes are then exported to the cell surface. Taken from reference 242.  Host immune defences     
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Peptides create a stable trimer with the HLA class I α-β2m complex if the interactions 
between the amino acids of the peptide and the amino acids in the groove where the 
peptide sits are sufficiently strong. The sizes of these peptides are influenced by the 
HLA allele and vary between eight and 12 amino acids,
40,249 but are usually eight or 
nine amino acids long.
250 Usually, peptides are bound by one or a few amino acids. 
These are called anchor residues because the side chains of a peptide’s amino acids 
extend into pockets of the HLA class I-α molecule and form strong hydrogen bonding.  
The peptides expressed on the cell surface in the HLA class I α-β2m-peptide trimer are 
derived from intracellular proteins and intracellular pathogen proteins. T-cell receptor 
(TCR) molecules on cytotoxic CD8+ T-cells (also called CTL) bind to the HLA class I 
α-β2m-peptide trimer. If the affinity of the complex is sufficient, combined with other 
secondary signals (see Figure 2.17), the interaction may then trigger the CTL to become 
                                                 
xv Reprinted with permission from Elsevier Science (The Lancet, 2001;357:1777-89). 
 
Figure 2.17. Antigen-presenting cell, TCR and co-signal interactions.  
CD4 molecules associate with TCRs on the cell surface. When the TCR interacts with the MHC 
molecule and peptide, the CD3 complex transmits signals into the cell. The T-cell is activated if co-
receptors also send signals by interaction with co-stimulatory molecules on the MHC-peptide presenting 
cell. Without the co-receptor signals, the cell may become unreactive or be programmed for apoptosis. 
The case is similar for CD8+ cells. Taken from reference 252.
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activated, starting both secretory (including perforin) and nonsecretory cytotoxic 
machinery to kill the cell expressing the peptide.
251 CTLs also release cytokines that 
induce inflammation and further stimulate antigen presentation. CTLs with activated 
TCRs that do not receive an appropriate secondary signal may apoptose. 
TCRs that are activated in response to cellular-derived proteins (self-proteins) are 
eliminated in the thymus, and not expressed on T-cells. TCRs reacting to self-proteins 
after leaving the thymus through strong interactions with the peptide in the absence of 
secondary signals can be made benign through peripheral tolerance. In these ways, the 
immune system is trained to "tolerate" self-proteins.
253 Individuals whose T-cells 
express TCRs that signal cell death to cells expressing cellular-derived proteins may 
suffer from autoimmune diseases.  
Molecular structures 
The major histocompatibility complex (MHC) [called HLA in humans] is located at 
6p21.31 in humans – on the short arm of chromosome six (see Figure 2.18). This region 
is divided into three classes - class I, class II and class III – and contains around 150 
genes. This is the most polymorphic region in the human genome and encodes for most 
of the genes important in the immune system. However, large sections of this region are 
often found to be the same between individuals (that is, chromosomal segments 
containing the same genes and alleles that are the same between some individuals). The 
most common of these are called ancestral haplotypes (AH) and around 70 percent of 
Caucasians have HLA AHs.
254 As a consequence, combinations of genes in this region 
are found to exist in linkage disequilibrium in different populations. That is, some gene 
and allele combinations are found to exist together (on the same chromosome) more 
commonly than would be expected by chance. The frequencies of genes, alleles and 
haplotypes vary between ethnic groups. Host immune defences     
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HLA class Ia genes 
The HLA class Ia genes (HLA-A, HLA-B and HLA-C) are genetically similar and have 
structural similarities. A number of groups have determined the three-dimensional 
structure of HLA class Ia molecules.
242,255-265,265-272 Bjorkman et al
256 first crystallised 
the HLA-A allele HLA-A2 in 1987, and later refined it to a resolution of 2.6 Å
257 (see 
Figure 2.19). 
The HLA class Ia molecule-β2m complex contains four domains (α-l, α-2, α-3 and β2m) 
made from two chains (a heavy chain - class I, and a light chain - β2m). α-3 and β2m are 
immunoglobulin-like domains that have cytoplasmic, trans-membrane and extracellular 
parts. The α-1 and α-2 domains are very similar and each contains an α-helical region 
 
Figure 2.18. The organisation and location of the HLA complex. 
The complex is located on chromosome six and is divided into three regions. Only some of the genes are 
shown for each region. HLA-A, and HLA-B are located in the HLA class I region. Taken from reference 
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on top of a four-strand β 
sheet.
257 The two domains 
form a groove between the α-
helical regions with the β 
sheets forming the base. 
Class Ia molecules associate 
non-covalently with β2m 
(which is encoded on 
chromosome 15) in the ER 
which stabilises the β sheets of 
α-l and α-2. The interaction of 
the peptide and this class Ia-
β2m complex creates a stable 
ternary complex.
257,273-276 
Intermediate complexes 
require helper molecules to 
keep the class I molecule 
stable.
277,278 Polymorphisms in the class I molecules affect which peptides can create a 
stable ternary complex. Natural polymorphisms in β2m have also been shown to affect 
the peptides that bind in the binding groove.
257  
Peptides bind in the peptide-binding groove through hydrogen bonding interactions, and 
to a lesser extent by van der Waals interactions. The peptides that a particular class Ia 
molecule can bind are determined by these interactions. These depend on the location 
and characteristics of the HLA molecule’s amino acids (see Figure 2.20) within the 
peptide-binding groove,
249 which has a high degree of polymorphism.
273 Many of the 
 
Figure 2.19. Ribbon model of the tertiary structure of an HLA 
class Ia molecule with a bound peptide.  
The colours represent: blue, α-helix of the α-1 subdomain; cyan, 
α-helix of α-2; yellow, β-sheet of α-1; orange, β-sheet of α-2; red, 
α-3 subdomain; pink, β2m; and green, peptide. Panel A. Peptide-
binding groove is located at the top between the α-helices of the 
α1 and α2 subdomains. Panel B. Shown from the top, looking into 
the peptide-binding groove, which is made from the two β-
pleated sheets and two α-helices of the α-1 and α-2 subdomains. 
Adapted from reference 255 using the software package 
RasMol.
159 
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polymorphic sites in HLA class Ia molecules are buried deep in the peptide-binding 
groove, and act directly with the peptide and not the TCR.
257 The ends of the peptides 
form contacts with conserved amino acids at both ends of the HLA peptide-binding 
groove,
260,279,280 which has a length of about 25 Å for all HLA class Ia molecules. 
Peptides greater than nine amino acids in length usually bulge in the centre of the 
binding groove
260,281 or crisscross in the groove,
262 and may result in the loss of some 
hydrogen bonding interactions. Many peptides that bind to HLA class I molecules have 
been identified.
14,15,239,282 
 
Figure 2.20. The structure of the 20 common amino acids. 
The amino acids are grouped into five categories: hydrophobic; hydrophobic, aromatic; hydrophilic, 
uncharged; hydrophilic positively charged; and hydrophilic negatively charged. The terms hydrophobic, 
nonpolar and aliphatic are interchangeable. Likewise are the words hydrophilic and polar. Negatively 
charged amino acids are also acidic as they gain an electron in solution, and positively charged amino 
acids are also basic as they lose an electron (or gain a H
+) in solution. For each amino acid the name is 
shown as well as the one and three letter codes which are written in brackets. The side chain determines 
the characteristic properties of each amino acid. The amino acid structures shown are those that exist at 
the pH of the cytoplasm. Common amino acids are alanine, valine, leucine, lysine, arginine, aspartate and 
glutamate, while cysteine, methionine and tryptophan are uncommon. Proline is the most rigid amino acid, 
glycine the smallest and cysteine is involved in forming sulphur bonds. Some publications list methionine 
as hydrophobic. Chapter 2 Literature review  36 
Pockets 
Saper  et al
257 have 
described the antigen 
binding groove as 
containing six pockets, 
or sub-sites. Other 
groups have found 
these pockets useful in 
making generalisations 
about HLA-peptide-
bindings.
249 The 
pockets below are described by Saper et al
257 for HLA-A2 and are labelled from left to 
right as pocket A through to pocket F when looking into the HLA binding groove from 
above with the N termini of the HLA at the bottom left (see Figure 2.21). Each pocket 
has different characteristics, specific to the HLA class Ia molecule, which determines 
the peptides they bind.
249 Peptides are usually bound deeply in pockets A, B and F with 
rigid configurations and these pockets are the most important in determining if a peptide 
will bind with high affinity to a class Ia molecule,
19 while pockets C, D and E - at the 
centre of the peptide-binding groove - are wider and allow a greater variety of residues 
(see Figure 2.22).
257  
Pocket A 
Pocket A consists of 10 amino acids - 5, 7, 59, 63, 66, 70, 159, 163, 167 and 171. Four 
of these (66, 70, 163 and 167) are polymorphic, and all of these are in the α-helices. The 
pocket is 7 Å wide by 8 Å long by 12 Å deep and is predominantly polar. The terminal 
amino group of the peptide’s first amino acid is located in this pocket.
249 
 
Figure 2.21. The HLA molecule peptide-binding groove and peptide.  
The HLA molecule is represented as spacefill balls, and the peptide is 
represented as a stick figure. The residues corresponding to pockets A, B, 
C, D, E and F are coloured red, green, blue, yellow, purple and cyan 
respectively, and labelled accordingly. The nine residues of the peptides 
are shown in alternating colours black and grey, and are labelled 1 to 9. 
Note the deep binding of residue two of the peptide in pocket B, and 
residue nine of the peptide in pocket F. Adapted from reference 255 using 
the software package RasMol.
159 Host immune defences     
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Pocket B 
Pocket B is not exposed and is positioned 
under the α-helix of α-l. It is made up of 
amino acids 9, 24, 25, 34, 45, 63, 66, 67 and 
70. All but two of these amino acids (25 and 
34) are polymorphic. It is 6 Å wide by 10 Å 
deep, with a polar rim and hydrophobic 
interior. 
Pocket C 
This pocket, made up of the amino acids 9, 
70, 73, 74 and 97 is located on the inner wall 
of the α-1 α helix. Four of the five residues 
(9, 70, 74 and 97) are polymorphic. 
Pocket D 
Four residues of pocket D are polymorphic 
(99, 155, 156 and 144) and the remaining 
two are conserved (160 and 159). It is 
positioned against the α-helix of α-2, is mainly hydrophobic and is 5 Å wide by 4 Å 
long by 7 Å deep. 
 
 
Figure 2.22. Interaction between peptide and 
HLA molecule.  
Panel A shows some nonamers that have been 
found complexed with the indicated HLA 
molecule. The anchor residues, P2 and P9, are 
highlighted. Panel B shows a cross-section of the 
peptide in the peptide-binding groove, with the 
pockets A to F labelled. Pockets B and F bind the 
peptide residues P2 and P9 respectively. Peptide 
residues that point into the HLA molecule have a 
greater influence over binding, while those that 
point outward affect TCR recognition. The 
positions of the residues in the pocket vary 
depending on the HLA molecule, peptide 
residues, and peptide length. Taken from 
reference 242.  Chapter 2 Literature review  38 
Pocket E 
Pocket E is positioned against the α-helix of α-2. It is made up of the amino acids 97, 
114, 133, 147, 152 and 156 of the α-chain and all except 147 are polymorphic. Two 
thirds of the pocket is hydrophobic with one side being polar. 
Pocket F 
Pocket F is made up of the amino acids 77, 80, 81, 84, 116, 123, 143, 146 and 147, of 
which 116, 77 and 80 are the only polymorphic amino acids. These are positioned on 
the inside wall. Half of the pocket is polar and is located at the right end of the peptide-
binding groove. Its opening is 6.5 Å wide by 7 Å long by 10 Å deep. 
This pocket buries the amino acid side chain of the terminal amino acids (PC) of all 
bound peptides. In most HLAs this amino acid is nonpolar: isoleucine, leucine, arginine 
or lysine, valine; aromatic: tyrosine or phenylalanine.
283 The similarity of peptide amino 
acid preferences between HLA alleles is probably due to the number of conserved 
amino acids in this pocket. Amino acid 116 is the main determinant of the PC that is 
bound. For example, HLA-A2 has tyrosine at 116 and binds peptides with a 
hydrophobic residue (valine or leucine) at PC.
260 HLA-B27 and HLA-Aw68 have 
asparagine at position 116 and bind basic PC residues.
284 
TCR structure  
The T-cell receptor (TCR) is a heterodimer composed of two chains, α and β (or γ and 
σ , depending on the nomenclature), each containing a constant (α–1 and β–1) and 
variable domain (α–2 and β–2). The variable domains each contain three variable loops, 
complementary-determining region 1 (CDR1), CDR2 and CDR3, and are encoded by 
multiple variable (V), diversity (D) and joining (J) gene segments. The CDRl and Host immune defences     
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CDR2 loops are encoded by 42 V-α and 46 V-β genes. CDR3 on the α chain is made 
from the joining of V-α genes to J-region gene segments, and the CDR3 on the β chain 
is made from the joining of V-β genes to J-region and D-region gene segments. The 
addition of non-germline bases at junctions and the addition and trimming of 
nucleotides at the V(D)J junctions also adds to the diversity of CDR3.
23,285,286 The 
number of different TCR combinations is greater than 10
15 (see reference 286). 
TCR-HLA-peptide interaction  
The CDRs of the TCR are involved in peptide recognition and HLA recognition (see 
Figure 2.23). The constant domain is important 
for membrane attachment (notably using non-
covalent bonds with the CD3 complex
287) and T-
cell activation.
288 The CDRs sit diagonally over 
the HLA molecule, between two ‘peaks’ near the 
N termini of the α-helical regions of the HLA 
molecule.
285 CDR1 and CDR2 of the TCRs α 
chain are positioned over the N-terminal of the 
peptide and the CDR1 and two of the β chain lie 
over the C-terminal of the peptide.
285,289-291 CDR1 
and CDR2 of both chains interact with conserved 
residues on the α helices of the HLA class Ia 
molecule. CDR3 of the α and β chains meet in the 
centre of the binding site and contact most of the 
protruding side chains of the residues of the 
peptide, and determine the specificity of the 
Figure 2.23. Interaction between TCR and 
HLA-peptide complex.  
Panel A shows the diagonal orientation of 
the TCR on the HLA-peptide complex. 
Panel B shows the interaction of the CDR2 
with HLA-α1 and -α2, and CDR3 with the 
peptide. Taken from reference 242.  Chapter 2 Literature review  40 
interaction.
242,292-294 The peptide’s residues with protruding side-chains vary depending 
on the residues themselves, length of the peptide and the HLA allele. The conformation 
of the HLA molecule also appears important in the TCR interaction.
295 The TCR covers 
over half of the peptide’s surface and the HLA’s binding groove, and contacts both 
conserved and polymorphic residues of the HLA.
285 However the peptide’s specificity is 
the main focus of the TCR.
262 
The TCR interaction with the peptide-HLA complex causes some small conformational 
changes. Notably, the peptide is pushed further into the HLA binding site by the TCR. 
These conformational changes do not appear to be responsible for TCR signalling, 
suggesting that signalling requires other mechanisms.
285 
Clinical studies 
The variability in HIV-1 infection and disease progression varies greatly between 
individuals. Some develop AIDS, and some die within a few years of infection, while 
others have been asymptomatic for over 20 years without antiretroviral therapy.
58,70 
Furthermore, not everyone exposed to HIV-1 gets established infection (see Table 2.2), 
and around five percent of individuals appear highly resistant to infection.
296 This 
variability cannot be explained totally by the infecting HIV-1 strain.
297 P a r t  o f  t h e  
variability has been associated with immune system competence and various gene 
alleles.
298  
Table 2.2. The incidence of established HIV-1 infection after different types of exposure. 
Type of exposure of HIV-1  Incidence of established 
infection per exposure 
1 unit of blood  90%
299 
Babies born to an HIV-1 positive mother not on treatment  30%
300 
1 needle stick incident  <1%
106 
1 homosexual encounter   <1%
299 
1 heterosexual encounter  <1%
301,302 Clinical studies     
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Most studies on gene associations with HIV-1 disease have examined the HLA 
complex.
303 Susceptibility to, or progression of, other infectious diseases that have been 
reported to be associated with different HLA alleles include hepatitis B virus 
(HBV),
304,305, leprosy,
306 malaria
307,308 and tuberculosis.
309 A list of factors that have 
been shown to be associated with increased or decreased infection or disease 
progression in vivo for HIV-1 are shown in Table 2.3.
xvi  
The phenomenon of linkage disequilibrium has the potential to result in an apparent 
association with one allelic gene when it is actually caused by another. Studies 
implicating one gene in progression or protection may actually be marking other genes 
that are commonly linked to it. For example, the association with DR1 and progression 
and Kaposi’s sarcoma
298,322,325,336,343,348,462-465 may be marking a true association with 
HLA-B*3502 and HLA-B*3503 through the 35.2 and 35.3 AHs. Likewise, the 
associations with HLA-Cw7,
348 HLA-DR3
313,354 and C4 null alleles
298,325,359,360 may be 
marking molecular subtypes of HLA-B8 through the 8.1 AH. Gao et al
342 also argue 
that the association found with HLA-Cw4 and disease progression is due to its linkage 
disequilibrium with the structurally and chemically similar HLA-B35 molecular 
subtypes HLA-B*3502, HLA-B*3503, HLA-B*3504 (combined frequency is 42 
percent in Caucasians). They go on to argue that the lack of an association between 
HLA-B35 and disease progression in African-American cohorts is because their most 
common HLA-B35 molecular subtype (B*3501, frequency is 95 percent) is structurally 
and chemically different to HLA-B*3502, HLA-B*3503 and HLA-B*3504.
xvii 
                                                 
xvi Our model of viral load support the protective associations with CCR5 ∆32, HLA-A11, HLA-B5, 
HLA-B17 and HLA-B27, and the disadvantageous association with HLA-B8 per se, without taking viral 
polymorphisms into account (see Chapter 16 and Table 16.4). 
xvii In our, mainly Caucasian, cohort 11.0% of individuals had HLA-B35 and of these 72%, 4%, 20% and 
4% were HLA-B*3501, HLA-B*3502, HLA-B*3503 and HLA-B*3508 respectively. No other subtype 
of HLA-B35 existed (see Chapter 14 and Figure 14.4). 
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Table 2.3. Studies that have shown association with susceptibility to, or protection from, HIV-1 infection 
and disease progression. 
The numbers in the table are the reference numbers for the studies. 
Infection   Disease Progression 
Factor  Decreased  Increased  Slower   Faster  
HLA Class I 
 
 
 
 
  HLA-A      
 
  HLA-A2 supermotif (HLA-
A*0202, *0205, *0214, *6802) 
310-312     
    HLA-A2      
   Caucasian  haemophiliacs    313     
   Africans  314       
    HLA-A11    315   
    HLA-A19   316-318    
   HLA-A32,  TAP2.3      319 
 
    HLA-A24     320 
    HLA-A25      
   HLA-A25,  TAP2.3      319 
 
    HLA-A26      
   HLA-A26,  TAP2.3      319 
 
    HLA-A28  316-318     
   HLA-A*6802  310 
    
   HLA-A69  316-318 
    
  HLA-B      
    HLA-B8     321-323 
 
    Parts of the 8.1 ancestral 
haplotype (HLA-A1-
Cw7-B8-C4AQ0- C4B1-
BfS-DR3-DQ2) 
 324   48,313,315,320,
324-329 
      HLA-B8,  TAP2.1     319 
    HLA-B18  310,316-318     
   HLA-B18,  TAP2.3      319 
 
    HLA-B13    330,331 
 
    HLA-B16     315 
    HLA-B21     315 
    HLA-B27    319,330-332 
 
    HLA-B35     298,315,333-338 
   In  Africans  339       
      HLA-B35,  TAP2.1     330,331 
 
    Parts of the 35.2 and 35.3 
ancestral haplotype 
(HLA-B35-C4-DR1-
DQ1) 
   319,323,329,337
,340,341 
 
  HLA-B35-PX  (HLA-
B*3502, HLA-B*3503, 
HLA-B*3504, HLA-
B*5301) [not HLA-B35-
PY (HLA-B*3501, HLA-
B*3508)] 
   342 
    HLA-B37     319 
  HLA-B44  303,343 
    
    HLA-B49     319 
    HLA-B5     337 
   HLA-B51    303  330,331 
 
  HLA-B52  303,313 
    
  HLA-B57   
  319,330,331  
   HLA-B*5701      344,345 
 
  HLA-B70  316-318     
 
    HLA-B  Bw4    346 
 
   HLA-B  Bw4-80Ile      346 
 
    HLA-B Bw4 homozygosity      230 
 
  HLA-C      
    HLA-Cw4   298   337,338 
   In  African-Americans  299,347       
    HLA-Cw7     348 
  Rare class I HLA alleles  297,316-318 
    
  Class I HLA homozygosity        349,350 
  Class I HLA concordance    351,352     
HLA  Class  II      
  HLA-DR      
    HLA-DR1    315  348 
 
  HLA-DRB1*0702-
DQA1*0201 
  336   
  HLA-DR2  353 
   338 
    HLA-DR3     313,354 Clinical studies     
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Infection   Disease Progression 
Factor  Decreased  Increased  Slower   Faster  
    HLA-DR4  313,315   315,348  
    HLA-DR5    355-357   
   DRB1*1102      358   
  HLA-DR6  299,347 
    
   DRB1*1301   
  358  
    HLA-DR11   303    
    HLA-DR12   303,306    
  HLA-DR13  314,353 
    
  HLA-DQ      
    HLA-DQ2     298,313 
    HLA-DQ3      
   DQB1*0302      330,331 
 
   DQB1*0303      330,331 
 
    HLA-DQ6      
   African-Americans    347     
   HLA-DQB1*0602    299     
   HLA-DQB1*0605    299     
   HLA-DQB1*0603  299 
    
HLA/HLA  related  Other      
  HLA-C4      
    C4 null alleles    298,359    325,360 
  T A P       
    TAP-2.1     330,331 
  K I R       
    3DS1     346 
  KIR 3DS1 and HLA-B Bw4-80Ile      346   
Chemokine  Receptors      
  CCR5      
 
  High levels of CCR5 on the cell 
surface 
   98,105,108,361 
    CCR5 ∆32 heterozygosity  105,362 
  108,362-376 
 
 
  CCR5 ∆32 homozygosity  98,106,108,362,
366,377-383 
   
 
  CCR5 ∆32 allele on one 
chromosome and the CCR5 
61785A polymorphism 
384,385     
    CCR5 59029G homozygosity      99,386   
  CCR2      
    CCR2 64I heterozygosity      385,387-392 
 
Chemokines      
  SDF-1        
    3’A  homozygosity    393 
 
 
High levels of CCR5 chemokine 
ligands  
 
 
 
  RANTES  394  395 
  396 
  MIP-1-α 394,395 
  395 395 
  MIP-1  β 394 
  397  
Immune  responses     
 
 
Strong HIV-1-specific CD8+ CTL 
responses 
308,310,339,394
,398-412 
 47,130,287,413-
420 
 
  Recognition of conserved epitopes      12,13,50,344   
 
Strong HIV-1-specific CD4+T-cell 
Helper responses 
399,406,421-425   213,426-429 
 
  High levels of neutralising antibody  406    430 
 
African  race   431    
Larger number of exposures  310  432,433   
Higher viral load of donor    434-439     
Breaks in the mucosal barrier, inflammation, 
urethritis or cervicitis  440 
 
  
Antiretroviral therapy  441 
    
Infection or exposure to HIV-2  339,442,443       
Older  age     444 
Higher viral load set-point        347,445-452 
Seroconversion  Illness     322,395,453-456 
Decreased CD28 (a co-stimulatory molecule) 
on CD8+ cells and CD4+ cells     
 457-461 
HIV      
  Defective  virus      
    Nef    214-216   
  HLA class I specific epitope escape        12,13,49-51 
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Linkage disequilibrium can also result in combinations of genes being more predictive 
than a single gene. A combination of genes linked on the 35.2 and 35.3 AHs show a 
stronger correlation with disease progression than an association with HLA-B35 
alone.
319,323,329-331,340,341 However, linkage through the AHs 35.2 and 35.3 may be 
marking molecular subtypes of HLA-B35, which have been shown to be more 
predictive of progression than HLA-B35.
342 Similarly, subtypes of DQ6 have been 
shown to be associated with infection differently.
299 Subtyping alleles may help explain 
discrepancies between different studies – particularly in those that were carried out in 
different ethnic cohorts.
xviii Linkage disequilibrium could also make a single allele 
appear stronger than individual haplotypes if the allele is on two haplotypes that have 
similar effects on progression. C4 null alleles are found on the 35.2, 35.3 and 8.1 AHs, 
which are all known to be associated with disease progression.
325 Circumstances unique 
to a cohort can also affect associations. The protective effect of HLA-B35 seen in a 
Gambian cohort where HIV-2 and HIV-1 is prevalent is believed to be partly because 
the local subtype of HLA-B35 can recognise epitopes conserved between HIV-1 and the 
less pathogenic HIV-2.
442  
Another reason for the conflicting data in different studies is the use of different 
measures of disease (for example, viral load, CD4 count, AIDS and death). While these 
may be correlated, some alleles have been shown to affect disease progression 
differently. For example, HLA-B8 appears to accelerate disease progression when the 
percentage of lymphocytes that are CD4 positive is greater than 20; while HLA-B35 
appears to affect disease progression when the CD4+ percentage is lower than 20.
466 A 
recent study by Martin et al
346 presents associations with HLA-B Bw4 alleles and a KIR 
                                                 
xviii We found that molecular subtyping improved associations between HLA and HIV-1 polymorphism 
(see Chapter 14, Table 14.1 and Table 14.2). 
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allele using four different definitions of progression (a CD4 count less than 200, death 
and two for AIDS) with P-values varying between 0.0005 and 0.1 depending on the 
definition used. This study also showed that the KIR allele KIR3DS1 is associated with 
faster progression but the combination of this allele and the HLA-B allele HLA-B Bw4-
80Ile is associated with slower progression. The definition used for progression may 
also greatly influence the results when modelling progression and the CCR5 allele, 
CCR5 ∆32. Being heterozygous for the CCR5 ∆32 mutation is known to be associated 
with lower levels of CCR5 on the surface of cells. CCR5 is the main co-receptor HIV-1 
uses to enter cells during the first half of progression. However, later in infection HIV-1 
uses a different coreceptor. Hence, association with CCR5 ∆32 heterozygosity and 
progression may only be seen in the first half of infection, and may potentially 
accelerate progression in the later half of infection by pressuring the virus to produce T-
tropic virus. Moreover, different alleles are associated with different opportunistic 
infections.
321,322,337 For example, HLA-B8 is associated with resistance to Kaposi’s 
sarcoma, but increased risk to other opportunistic infections.
321-323,463 Similarly, DR5 in 
Caucasians is associated with Kaposi’s sarcoma,
105,322,343,348,463,465 but decreased HIV-1 
disease progression.
355,357,358;xix 
The issue of association and causality is also important for other factors associated with 
HIV-1 disease. The presence of HIV-1-specific CD8+ CTL cells in seronegative HIV-1 
exposed individuals does not necessarily mean that CTL cleared infection. It may just 
indicate that HIV-1 entered the class I pathway and was expressed in class I HLA 
molecules. The virus may have not been replication-competent or infection may have 
been cleared by other means. Likewise, it may be difficult to distinguish cause and 
effect. For example, an increased level of chemokines or cytokines associated with 
                                                 
xix We use viral load as our indicator of disease status (see Chapter 16).  Chapter 2 Literature review  46 
progression may be simply marking the state of the immune system and not actually be 
influencing it. The same may be true for the NSI to SI tropism switch and disease 
progression. Additional information (for example, the effect of an intervention) besides 
the statistical significance of an association would be required to provide a convincing 
argument of causation.
xx 
Many of the studies on factors associated with HIV-1 disease are hampered by the 
problem of multiple comparisons and the risk of type I errors, and may report erroneous 
results. For this reason some authors have cautioned over-interpretation of reported 
genetic effects.
467 However, subsequent studies that confirm the results from previous 
studies or studies that remain significant after conservative correction for the number of 
alleles examined have more credibility.
xxi 
The great majority of studies on HIV-1 disease protection and progression have 
focussed on differences in the human. Few studies have focussed on differences in the 
virus as a possible reason for differing rates of protection and progression. A study of a 
cohort of haemophiliac patients with slow progression that were infected with HIV-1 by 
a single contaminated batch of blood discovered that the slow progression was due to a 
defective nef gene in the virus.
214-216 A few studies of individuals have found that a 
mutation within a recognised CTL epitope in HIV-1 can result in higher viral loads and 
increased disease progression.
12,13,49-51 Furthermore, some strains of SIV are more 
pathogenic than others, and HIV-2 and clade C of HIV-1 is believed to be less 
pathogenic than other major strains of HIV-1.
468-475 However, genetic studies to date 
                                                 
xx In our study of clinical progression we use HLA associations associated with viral polymorphism from 
another study to explain viral load variability in patients, with the hypothesis that virus adapted to the 
patient’s HLA are likely to have higher viral loads (see Chapter 6 and Chapter 16). 
xxi We perform a single test for association between HLA alleles and polymorphism, which overcomes 
the need to perform multiple corrections (see Chapter 12). Furthermore, we correct for multiple 
comparisons in our study of HLA and polymorphism to identify where HLA alleles are more likely to be 
occurring (see Chapter 11), provide biological evidence from others for the relevance of our results (see 
Chapter 7) and independently associate this with viral load (see Chapter 16). Clinical studies     
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have generally not taken viral genotypic variation or host-viral interactions into 
account.
xxii 
Protection from infection 
Resistance to HIV-1 infection is relatively frequent and seen in all types of transmission 
types: homosexual,
405 mother to infant,
407,408,410,421 needle stick
399,422 and heterosexual 
contact
339,398,476,477 (see Table 2.2). Five percent of the population seem to be highly 
resistant to infection (see reference 296 and references therein). In some seronegative 
HIV-1 exposed individuals HIV-1-specific T-helper and CTL cells are detectable.
411,478 
To produce a CTL response, the virus would have almost certainly infected the host’s 
cells. This implies that these individuals did not afford protection by blocking viral 
entry, but rather by mounting a response after active viral replication. In other 
individuals, viral entry blockage is possible, particularly in those individuals that lack 
functional CCR5.
98,105,106,108,362,366,377-382,479 Protection in some individuals is believed to 
be due to previous low-dose or defective virus immunisation.
310,339 However, no one 
factor has been shown to offer complete protection to infection, and those individuals 
that are highly resistant to infection may have a unique combination of genes, gene 
alleles and exposure history to HIV-1 variants, other pathogens or immune stimulants.  
Individuals that do not express CCR5 on their cell surface are highly protected from 
HIV-1 infection. Approximately one percent of Caucasians are homozygous for a 
polymorphism in the HIV-1 coreceptor CCR5, CCR5 ∆32, but up to 30 percent of 
highly exposed uninfected individuals are homozygous.
105,108,362,366,373 Different 
                                                 
xxii We argue that both the human and virus genetics are important in disease progression and we combine 
the information about a patient’s HLA and virus to show escape from described HLA-restricted CTL 
epitopes at a population level (see Chapter 6 and Chapter 7). Furthermore we show an association of this 
with viral load (see Chapter 16). 
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exposures may alter the risk, but protection has been shown in both sexual
480 and blood-
borne contact.
108 This suggests that M-tropic strains of HIV-1 are required for both 
sexual and non-sexual transmission. However, this protection is not absolute as at least 
five homozygotes are infected with HIV-1,
377-379,481;xxiii suggesting that some strains of 
HIV-1 that use other receptors for cell entry can initiate infection. The protection has 
been estimated at 10-fold.
377-382 Individuals with the CCR5 ∆32 allele on one 
chromosome and the CCR5 61785A polymorphism (which also produces a non-
functional protein) on the other allele are also protected.
384,385 One study has shown 
protection in CCR5 ∆32 heterozygotes
362 while others have not detected a protective 
effect.
108,366,482-486  
Several rare HLA alleles have been associated with protection from HIV-1 infection. It 
has been proposed that these alleles offer protection through an increased chance of 
making an alloimmune response to HLA molecules from the donor that are incorporated 
in the virion lipid bilayer (see Figure 2.2, page 11). This response could cause rapid 
recognition of HIV-1.
297,316-318 An alloimmune response has also been suggested to 
provide protection by recognition of a region of HIV-1 that mimics an HLA 
molecule.
328,487 
CTLs are important for the control of HIV-1 infection;
287,417-419 in protection and 
eradication of other intracellular pathogens;
308,488-493 in protection against viruses in 
animals by the transfer of memory CTL to naïve animals;
494-496 and  immunisation 
induced CTL.
236,491,497-500 HIV-1-specific CTLs have been detected in some highly 
exposed HIV-1 seronegative individuals
308,310,339,394,398-406 and in babies born to HIV-1 
positive mothers
407-412 without antibody. HIV-1-specific T-helper
399,406,421-425 and 
antibody
406 responses have also been seen in highly HIV-1 exposed, seronegative 
                                                 
xxiii One HIV-1 positive individual in the WAHIVCS is also homozygous for the CCR5 ∆32 deletion. Clinical studies     
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individuals. Hence, it is believed that HIV-1-specific CTL, T-helper cells and antibodies 
can act to protect some individuals from becoming HIV-1 infected.
283,501 In other 
individuals, these immune responses could result in lower viral loads, preservation of 
HIV-1-specific T-help and CTL, and slower disease progression.
164 
Exposure to low doses of virus favours a cellular immune response over a humoral 
response
424,425 and has been shown in SIV to protect rhesus macaques against a high-
dose challenge.
502 However, because detectable memory CTLs for HIV-1 are not seen 
after single exposures
399,408 it may require several exposures to become immunised by 
these natural means.
164 Occurrence of many low dose exposures is believed to be the 
reason for the apparent protection seen in two groups of HIV-1 seronegative prostitutes 
in Africa.
310,339 Other work on immunisation to SIV and SHIV in primates with 
replication-competent virus has been shown to produce a strong CTL and/or T-helper 
response.
503-507 While these studies have not shown prevention from infection in the 
majority of cases they do suggest that CTLs may be able to offer some protection.
508 
Exposure to, or infection by, other pathogens, such as HIV-2 (which is genetically 
similar to, but less pathogenic than, HIV-1), could also provide immunisation.
406,472 Not 
all individuals that are seroreactive for both HIV-1 and HIV-2 are infected with both 
viruses.
509-511 Cross-reactivity of CTLs between HIV-1 and HIV-2 has been shown, and 
infection with one virus may provide protection through effective immunisation against 
the other.
339,442,443 This has also been seen for HIV-2 and SIV in rhesus macaques.
512 
Furthermore, HLA-B35 may be associated with protection from HIV-1 in West Africa 
where HIV-2 is endemic, because the local subtype of HLA-B35 presents several 
conserved HIV-1/HIV-2 cross-reactive epitopes.
442,443,467 
Other factors have been associated with protection. These include some HLA 
alleles,
298,299,303,306,310,314-318,324,339,343,347,353 CCR5 ∆32 heterozygosity,
105,362 race,
431 high Chapter 2 Literature review  50 
levels of chemokines
394,395 and the viral load of the donor
434-439 (see Table 2.3). 
However, few of these associations have been adjusted for multiple comparisons or 
confirmed in other cohorts. 
Disease progression 
Several HLA alleles and haplotypes have been associated with HIV-1 disease 
progression (see Table 2.3). The association of accelerated disease progression and the 
HLA-B allele on the 8.1 AH,
313,315,319,320,320-329 and 35.2 and 35.3 AHs
319,323,329-331,337,340-
342 have been reproduced in several Caucasian cohorts. Similarly, the association 
between slower progression and HLA-B27
13,319,330-332 and HLA-B57
319,330,331,344,345 has 
also been shown in several cohorts. Further evidence to implicate these alleles in 
progression comes from the observation that HLA-B35
49,339,513-516 and HLA-B8
46 
present epitopes that are less conserved than those presented by HLA-B27
516 and HLA-
B57
344,345. Furthermore, escape from the recognised immunodominant HLA-B27 
restricted epitope can only be tolerated after compensatory changes, after which there is 
marked disease progression.
13 
It is interesting to note the lack of HLA-A associations and disease progression. This 
may in part be because there is less polymorphism in the HLA-A gene and more 
homogeneity between individuals. It is also interesting to note that some alleles that 
have been associated with protection from disease progression have often been shown 
to offer protection from infection as well (see Table 2.3; for example, HLA-DR4). 
Likewise those that have been associated increased transmission have been associated 
with more rapid disease progression (Table 2.3; for example, HLA-B8, HLA-Cw4, 
HLA-C4 null alleles, CCR5 ∆32 heterozygosity). However, this could be a result of 
ascertainment bias, with, for example, those alleles associated with rapid progression Clinical studies     
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being over represented and those alleles associated with slower progression being 
underrepresented in the HIV-1 positive group compared to the control group. 
Individuals that are heterozygous for CCR5 ∆32 have lower viral loads and a mean 
delay in progression to AIDS of about two years.
349,362-372 However, this is not the only 
factor protecting against progression, as up to 50 percent of long term nonprogressors 
(LTNPs) are CCR5 heterozygotes.
368,373 Individuals who are heterozygous for a 
polymorphism in the chemokine receptor CCR2 (CCR2 64I) also have delayed 
progression to AIDS and are over represented in LTNPs.
385,387-391 The chemokine 
receptor CCR2 has been shown in vivo to be used by HIV-1 for cell entry, but only 
rarely. Hence, the association may be due to linkage to another 
polymorphism.
389,390,392,517 
The amounts of various cytokines, chemokines and cell surface expression of 
chemokine receptors have been associated with varying degrees of disease 
progression.
98,105,108,110,361 Individuals with increased CCR5 expression have enhanced 
production of HIV-1 and more rapid disease progression (see Figure 2.24).
98,105,108,361,518 
Various polymorphisms in the chemokines and chemokine receptors have been shown 
to affect the amount expressed, and have been associated with HIV-1 disease 
progression. Individuals homozygous for a polymorphism in the promoter region of 
CCR5 (CCR5 59029G) have lower amounts of CCR5 on their cells’ surface and have 
decreased progression to AIDS.
99,386 This effect appears to be twice as protective from 
progression as CCR5 ∆32 and CCR2-64I,
99 and stronger than any other polymorphism 
in the promoter region of CCR5.
106,349,362,368,389,392,393,519 The polymorphism SDF-1 3’A 
in the chemokine SDF-1 has also been found to be associated with decreased viral load 
and slower disease progression in some studies
393 with good biological reasoning as Chapter 2 Literature review  52 
SDF-1 can inhibit HIV-1 by binding to or internalising the HIV-1 coreceptor 
CXCR4.
394,426,431,520,521 However this has not been seen in all studies.
388,522,523  
Other factors shown to increase the rate of progression include older age,
444 presence of 
seroconversion illness,
322,395,453,454 competent virus,
214-216 less HIV-1-specific 
antibody,
430 loss of co-stimulatory molecules,
457-461 a higher viral load set-point,
347,445-
452 escape from CD8+ CTL epitopes (see CD8+ cytotoxic T-lymphocytes in HIV-1, 
page 55),
12,13,49-51;xxv less HIV-1-specific CD4+ T-help (see CD4+ T-cell helper cells in 
HIV-1, page 64)
164,213,426,427 and less HIV-1-specific CTL (see CD8+ cytotoxic T-
lymphocytes in HIV-1, page 55).
130,287,413-419 
                                                 
xxiv Reprinted from Seminars in Immunology, 10, Paxton WA and Kang S, Chemokine receptor allelic 
polymorphisms: relationships to HIV resistance and disease progression, pages 187-94, Copyright 1998, 
with permission from Elsevier. 
xxv We hypothesise and show that escape from CTL is associated with disease progression in a population 
of HLA diverse individuals (see Chapter 16). 
 
Figure 2.24. CCR5 genotype, CCR5 expression and disease progression. 
Panel A. CCR5 genotype does separate, albeit with substantial overlap, slow and fast progressors. Panel 
B. CCR5 chemokine cell surface expression separates these two groups better. Taken from reference 
110.
xxiv  
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Host-viral interactions 
The course of HIV-1 disease progression varies greatly between individuals – with 20 
percent of individuals developing AIDS within five years of infection and five percent 
remaining asymptomatic for greater than 10 years.
58,70 A schematic model of viral 
dynamics from HIV-1 infection to death is shown in Figure 2.25. After infection, the 
virus replicates to very high levels. This coincides with a decrease in the CD4 T-cell 
count. Within weeks of infection, most individuals have an immune response, 
 
Figure 2.25. Schematic model of viral dynamics over the course of HIV-1 infection. 
After the initial control of infection, the viral load stabilises to the viral load set-point, which varies 
between individuals. The set-point is predictive of subsequent disease progression. Individuals with a 
high viral load set-point have more rapid disease progression. This can be seen in the faster rate of CD4 
cell loss, and the less time of asymptomatic infection. Adapted from references 53 and 58.  Chapter 2 Literature review  54 
consisting of HIV-1-specific CD4+ T-helper cells, and cytotoxic and noncytolytic 
CD8+ CTLs. This is associated with an increase in the CD4 count to a level below the 
preinfection count. HIV-1-specific antibodies are not usually detected until weeks to 
months later.
50,524 The immune response during primary infection is usually associated 
with a transient illness with symptoms of muscle pains, fever, headache, swollen lymph 
nodes, sore throat and rash.
395,525-528 Many of these symptoms are probably the result of 
the large immune response to infection.
529 The severity of symptoms usually peak 
around six to 15 days from the beginning of symptoms and occurs around the time of 
the peak in viral load. These symptoms may not be solely due to the CTL response as 
individuals with no CTL response have long symptomatic disease.
524 Absence of 
symptoms during seroconversion, possibly due to early and effective CTL responses 
that reduces the viral load quickly, is predictive of slower progression.
322,395,453-456 In 
most individuals, symptoms usually resolve within 12 weeks from infection and 
coincide with decreased viral load.
528  
The CTL immune response also coincides with a decrease in viral load,
524 which 
plateaus to a steady state. This is called the viral load set-point, and is predictive of 
long-term clinical outcome (see Figure 2.25).
347,445-452 It is achieved through a balance 
of the following viral and immune factors:
53,530 1) Rate of infection of new cells and the 
rate of death of infected cells; 2) Rate of production of new cells and the rate of death of 
infected plus uninfected cells; and 3) The rate of virus release into the blood and the rate 
of clearance from the blood. Gradually, over time, the CD4 count decreases and viral 
load increases, until, ultimately, the immune responses cannot control the virus. This 
results in a large increase in the viral load and a marked decline in the number of CD4+ 
lymphocytes. This marks the late stage of infection and often coincides with 
opportunistic infections that mark AIDS (see Figure 2.26). Host-viral interactions     
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CD8+ cytotoxic T-lymphocytes in HIV-1 disease 
CTLs are believed to have the potential to prevent the establishment of infection, are 
important in the initial control of HIV-1 and control replication throughout the chronic 
phase of infection. Several observations support this conclusion. HIV-1-specific CTLs 
are often found in HIV-1 exposed but seronegative individuals.
308,310,339,394,398-412 The 
reduction of viral load seen in primary infection coincides with a rise in HIV-1-specific 
CTL
326,524,531,532 and occurs before a substantial antibody response (see Figure 
2.26).
50,326,524 Vaccines that invoke a CTL response (without antibodies) against SHIV 
in rhesus macaques, while not able to prevent infection in the majority of cases, are able 
to preserve the immune system, reduce the viral load set-point by 1,000 to 10,000 fold 
and induce long-term nonprogression.
503-507 The removal of CTL using anti-CD8+ 
antibodies in rhesus macaques infected with SIV and SHIV infection, both in acute and 
 
Figure 2.26. Immune responses and viral load throughout HIV-1 infection. 
After infection, the virus replicates to high levels in the absence of a HIV-1-specific immune response. 
During this time, the number of CD4 cells drops as they are killed directly or indirectly by the virus. 
After the emergence of the CTL response, the viral load drops and CD4 increases. Later an antibody 
response is seen. After three three to four months, the viral load drops to its ‘set-point’, after which it 
gradually increases inversely while the CD4 count decreases. Late in infection, when the immune system 
is heavily compromised, the CTL and antibody decline and viral load increases. rapidly Taken from 
reference 50.
iv 
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chronic infection, coincides with an increase in viral load.
533-536 The gradual loss of 
CTL over the course of disease correlates inversely with a rise in viral load.
416,531,537  
The CTL response in HIV-1 is both cytotoxic and noncytolytic.
164 CTLs secrete 
cytokines (IL-8, IL-16 and IFN-γ ),
520,538,539 chemokines (MIP-1 α  and MIP-1 β, 
RANTES)
444,520,540,541 and CD8+ T-cell antiviral factor
542 after epitope-specific 
stimulation.
541 Both SDF-1 and RANTES induce up to 60 percent downmodulation of 
CCR5
543 and in doing so inhibit HIV-1 R5 strains.
544 IL-16
545,546 and the CD8+ T-cell 
antiviral factor
542 have also been shown to inhibit HIV-1 replication. However, the 
importance and contributions of these cytotoxic and noncytolytic responses to viral 
evolution and disease progression have not been determined
164 and in vivo studies of 
these cytokines and chemokines and disease progression have been controversial.
394-
397,547-549 This may be because other cells can secrete the same soluble factors
550,551 and 
each appears to vary differently through the course of disease.
552 
The potential importance of CTL in developing a preventative or therapeutic vaccine 
has seen over 200 CTL epitopes defined for HIV-1. The majority of these have been 
defined in conserved regions between clade B viruses, and around 30 percent for other 
clades.
52,553,554;xxvi 
Acute infection 
In sexual exposure, HIV-1 penetrates the mucosal barriers and infects Langerhan cells 
in the mucosa of the vagina or rectum. These cells then fuse with CD4+ lymphocytes 
and travel to local lymph nodes.
302,406,555 After infection there is rapid and exponential 
replication of HIV-1 prior to the onset of an HIV-1-specific immune response. During 
                                                 
xxvi We use the HLA-restricted CTL epitopes defined in HIV-1 RT to validate our associations with HLA 
and viral polymorphism (see Chapter 7). We also use information on the different HLA-specificities for 
peptide-binding to predict putative HLA-restricted CTL epitopes (see Chapter 10). Host-viral interactions     
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this time, the number of different HIV-1 variants is narrow as the fittest infecting 
variant in this environment quickly outgrows other variants.
141 From infant transmission 
studies it appears that the fittest (in the absence of immune pressure) variant from the 
infecting partner is selected for in the host.
556,557;xxvii This may, in part, explain why the 
most common variant that establishes in individuals is CCR5-tropic and non-syncytia 
inducing.
558 The subsequent HIV-1-specific response may also be responsible for 
suppressing syncytia-inducing variants early in infection.
559 
After the large expansion of virus a reduction is observed. Two models have been 
proposed to explain the reduction. The first proposes that the decrease is the result of 
depletion of cells (for example, CD4+ lymphocytes and macrophages) that HIV-1 can 
infect.
560,561 The alternative model is that CTLs eliminate HIV-1 infected cells and 
thereby reduce the viral load. Both models probably contribute to the reduction but the 
latter appears to contribute more
562 as the viral load is observed to decrease in 
association with an increasing HIV-1-specific CTL response
229,326,524,563,564 and occurs 
before the emergence of neutralising antibodies
50,326,524 (see Figure 2.26).  
During primary infection, the CTL response is weak but strengthening with a narrow 
but expanding repertoire, and the HIV-1 viral load is high. CTL escape has been 
observed during this time in HIV-1
47,48,524 and in a study of 21 rhesus macaques infected 
with SIV, in which 19 developed escape mutations during seroconversion.
561 The 
observation of CTL escape mutations during primary infection provides further support 
that CTLs induce strong selective pressure on viral replication. Escape from these early, 
                                                 
xxvii We observe little viral variation between the clade B reference sequence, HXB2CG, and our 
population consensus (see Chapter 4, Figure 4.1). Over time we observe increased polymorphism (see 
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and arguably best, epitopes during acute infection may partly explain why CTL is 
usually unable to eliminate HIV-1.
xxviii 
The effectiveness of the CTL response in reducing the viral load early in infection plays 
an important part in the future course of HIV-1 disease. An early and strong CTL 
response (measured by chromium release and limiting-dilution assays) is associated 
with lower viral loads,
326,565 while failure to generate an early or detectable CTL 
response is associated with higher viral loads
326,566 and more rapid disease 
progression.
47,420,524,566 These observations have also been observed in SIV in rhesus 
macaques.
534,535 Most individuals generate an early and broad CTL response,
126,164 with 
greater than 10 percent of their CTLs being HIV-1-specific.
47,562,567  
The HIV-1 epitopes recognised by an individual’s CTLs appear to be important in the 
future progression of disease. CTLs directed towards epitopes that the virus cannot 
change easily (due to a higher viral genetic barrier to change), correlate with lack of 
disease progression.
12,13,46,49,50,339,513-516 CTL directed towards epitopes in proteins that 
are expressed early in the HIV-1 lifecycle (such as rev and tat) also correlate with 
slower progression.
164 CTLs recognising most of the HIV-1 genes (including env, gag, 
pol, nef, rev and tat) have been documented in primary infection.
7,164,524,550 
Early intervention with antiretroviral therapy reduces CD4 T-cell depletion but also 
reduces the CTL response towards HIV-1 due to reduced HIV-1 antigen.
550,568 
Individuals exposed to low doses of HIV-1 also have low or delayed CTL responses, 
suggesting that a minimum threshold of virus antigen expression is required to elicit a 
CTL response.
550,569 
                                                 
xxviii In all but one individual with HLA-B*5101 (39 out of 40), a polymorphism was observed at position 
135 of HIV-1 by their first sequence. This position is an anchor residue for an HLA-B*5101 restricted 
CTL epitope. The one individual that did not have a polymorphism at this position was treated with 
antiretroviral therapy in primary infection which probably aborted the natural high viral load and 
decreased the chance of the polymorphism being selected (see Chapter 14). Host-viral interactions     
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Clinically asymptomatic stage of disease 
Until 1989 it was commonly believed that after the symptoms during the establishment 
of HIV-1 infection, HIV-1 entered latency. This resulted in a variable time of clinically 
asymptomatic infection. The late stages of infection were thought to be the result of the 
virus coming out of latency. However, it is now known that CTLs are present
20,415,420,570 
and are continually controlling infection throughout the clinically asymptomatic stage 
of infection.
562,565  
The strength of the CTL response after primary infection is inversely correlated with 
viral load
413-416 and an inadequate CTL response correlates with more rapid disease 
progression in humans
130 and primates.
571 During this stage of infection CD8+ 
responses can develop and respond to new epitopes or mutations within previously 
recognised epitopes for many years,
572-574 after which there is a progressive loss of 
CTLs as the individual progresses to AIDS.
7,415,417-419,515,575-582 During asymptomatic 
disease around one percent of peripheral blood mononuclear cells (PBMCs) are effector 
CTLs (eCTLs) specific for HIV-1,
575 as measured by limiting-dilution, and 0.01 to 0.1 
percent are CTL memory cells that are specific for HIV-1 (reviewed in reference 164). 
CTLs are usually directed towards multiple epitopes during chronic infection
164 and 
escape from these are likely to be occurring throughout infection,
283 with each escape 
giving the virus a slight survival advantage.
583,584 Escape during this stage of disease 
may affect TCR recognition and hence may not occur to fixation.
565 This may 
contribute to the increase in the genetic diversity of the quasispecies of HIV-1 that is 
observed
13,41-48. Several studies have reported escape during this stage of 
infection,
13,585,586 even in individuals with low viral loads.
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HIV-1-specific T-helper cells are detectable in most individuals with chronic 
infection
428 and appear to be sufficient to maintain CTL function.
427,587 Only about half 
of individuals have a decline in these cells during asymptomatic infection.
428 Long-term 
non-progressors maintain very strong HIV-1-specific T-helper cells during chronic 
infection.
426,428,429 This stage of infection sees a gradual increase in the viral load and an 
increase in the fitness of the virus in vitro.
109 This may be due to escape from CTL and 
compensatory mutations to these, other induced mutations and polymorphisms in the 
founding virus. 
Advanced stage of disease 
Late infection is characterised by a decline in HIV-1-specific CD8+ and CD4+ T-cell 
responses.
7,124,149,415-419,515,572-582,588,589 The loss of HIV-1-specific CD8+ T-cell 
responses may be the result of HIV-1-specific CD4+ memory cells falling below a 
critical level.
428 However, some reports show that HIV-1-specific CD8+ T-cell 
responses are detectable even in very late infection.
7,124,562 These responses may be 
more important in late infection as other immune responses (for example, antibody 
responses) are likely to be absent when the T-help is low.
50 However, the loss of the 
costimulatory molecules (for example, CD28) on the surface of CTLs in late infection 
results in many of the CTLs becoming anergic and losing function.
457-461 
Large increases in viral load are seen in late infection and correlate with loss of CTL
533-
535 and are responsible for the destruction of the lymphoid tissues. The turnover is so 
great that the generation of CD4+ T-lymphocytes cannot match the death rate. This 
leads to a faster rate of CD4+ cell decline and an increase in clinical symptoms and 
AIDS. High viral loads together with a low or absent T-help, and hence a reduced 
ability for CD8+ T-cells to respond to mutations within epitopes, makes escape from 
CTL likely in late infection.
13,50,520,542 CTL escape has been documented in several Host-viral interactions     
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studies during this stage of disease.
12,13,283,565,590 When the CTL selective pressure is 
weak, the virus may revert to wild-type.
12 This reversion is similar to that seen in drug 
resistant strains when drugs are stopped.
591-595 
Late stage infection also coincides with the virus’s ability to produce T-cell syncytia in 
vitro – the fusion of cells into a single, large multinuclear cell. This occurs when the 
HIV-1 envelope glycoproteins bind to CD4 on other cells. This is associated with a 
change in the chemokine co-receptor usage by the virus. Syncytia inducing (SI) viruses 
tend to be CXCR4 tropic and NSI viruses tend to be CCR5 tropic
95,96,596-599 (see Figure 
2.9, page 17). The appearance of SI viruses in late infection occurs around 18 months 
before AIDS and preceeds a more rapid rate of CD4 decline. These viruses may not 
appear until this time because they are more easily eradicated than the more slowly 
replicating NSI viruses when the immune system is competent.
600 This has been shown 
in mathematical models.
601 SI viruses may also contribute to an increase in the amount 
of CTL escape because SI viruses are not inhibited by the release of soluble beta-
chemokines from CD8+ T-cells
520 and hence the CTL response is restricted to the direct 
lytic activity of CD8+ T-cells.
12 
Immunodominance 
Immunodominance is the phenomenon where the CTL response focuses on few 
epitopes in vivo despite being able to recognise many more in vitro. These epitopes are 
determined by the CTL efficacy of the epitopes. The CTL efficacy is the overall ability 
of an epitope to be processed, presented and recognised. CTLs that respond to low 
peptide concentration tend to have greater CTL efficacy, however this is dependent on 
the ability of the peptide to be processed and presented by the individual’s class I 
pathway.
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active CTLs produce inhibitory factors that reduce the ability of other CTL clones to 
grow. For this reason, only the CTL response against the strongest and/or earliest 
epitopes can proliferate. However, a potentially undesirable consequence of 
immunodominance is the phenomenon of ‘original antigenic sin’.
296,606-608 This is where 
a mutation in an immunodominant epitope reduces the CTL efficacy, but remains strong 
enough to prevent proliferation of a new CTL clone to a more useful epitope.
608 
Mutation in immunodominant epitopes that lower the CTL efficacy can result in other 
epitopes being selected.
584 This is advantageous to the virus because these new epitopes 
are likely to have a lower CTL efficacy, requiring more time to kill cells infected with 
the mutant variant.
609,610 Polymorphic human genetic factors (for example, up to six 
different class Ia genes in individuals presenting peptides that compete for 
immundominance, and other polymorphisms in genes involved in the class I pathway) 
make prediction of the epitopes utilised in disease difficult. The stochastic nature of 
escape also contributes to the complexity. This was very clearly seen in one study of 
two HLA-identical individuals, where one individual developed an escape mutation 
more quickly than the other and progressed more quickly in disease.
51;xxix 
A mathematical model has suggested that HIV-1 disease progression may be the result 
of mutations in epitopes recognised by CTLs, resulting in the CTL response recognising 
other epitopes with lower efficacy.
583 This model supports the in vivo phenomenon of 
immunodominance with one or two epitopes providing the optimal number of epitopes 
for viral control. 
                                                 
xxix However, at a population level, the utilisation of these immunodominant epitopes and escape from 
them is seen and is associated with increased viral loads (see Chapter 7, Figure 6.3 and Chapter 14). 
Escape from one epitope in HIV-1 RT appears to occur characteristically in primary information in HLA-
B*5101 individuals (see Chapter 16). Host-viral interactions     
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Measures 
The only in vivo measure of CTL efficacy is through CTL escape analyses.
561 The 
epitopes that are subject to the strongest CTL pressure on HIV-1 and with the lowest 
genetic barrier to escape are those that are most likely to escape. The 
immunodominance hierarchy of an individual can be determined by analysing the 
progressive order that epitopes are escaped. The phenomenon of immunodominance 
and ‘original antigenic sin’ reduces the chance of new epitopes being recognised while 
the existing ones have not escaped. This makes this type of analysis possible. Analysing 
genomes for CTL escape mutations would indicate which epitopes are utilised by 
individuals and thereby which have the highest efficacy in vivo.
xxx This combined with 
knowledge of the genetic barrier to escape from these epitopes could determine which 
epitopes are the most effective at eradicating or controlling the virus.  
There are two in vitro assays that can be used to predict the immunodominance epitope 
hierarchy. Both methods are usually restricted to analysing conserved and common 
clade B consensus virus and as a result most immunodominant CTL epitopes that have 
been described are in conserved consensus sequence.
124 They both measure the 
immunogenicity of epitopes. However, unlike CTL efficacy, immunogenicity does not 
take into account the effectiveness of CTL killing. The first assay measures the binding 
affinity of peptides in the HLA molecule by measuring the concentration of peptide 
required to inhibit 50 percent of the binding of a reference peptide [50% inhibitory 
concentration (IC50)].
611-625 An IC50 of less than five µM is classified as high and an 
IC50 of greater than 15 µM is classified as low.
626 
                                                 
xxx Our analysis of HLA associated polymorphism can help identify these immunodominant epitopes. Chapter 2 Literature review  64 
The other measure of immunogenicity is the dissociation rate. The dissociation rate 
gives an indication of the stability of an HLA-peptide complex by estimating the time a 
peptide will be bound to an HLA molecule. Hence the dissociation rate gives an 
indication of how likely a peptide will be bound long enough to an HLA molecule to be 
transported to the cell surface and recognised by T-cells.
626 However, unlike the binding 
affinity, the dissociation rate is not influenced by competing peptides
627 or by the 
concentration of the peptide.
628 The loss of peptide-HLA complexes is exponential and 
can be measured as the time for half of the peptide-HLA complex to decay (DT50). A 
DT50 of three hours is the cut-off used by van der Burg et al
626 to define a strong 
immunogenic peptide for a particular HLA molecule. However, unlike the binding 
affinity, it does not predict whether a peptide will be endogenously processed and 
presented. This will be influenced by flanking sequences in the virus and the molecules 
in the HLA class I processing pathway.
14 Van der Burg et al
626 found that HLA class I-
peptide immunogenicity of HIV-1-derived peptides could be predicted more accurately 
by their dissociation rate than by the binding affinity.  
CD4+ T-cell helper cells in HIV-1 disease 
HIV-1-specific T-helper cells are important in HIV-1 disease by releasing antiviral 
cytokines and by providing help in controlling the magnitude and maintenance of the 
CTL response.
426,491 Animal studies have also shown that proper CTL function is 
dependent on T-helper cells.
587,629-637 See references 164, 427 and 508 for reviews. 
However, the exact role of CD4+ T-cells in HIV-1 host defence is unclear and 
complicated by the fact that these cells are infected by HIV-1.
428 There is a delicate 
balance between the T-helper response, antigen load and CTL response in HIV-1. 
Strong T-help responses enable a strong CTL response that selectively kills the 
activated CD4+ T-cells that are providing the help. A weak T-help response can result Host-viral interactions     
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in a higher antigen load through the subsequent weak CTL response. This in turn can 
lead to more CD4+ T-cell killing through apoptosis. Where this balance is set 
determines the rate of disease progression. Treating individuals with potent 
antiretroviral therapy during seroconversion appears to improve the set-point of viral 
load, subsequent disease progression, the T-help responses and CTL responses.
638 The 
benefit remains even after treatment is stopped.
638 Furthermore, in HIV-1 non-
progressors virus-specific T-helper cells are preserved.
213,426-428,639 This indicates that 
the loss of HIV-1-specific T-helper cells during seroconversion contributes to the rate of 
future progression.  
Further support for the protective effect of T-helper responses come from studies of 
highly HIV-1 exposed but seronegative individuals that have shown the presence of 
both T-helper and CTL responses.
339,399,406-408,410,421-423,433 Vaccine studies also indicate 
a protective effect of T-helper responses with the addition of a T-helper epitope 
enhancing the ability of a vaccine to induce CTL immunity.
640-643 Moreover, the most 
effective vaccines have been live-attenuated viruses. This may be, in part, due to their 
ability to induce T-helper responses.
283 Recent studies have shown that T-helper and 
CTL responses that are directed towards the same region of the virus provides an 
enhanced CTL response.
644 This appears to be because it involves antigen-specific 
interaction of both CD4+ and CD8+ cells with the same antigen-presenting cell.
645-647 
Despite the fact that HIV-1-specific T-helper cells are selectively killed during 
infection, most HIV-1 infected individuals have HIV-1-specific CD4+ T-help 
throughout infection.
428 This, in part, allows CTL responses to develop and 
mature.
562,572-574 However, as disease progresses, the amount of effective co-stimulatory 
molecules on the cell-surface decreases, possibly resulting in anergy and non-functional 
CD4+ T-helper cells.
457-461 The progressive loss of CTL activity
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activity late in disease
427,572-574 appears to be mainly due to loss of CD4+ T-help.
426,427 
Other studies have suggested that CD4+ T-help is not required for a CTL response to 
develop and mature when there is high epitope density of the virus on the cell 
surface.
287,649-659 The explanation for this may come from the fact that IL-2, a cytokine 
produced by CD4+ T-cells that is important in the maintenance of the CTL response, 
can also be produced by B lymphocytes, dendritic cells and CTLs themselves.
164 This 
reduces the possibility of T-cell inactivation, anergy and exhaustion, which occurs when 
there is an absence of costimulatory signals.
660 
Escape from HIV-1 T-helper cell epitopes through mutation within or flanking these 
epitopes is possible. Little has been published in this area, but escape from T-helper cell 
epitopes has been shown in humans
661-665 and in animals.
666  
Cytotoxic T-lymphocyte and T-helper cell avoidance 
Generic forms of avoidance 
Viral infections in which there are greater numbers of CD4+ than CD8+ CTLs indicate 
that there may be interference in the class I antigen processing.
667 Interference 
mechanisms can occur at various levels in the immune system pathways (reviewed in 
reference 668). Proteins of various viruses that are known to interfere with the pathway 
at a generic host level rather than in a way specific to the individual (for example, 
through CTL escape mutations to an individual’s unique CTL responses) are shown in 
Table 2.4. Host-viral interactions     
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Table 2.4. Proteins encoded in viruses that have been shown to interfere with the HLA/MHC class I and 
II pathways. 
EBV is Epstein-Barr virus, HSV is herpes simplex virus, and HCMV and MCMV are human and murine 
cytomegalovirus, respectively. 
Virus Protein  Mechanism(s)  Effect 
EBV EBNA-
1 
1) Is the only expressed protein during EBV 
latency. 2) Has a run of repeated glycine-
alanine residues which prevent it being fully
processed in the HLA class I pathway.
669 
No EBV protein is expressed on the 
cell surface during latency, and hence 
infected cells are not seen by CTL. 
HSV ICP-47
 
Inhibits binding of its peptides to TAP.
667  Reduces the amount of antigen 
transported into the ER for binding to 
HLA molecules. 
HCMV US11  Exports  the HLA heavy chain (α-1, α-2 and 
β-1) from the ER into the cytosol.
670,671 
Reduces expression of the 
HLA/peptide on the cell surface for 
recognition by CTL. 
  US2  Similar mechanism to US11.   
  US3  Retains HLA molecules in the ER.
672 Reduces  expression  of  the 
HLA/peptide on the cell surface for 
recognition by CTL. 
  US6  Inhibits peptide translocation by TAP.
673 
 
Reduces the amount of antigen 
transported into the ER for binding to 
HLA molecules. 
  UL18  Homolog of the class I heavy chain
674 which 
associates with β2m
675 and binds peptides.
676 
Inhibits NK cell killing. 
MCMV M152
 
Prevents MHC trafficking out of the ER.
677 Reduces  expression  of  the 
MHC/peptide on the cell surface for 
recognition by CTL. 
  P34  Binds to MHC class I molecules on the
plasma membrane.
667 
Prevents the interaction of the 
MHC/peptide complex with the TCR.
Adenovirus E3/19K Attaches six amino acids to the end of
membrane proteins that would otherwise 
leave the ER.
678,679 
Inhibits MHC class I antigen 
presentation. 
Lentiviruses RT  High error and replication rate.
141-148  Potentially allows mutations in 
antigens recognised by the immune 
system to occur and reduce or 
eliminate this recognition. May affect 
proteasome processing, TAP 
transportation, MHC binding and 
TCR recognition or function. 
HIV-1  tat  Regulation of protein expression
(latency).
62,63,181-184 
Reduced antigen recognition of 
infected cells. 
    Regulation of various cytokines and
chemokines.
185-189 
May reduce the immune response, 
increase infectivity of cells and 
reduce the anti-HIV effect of 
chemokines. 
    Interference with the human proteasome.
190 Reduces the amount of antigen 
available for binding to HLA 
molecules. 
  nef  Downregulates the cell surface expression of
CD4.
208 
Reduces the amount of T-cell 
signalling
680 and IL-2 expression.
681 
   Delays
213 or downregulates
204-206 HLA class I 
molecules. 
Reduces the amount of HLA 
molecules presenting antigen to T-
cells. 
  vpu  Binds with CD4 molecules in the ER.
222  Reduces the amount of functional 
CD4 molecules and the amount of 
intracellular env-CD4 complexes.
61 
  vif  Blocks an antiviral factor in CD4+ T-cells.
224 Increases the number of viable 
virions released. 
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HIV-1 encodes for three proteins that are known to interfere with the recognition of 
infected cells – tat, nef and vpu. The tat gene encodes for the tat protein that interferes 
in three different ways. It can regulate the production of HIV-1 proteins, hence reducing 
the amount of virus that can be presented.
62,63,181-184 Tat can also regulate various 
cytokines and chemokines.
185-189 This can reduce the immune response, increase 
infectivity of cells and reduce the anti-HIV-1 effect of chemokines. Finally, tat affects 
the class I processing pathway by interfering with the processing of the human 
proteasome
190 - potentially reducing the amount of antigen available for binding to HLA 
molecules. Nef also interferes with antigen presentation and recognition using more 
than one mechanism. It downregulates the cell surface expression of CD4,
208 reducing 
the amount of T-cell signalling
680 and IL-2 expression;
681 and it delays
213 or 
downregulates
204-206 HLA class I molecules, which reduces the number of HLA 
molecules that can present antigen to CTLs. The vpu protein binds with CD4 molecules 
in the ER,
222 reducing the amount of functional CD4 molecules
61 and hence the amount 
of T-cell help and co-infection. 
Other generic mechanisms by which HIV-1 can escape CTL immune surveillance 
include infecting the thymus and thereby removing T-lymphocytes that ordinarily 
would recognise the virus through the negative selection elimination process in 
lymphocyte training;
682,683 and lowering or removing the CD4+ lymphocytes and hence 
the help required to maintain eCTLs.  
Epitope escape 
Because of the limited size of RNA viruses, they probably rely more on mutation to 
avoid immune recognition than other pathogens.
20 Lentiviruses encode for a reverse 
transcriptase that has a high error rate, allowing for direct modification of its proteins’ Host-viral interactions     
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structure and sequence that are recognised by antibodies, T-helper cells and CTL. 
Evolution of these viruses appears to have shaped the current structure and critical 
residues of the viral genome such that conserved structural regions of proteins 
expressed on the outside of the virion expressed to antibody are concealed
169,170 and 
long regions of consecutive invariant residues are uncommon.
52,553;xxxi 
Cytotoxic T-lymphocytes  
Escape from antibody responses is well accepted.
50,684 Escape from CTL is less 
accepted, but a large body of evidence supports its existence. CTLs are a major defence 
against HIV-1 progression as they can kill virus-infected cells by recognising segments 
of the virus. This can prematurely kill the virally infected cell before the end of its HIV-
1 replication life. Hence CTL killing is probably a strong defence against HIV-1 
progression and therefore exerts pressure on the virus to escape the CTL 
response.
238,565,685  
Viral escape from CTLs was first described in vivo in animals in 1990
686 and in HIV-1 
in 1991.
46 Since then several studies, some longitudinal, have shown evidence for 
escape of HIV-1 from HIV-1-specific CTL responses via epitope specific mutations in 
vivo at seroconversion, during asymptomatic infection, during AIDS and after CTL 
immunotherapy in various genes including env, gag, nef and pol (reviewed in reference 
164).
1,12,13,46-48,283,524,565,583,585,586,590 Similar findings have been seen in SIV
2,3 and 
SHIV.
4 Criticism of these studies has been the small numbers of individuals studied and 
their absence of statistically significant selection.
2,571,687,688 Other criticisms, identified 
by Goulder and Walker,
571 are the lack of knowledge of the infecting viral strain, focus 
                                                 
xxxi We observed few runs of invariant residues in HIV-RT greater than the length of a CTL epitope (see 
Chapter 5 and Figure 5.2). 
 Chapter 2 Literature review  70 
on single epitopes and HLA molecules, lack of suitably HLA-mismatched controls, and 
cross-sectional data. Furthermore none of these studies address the question of how 
much immune escape is happening in a population in vivo.
689;xxxii 
One strong example of CTL escape in a human population can be seen in Southeast 
Asia where HLA-A11 is a common allele. Variants of Epstein-Barr virus (EBV) in 
these populations have a mutation within an immunodominant HLA-A11 epitope that 
eliminates its presentation.
22-25 Many studies in HIV-1, however, have failed to show 
clear evidence of positive selection of viral variants in vivo.
46,238,688,690-694 This may be 
due to epitopes acting at other regions in HIV-1 and other immune forces restricting the 
outgrowth of the viral escape variant.
693 
T-helper cells 
The neutralising antibody and CTL response depend largely on virus-specific CD4+ T-
help response. Hence it is likely that mutation that affects the recognition of the virus by 
T-helper cells would be advantageous to the virus.
661 Escape from T-helper epitopes has 
been described in HIV-1 in vitro in humans
661-665 and in a rhesus macaque model.
666 T-
helper escape has also been seen in influenza virus.
695 T-helper TCRs appear to have 
some ability to recognise epitope variants,
696-698 but some HIV-1 variants can eliminate 
the function of virus-specific T-help.
666 The extent of T-helper escape in vivo is 
unknown but is likely to be less than CTL and antibody escape because a mutation in a 
T-helper epitope would not directly affect the mutated virus.
666,699  
                                                 
xxxii The study we present in this thesis addresses most of these concerns by analysing a large population 
of HLA diverse individuals for in vivo HIV-1 polymorphism (see the introduction and discussion to 
Chapter 6). Other studies in this thesis adjust for multiple comparisons (see Chapter 11) and verify the 
results with independent biological data such as known HLA-restricted CTL epitopes (see Chapter 7) and 
viral load (see Chapter 16).  Host-viral interactions     
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Effects of escape 
Escape from CTL epitopes via polymorphism can affect recognition of the infected cell 
in a number of ways. Studies of polymorphisms within epitopes that affect recognition 
are shown in Table 2.5. These examples and knowledge of the HLA-peptide-TCR 
interaction indicate that two thirds of polymorphisms within an epitope would affect T-
cell recognition. This could result in no effect on recognition;
700 reduced TCR affinity 
leading to T-cell antagonism and impaired responses;
258,701 or no recognition, possibly 
because of 'original antigenic sin'.
296,606-608 The other one third of polymorphisms could 
affect HLA-peptide-binding resulting in absence of binding or a decreased time of 
peptide being bound.  
Table 2.5. Some well-defined examples of HIV-1 CTL escape mutations in individuals. 
Taken from reference 50.
iv 
HLA 
HIV gene 
(protein) Sequence Effect  Reference 
B8 gag  (p17)  GGKKKYKL   46,258 
   --R-----  Distorts α -1 helix.   
B8 gag  (p24)  DIYKRWII   46 
   E-------  Not seen by some CTL   
B8 gag  (p17)  GGKKKYKL   48 
   ----Q---  Predicted not to bind   
B8 nef  FlKEKGGL   48 
   ----E---  Predicted not to bind   
   ----N---  Predicted not to bind   
   ----Q---  Predicted not to bind   
   ........  Deleted  
B8 pol  (RT) GPKVKQWPL   702 
   --R------  Antagonises  
   --E------  Predicted not to bind   
B27 gag  (p24) KRWIILGLNK  13 
   -K-------  Rapid off-rate   
B44 env  (gp120)  AENLWVTVYY  47 
   -K-------- Does not bind   
A11 nef  AVDLSHFLK   200 
     -R-------  Does not bind   
     -F------R  Does not bind   
A3 nef  QVPLRPMTYK  590 
     .......... Deleted  
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Escape via mutation within, or flanking, 
CTL epitopes would be more likely if 
the mutation directly reduced 
recognition and killing of the infected 
cell. Hence, escape by CTL-mediated 
noncytolytic immune control that 
affects not just the recognised cell but 
all cells in the vicinity would be more 
difficult for the virus to escape 
from.
50,703  
The different types of evasion 
mechanisms are summarised in Figure 
2.27. Of these, escape mutation or 
deletion is the only one that is specific 
for the individual. The different effects 
that a mutation within or flanking an 
HLA-restricted CTL epitope can have 
on recognition are described below. 
Decreased HLA binding 
This type of escape is where amino acid mutations abrogate HLA binding, reduce the 
time the peptide is bound to the HLA molecule or result in a reduced amount of time the 
epitope will be exposed to TCR surveillance. Several mutations have been described at 
HLA binding sites.
667 
 
 
Figure 2.27. CTL evasion mechanisms used by HIV-1. 
An HIV-1-infected cell generating new virions, a CTL 
and a T-helper cell are shown. Evasion mechanisms 
are shown in boxes. Sequestration: HIV-1 may infect 
cells in sites that are not effectively accessed by CTL, 
such as the central nervous system. Latent provirus: 
virus may be integrated into the cells genome, but the 
genes not expressed and hence not able to be presented 
to CTL. CXCR5 using virus: HIV-1 variants that use 
the coreceptors CXCR5 are not affected by the anti-
viral actively of β-chemokines. Downregulation of 
HLA class I: the viral protein nef is able to reduce the 
amount of HLA class I on the cell surface, and hence 
the amount of HIV-1 expressed to CTL. Epitope 
mutation or deletion: can reduce the ability of the 
infected cell to express HIV-1 proteins to CTL, and 
can impair the TCR interaction. Upregulation of FasL: 
nef may increase the amount of FasL expression on the 
infected cells surface, which can kill or inhibit Fas-
positive CTL. CTL exhaustion: HIV-1 may induce a 
strong CTL monoclonal response that may result in 
exhaustion of the responding CTL clone. Deletion of 
HIV-1-specific Th: HIV-1 infects activated T-helper 
cells, which are targets for CTL killing and apoptosis. 
Deletion of these cells compromises the CTL response. 
Taken from reference 562. Host-viral interactions     
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TCR recognition 
Several mutations associated with escape that do not interfere with HLA binding but 
interact with the TCR have been reported in vivo
13,47,48 and in vitro.
704,705 This type of 
escape may result in non-recognition by, or reduced cytotoxicity of, the TCR that 
recognised the non-mutated epitope. 
Antagonism 
Antagonism is the phenomenon where mutations in an epitope of one variant affect the 
TCR so that it no longer triggers a cytotoxic or noncytolytic response when it 
encounters the wild-type variant resulting in anergy.
701 The molecular mechanism 
behind this failed response is not clear, but the result is that neither the wild-type nor 
variant grow to fixation as the wild-type is fitter than the variant, but requires the 
variant to avoid being killed by CTL.
126,701 Antagonism also allows the growth of other 
variants.
702 Escape via antagonism may be more advantageous to the virus than escape 
by other means because the killing via one epitope is removed without the immune 
system targeting a new epitope elsewhere in the virus.
702 Antagonistic mutations have 
been described in HIV-1
701,702 and HBV
706 infection.
xxxiii 
Insertions and deletions 
Insertions and deletions in HIV-1 are common. Selection of variants with deletions that 
remove a segment of a CTL epitope have been reported.
48,590 Deletions and insertions 
have also been described in antiretroviral drug resistance.
22,707-710 Insertions and 
deletions that result in a frame shift or a polymorphism that results in a stop codon and 
                                                 
xxxiii For these reasons we modelled polymorphism at a residue as any deviation different from the 
consensus amino acid (see Chapter 6). 
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premature truncation of the protein may be another mechanism of escape. This has been 
seen in nef.
711,712 
Proteasome and TAP processing 
Human proteasome-mediated digestion has preference for different residues. Amino 
acid mutation within or flanking an epitope can alter the amount of epitope available for 
loading on to HLA molecules. The TAP molecule also has amino acid preferences and 
mutation within or flanking an epitope can, likewise, reduce the amount of the epitope 
transported for peptide loading on to the HLA.
200,667;xxxiv 
Factors affecting escape 
The chance of escape from a CTL epitope is multifactorial. Firstly, the greater the viral 
replication, the greater the chance that a mutation will be generated that affects epitope 
presentation and/or recognition. Immune pressures (for example, antibody, CTL, 
cytokines and chemokines, et cetera), drug pressures and patient genetic makeup (for 
example, chemokine receptor polmorphisms) can reduce the viral load. Secondly, the 
greater the error rate the greater the chance that an escape mutation will be produced. 
However, the error rate is limited to preserve the virus’s genetic information. Thirdly, 
the greater the marginal benefit in viral replication that a mutation achieves will 
increase the chance that the viral variant with the mutation will get established. This 
will be affected by the efficacy of the mutated epitope, the efficacy of new epitopes 
distant from the escaped epitope, and the sacrifice in viral fitness (in vitro) in making 
the amino acid change (mutations at residues that do not affect viral fitness will be more 
easily tolerated than residues that do). Fourthly, the fewer compensatory mutations, if 
                                                 
xxxiv In Chapter 9 we look for escape from HLA restricted CTL epitopes via polymorphism that are 
predicted by others to influence proteasome cleavage within or near epitopes. Host-viral interactions     
 
 
75
any, required to increase the fitness of the virus in vivo would increase the chance of the 
fitter variant appearing. Fifthly, if two, as opposed to one, nucleotide changes are 
required to make the amino acid change to escape, the chance of it appearing will be 
decreased. Finally, killing of the cell before it releases progeny by 1) direct killing by 
recognising other epitopes in the virus or by TCR that can recognise the mutated 
epitope; 2) indirect killing by chemokines and cytokines by CTL recognising unmutated 
variants in other cells; and 3) direct or indirect killing by other factors (for example, 
suppressive chemokines and cytokines released by T-helper cells and antibody 
responses, et cetera; killing by antibody and blocking replication by drugs). These are 
summarised in Table 2.6. 
Table 2.6. Conditions that favour mutation. 
Factor  Favours mutation  Favours consensus 
HIV-1 viral replication rate  High  Low 
HIV-1 Error rate  High  Low 
Number of antiretroviral drugs  Single drug  Multiple drugs 
Type/class of antiretroviral drugs  Same place of action  Different places of action 
Broadness of immune pressure  Monospecific  Broad 
Strength of immune pressure  Strong  Weak 
Type of killing  Direct (e.g. cytotoxic) Indirect  (e.g.  non-
cytolytic, souble factors, 
?T-helper responses) 
Marginal increase in viral fitness after 
mutation 
Greater Lower 
Number of nucleotide mutations required to 
achieve the amino acid 
One Three 
Number of compensatory mutations required 
to increase the viral fitness 
None Many 
 
Optimal conditions for escape are high viral replication, low fidelity replication, a 
strong and monospecific CTL response towards a single epitope where mutation can be 
tolerated, and a cytotoxic response that directly affects the infected cell.
20,229 Strong 
monospecific CTL pressure where the virus is not adequately suppressed can result in 
the rapid selection of a viral strain and the elimination of the epitope.
47,48,287,590,713 This Chapter 2 Literature review  76 
is often seen in primary infection and escape often occurs to fixation.
xxxv A limited 
adaptive CTL response also leads to more rapid escape.
532,567 This is most clearly seen 
late in infection when there is a lack of T-cell help. This combined with high viral loads, 
reduced or absent suppression by antibodies, cytokines, chemokines and a competent 
immune system limits the CTL’s ability to control and eliminate escape mutations.
50 
Epitopes in more conserved regions may require compensatory mutation(s) to restore 
viral fitness and as a consequence take longer to appear.
12,13,50 In cases of a broad CTL 
response utilising multiple epitopes, CTL escape mutations are less often seen to be 
selected to fixation.
703  
The theoretical chance of a 
single mutation resulting in 
increased viral fitness (that is, 
a higher viral load) is shown in 
Figure 2.28. The bell shape 
curve of escape versus total 
pressure is the result of two 
competing forces. The greater 
the total pressure (for example, 
from all antiretroviral treatments, antibody and CTL responses), the lower the viral 
load, and hence a reduced probability of a mutation being produced by chance by the 
virus. Weak selective pressures will also have a reduced probably of a mutation being 
selected. The midpoint of the curve represents the optimal conditions for a mutation 
                                                 
xxxv We observed that all individuals except one with the HLA-B*5101 allele (39 out of 40) had a 
polymorphism at position 135 of HIV-1 RT in their first sequence. Position 135 is at an anchor residue of 
an HLA-B*5101 restricted CTL epitope. The individual without a polymorphism at this position was 
treated with antiretroviral therapy in primary infection. These observations are highly suggestive that this 
epitope is recognised in primary infection during which time individuals with HLA-B*5101 make a 
strong response toward it. 
Total selective pressure (~inverse of viral load)
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Figure 2.28. Schematic representation of the theoretical chance of 
a single induced mutation. 
The height of the curve depends on the gain in viral fitness after a 
mutation. Pressure could be due to immune responses or 
antiretroviral therapy. Host-viral interactions     
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being selected – where the total pressure and viral load are moderate. The height of the 
curve will depend on the increase in viral fitness after a mutation. A mutation that does 
not increase or reduces the viral fitness will have a theoretical probably of zero. A 
mutation that results in a large increase in the viral fitness will have a greater probably 
of occurring than a mutation that increases the viral fitness less. The change in viral 
fitness will depend on the genetic barrier to change and the strength of the pressures (for 
example, other concurrent and new CTL responses) after mutation. The total chance of 
a mutation that increases viral fitness appearing over all selective pressures is the 
probabilistic sum of the curves for each amino acid polymorphism. This will be lower 
for a greater number of pressures with similar magnitudes, and higher for a single 
pressure.  
TCR adaptation 
Mutations within epitopes at residues that interact with the TCR may result in: 1) a 
(possibly weaker) response by the same TCR; 2) a new (possibly weaker) TCR 
response; 3) failure to generate a new TCR response; or 4) an antagonistic response by 
the current or new TCR.
714 Variants that lead to a new TCR response have a temporary 
amplification, followed by an expansion of the variant-specific TCR that reduces the 
variant. In most cases the variant is eliminated or reduced to a level of latency.
283,703 
Slow progressors appear to be more capable of adapting to viral variation and have 
more diversified HIV-1 variants.
585,715 This suggests that slow progressors are able to 
recognise several mutations affecting the TCR with similar affinities and therefore there 
is a low probability of becoming fixed to just one variant. 
Most TCRs specific for an epitope can tolerate a single or double amino acid 
substitution without effecting recognition (heterologous TCRs).
400,716,717 Multiple TCRs Chapter 2 Literature review  78 
directed against the same epitope offer an increased ability to tolerate amino acid 
substitutions.
718 Often, however, mutations at residues that interact with the TCR result 
in a new TCR specific for the variant,
46,287,583 and in some cases there is a failure to 
recognise the variant.
714 Alternately, mutation may result in the next epitope in the 
hierarchy being recognised.
50 
Limitations with current methods of measuring escape 
Current methods and techniques to measure CTL escape mutations are likely to 
underestimate the actual amount of escape
565,571;xxxvi because 1) in most cases, the 
infecting strain or strains are unknown; 2) there is often a lack of longitudinal data; 3) 
the use of antiretroviral drugs can independently influence viral sequence; 4) 
appropriate control subjects can be difficult to define as HLA-mismatched individuals 
may have epitopes within or near the epitope being studied; 5) mutations outside the 
epitope being studied may affect presentation due to amino acid motif preferences for 
proteasomes and transporters in the class I pathway;
5;xxxvii 6) results from in vitro studies 
do not always translate in vivo as these methods use assays that use synthetic peptides 
and do not detect the effect of intracellular processing (this is especially important when 
choosing candidate peptides to include in immunisations
571,719);
20,124,571,689 and 7) escape 
may not occur to fixation. These problems are usually difficult to overcome in a human 
model because of uncertainty about the infecting strain and lack of assessment from the 
time of infection. Furthermore, animal models suffer from the problem that they are not 
directly applicable in the human context – especially as primates and humans do not 
have a single HLA class Ia allele in common. Hence, other approaches are needed. 
                                                 
xxxvi See Chapter 6 for arguments that address these issues in our method for identifying putative CTL 
escape mutations. 
xxxvii We tested for the effect of proteasomes (see Chapter 9). Furthermore, our method for detecting 
putative escape mutation did not limit to residues within epitopes. Host-viral interactions     
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Effect of antiretroviral therapy 
Current antiretroviral therapy can reduce the chance of CTL and T-helper cell escape 
mutants appearing by 1) reducing the rate and amount of mutation by reducing the viral 
load; 2) reducing the mutational space of the virus; 3) reducing HIV-1-specific CTL 
responses by reducing the viral load;
720 and 4) preserving HIV-1-specific T-helper cells 
by reducing their clonal deletion in acute infection.
427 Other therapies, such as 
therapeutic vaccination to boost T-helper cell
213,426 and CTL responses,
319,350 have been 
proposed as possible ways to prevent escape.
571  
Similar to CTL escape mutations, HIV-1 mutations conferring resistance to drugs can 
be selected. These appear to develop more rapidly than CTL escape mutations.
565 This 
may be because the CTL can often eliminate viral mutations before they become 
dominant through a promiscuous TCR, adaptation of a new CTL response to the 
variant, killing of the variant by recognition at other epitopes and killing through 
soluble factors. 
Antiretroviral therapy 
Antiretroviral therapy has dramatically decreased the morbidity and mortality caused by 
HIV-1.
721,722 Its main and direct benefit is due to a decreased viral load.
445,723 
Drug mechanism 
The two HIV-1 proteins currently targeted by licensed antiretroviral drugs are RT and 
protease. Nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse 
transcriptase inhibitors (NtRTIs) and non-nucleoside reverse transcriptase inhibitors Chapter 2 Literature review  80 
(NNRTIs) inhibit replication by interfering with the RT protein. Protease inhibitors 
(PIs) interfere with the protease protein. 
Reverse transcriptase inhibitors  
RT inhibitors inhibit HIV-1 replication in newly infected cells before HIV-1 genome 
integration in the host. They do not inhibit replication of HIV-1 in cells that are already 
infected.  
Nucleoside reverse transcriptase inhibitors 
NRTIs, also called nucleoside analogues, mimic nucleosides. The currently licensed 
NRTIs in Australia are zidovudine, didanosine, zalcitabine, stavudine, lamivudine and 
abacavir.  
They work by inhibiting replication by competing with natural deoxynucleoside 
triphosphates for binding to RT and by competing with deoxynucleoside triphosphates 
for incorporation into newly synthesised viral DNA chains. Because NRTIs lack a 3' 
hydroxyl their binding results in HIV-1 DNA chain termination.
724 Different NRTIs are 
phosphorylated to differing extents in activated and resting CD4+ cells and hence may 
have different effectiveness in different cell types.
115 
Nucleotide reverse transcriptase inhibitors 
Nucleotide Reverse Transcriptase Inhibitors (NtRTIs) work in the same way as NRTIs 
but are already mono-phosphorylated and require fewer metabolic steps to achieve their 
active form. As a consequence they are active in more cell types than NRTIs, including 
resting lymphocytes and macrophages. NtRTIs are also known as nucleotide analogues. 
Only one drug in this group, tenofovir, is currently licensed. Antiretroviral therapy     
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Non-nucleoside reverse transcriptase inhibitors 
NNRTIs bind to a pocket between the β-sheet and palm at the base of the thumb 
subdomains of the p66 subunit of RT.
725 They appear to work either by reducing 
movement of the thumb relative to the palm or by affecting the conformation of the 
catalytic site.
131 This inhibits the reverse transcriptase polymerisation.
726 NNRTIs do 
not require intracellular metabolism. The currently licensed NNRTIs are nevirapine, 
delavirdine and efavirenz. 
Protease inhibitors 
PIs block the cleavage mechanism of the protease protein. The protease is involved in 
the post-translational processing of the gag-pol protein. It cleaves the gag-pol protein 
into its functional parts – six structural proteins (p17, p24, p2, p7, p1 and p6) and three 
other proteins (protease, reverse transcriptase and integrase). This occurs in the late 
stage of viral replication. Hence PIs inhibit or prevent HIV-1 replication in newly as 
well as chronically infected cells. 
PIs are metabolised by the hepatic cytochrome P450 3A4 enzyme system. The PI, 
saquinavir, is extensively metabolised by this system and as a consequence only four 
percent of the oral dose is actively available against HIV-1. Another PI, ritonavir, 
blocks this pathway and has much higher concentrations of drug available. Ritonavir 
can be used with other PIs to reduce the amount of cytochrome P450 metabolised and 
increase the amount of drug available. Four other PIs are licensed; these are indinavir, 
nelfinavir, amprenavir and lopinavir. Chapter 2 Literature review  82 
Effect on HIV-1 
Prior drug exposure (especially to the same class of drug), cross-resistance, 
pharmacokinetics and adherence all influence response to therapy.  
Viral load 
Protease inhibitor monotherapy can cause a greater than two log (100 fold) reduction in 
plasma viral load.
727,728 NRTI monotherapy can cause a one log (10 fold) decrease in 
viral load that is sustained for about six months to one year.  
Antiretroviral therapy reduces the viral load by reducing the production of new viable 
virions. The effect on viral load can be seen in three stages. The first stage reduces the 
number of newly infected active T-lymphocytes and macrophages/monocytes. These 
cells have a half-life of about 3.3 days,
81,729 and the viral load is reduced at a rate of 21 
to 54 percent per day. The second stage involves the death of infected cells that have a 
longer half-life. These include resting T-lymphocytes and macrophages/monocytes.
82 
The final stage comes from the death of infected CD4+ cells that are longer lived (for 
example, memory T-cells, which have a half-life of around seven months).
82,89,730 
Individuals on potent antiretroviral therapy with undetectable viral loads for up to 2.5 
years can still produce viable virus from latently infected cells.
89,730,731 However, the 
evolution of strains in individuals with undetectable viral loads is very small, suggesting 
that there are very few cells producing viable virus and very few newly infected cells.
595 
Drug resistance mutations and drug failure 
A number of reports have documented drug resistant infecting strains.
732-744 However 
the number of strains is much lower than would be expected by simple transmission of Antiretroviral therapy     
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the infecting person’s dominant strain.
xxxviii This may be because the strain established 
in the new individual is the strain that is fittest in the new host in the absence of immune 
and drug pressures.
48,141,165,601,690,745-749 In Western countries, the prevalence of one or 
more mutations known to confer drug resistance is between three and 12 percent in 
newly infected cases
750,751 for RT and four percent for protease.
750 
About 20 to 55 percent of individuals that start taking highly active antiretroviral 
therapy fail due to adverse side effects, toxicities or the development of drug-resistant 
virus. Resistance may occur because of insufficient control of viral replication as a 
result of ineffective drug concentrations due to interactions with other drugs,
752 
impaired drug absorption and lack of compliance.
752-760 In the majority of patients 
complete viral suppression is not achieved
761-763 and drug-resistant mutations and 
subsequent drug failure is inevitable
752,764 and can occur within 14 to 28 days.
729,764 
Subsequent regimens containing drugs within the same class have higher failure rates 
because many mutations that confer resistance to one drug also confer resistance to 
other drugs within the same class.
755,765-771 The longer an individual remains on a 
regimen that does not suppress the virus, the greater the chance of cross-resistance.
772 
However, the majority of individuals who fail on a protease inhibitor still have virus 
that is susceptible to at least one other licensed PI.
759 
Most primary drug resistance mutations occur at the drug binding site and only a single 
mutation is required to greatly reduce susceptibility to most drugs.
773-777 Most mutations 
in RT conferring resistance to NRTIs alter the protein’s structure so that it takes up the 
natural deoxynucleoside triphosphates in preference to triphosphorylated NRTIs. 
                                                 
xxxviii We observed no individual with the M184V drug resistance mutation prior to treatment (see Figure 
5.2) even though this mutation has a polymorphism frequency of 10 percent in viruses that individuals are 
likely to be exposed to (see Figure 6.3). 
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Secondary mutations, are often distant from the binding site, and work by creating 
conformational changes that either affect binding further or improve the viral 
fitness.
161,778-781 These secondary mutations often confer cross-resistance to other drugs 
within the same class. Some sets of mutations confer resistance to all drugs within the 
same class.
154,782-784 Multiple mutations can occur through either multiple single 
nucleotide mutations or recombination. Recombination in retroviruses was once thought 
to be rare but now appears common.
109 The primary and subsequent drug mutations 
conferring resistance are well characterised, but can usually take one of a few stochastic 
routes.
752 This is affected by use of other drugs
785 and prior drug induced 
mutations.
759,786-788 
Most primary resistance mutations to NRTIs
789 and PIs
790 decrease the fitness 
(replicating ability) of the virus (when measured without drug pressure). However, the 
virus can (through compensatory mutations to restore its structure, function
778 and 
increase its polymerase fidelity
449,450,791,792) evolve in the presence of drugs to a fitness 
similar to the original wild-type virus.
778 However, it may be possible to confine the 
virus to a limited sequence space and reduce the fitness to which the virus can evolve.
778 
This has some merit given that both RT and protease are relatively conserved proteins, 
and protease is only 99 amino acids long.
793 However, both proteins appear to be able to 
tolerate a high degree of polymorphism, with protease being able to mutate 20 percent 
of its amino acids in response to the currently available protease inhibitors.
794,795 Other 
inhibitors may see the emergence of other characteristic and novel mutations. 
Drug resistance mutations can revert after removing the drug.
591-594 However, they often 
reappear quickly (by the selection of a minor, archived variant) on recommencement of 
the same drug, or another drug for which the mutation confers resistance.
137 Drug 
resistant mutations can also be transmitted, either as the major or minor strain. These Antiretroviral therapy     
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drug-resistant strains may be replaced by wild-type virus during acute infection, but are 
increasingly being seen to reappear after seroconversion. 
Some drug-induced mutations can resensitise the virus to a drug that was previously 
resistant.
162 Some NNRTI resistance mutations can partially resensitise the virus to 
NRTIs.
154 Likewise, the lamivudine, didanosine, zalcitabine and abacavir induced 
resistance mutation M184V,
594,789,796-798  didanosine resistance mutation L74V,
799,800 
and nevirapine and delavirdine resistance mutation Y181C
801 can reverse the effect 
conferred by the zidovudine mutation T215Y. The M184V mutation can also resensitise 
strains with the zidovudine resistance mutations D67N and K219Q/E,
796 and increase 
the susceptibility to adefovir
802,802 and tenofovir.
752 Possibly through similar 
mechanisms, zidovudine has been shown to suppress the development of the M184V 
resistance mutation to lamivudine.
803  
For reviews on HIV-1 drug resistance mutations see references 804, 805, 806 and 807. 
Effect on the immune control of HIV-1 
The effect of antiretroviral therapy on the immune system depends on the stage of 
infection.
720 Effective antiroviral therapy in primary infection is correlated with 
preservation of lymphoid architecture
568 and normalisation of the CD4:CD8 ratio,
568,808 
but this is not so in individuals treated later in infection.
809 The class of antiretroviral 
drugs directed towards the HIV-protease protein may potentially have a side-effect of 
interfering with human proteasome. This has been shown in LCMV in mice treated with 
the antiretroviral protease drug ritonavir.
810 
Antiretroviral therapy lowers the amount of virus and thereby results in a partial 
reconstitution of immune system.
809,811-817 However, it is unlikely that a damaged 
immune system can be fully reconstituted on antiretroviral therapy as the immune Chapter 2 Literature review  86 
system regeneration after chemotherapy is very slow.
818 The reduction of HIV-1 antigen 
also reduces the amount of HIV-1-specific antibodies,
727 CTL and T-helper cells, but 
could be beneficial by reducing the appearance of escape mutants to CTL, T-helper cell 
and antibody epitopes.
448;xxxix 
CD8+ cytotoxic T-lymphocytes 
After effective antiretroviral therapy that reduces the amount of virus to undetectable 
levels, there are fluctuations in the HIV-1-specific CTL response that lasts for about as 
long as the first stage of viral load decay – one to two weeks.
819 This is followed by an 
exponential reduction in HIV-1-specific CTLs.
428,531,568,720,819 The half-life for CTLs to 
become undetectable in these individuals is 45 days.
819 The reduction in HIV-1-specific 
CD4+ T-cells also contributes to the decreased HIV-1-specific CD8+ T-cell levels.
428 
For individuals with viral loads below a level sufficient to sustain immunologic 
stimulation at a maximum level, there is an inverse correlation between the level of 
eCTLs and viral load.
531 This inverse correlation is also seen in chronic infection even 
though lower virus levels are helping restore the effectiveness of the damaged immune 
system.
809,819-824 
Treating individuals with antiretroviral therapy during acute infection can prevent the 
onset of chronic immune activation, exhaustion of CTL clones and CTL 
escape.
448,567,825,826 Individuals treated during acute infection show enhancement and 
                                                 
xxxix This thesis provides some support that preservation of CTL epitopes, by reducing CTL escape 
improves disease outcome. We show that CTL escape mutations accumulate over time (see Chapter 15) 
and are associated with increased viral loads (see Chapter 16) in chronic infection, suggesting that 
delaying their emergence may be result in slower disease progression. Furthermore, the one patient in our 
study group with HLA-B*5101 who was treated with antiretroviral treatment during primary infection, 
was the only patient who did not have a characteristic CTL escape mutation to an HLA-B*5101 restricted 
CTL epitope (see Chapter 14). This patient is still on treatment and currently has an undetectable viral 
load, but may be offered some protection by recognising this epitope if his HIV-1 antigen level rises. If 
this happens, there is a reduced chance that an escape mutation will appear for this epitope because it is 
unlikely that the level of viral load seen in natural HIV-1 primary infection will be reached. Antiretroviral therapy     
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preservation of HIV-1-specific CTL cell responses,
638 even after ceasing 
treatment.
638,827  
CD4+ T-helper cells 
Activated CD4+ T-helper cells, in particular HIV-1-specific CD4+ T-helper cells, are 
preferentially infected by HIV-1 and are subsequently eliminated by apoptosis or CTLs 
in the early stages of infection.
828-831 This leads to irreversible deletion of HIV-1-
specific CD4+ T-helper cells, which cannot be restored by antiretroviral therapy, even 
six months after seroconversion
426,638 or during chronic infection.
809,818,832,833 Hence, 
individuals treated with antiretroviral therapy during acute infection, even transiently, 
have improved disease outcome and characteristics similar to long-term non-
progressors.
344,426,429,827,834 This appears to be largely due to the preservation of HIV-1-
specific CD4+ T-helper cells.
426,427,638,835,836 
Individuals treated with potent antiretroviral therapy after the acute stage of infection 
have an increase in their naïve and memory CD4+ T-helper cells.
809 These naïve and 
memory cells increase in the same proportions except when there are no naïve CD4 
cells prior to treatment, in which case the naïve cells remain absent.
818 However, these 
increases do not result in strong or persistent HIV-1-specific CD4+ T-helper cell 
responses,
809,818,832,833 and wane with continued viral suppression.
428 
Drug induced resistance mutations 
HIV drug resistance mutations have the potential to influence CTL responses,
126 
especially since RT is an important target for CTL throughout infection.
7,126,837 
However, only two epitopes have been described that are influenced by antiretroviral 
drug induced mutations.
837,838 Both were described in the same region of HIV-1 RT that Chapter 2 Literature review  88 
includes the residues 181 (which is known to induce a mutation from a tyrosine to a 
cysteine or isoleucine under the pressure of the drugs nevirapine or delavirdine) and 184 
(which is known to mutate from a methionine to a valine or isoleucine under the 
pressure of the drugs lamivudine, didanosine, zalcitabine or abacavir). The first report 
was in a single individual whose CTL recognised the wild-type epitope but did not 
recognise the drug resistant sequence.
837 The second study involved 28 LTNPs, and 
showed one individual who could recognise the drug resistant epitope (described in the 
previous study) but could not recognise the wild-type sequence.
838 This study confirmed 
the finding of the first, and also showed decreased CTL recognition in the 181 mutant 
sequences. No other studies have examined the loss or gain of epitope recognition 
(including T-help epitope recognition) due to drug induced polymorphisms or 
mutations, and even the two described were in single individuals, with no beneficial 
consequence described. However, as synergies exist between drugs through induced 
mutations, other interactions between CTL and drugs are likely to exist. 
Future treatments 
Strategies using currently available anti-HIV drugs include: concurrent use of inhibitors 
of different proteins;
839-842 concurrent use of inhibitors of the same protein and saving 
other inhibitors for salvage therapy;
807 using drugs with increasing potency if initial 
therapy fails;
807 using potent drugs to reduce the chance of resistance mutations;
807 
giving patients structured treatment interruptions to reduce the chance of drug resistance 
and side-effects and to boost the immune system (reviewed in reference 843);
844-858 and 
using combinations of drugs that exploit HIV’s functional and structural limitations, or 
increase HIV’s fidelity.
107,859 
Future treatments appear to represent a combination of control by enhancing the body’s 
own immune system and antiretroviral treatments. Immunologic control by itself may Antiretroviral therapy     
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not be optimal because the central nervous system and genital secretions are 
immunologically privileged sites.
568 Furthermore, given that on present estimates it 
would take at least several decades to eradicate HIV-1 from an individual using existing 
antiretroviral drugs and the severe long term and unknown toxicities of these drugs,
724 
future management of HIV-1 may involve treatment suppression of HIV-1 using 
antiretroviral drugs, followed by immunisation against HIV-1 to kill any virus produced 
from cells that come out of latency after antiretroviral therapy is ceased.
402,568,730  
Research into an HIV-1 vaccine started in 1986, and has proved more difficult than first 
thought.
860 Traditional vaccines have relied on a good antibody response to provide 
protection to pathogens. However due to the concealed conserved envelope structures of 
HIV-1, with variable loops and non-antigenic carbohydrates covering them, antibody 
induced vaccination has not proven to be successful. Several observations have now 
focused the vaccine effort on inducing strong CTL and T-helper responses: 1) the 
presence of HIV-1-specific CTL and T-help response in exposed, but seronegative 
individuals; 2) the large CTL response seen in seroconversion and its correlation with 
viral load and progression; 3) the presence of a strong HIV-1-specific T-helper response 
in LTNPs, and their importance in maintaining a functional CTL response;
587,861 4) the 
presence of CTLs at the site of challenge;
862 and 5) the fact that live-attenuated virus 
vaccines have been the best traditionally at offering protection. Current strategies to 
induce these responses include DNA vaccines, optimised codons (to the human) and 
large segments of HIV-1 proteins that integrate into the host genome, and produce 
proteins that are presented and induce a CTL and T-helper response. Current studies in 
primates show vaccines of this type are unable to prevent infection, but are able to 
reduce the viral load set-point by 1,000 to 10,000 fold – effectively rendering the 
subjects into LTNPs.
503-507 These studies, and observations from a well studied cohort Chapter 2 Literature review  90 
of highly exposed, seronegative Nairobi sex-workers,
310 where some women who 
stopped working became infected with HIV-1, suggest that CTL responses have to 
remain active to prevent infection.
296 Vaccines may also have to consider the 
phenomenon of immunodominance. One idea to overcome this problem is to make 
several small vaccines to induce the immune system into making many responses.
296 
Recently, it has been recognised that optimal vaccines need to consider the diversity of 
HIV-1 in the population to be immunised.
21;xl 
Knowledge of molecular interactions of gene products and host cell factors will inform 
the development of new drugs. Soluble CD4, CD4 immunoadhesions
863 and a peptide 
from HIV-1 gp41
864 have been used to bind with the CD4 and block the viral envelope-
CD4 fusion. Similarly, antigens that bind the coreceptors used by HIV-1 (for example, 
CCR5 and CXCR4) are also being studied.
479 Methods for boosting the immune 
response (CD8+ CTL, CD4+ T-help and antibody) through vaccination and cytokines 
have already been studied with some success.
229,865-867 Vaccines targeting proteins that 
are expressed in latently infected cells may exist as in EBVP
669 and may be able to kill 
these cells by CTL before they come out of latency. Vaccines could also target proteins 
expressed early in the HIV-1 lifecycle
64,69 to kill infected cells when they come out of 
latency but before they produce progeny. Inhibitors of other viral proteins, such as 
integrase and new NRTIs, NtRTIs, NNRTIs and PIs that are effective against those 
strains of HIV-1 that are resistant to the first generation drugs and require multiple 
mutations to have significant resistance are in development and in trials.
868-871 
Knowledge of HIV-1’s proteins’ structures are being used to assist in making new 
inhibitors.
131 Knowledge of CTL and drug induced mutation could also be used to 
                                                 
xl Our results support the need to consider both HLA and viral diversity in designing a population 
vaccine. Furthermore, our method indicates where the most dominant CTL responses are in a population 
(see Chapter 6). 
 Antiretroviral therapy     
 
 
91
reduce the chance of the virus evading the immune system through drug-resistant 
mutation and CTL escape. It may also be possible to prevent the tropism switch from 
NSI to SI strains. 
Other therapeutic possibilities include; increasing the polymerase fidelity of the virus to 
decrease the chance of drug-resistant mutations;
107 targeting the proteins that 
downregulate the class I pathway to make infected cells visible to immune surveillance 
prior to release of viral progeny; and boosting the T-helper response.  
Eradication 
The clearance of established HIV-1 infection in children born to HIV-1 infected 
mothers has been described,
412,872 but is debatable. Most HIV-1 infected individuals, 
however, fail to clear the virus.
411 Current antiretroviral therapies can completely 
suppress viral replication in blood, tissue, genital secretions, and germinal centres.
568 
However, even individuals that have undetectable levels of virus for several years can 
still produce viable virus from latently infected CD4+ cells.
89,568,730,731 This virus 
appears to come from the long lived CD4+ memory T-cells.
85,568 These cells have the 
HIV-1 genome integrated into the cell’s DNA, and hence may not be immunologically 
detectable until activated.  
An estimate of the time to eradication of HIV-1 by completely suppressing HIV-1 viral 
replication through antiretroviral therapy can be calculated from the half-life of these 
CD4+ memory T-cells. These cells have a half-life of around seven months, hence 
requiring decades of complete and sustained viral suppression to eradicate HIV-1.
595 
For this reason many people believe antiretroviral therapy may never be able to 
completely eradicate HIV-1. However, further research into the proteins involved in Chapter 2 Literature review  92 
latency and expression, may help devise treatments that can bring infected cells out of 
latency and make them susceptible to the immune system or antiretroviral treatments. 
Evolution 
Human evolution to pathogens 
The HLA complex has many similar genes each with multiple alleles.
873,874 Selection 
for class I molecules is believed to be due to the interaction of the immune system and 
endogenous or intracellular pathogens.
27-40 While this selection of HLA molecules can 
be short lived and episodic (for example, the bubonic plague), its effect on the HLA 
allele frequencies can be seen over much longer time periods.
40 The HLA-B53 allele 
may have been selected in the West African population for its protective effect against 
severe malaria. The allele frequency of HLA-B53 in West Africa is 25 percent 
compared to one percent in Europe.
307,308 This episodic disease-induced evolution is 
considered one of the reasons that linkage between genes in the HLA exists, and 
represents human adaptation at a population level.
307,874 At the individual level, the host 
uses the large diversity and short time cycle of TCRs and antibodies to recognise and 
adapt to new and evolving pathogens.  
One could postulate that without the use of preventive strategies to control HIV-1 
disease, the frequency of alleles that provide protection (for example, CCR5 ∆32) and 
slow progression (for example, HLA-B27 and HLA-B57) would become more 
prevalent in the human population. The high frequency of the protective genotypes 
CCR5, CCR2 and SDF1 in the Caucasian (39.1 percent) and African-American (31.5 
percent) populations would suggest that these have been selected for by past pathogens 
that used chemokine receptors in their pathogenesis.
99,386 It is interesting to note this Evolution 
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high polymorphism and the fact that CD8+ cells release HIV-1-inhibiting chemokines, 
as HIV is the only known virus in humans to use chemokine receptors for cell entry.
164  
HIV-1 evolution to the human host 
There are two major subtypes of HIV – HIV-1 and HIV-2. These major subtypes vary 
by about 50 percent at the nucleotide level,
109 with HIV-1 being more common 
worldwide. HIV-2 is primarily found in West Africa,
875 is more closely related to SIV 
in rhesus macaques and sooty mangabeys than HIV-1 is, and may have been widespread 
there since the 1960s.
469 Variants within HIV-2 have been grouped into five subtypes 
(A through E).
469 Similarly, HIV-1 variants have been classified into three major 
subtypes – M (majority or main), O (outlier) and N (non-M and non-O). They are 
grouped because of sequence differences and each is believed to be derived from 
separate cross-species infections from SIV in chimpanzees.
876 The most widespread 
major subtype of HIV-1 is M, and accounts for 99 percent of HIV-1 infections.
877 
Within the M subtype, 11 subtypes have been classified (named A through K).
878 These 
subtypes are believed to have evolved from a single transmission from primates to 
humans around 1930
879 and have since evolved in humans such that their sequences 
differ by about 25 to 30 percent at the nucleotide level and seven to 15 percent at the 
amino acid level.
553  
Recombinant forms of various HIV-1 subtypes have been reported (called circulating 
recombinant forms [CRFs]), and are believed to be the result of infection by more than 
one subtype.
469,475,875,880 Recombination was once thought to be rare because infection 
by one retrovirus often prevents infection by another due to the downregulation of the 
viral receptor and virus-specific activated immune system.
109 However, in cohorts with Chapter 2 Literature review  94 
multiple clades, up to one fifth of individuals have HIV-CRFs
881 – particularly clades A 
and G in western and central Africa.
881  
The distribution of HIV-1 subtypes through the world is consistent with the hypothesis 
that the regional epidemics started with one or a few variants that diversified locally.
26 
Subtype B is found in most Caucasoid countries, such as Australia, Europe, and North 
and South America. Most subtypes are found in Africa. Subtypes A and D are most 
common in eastern Africa, and C is the most common clade in southern Africa. In 
Southeast Asia, subtype E is common
882-885 (see Figure 2.29). The amount of 
polymorphism due to selection and stochastic processes is controversial.
109,886 
It is likely that pathogens evolve at a population and individual level. Major pathogens 
often have host-specific genes that interfere with the host’s ability to eradicate it and 
                                                 
xli From: JAMA 196 265(3):210-6. 
xlii In Chapter 4 we observe that clade B is the prevalent clade in our study group, which is taken from the 
Western Australia HIV Cohort Study, which captures all HIV-1 cases in the state of Western Australia. 
 
Figure 2.29. Distribution of HIV subtypes throughout the world. 
HIV-1 M subtypes A through I are represented as letters ‘A’ through ‘I’ (subtypes J and K are not 
shown); HIV-1 O is represented as ‘O’; and HIV-2 and its subtypes are represented as ‘HIV-2’. Most 
subtypes can be found in Africa, with subtype (or clade) B found mostly in Australia, Europe, Japan, and 
North and South America. Adapted from reference 875
xli with data from Western Australia added
xlii. Evolution 
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have the ability to mutate in response to specific selection. Many major pathogens have 
evolved to co-exist with their host and remain with the host for its lifetime
427,887 – 
increasing their population infectivity over the individual. This is seen in natural SIV 
infection, which does not cause observable disease. HIV and the human population, 
however, have not had enough evolutionary time to coexist as it has only recently 
become endemic.
319,469,879 The same is true for SIV in their unnatural hosts. Passage of 
SIV
888 and SHIV
889 in rhesus macaques sees a progressive increase in viral load. 
However, in SIV, hypermutation (see page 291) has been observed and correlated with 
reduced viral pathogenicity.
890 Hypermutation has also been observed in HIV-
1.
137,157,891-893 Hypermutation may exist because HIV-1’s high copy rate contributes to 
an imbalance in intracellular nucleosides and results in transcription errors.
157 Hence, 
hypermutation may be a regulatory type of mechanism in which a virus can reduce its 
pathogenicity by reducing its replication rate.  
Infection with drug-resistant strains of transmitted virus in countries where there is large 
usage of antiretroviral drugs has been described and is well understood.
751 Similarly, 
viral escape from HLA-restricted CTL epitopes that are restricted to common HLA 
class I alleles are advantageous and may be selected and accumulate at the population 
level, resulting in population induced evolution.
20,22-25,50,164,561 Selection for escaped 
HLA-restricted CTL epitopes has been seen in a mother to infant study and has 
implications for population escape.
894 In EBV, a polymorphism that abrogates binding 
of an HLA-A11 epitope has been seen at a population level in the local strain found in 
South East Asia where HLA-A11 is the most common HLA allele (allele frequency is 
greater than 50 percent). Furthermore, in half of the viral isolates from this region, 
escape is seen in a subdominant HLA-A11 epitope.
22-25,895 This may have resulted from 
the virus having a survival advantage in the host population.
24 In populations where Chapter 2 Literature review  96 
HLA-A11 is rare, the HLA-A11 epitope is conserved. This type of escape may have 
influenced and shaped the different clades of HIV-1. Durali et al
896 showed that for 
some epitopes, a stronger response was seen for different clades to that which was most 
prevalent in the population. Altfeld et al
897 showed that in six out of seven HLA-
A*0201 epitopes studied, individuals with an HLA-A2 subtype other than HLA-
A*0201 (the most common worldwide allele
898) had a higher binding affinity than those 
with HLA-A*0201. While far from conclusive, this gives some support to the idea that 
HIV has partially adapted at a population level to the most common HLA class I 
allele.
xliii
                                                 
xliii In this thesis we observed, with statistical significance, that the polymorphisms in HIV-1 RT are 
associated with HLA alleles and are less common with the more common alleles, suggesting that HIV-1 
has already partly adapted to the most common CTL responses in the population (see Chapter 13). 
Summary 
HIV-1 is a relatively new virus in humans. Its large diversity throughout the world and 
its highly pathogenic nature suggest that it has not had enough time to fully evolve with 
its host. Humans have a number of immune strategies to prevent infection and disease 
progression of novel pathogens. One of these is through recognition of cells infected 
with intracellular pathogens by the HLA class I pathway. Several HLA alleles have 
been associated with HIV-1 infection and progression. This provides good 
circumstantial evidence of a relationship between HIV-1 adaptations to the HLA 
immune responses.   
Chapter 3 Study group and general methods 
The Western Australian HIV Cohort Study (WAHIVCS) was established in 1983 as a 
prospective observational cohort study of HIV infected individuals and since then has 
captured data from all notified AIDS cases and 80% of all HIV-infected cases in the 
state of Western Australia.
9 The vast majority of individuals in the cohort reside in or 
near Perth, the capital of Western Australia, which is one of the most geographically 
isolated cities in the world. Routine laboratory test results (including HLA typing, HIV 
sequencing and viral load results) are automatically downloaded from the laboratory 
directly into the cohort database (see WA HIV Cohort Study database user manual, 
page 331 of Appendices).
11 
Individuals from the WAHIVCS who gave consent, had HIV-1 reverse transcriptase 
sequencing, and HLA-A and HLA-B typing by serology or sequencing performed prior 
to 11 October 2000, were included in the study reported in this thesis. There were 473 
individuals in this group. The demographics of these individuals are shown in Table 3.1. 
Of note, most individuals acquired their infection from sources within Western 
Australia (53.3%) or other states in Australia (24.3%), and less commonly from Asia 
(8.2%), Africa (5.1%), Europe (4.9%), North America (3.4%) and South America 
(0.8%).  
The HLA allele frequencies of the individuals in this cohort are shown in Table 3.2. For 
all analyses, except where otherwise specified, HLA alleles were grouped into their 
broadest serological specificity. This grouping, the molecular subtypes they encompass 
and the estimated frequencies of each subtype within each group are also shown in 
Table 3.2. The estimated frequencies were determined by counting the number of 
individuals in the Western Australian bone marrow registry database (WABMRDB) Chapter 3 Study group and general methods  98 
with each subtype. This database records the majority of HLA typing performed for 
transplantation screening in Western Australia and was assumed to represent a sample 
of individuals with a similar frequency of HLA to the individuals in our study group. 
The HLA typing from individuals in the WAHIVCS could not be used as too few had 
HLA-A and HLA-B typing performed by sequencing. Information on the estimated 
HLA-A and HLA-B subtype frequencies are used in Chapter 10 to determine the most 
likely motif an association with a broad HLA is representing; in Chapter 12 and Chapter 
13 to limit analyses to those with broad HLA groupings that are representative of a 
single subtype; and in Chapter 14 they are compared with molecular subtyping results 
from our study group. 
Table 3.1. Demographics for the cohort. 
*CD4 %, CD4 count and viral load measurements were taken closest to the most recent HIV-1 RT 
sequence and included individuals on antiretroviral treatment. 
!The percentages were calculated after 
removing the ‘Unknown’ and ‘Not done’ categories. 
@The HIV seroconversion date was calculated as the 
mid point between the last HIV seronegative date and the first HIV seropositive date, if the exact date 
was unknown. 
   Number Percentage
! Sum  Mean 
Standard 
deviation 
n  473        
CD4 %
*  469     19.0  11.3 
CD4 count (cells x10
6/mL)
 * 469      391.8  279.0 
Viral load (copies/mL)
 *          
 <400  137  31.9       
 400-10,000  84  19.5       
 10,000-75,000  96  22.3       
 >75,000  113  26.3       
 Not  done  43         
Sex          
 Male  422  89.2       
 Female  51  10.8       
Ethnic background           
 Caucasian  392  86.2       
 Oriental  25  5.5       
 Australian  aboriginal  21  4.6       
 African  12  2.6       
 Indian  5  1.1       
 Unknown  18         
Place of infection           
 Western  Australia  186  53.3       
  Rest of Australia   85  24.3       
 Asia  29  8.2       
 Africa  18  5.1       
 Europe  17  4.9       
 North  America  12  3.4       
 South  America  3  0.8       
 Unknown  23         
          Chapter 3 Study group and general methods 
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   Number Percentage
! Sum  Mean 
Standard 
deviation 
Risk transmission groups           
 Male-to-male  only  309  68.7       
 
Male-to-male and 
intravenous drug use  11  2.4       
 Female-to-female  1  0.2       
 Heterosexual  only  85  18.9       
 
Heterosexual and 
intravenous drug use  13 2.9       
  Intravenous drug use only  12  2.7       
 Maternal-to-infant  1  0.2       
 Blood  products  18  4.0       
 Unknown  23         
Years since HIV sero- 
conversion date (if known)
@          
 Total  years  205    1432  6.99  4.36 
 Number  of  patients:           
    0 to 1 years  17  8.3       
    1 to 5 years  57  27.8       
    5 to 10 years  85  41.5       
    Greater than 10 years  46  22.4       
  Unknown  268         
Years since first HIV 
seropositive date     
 
  
 Total  years  473    3062  6.47  4.54 
 Number  of  patients:           
    0 to 1 years  73  15.4       
    1 to 5 years  121  25.6       
    5 to 10 years  164  34.7       
    Greater than 10 years  115  24.3       
Years of follow-up           
 Total  years  473    2210  4.67  4.09 
 Number  of  patients:           
    0 to 1 years  130  27.5       
  1 to 5 years  139  29.4       
  5 to 10 years  147  31.1       
  Greater than 10 years  57  12.1       
Enrolment date           
  Prior to 1989  62  13.1       
  1989 to 1992  118  24.9       
  1993 to 1996  155  32.8       
  1997 to 2001  138  29.2       
 
 
Table 3.2. HLA allele frequencies in the cohort and the estimated frequency of each molecular subtype of 
each broad HLA group. 
For example, 228 (48.2%) individuals in the cohort of 473 had HLA-A2, and we would estimate that 88 
percent of these (i.e. 228 x 88% = 201 individuals) would have HLA-A*0201. These estimates were 
based on the frequency of alleles from individuals in the WABMRDB that were defined to 4 digits. N.A. 
means not applicable and occurred when no individual in the WABMRDB had an HLA molecular 
subtype that belonged to the broad HLA group. 
Broad 
HLA 
group 
Number 
with 
HLA 
allele 
Frequency 
(%) 
Molecular 
subtypes 
Estimated percentage 
of individuals in the 
broad group that have 
the molecular subtype 
A1 139  29.4  A*0101  100 
A2 228  48.2  A*0201  88 
    A*0202  8 
    A*0206  4 
A3 112  23.7  A*0301  100 Chapter 3 Study group and general methods  100 
Broad 
HLA 
group 
Number 
with 
HLA 
allele 
Frequency 
(%) 
Molecular 
subtypes 
Estimated percentage 
of individuals in the 
broad group that have 
the molecular subtype 
A9 98  20.7  A*2301  64 
    A*2403  12 
    A*2407  12 
    A*2410  12 
A10 49  10.4  A*2501  27 
    A*2601  32 
    A*3401  23 
    A*6601  14 
    A*6602  5 
A11 82  17.3  A*1101  100 
A19 92  19.5  A*2901  6 
    A*2902  24 
    A*3001  24 
    A*3002  6 
    A*3201  24 
    A*3301  6 
    A*3303  12 
A28 31  6.6  A*6801  60 
    A*6802  20 
    A*6901  20 
A31 2  0.4  A*3101  100 
A36 1  0.2    N.A. 
B5 52  11  B*5101  77 
    B*5102  1 
    B*5107  1 
    B*5108  1 
    B*5201  17 
    B*5301  4 
B7 125  26.4  B*0702  99 
    B*0703  1 
B8 111  23.5  B*0801  100 
B12 128  27.1  B*4402  56 
    B*4403  34 
    B*4404  1 
    B*4405  1 
    B*4501  8 
B13 27  5.7  B*1301  24 
    B*1302  76 
B14 42  8.9  B*1401  42 
    B*1402  58 
B15 62  13.1  B*1501  38 
    B*1502  8 
    B*1503  6 
    B*1505  1 
    B*1509  2 
    B*1510  4 
    B*1513  1 
    B*1514  1 
    B*1515  1 
    B*1516  3 
    B*1517  7 
    B*1518  14 
    B*1521  6 
    B*1524  1 
    B*1525  6 
    B*1529  2 
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Broad 
HLA 
group 
Number 
with 
HLA 
allele 
Frequency 
(%) 
Molecular 
subtypes 
Estimated percentage 
of individuals in the 
broad group that have 
the molecular subtype 
B16 36  7.6  B*3801  55 
    B*3802  6 
    B*3901  28 
    B*3905  4 
    B*3906  6 
    B*3909  2 
B17 46  9.7  B*5701  93 
    B*5703  5 
    B*5704  3 
B18 30  6.3  B*1801  97 
    B*1803  3 
B21 17  3.6  B*4901  38 
    B*5001  58 
    B*5002  4 
B22 22  4.2  B*5401  3 
    B*5501  45 
    B*5502  12 
    B*5601  24 
    B*5602  15 
B27 30  6.3  B*2702  70 
    B*2703  2 
    B*2704  1 
    B*2705  22 
    B*2706  2 
    B*2707  2 
    B*2708  1 
B35 57  12.1  B*3501  63 
    B*3502  9 
    B*3503  15 
    B*3505  10 
    B*3508  4 
B37 7  1.5  B*3701  96 
    B*3702  4 
B40 68  13.3  B*4001  58 
    B*4002  30 
    B*4006  11 
    B*4008  1 
B41 4  0.8  B*4101  71 
    B*4102  29 
B42 3  0.6  B*4201  100 
B46     B*4601  100 
B47     B*4701  100 
B48     B*4801  100 
B58 1  0.2  B*5801  86 
    B*5802  14 
B67 0  0  B*6701  100 
B78 0  0  B*7801  100 
B81 0  0  B*8101  100 
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Laboratory assay methods 
The following methods were carried out by the laboratory staff at the Department of 
Clinical Immunology and Biochemical Genetics as part of routine patient care. 
HIV sequencing 
HIV-1 DNA was extracted from buffy coats (QI-AMP viral load RNA mini spit kit; 
Qiagen, Hilden, Germany) and codons 20 to 227 of RT were amplified by polymerase 
chain reaction (PCR) (PCR kit; Life Technologies, Mulgrave, Victoria, Australia). A 
nested second round PCR reaction were done, and the PCR product was purified with 
Bresatec purification columns and sequenced in both forward and reverse directions 
with a model 373 ABI DNA Sequencer. Raw sequence data was manually edited using 
software packages Factura and MT Navigator (PE Biosystems, Foster City, CA, USA). 
HLA typing 
All HLA-A and HLA-B alleles were typed by microcytotoxicity assay using standard 
NIH techniques and in some cases by sequencing to resolve ambigious serological 
typing. In these cases, HLA was amplified using primers to the first intronic 
dimorphism. Products were sequenced by automated sequencing, manually checked and 
edited for incorrect base calls, and automatically assigned HLA specificities by 
comparison of the sequence to the IMGT/HLA sequence database.
899 
Viral loads 
The viral load assay used exclusively from December 1995 until November 1999 was 
the HIV Amplicor
TM (Roche, Branchburg, USA; limit of detection 400 to 750,000 
copies/mL). The Roche Amplicor HIV monitor Version 1.5, Ultrasensitive, limit of Laboratory assay methods 
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detection 50 to 75,000 copies/mL, became the routine assay used thereafter. Viral load 
assays were typically performed at least three monthly in all individuals that attended 
clinic. 
Database management and data analysis software 
The WAHIVCS database was developed as part of my Honours thesis,
11 and was 
modified substantially since to manage and present new information used in clinical 
care (for example, HIV RT and protease sequencing), and to allow easier entry and 
access of patient information (see WA HIV Cohort Study database user manual, page 
331 of Appendices). The Epipop computer program was also developed by myself to 
directly access patient information from the database and to facilitate the analyses in the 
following chapters (see EpiPop user manual, page 290 of Appendices).
10  
EpiPop performed customised logistic regression modelling of HLA and polymorphism, 
Fisher’s exact tests and graphs of the results. Other graphs were produced using 
Microsoft Excel (Microsoft Corporation, Bellevue, Washington, USA).
900 Excel was 
also used to perform sign tests and to calculate means, medians, standard deviations and 
inter-quartile ranges. Cox, Wilcoxon and linear regression models were performed using 
the SAS statistical package (SAS Institute, Cary, North Carolina, USA).
901   
Chapter 4 Determining the population consensus 
sequence 
Introduction 
After infection, HIV-1 replicates to very high levels in the absence of HIV-1-specific 
cellular and antibody selection pressures. During this time the fittest virus variant (in the 
absence of immune and antiretroviral drug pressures) is selected.
141,164,745,746 This often 
sees the loss of drug resistance mutations
12,141 and may see the loss of escape mutations 
from the previous host’s immune system.
12 This usually results in the dominance of a 
single variant or limited number of similar variants,
556,557,745,746,749 which are usually 
similar between individuals in vivo.
48,165,690,747,748 After cellular and antibody responses 
mature, virus variants may be selected that have mutations representing escape from 
these responses.
50 
This study uses a standard definition of a consensus sequence as the most common 
amino acid at each position after an alignment.
553,902 Using the earliest recorded pre-
treatment sequence from individuals to estimate this sequence reduces the effects of 
HLA-restricted CTL, drug and other induced mutations.
3 The consensus sequence 
determined in this chapter is used in subsequent analyses as a baseline from which to 
define differences in individuals’ sequences. 
Methods 
To determine the consensus HIV-1 sequence, the earliest pre-antiretroviral treatment 
sequence (where known) from all individuals in the cohort with HLA-A and HLA-B Chapter 4 Determining the population consensus sequence  106 
typing was used. The most common amino acid at each position from positions 20 to 
227 of HIV-1 RT was determined. This was also repeated for nucleotides, where the 
most common nucleotide was determined for each position. 
The numbering system for amino acid positions was taken from reference 903. In this 
system, sequences are aligned to the clade B reference sequence HXB2CG (GeneBank 
accession number K03455),
54 and the first amino acid of each protein is designated as 1, 
with the proceeding amino acids designated 2, 3, 4, et cetera. 
Results 
There were 185 individuals with HLA-A and HLA-B typing and a pre-antiretroviral 
treatment sequence. The nucleotide consensus sequence matched the clade B reference 
sequence HIV-1 HXB2CG
54 at all but four nucleotide positions – two synonymous 
[codon 40, nucleotide three, A (adenine) instead of G (guanine); and codon 204, 
nucleotide three, adenine instead of guanine] and two nonsynonymous [codon 122 
nucleotide one, adenine instead of guanine, resulting in an amino acid of K (lysine) 
instead of E (glutamate); and codon 214, nucleotide one, T (thymine) instead of C 
(cytosine), resulting in an amino acid of F (phenylalanine) instead of a L (leucine)] (see 
Figure 4.1). There were no insertions or deletions in any sequence in this region of RT 
for any individual. Results 
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Discussion 
The clade B reference sequence, HXB2CG, was the first complete genome sequence 
determined for HIV-1 in 1985.
54 Given the large diversity in HIV-1 variants seen within 
individuals and different populations,
553 it is interesting to note that our consensus 
sequence matched this reference sequence at all but two amino acids (99 percent). A 
similar observation is also seen in the absence of population adaptation to anti-HIV 
drugs that target HIV-1 RT, despite the high prevalence of mutations in individuals that 
confer resistance to these drugs. Hence, while the virus may be able to tolerate 
mutations, it prefers the wild-type virus and can quickly mutate to, or select, this virus 
on infecting a new individual, after which the virus evolves.
50 This may reflect HIV-1 
RT’s importance in replication, especially pre-seroconversion. Furthermore, the absence 
of insertions and deletions, which are common in other HIV-1 proteins,
904 also support 
HIV-1 RT’s importance in replication. Others have also noted that this gene is relatively 
conserved (that is, has little polymorphism) among HIV-1 isolates from different 
individuals.
52,127-129,905,906 Adaptation to HLA-restricted CTL immune responses may be 
more common in other, less conserved, genes. 
Although the number of nucleotide differences between the population consensus and 
HXB2CG is small, it is interesting to note that three of the four polymorphisms were 
from guanine to adenine, two of which occurred at a synonymous third base position. A 
high mutation rate of guanine to adenine in HIV-1 has been described in HIV-
1,
137,157,891,892 and has been termed G Æ A hypermutation. It is possible that the 
consensus sequence in our population is evolving at a nucleotide level to be adenine 
rich, where codons contain as many adenines as possible without changing the amino 
acid for which it encodes. Hypermutation is believed to exist because of HIV-1’s high Chapter 4 Determining the population consensus sequence  110 
copy rate, which is believed to contribute to an imbalance in intracellular nucleosides 
and results in transcription errors favouring guanine to adenine substitutions.
157 In SIV, 
hypermutation has been observed and correlated with less pathogenicity.
890 Therefore, 
hypermutation may be a regulatory type of mechanism in which a virus can reduce its 
pathogenicity by reducing its replication rate. 
The only nucleotide change that was not from a guanine to adenine was a 
polymorphism from a leucine (coded as CTT) to a phenylalanine (TTT) at amino acid 
position 214. A leucine to phenylalanine amion acid change cannot be achieved by a 
guanine to adenine nucleotide substitution.  
Chapter 5 Functional constraints of HIV-1 reverse 
transcriptase 
Introduction 
HIV-1 RT is relatively conserved compared to other HIV-1 proteins.
52,127-129,905,906 
Several studies have shown that the ability of RT to tolerate changes in amino acids 
varies at different positions. Most notably, the YMDD sequence (residues 183 to 186) 
of the catalytic site is very highly conserved in HIV-1 RT and other DNA/RNA RTs.
135 
Other highly conserved residues are 91 to 119 (within the palm subdomain), 151 to 157 
(also within the palm subdomain), and residues 120 to 150 (within the fingers 
subdomain; see Figure 2.12, page 20).
136 
Recognition by CTLs of epitopes that are highly conserved, presumably due to 
structural and functional constraints, is associated with slower disease 
progression.
12,13,50,344 In a longitudinal study of HIV-1 infected individuals with HLA-
B27 it was observed that CTLs from all individuals recognised a single 
immunodominant epitope at a highly conserved region of gag. Despite the essentially 
monospecific response seen to this epitope, escape was only observed in two out of the 
six individuals after greater than nine years of infection, and only occurred together 
with a compensatory mutation made outside of the epitope.
12,13 In studies of drug 
resistance, mutations are less likely to occur if the drug resistance escape mutations 
require a two nucleotide change to become resistant or if the viral load is suppressed. 
These studies have also shown that viruses with drug resistance mutations are often less 
fit in the absence of the drug, and often revert back to wild-type when drug exposure is 
stopped.
591-595  Chapter 5 Functional constraints of HIV-1 reverse transcriptase  112 
Mutagenesis analyses using induced and natural variants of HIV-1 RT have examined 
the effects of mutation on the HIV-1 RT structure, stability and viral replication 
ability.
136,151-154 The critical residues identified for DNA polymerisation are 110, 185 
and 186.
153 Residues 107, 198 and 191 are important for hydrogen bonding and protein 
stability;
152 residues 74, 110, 115, 116, 151, 184 and 185 help define the polymerisation 
complex;
154 residues 94, 96, 113, 114, 115, 116, 119, 151 appear to be important for 
RNase H activity;
136 and residues 443, 473 and 498 form the catalytic sites of RNase 
H.
126 The study by Wrobel et al
152 have assigned different residues as catalytic, 
stability, functional and external, in HIV-1 RT between positions 95 and 202. 
As conservation implies important function or little pressure to change,
907 we 
hypothesise that the residues defined as critically important by these studies have less 
polymorphism than other sites.  
Methods 
To remove the confounding selection pressures induced by antiretroviral treatment (for 
example, the M184V mutation that is induced by the antiretroviral drugs abacavir, 
didanosine, lamivudine and zalcitabine), only individuals with a pre-antiretroviral 
sequence were analysed. The frequency of polymorphism seen for each residue between 
20 and 227 in RT was determined by calculating the proportion of individuals that had 
an amino acid in their first pre-antiretroviral sequence that was different to the 
population consensus.  
Due to the non-normal distribution of the data, a Wilcoxon rank test was performed to 
compare the frequency of polymorphism seen at those 24 sites that have been defined as 
critically important for HIV-1 RT function (see those listed in the Introduction) with the 
remaining sites. We also performed a Wilcoxon rank test on the four residue categories Methods      
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defined by Wrobel et al
152  - catalytic, functional, stability and external - and 
polymorphism. 
Results 
There were 185 individuals with a pre-antiretroviral treatment sequence. The frequency 
of polymorphism pre-antiretroviral treatment was plotted against amino acid position 
for residues 20 to 227 (see Figure 5.2). The frequency of polymorphism varied between 
zero and 40 percent.  
No individual in our cohort had a 
polymorphism at residues 94, 96, 
116, 119, 184, 185, 191 and 198. 
Residues 107, 113, 114, 151 and 
186 had a polymorphism frequency 
of less than 0.5 percent. The 
remaining residues defined as 
critically important - 74, 110 and 
115 - had polymorphism 
frequencies less than 1.5 percent. 
These frequencies were 
significantly lower than the mean polymorphism frequency of 3.84 percent for other 
residues (P<0.0001, Wilcoxon).  
The frequencies of polymorphisms for catalytic, functional, stability, and catalytic 
residues are shown in Figure 5.1. The median polymorphism frequency for the three 
catalytic residues was 0.27 percent, for the 37 stability residues was 0.27 percent, for 
the 11 functional residues was 0.55 percent, and for the 10 external residues was 4.25 
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Figure 5.1. Polymorphism frequency of catalytic, 
functional, stability and external residues in HIV-1 RT. 
Note; data points, which represent individual residues, are 
scattered horizontally so the number of points can be 
visualised. 
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percent (P<0.0001, Wilcoxon). External residues had statistically more polymorphism 
than each of the catalytic, stability and functional residue groups (P=0.0278, <0.0001 
and 0.0048, respectively). There were no statistical differences between the catalytic, 
functional and stability groups. Results      
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Discussion 
HIV-1 RT sequence is relatively conserved among isolates,
52,127-129,905,906 however, in a 
stable, geographically isolated population of HIV-1 infected individuals, there is 
sequence diversity even in a segment of HIV-1 RT. These findings suggest that this 
diversity is the net result of at least two competing evolutionary pressures selecting for 
and against change at each amino acid. Foremost is the need to maintain functional and 
structural integrity of the virus. We observed in this study that residues critical to the 
function of the protein are less polymorphic than other residues. Others have also 
observed that external residues have the most polymorphism between viral 
isolates.
152,155,156 Within the bounds of this fundamental constraint, the presence or 
absence of selective pressure from the immune system (for example, CTL) is also likely 
to contribute to the amount of polymorphism seen – either directly at or flanking 
epitopes recognised by the immune system, or indirectly through compensatory 
changes. This may partly explain the large number of ‘natural’ polymorphisms seen in 
some HIV-1 proteins.
155,908-911  
It is interesting to note that it is uncommon to see a long continuous sequence of critical 
and non-polymorphic residues. It is tempting to speculate that this may be because 
evolution of the virus has been subjected to intense selective pressure from CTL 
responses, mediated by class I molecules which bind and present contiguous sequences 
of between eight and 12 amino acids.
40,249 The ability of the virus to tolerate a change of 
at least one amino acid within most stretches of eight to 12 amino acids may provide a 
mechanism to allow the virus to potentially escape recognition by CTL. Nonetheless, 
epitopes that fall within highly invariant stretches of amino acids have been described. 
Although, individuals with CTL that can make a strong response toward these 
conserved epitope(s) are relatively rare, and interestingly they have been shown to have Discussion      
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low viral loads and slow disease progression.
12,13,50,344 Our results support the notion 
that there is significantly less polymorphism at critically important residues, but only at 
eight of these was none detected.  
Chapter 6 Determining putative escape mutation sites 
in HIV-1 reverse transcriptase 
Introduction 
Mutations selected by CTLs that reduce the CTL responsiveness (CTL escape) have 
been difficult to demonstrate in individuals infected with HIV-1. There are several 
reasons for this:
565,571 1) In most cases one does not know the sequence of the infecting 
strain or strains; 2) there is often a lack of longitudinal data; 3) the use of antiretroviral 
drugs can independently influence viral sequence; 4) appropriate control subjects can be 
difficult to define as HLA-mismatched individuals may have epitopes within or near the 
epitope being studied, and hence may select for mutations within or near this epitope; 5) 
mutations outside the epitope being studied may affect presentation due to amino acid 
motif preferences for proteasomes and transporters in the class I pathway;
5 6) escape 
may not occur to fixation; and 7) results from in vitro studies do not always translate in 
vivo.
20,124,571,689 The traditional methods which attempt to take account of these 
problems are unlikely to be successful in a human model because of uncertainty about 
the infecting strain and lack of assessment from the time of infection. In rhesus 
macaques infected with a known SIV clone, escape from CTL has been “convincingly” 
shown.
2,571 It remains questionable, however, if results from animals can be translated 
to humans. No one study has been able to address all of the problems identified 
here.
2,571 These problems are discussed below.  
Unknown infecting strains. There is a bottleneck of strains that are capable of 
infection, after which HIV-1 replicates to high levels in the absence of CTL recognition. 
This sees the virus tends to revert back to the ‘wild-type’ virus.
48,141,165,601,690,745-749 This Chapter 6 Determining putative escape mutation sites in HIV-1 reverse 
transcriptase 
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virus is similar between individuals within the same population.
141 While the infecting 
virus may not be known, the population wild-type virus (as estimated by the consensus 
sequence) can arguably be used as a reference against which all sequences for all 
individuals can be compared. Any change in a viral residue from this baseline once 
following the HIV-1-specific CTL response may be associated with a particular HLA 
specificity.
50 Furthermore, adjusting for polymorphisms at other residues can partially 
compensate for any differences between the population’s wild-type and the virus that 
established infection in the individual. In other words, this adjustment minimises the 
founder effect of the infecting virus and increases the ability to detect host effects. 
Lack of longitudinal data. Once a CTL response against HIV-1 develops, it remains 
and exerts selective pressure on the virus throughout infection.
565 This can be seen not 
only in assays that measure CTL but also in mutations that appear within CTL epitopes. 
These have been documented in individuals early in infection,
47,48,524 during mid-
infection
13,46,583,585,586 and in late infection.
12,13,283,565,590 Unlike in antiretroviral therapy, 
however, where the virus is seen to revert back to wild-type when a drug is stopped,
591-
594 the persistence and broadening of CTL responses result in accumulation of HIV-1 
escape mutations. Even after the virus has escaped from one epitope and the dominant 
recognised epitopes change, the persistence of CTL clones means the immune system 
can still recognise and kill viruses that revert back to the wild-type (or previous) 
epitopes. Hence, sequences provide a partial record of past escape mutations.
565 
Therefore an HLA diverse cohort can be used to analyse putative CTL escape using 
consensus sequence as the baseline. 
Use of antiretroviral drugs. Mutations that are induced by antiretroviral drugs, to 
directly increase viral fitness in the presence of the drug or to compensate for other drug 
mutations, have been well described both in vivo and in vitro.
155,161,162,778,788,912 These Introduction      
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mutations are drug, position and amino acid specific, and often occur at residues that are 
conserved in untreated individuals. However, mutations at positions not affected by 
drugs can still be analysed without considering the individual’s drug history. With this 
in mind, analyses of mutations at positions that are affected by drugs can also be 
undertaken, and can allow the development of testable hypotheses about possible HLA-
drug interactions. One concern about studies on individuals on antiretroviral treatment 
is that the strength of the CTL response is known to reduce proportionally to the drop in 
viral load, and wane in the absence of an undetectable viral load and HIV-1 
antigen.
428,531,568,638,720,819-823,913,914 With this reduced CTL response it is possible that the 
virus may revert back to wild-type at escaped mutation sites. However, the ability of the 
virus to do this is greatly reduced in these individuals because of the suppressed viral 
replication. Therefore an individual’s sequence is still likely to contain a good record of 
most, if not all, previous escape mutations, even in individuals with currently low or no 
detectable CTL response due to low HIV-1 antigen levels. 
Need for control subjects. Analysing a large random sample of a population allows the 
effects of different strengths (including conflicting selective pressures at the same 
residues) to be elucidated. Also, multivariate analyses can overcome the problem of 
HLA haplotype linkage when enough individuals with broken haplotypes are included. 
Furthermore, modelling with polymorphisms at other positions adjusts for potential 
confounding by different clades, place of infection, et cetera. Hence control subjects 
with appropriately different HLA and similar demographics and infecting virus are not 
needed in population based multivariable modelling. 
CTL escape by mutations outside epitopes. Traditional methods of looking for CTL 
escape use assays that use synthetic peptides that usually match a consensus clade B 
sequence (for example, HIV-1 HXB2CG, LAI, SF2 and IIIB) and test for a CTL Chapter 6 Determining putative escape mutation sites in HIV-1 reverse 
transcriptase 
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response.
20,124,571,689 These methods do not detect any potential effects of intracellular 
processing. These effects can be substantial and have been acknowledged to be 
important in choosing candidate peptides to include in vaccines.
571,719 Analysis of all 
residues from sequences from a population of individuals provides the potential to 
detect any mutations selected through these by interference in the intracellular 
processing pathway, both within an epitope or flanking it. 
Escape not to fixation. Variation of an epitope that interacts with the TCRs on CTLs 
may allow a mutation that never grows to fixation but which can cause antagonism to 
interactions with the wild-type epitope.
701 TCRs on CTLs that contact HLA molecules 
containing wild-type peptides expressed on target cells may be inhibited by prior 
contact with other cells presenting HLA molecules containing the mutant peptide. The 
result is a mixed population of wild-type and variant viruses.
126 This type of escape is 
common in mid-infection.
565 Mixed populations can also be seen when the virus is in a 
transition between wild-type virus and mutant virus. Also, viral populations within an 
individual may be different in different cells or compartments depending on the strength 
of different host and drug effects. In these cases mutation may be appropriately defined 
as any degree of detectable mutation.  
Effects in vivo. In vitro methods to identify CTL escape may fail to detect escape from 
the infecting virus if the epitope examined is different to the reference strain used. Even 
autologous virus may have already escaped and may not be appropriate for in vitro use. 
This type of escape could be common, especially if the reference virus (similar to wild-
type virus or consensus sequence) is already adapted to common CTL responses or if 
individuals are infected with non clade B virus. Population analyses do not have this 
limitation as they allow for comparisons of individuals with or without the consensus 
residue. Use of statistical analyses on the viral sequence and host factors does not Introduction      
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require  in vitro experiments. However, attainment of statistical significance in 
population-based analyses does not imply fact, and significant associations may be 
found as a result of type I errors or potential surrogacy. Strict, appropriate modelling 
and biological verification may be necessary to confirm results. 
It is known from resistance mutations induced by antiretroviral therapy that 
compensatory mutations are sometimes seen and often follow the primary mutation that 
occurs at the drug binding site. These compensatory mutations improve the virus fitness 
or increase its fidelity in the presence of the primary mutation(s).
161,778-781 
Compensatory mutations have also been observed for CTL escape mutations. An escape 
mutation in an HIV-1 epitope in gag has been described that can only be tolerated by 
the virus after a compensatory mutation outside of that epitope.
12,13 These compensatory 
or secondary mutations can occasionally act as markers of escape from CTL and can 
result in erroneous interpretation of where the CTL epitope actually is. This was 
demonstrated in pilot analyses of polymorphism at amino acid positions 135 and 162 of 
HIV-1 RT in our cohort. Position 135 is within a known HLA-B5 restricted CTL 
epitope [RT(128-135 IIIB)
49,126,400,516,915,916] and position 162 is within two known 
HLA-B7 restricted CTL epitopes [RT(156-164 HXB2CG)
917 and RT(156-165 
SF2)
126,918]. Modelling each of these positions for polymorphism showed that both 
HLA-B5 and HLA-B7 were significantly associated with mutation. After adding 
compensatory polymorphisms as covariates to the models, the significant association 
with HLA-B7 at position 135 was replaced by association with polymorphism at 
position 162. Likewise, the same was seen for the model of polymorphism at 162 (see 
Table 6.1). These observations support analyses that allow compensatory 
polymorphisms to identify and adjust for this possible confounding effect. Further 
justification is that this approach would provide a conservative bias and it would allow 
for adjustment of potential confounding by the viral founder effect. For example, HLA Chapter 6 Determining putative escape mutation sites in HIV-1 reverse 
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alleles common in African people could act as surrogate markers for strains found in 
Africa. Modelling with other polymorphisms would allow such confounding biases to 
be identified and used as adjustments to minimise the effects. 
We hypothesise that, as CTL epitopes are HLA-restricted, CTL escape mutations 
selected within an individual host would be characteristic for specific HLA class I 
alleles across an HLA-diverse host population. 
Table 6.1. Multivariate analysis of positions 135 and 162 with and without adjustment for polymorphisms 
at other positions. 
Only the covariates for HLA-B5, HLA-B7, polymorphism at 162 and polymorphism at 135 are shown. 
NS = not significant (P > 0.05). 
 
   
No adjustment for 
polymorphisms at 
other positions   
Adjustment for other 
polymorphisms at 
other positions 
Modelling outcome  Covariates  OR  P-value   OR  P-value 
Polymorphism at 135           
  HLA-B5  10.4 <0.0001    12.0 <0.0001 
 HLA-B7  2.0  0.04      NS 
  Polymorphism at 162        4.1  <0.0001 
Polymorphism at 162          
 HLA-B5  4.4  0.02      NS 
  HLA-B7  17.4 <0.0001    15.0 <0.0001 
  Polymorphism at 135        3.8  0.0015 
 
Methods 
We examined the relationship between the presence of HLA-A and HLA-B broad 
alleles, and the presence of polymorphism at all other positions in HIV-1 RT (as 
explanatory covariates) and polymorphism at a single residue in HIV-1 RT (as the 
outcome or response variable) in multivariate logistic regression analyses. 
Polymorphism was defined as the presence of any detectable amino acid different to the 
consensus amino acid because of the arguments in the introduction and the inability to 
determine the relative amounts of each amino acid by the assay used for bulk 
sequencing. The most recent HIV-1 RT sequence in each individual was used in these 
analyses. Single amino acid residues in HIV-1 RT were examined in separate models. 
Several modelling steps were carried out: An initial power calculation was undertaken Methods      
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for each position to determine HLA-A and HLA-B alleles which had sufficient power to 
detect an association if it existed (at least 30 percent power to detect an OR>2.0 or 
<0.5); a further selection procedure based on univariate P-values, forward selection and 
backwards elimination; and randomisation tests based on logistic models to determine 
the “exact” P-values for associations was undertaken.
919 The final step in this process 
determined the statistical significance of association(s) between the covariates (HLA 
alleles) and the outcome (polymorphism at that residue only), and the odds ratios (OR) 
for these associations. These steps, and their justification, are described in detail below.  
Covariates considered before modelling 
The outcome/response variable was defined as any substitution of population consensus 
amino acid (that is, HIV RT viral sequence polymorphism). The starting 
covariates/explanatory variables were all HLA-A and HLA-B alleles present in all 
individuals. In our cohort these are HLA-A1, -A2, -A3, -A9, -A10, -A11, -A19, -A28, -
A36, -B5, -B7, -B8, -B12, -B13, -B14, -B15, -B16, -B17, -B18, -B21, -B22, -B27, -
B35, -B37, -B40, -B41, -B42, -B55, -B56, -B58, -B60 and -B61 (see Table 3.2). 
Serologically defined broad alleles were considered, rather than subtypes defined by 
high resolution DNA sequence based typing, so that data on all individuals in the cohort 
could be included. Furthermore, for several published CTL epitopes in HIV-1 RT, the 
HLA restriction of the epitope to the level of high resolution typing was not known.  
For each model, polymorphisms at all ‘other’ positions in HIV-1 RT (that is, other than 
the response/outcome position), along with HLA alleles, were included as covariates in 
all multivariate logistic regression analyses. These were included for the reasons 
discussed in the introduction. Chapter 6 Determining putative escape mutation sites in HIV-1 reverse 
transcriptase 
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Step 1. Power calculations 
Formal power calculations effectively exclude at the outset any HLA allele/position 
combinations for which there is insufficient statistical power (because of the rarity of 
polymorphism, the rarity of HLA allele or both) to allow an appropriate assessment for 
association. This not only restricts the number of covariates and comparisons, but 
formally identifies which HLA associations cannot be excluded by this analysis and 
would need examination in a larger dataset. We therefore performed power calculations 
at each position to determine for which alleles we had at least 30 percent power to 
detect an association with an odds ratio of greater than 2 of less than 0.5. Standard 
formulae were used for power calculations.
920 
Step 2. Removing covariates with small numbers of cases 
The numbers of individuals with and without each HLA allele, and with and without 
polymorphism were calculated. In order to remove covariates that may lead to an 
unstable logistic regression model, HLA alleles were eliminated if there were fewer 
than five individuals in any of these comparison groups.  
Step 3. Removing covariates with high univariate P-values 
Covariates were assessed separately for association with polymorphism using Fisher's 
exact tests, and those with a univariate P-value > 0.1 were excluded. This step reduced 
the possibility of subsequent multivariate models containing complex and/or unintuitive 
significant associations that were model-dependent.  Methods      
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Step 4. Logistic regression forward selection 
If the number of covariates remaining by this step exceeded 10 percent of the number of 
individuals, forward selection using logistic regression was used to choose the 
covariates that were to remain in the analysis. Covariates were selected sequentially 
based on the smallest P-value for an added covariate, until the number of covariates 
equalled 10 percent of the number of individuals. This step reduced the possibility of 
over-modelling by limiting the covariate:n ratio to 1:10. 
Step 5. Logistic regression backwards elimination 
A standard backwards elimination procedure was then carried out. Logistic regression 
models were fitted for the remaining covariates. If any of the P-values for the covariates 
were greater than 0.1 after accounting for the other included covariates, then the 
covariate with the largest P-value was removed and the logistic model refitted. This was 
repeated until all covariates had a P-value less than 0.1. This process stopped at a P-
value of 0.1 instead of 0.05 to allow inexact P-values greater than 0.05 to be included in 
calculating exact P-values in the subsequent step. 
Step 6. Calculating exact P-values 
To accommodate relatively small sample sizes (in this case, small numbers of 
individuals with rare HLA alleles and small amounts of polymorphism at a residue), 
“exact”  P-values based on randomisation tests rather than the usual large sample 
approximations were used.
919 In this procedure, the final covariate sets were randomly 
permuted amongst individuals and the standard test statistics for association with 
polymorphism calculated for each permutation. One thousand random permutations 
were generated for each model and the P-value based on the appropriate percentage of Chapter 6 Determining putative escape mutation sites in HIV-1 reverse 
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test values more extreme than that pertaining to the actual data. The proportion of times 
that a covariate had a test statistic in the random datasets exceeding that from the actual 
data was calculated for each covariate. This proportion gives a randomisation (exact) P-
value. Covariates with P-values less than 0.05 are considered significant. 
Results 
As described above, for each residue a number of HLA alleles remained after each step 
in the modelling process. Details of these are provided in Appendices (see Table A.1, 
page 291). The odds ratio, and exact and inexact P-values of each HLA allele covariate 
remaining prior to step 5 are shown in Table A.4 (see Appendices, page 303). For most 
residues all HLA allele covariates were removed in steps 1 and 2, before statistical 
modelling. All but two of the 72 models with significant HLA allele associations were 
also significantly associated with polymorphism at other sites (data not shown). There 
were a maximum of 473 individuals in each model. 
For the majority of 
associations between HLA-A 
and HLA-B alleles and 
polymorphism, the exact P-
value was smaller than the 
inexact  P-value (see Figure 
6.1). A simple log-linear 
regression with an outcome 
taken to be inexact P-value 
minus exact P-value, and 
predictor the HLA allele 
0
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Figure 6.1. The exact P-value versus the original inexact P-value 
for association of HLA-A and HLA-B with polymorphism. 
In the majority of cases, the exact P-value was smaller than the 
inexact P-value (i.e. below the 1-1 line in the graph). There was no 
instance of an association that had a significant inexact P-value and 
a nonsignificant exact P-value.  Results      
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frequency multiplied by amount of polymorphism for each association showed a 
negative association (P=0.00001) (see Figure 6.2). 
The results of all the 
individual models were 
plotted together on a map of 
HIV-1 RT amino acid 
sequence from position 20 to 
227 (see Figure 6.3). There 
were 64 positive associations 
(that is, OR>1) between 
specific HLA-A or HLA-B 
alleles and polymorphisms of 
single residues with an exact P-value < 0.05 (see Figure 6.3, Panel B; and Table A.4 of 
Appendices, page 303). Ten of these associations had exact P-values less than the limit 
of detection of 0.001 (that is, P<0.001).  
Polymorphisms specific for a particular HLA allele appeared to cluster along the 
sequence. For example, HLA-B7 was associated with polymorphism at positions 158 
(OR=4), 162 (OR=10), 165 (OR=2) and 169 (OR=13), which are all within or flanking 
two known HLA-B7 restricted CTL epitopes: RT(156-164 HXB2CG)
917 and RT(156-
165 SF2).
126,918 There was also clustering of associations for HLA-B12 (at positions 100 
and 102, 115 and 118, 203 and 211), HLA-B35 (121 and 123), HLA-B18 (at 135 and 
142), and HLA-B15 (at 207, 211 and 214). 
Fifteen HLA class I allele-associated polymorphisms (see Figure 6.3, Panel B, shown in 
red text) occurred at residues within the 29 CTL epitopes (see in Figure 6.3, Panel A) 
that are characterised, published and known to be restricted to those alleles. Four of 
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Figure 6.2. The difference in inexact and exact P-values for 
association of HLA-A and HLA-B with polymorphism. 
The difference was greater in those instances with smaller number 
of cases (i.e. [HLA frequency].[Polymorphism frequency]). Chapter 6 Determining putative escape mutation sites in HIV-1 reverse 
transcriptase 
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these residues (101, 135, 165 and 166) were at primary anchor positions within CTL 
epitopes [HLA-A3, RT(93-101);
916 HLA-B5, RT(128-135 IIIB);
49,126,516,915,916 HLA-B7, 
RT(156-165 SF2);
126,918 and HLA-A11, RT(158-166 LAI)
126,283,295,541,916,921 restricted, 
respectively]. The remaining 11 associations were at non-primary anchor positions of 
published CTL epitopes. There were a further five HLA allele-specific polymorphic 
residues that flanked CTL epitopes restricted to the same HLA alleles (see Figure 6.3, 
shown in blue text). 
There were fewer negative associations (that is, OR<1) (see Figure 6.3, Panel C, and 
Table A.4), and none of these had an exact P-value less than 0.001. There were more 
associations for the more common HLA alleles, especially for negative associations. 
For example, polymorphisms at positions 32, 101, 122, 169, and 210 were significantly 
negatively associated with presence of HLA-A2.  Results      
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Discussion 
The vast majority of HLA allele associations with polymorphism determined using 
standard logistic method regression underestimated the true significance of the 
association. The magnitude of this underestimation correlated positively with the 
rareness of the allele in the cohort. This is an important observation as it is likely that 
future studies will have limited numbers of individuals and will include several rare 
HLA alleles – especially if molecular splits of alleles are used and some type of 
correction for multiple comparisons is undertaken. Furthermore, analysis of sites with 
little polymorphism will require very large numbers to have power to find an 
association. Hence the use of exact P-values, or a correction to adjust an association’s 
significance after considering its allele frequency and the polymorphism frequency of 
the site analysed, should become a standard approach in future analyses. 
There were 64, often clustered, polymorphisms in HIV-1 RT significantly associated 
with specific HLA-A or HLA-B alleles. Polymorphisms occurred at sites that were 
within or proximate to published CTL epitopes, and correlated with the HLA alleles to 
which these epitopes are known to be restricted. Polymorphisms at non-primary anchor 
residues of CTL epitopes, such as HLA-B35 associated D177x, HLA-B7 associated 
S162x and others may confer a survival advantage to the virus by disrupting T-cell 
receptor-peptide recognition,
689 epitope processing from precursor protein
566 or by 
inducing antagonistic CTL responses.
608,689,701 The five HLA-specific polymorphisms at 
residues flanking CTL epitopes may indicate viral escape by disruption of proteasome 
peptide cleavage. This form of escape has been particularly difficult to identify by 
standard techniques that use only the epitope peptide to measure CTL responses.
5 The 
approach presented makes no assumptions about HLA binding motifs, amino acid 
interactions, or knowledge about known epitopes, escape sites, drug induced mutation Discussion      
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sites, and functional and structural protein information; and includes the possibility of 
escape from processing and peptide-HLA binding, the effect on TCR recognition, and 
the effect of interfering with processing. HLA association with polymorphisms not 
within or flanking published corresponding CTL epitopes may indicate where 
undiscovered CTL epitopes are located. 
CTL escape mutation has been well characterised in individuals with HLA-B8 (most 
commonly),
46,48,702 HLA-B44,
47 HLA-B27,
12 HLA-A11
200 and HLA-A3,
590 who may 
have been more escape-prone because of narrow range, oligoclonal CTL responses. 
This data suggests that CTL escape mutation is common and widespread, and is 
selected by responses restricted to a much wider range of HLA alleles than has been 
studied in individual cases.  
HLA alleles were also associated with lack  of polymorphism at certain residues, 
including at residues without functional constraints (see Figure 6.3, Panel C). Unlike 
positive immune selection causing demonstrable escape over time in individuals, 
negative immune selection favours preservation of wild-type virus in vivo and so could 
only be evident at a population level. It is possible that consensus or wild-type virus is 
primordially adapted to the CTL responses that have most often been encountered (that 
is, those restricted to the most common or evolutionary conserved HLA alleles in the 
host population). It has been shown that weakly immunogenic variants of EBV appear 
to be selected by the predominant HLA types of a host population.
22-25,895 While the 
major differences between the clades in HIV-1 are probably due to founder effects,
922 
we speculate with others that some of differences are due to the predominant HLA types 
in the host populations.
20,21 Population adaptation could also explain why selection of 
escape polymorphisms in CTL epitopes restricted to the common allele HLA-A*0201 
was not demonstrated in studies that have argued against an important role for immune Chapter 6 Determining putative escape mutation sites in HIV-1 reverse 
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escape
688,917 and even why surprisingly few HLA-A2 and HLA-A1 restricted epitopes 
have been mapped in HIV-1.
719 Furthermore, studies of HIV-1 exposed seronegative 
individuals suggest that CTL responses can alter viral infectivity and susceptibility to 
established primary HIV-1 infection.
310,339,406,433,442 The HLA class I alleles associated 
with natural HIV-1 resistance or susceptibility appear to differ between racially distinct 
populations.
310,339,433 To some extent this may reflect differences in the HLA alleles that 
are common in different populations and the degree to which a ‘population-adapted’ 
consensus virus can adapt to the individual. 
This novel, population-based approach reveals that both positive and negative selection 
forces compete at single residues to drive primordial and current viral evolution in vivo. 
These results are especially notable considering the factors that reduce the likelihood of 
observing significant HLA associations in such analyses. Firstly, the power to detect 
associations is not constant for all HLA allele/viral residue combinations. Large 
numbers of individuals would be needed to observe any associations with infrequent 
polymorphism at residues under immune pressure to mutate but with strong functional 
constraint, or any associations with HLA alleles that are rare. The use of formal power 
calculation helps identify those HLA associations that cannot be excluded at each 
position and which need larger data sets to be examined. Secondly, the use of broad 
HLA typing is a conservative bias as for at least many alleles the molecular subtype of 
an HLA allele better predicts its binding properties in vivo. Alleles with multiple splits 
of similar frequency (for example, HLA-A10 and HLA-A19; see Table 3.2, page 99) 
may have had associations that we did not detect because only broad alleles were 
considered. Furthermore, molecular splits that have opposing effects at the same viral 
residue would negate any association with the broad allele. Thirdly, the use of ‘other’ 
positions in the models can introduce a conservative bias as characteristic 
polymorphism(s) from early escaped immunodominant epitope(s) have the potential to Discussion      
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mark the presence of a particular HLA type. As most individuals are likely to escape 
from characteristic epitopes during seroconversion
561 this could be a concern if the 
region being analysed included such polymorphism(s). This bias would be exaggerated 
if it is associated with the HLA subtype more strongly than the broad HLA specificity 
used in the analysis. Finally, published epitopes are more likely to be in conserved 
regions, as studies tend to use laboratory reference strains as target antigens and 
conserved regions are more likely to have measurable immune responses in vivo.
565 In 
contrast, the approach described detects putative immune epitopes in variable regions, 
making it complementary to standard epitope mapping methods.  
This type of analysis can only show escape and indicate the presence of an epitope with 
the corresponding HLA-restriction. It cannot indicate where epitopes are that have no 
escape, possibility due to residues that cannot tolerate mutation. However, known CTL 
epitopes that, by our analysis, do not appear to escape CTL could indicate epitopes 
where the virus cannot tolerate a mutation or in vivo are non-immunogenic epitopes. 
This may explain why some studies have been unable to show evidence for escape by 
analysing a few HLA-restricted CTL epitopes.
46,238,688,690-694 Furthermore, this method 
should detect escape mutations that cause antagonism because we did not restrict our 
definition of polymorphism to those that have evolved to fixation.  
As the epitopes that induce the strongest pressure on HIV-1 selection are those that are 
most likely to escape,
561 this analysis is able to give an indication of the strongest CTL 
responses. For example, the significant association with the highest odds ratio for HLA-
B5 was at position 135. This is within a known HLA-B5 restricted CTL epitope 
[RT(128-135 IIIB)
49,126,400,516,915,916]. The high odds ratio would suggest that this epitope 
applies strong selective pressure and is the most immunodominant epitope in this region 
of HIV-1. The phenomenon of immunodominance and ‘original antigenic sin’ reduces Chapter 6 Determining putative escape mutation sites in HIV-1 reverse 
transcriptase 
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the chance of new epitopes being recognised while the existing ones have not escaped. 
If the virus had not escaped the HLA-B5 restricted epitope in individuals with HLA-B5 
(possibly because the virus could not tolerate a mutation that reduced the CTL 
response), then it is likely that other HLA-B5 epitopes would not be recognised. Hence 
this analysis indicates which epitopes have the highest efficacy in vivo. This 
information combined with knowledge of the genetic barrier to escape from these 
epitopes could determine which epitopes are the most effective at eradicating or 
controlling the virus. 
Population-based approaches provide independent in vivo evidence to support the extent 
and importance of CTL escape through HLA-specific associations.
164 Identified putative 
CTL escape mutations can also be tested or compared with in vitro and  ex vivo 
laboratory results (see Chapter 7 and Chapter 10). Modelling individuals’ viral loads 
can also be used to verify the putative escape mutations observed (see Chapter 16). 
Moreover, the strengths of associations can provide insights into the relative 
contributions of these mutations to disease progression.
571,689 
This population-based analysis provides evidence that CTL escape mutations specific to 
individuals’ HLA are selected in HIV-1. 
  
Chapter 7 Correlation between putative escape 
mutation sites and known HLA-restricted CTL 
epitopes 
Introduction 
Several previously published HLA-A and HLA-B restricted CTL epitopes have been 
mapped to HIV-1 RT (see Figure 6.3, panel A). These known epitopes provide a good, 
biological and independent set of data with which to validate the putative CTL escape 
mutations identified in this thesis (see Chapter 6). For most of these epitopes, escape 
has not been shown, and where it has, it has only been shown for a few individuals. Our 
results give some indication of the immunodominance of these epitopes, how common 
escape from them is, and which amino acid(s) within the epitopes are most likely to be 
involved in escape. 
We found 15 positive HLA class I allele-associated polymorphisms (see Chapter 6 and 
Figure 6.3, Panel B, shown in red text) which occurred at residues within the 29 CTL 
epitopes that are characterised, published and known to be restricted to those alleles 
within the analysed region of HIV-1 RT (see Chapter 6 and Figure 6.3, Panel A). Four 
of these residues (101, 135, 165 and 166) were at primary anchor positions within 
known CTL epitopes where mutation could abrogate binding to the HLA molecule. The 
remaining 11 associations were at non-primary anchor positions of published CTL 
epitopes. 
We hypothesise that the putative escape mutations identified in Chapter 6 correlate with 
known epitopes of corresponding HLA-A and HLA-B restriction.  Chapter 7 Correlation between putative escape mutation sites and known HLA-
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Methods 
We conducted analyses to determine the probability of finding by chance at least fifteen 
significant positive associations within corresponding known CTL epitopes (that is, 
restricted to the same HLA allele).  
If significant HLA associations from our previous study occurred randomly across 
residues, the probability that an HLA association would occur within the known CTL 
epitope restricted to that allele equates to the relative proportion of all residues falling 
within that epitope. Hence, for each HLA allele, the expected number of associations to 
fall within corresponding HLA epitope(s) can be calculated as follows:  
1)  Define AHLA as the number of residues within the HLA-restricted CTL epitopes. 
2)  Define BHLA as the number of residues outside the HLA-restricted CTL epitopes. 
Since we only analysed a region of HIV-1 containing 208 residues, B=208-A. 
This can also be defined only using the number of residues with sufficient power 
to detect an association for this HLA allele.  
3)  Define  XHLA as the number of positive HLA associations that fall within 
corresponding HLA-restricted CTL epitope(s). 
4)  Define  DHLA as the number of positive HLA associations that fall outside 
corresponding HLA-restricted CTL epitope(s).  
5)  The probability, pHLA, of a random association falling within a known 
corresponding epitope is AHLA/(AHLA+BHLA). 
6)  The number of associations, nHLA, is XHLA+DHLA. 
7)  The expected number of random associations falling within known 
corresponding epitopes,λ HLA, is nHLA.pHLA. Methods      
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The number of significant associations for each HLA, XHLA, can be considered as a 
binomial variable with a binomial distribution: XHLA ~ Bin(nHLA,  pHLA). The total 
number of significant associations within known epitopes, across all HLA, is then a sum 
of these non-identical binomial variables, whose distribution can be approximated by 
simulation or by using a Poisson approximation with: X ~ Poi(λ ), where 
and . 
This analysis was repeated only considering those residues with sufficient power to 
detect an association. Positive and negative associations were also considered 
separately.
Results 
The numbers for each variable defined in the methods are shown in Table 7.1. The 
expected number of positive associations to be found within known corresponding CTL 
epitopes across all HLA was 4.27. The observed number of 15 was significantly higher 
than this (P≈3.25 x 10
-5). Furthermore, an excess of associations over that expected was 
seen for 10 of the 11 HLA specificities with epitopes in this segment of HIV-1 RT 
(P=0.006, sign test). 
When considering only those residues with sufficient power to detect an association, the 
expected number of associations (4.01) and P-value (P≈2.07x10
-5) were similar (see 
Table 7.2).  
There were also four negative associations within corresponding HLA epitopes. This 
was not significantly different to the expected number of 4.18 (P=0.312) (data not 
shown). However, when the positive and negative associations were combined, the 
correlation was still significant (P ≈ 1.29x10
-4), albeit less so (data not shown). 
∑  = 
∀HLA 
HLA  λ λ 
∑ = 
∀HLA
HLA X X Chapter 7 Correlation between putative escape mutation sites and known HLA-
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Table 7.1. The actual and expected numbers of positive associations (based on all amino acid positions) 
within their corresponding epitopes between residues 20 and 227. 
HLA 
allele 
No of 
residues  
within 
known 
epitopes 
(AHLA) 
No of 
residues 
outside 
known 
epitopes  
(BHLA = 
208-
AHLA) 
Probability of 
a random 
association 
falling within 
a known 
epitope 
(pHLA=AHLA / 
(AHLA+BHLA)) 
Actual 
no of 
associ-
ations in 
known 
epitopes 
(XHLA) 
Actual no of 
associations 
outside 
known, 
correspond-
ing epitopes
(DHLA) 
Actual 
number 
of assoc-
iations 
(n = 
XHLA + 
DHLA) 
Expected 
number of 
associations 
within known, 
corresponding 
epitopes  
(λ HLA =  
nHLA.pHLA) 
A1 0  208  0  0 2 2 0 
A2 62  146  0.298  1 2 3 0.89 
A3 38  170  0.183  1 2 3 0.55 
A9 8  200  0.038  1 6 7 0.27 
A10 0  208  0  0 1 1 0 
A11 9  199  0.043  1 2 3 0.13 
A19 18  190 0.087  1 0 1 0.09 
A28 9  199  0.043  0 0 0 0 
B5 34  174  0.163  1 4 5 0.82 
B7 10  198  0.048  3 3 6 0.29 
B8 7  201  0.034  0 3 3 0.10 
B12 10  198 0.048  2 4 6 0.29 
B13 0  208  0  0 0 0 0 
B14 0  208  0  0 1 1 0 
B15 0  208  0  0 5 5 0 
B16 0  208  0  0 1 1 0 
B17 0  208  0  0 2 2 0 
B18 0  208  0  0 4 4 0 
B21 0  208  0  0 1 1 0 
B22 0  208  0  0 0 0 0 
B27 0  208  0  0 1 1 0 
B35 37  171 0.178  3 1 4 0.71 
B37 0  208  0  0 2 2 0 
B40 9  199  0.043  1 2 3 0.13 
B41 0  208  0  0 0 0 0 
B60 0  208  0  0 0 0 0 
SUM       X = 15 λ = 4.27 
P-value ≈ 3.25 x 10
-5
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Table 7.2. The actual and expected numbers of positive associations (based on those amino acid positions 
with power to detect an association) within their corresponding epitopes between residues 20 and 227. 
HLA 
allele 
No of 
residues 
 with 
power to 
show an 
association 
No of residues 
within known, 
corresponding 
epitopes with 
power to show 
an association 
(AHLA) 
No of residues 
outside known 
epitopes that 
have power to 
show an 
association for 
the HLA allele
(BHLA) 
Actual no 
of 
associations 
in known 
epitopes 
(XHLA)  
Actual no of 
associations  
outside known, 
corresponding 
epitopes  
(DHLA) 
Expected 
number of 
associations 
within known, 
corresponding 
epitopes  
[λ HLA = 
(XHLA+DHLA). 
(AHLA/ 
(AHLA+BHLA))] 
A1 78  0 78 0 2  0
A2 70  21 49 1 2  0.89
A3 78  14 64 1 2  0.53
A9 78  3 75 1 6  0.23
A10 64  0 64 0 1  0
A11 74  4 70 1 2 0.16
A19 74  10 64 1 0 0.13
A28 48  4 71 0 0  0
B5 64  7 57 1 4  0.54
B7 78  3 75 3 3  0.23
B8 78  4 74 0 3  0.15
B12 78  6 72 2 4 0.38
B13 45  0 45 0 0  0
B14 61  0 60 0 1  0
B15 71  0 70 0 5  0
B16 56  0 55 0 1  0
B17 65  0 64 0 2  0
B18 48  0 47 0 4  0
B21 31  0 31 0 1  0
B22 38  0 37 0 0  0
B27 49  0 48 0 1  0
B35 65  10 55 3 1 0.61
B37 10  0 10 0 2  0
B40 70  4 66 1 2 0.17
B41 3  0 3 0 0  0
B60 3  0 3 0 0  0
SUM   X = 15   λ  = 4.01
P-value ≈ 2.07 x 10
-5 
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Discussion 
The results of the analyses described in this chapter provide evidence that our method 
for identifying putative CTL escape mutations can identify true CTL escape mutations, 
since these correspond to independently described CTL epitopes. This supports our 
hypothesis that other associations, not within or flanking known CTL epitopes, could 
represent escape mutations from other, as yet undefined, CTL epitopes.  
A more complicated method for finding an association between putative escape 
mutations incorporating the P-value of the association, strength of the association, 
specificity of the broad allele definition, extensiveness of HLA allele epitope mapping, 
clustering within individual epitopes, and power to detect an association may be 
devised. However, even our simple method, which did not take any of these factors into 
account, still provided very strong evidence that putative escape mutations were 
occurring at a higher rate than expected within known CTL epitopes, even in the small 
region of HIV-1 analysed.  
A number of factors may explain our inability to detect escape within CTL epitopes. 
Firstly, we may not have had enough power to detect an association. Secondly, the virus 
may not be able to easily tolerate such a mutation due to its effects on viral fitness. 
Thirdly, the CTL epitope defined may be of relatively limited immunogenicity. Finally, 
the epitope may be acting antagonistically or escape from the epitope may lead to 
another stronger epitope being recognised elsewhere, thus failing to produce effective 
viral escape.  
In conclusion, the analyses described in this chapter uses independent epitope mapping 
data to add to the evidence that escape from multiple HLA-restricted CTL epitopes is 
occurring at a population level.   
Chapter 8 Clustering of putative escape mutations sites 
Introduction 
In Chapter 6 we observed apparent clustering of polymorphisms significantly associated 
with HLA-A3 (at positions 36, 38 and 41), HLA-B12 (at positions 100 and 102; 115 
and 118; and 203 and 211), HLA-B35 (121 and 123), HLA-B18 (at 135 and 142), HLA-
B7 (at 158, 162, 165 and 169) and HLA-B15 (at 207, 211 and 214). Some of these 
HLA-specific associations were within or proximate to known HLA restricted and 
corresponding epitopes for HLA-A3 (HLA-A*0301: positions 33 to 43),
124,916 HLA-
B35 (HLA-B35 and HLA-B*3501: 118-127 SF2/IIIB),
49,126,513,916,923 HLA-B7 (156-164 
HXB2CG),
917 HLA-B7 (156-165 SF2)
126,918 and HLA-B12 (HLA-B44: 203-212).
126,149 
Others have also observed clustering of viral polymorphisms in and around known CTL 
epitopes.
3,12 Similar to our observations, clustering described in these reports is limited 
to regions within and proximate to a CTL epitope. Localised HLA-associated clustering 
of viral polymorphisms is likely to be due to the fact that HLA class Ia-specific immune 
recognition is restricted to eight to 10 consecutive viral amino acids. Polymorphisms 
that alter the processing by the proteasome and thus affect the immunogenicity of a 
peptide have been described within the actual epitope or within a few amino acids 
outside of the epitope.
924-926 Also, well characterised compensatory polymorphisms to 
escape mutations have been described to within a few amino acids of an epitope.
12,13 
Clustering of polymorphisms may occur for a number of reasons. First, polymorphism 
at a single anchor residue or a residue that interacts with the TCR may not completely 
prevent presentation or recognition, and may only provide a partial selective advantage 
to the virus.
164 Hence, multiple polymorphisms may be selected as they provide more Chapter 8 Clustering of putative escape mutations sites  144 
effective escape. Second, compensatory or secondary mutations may be selected or 
induced by the virus to sustain its fidelity or function. Third, different polymorphisms 
may be arbitrarily selected in different individuals due to the stochastic nature of 
mutation. 
The aim of this study is to show that the clustering observed was statistically greater 
than that expected by chance for the putative CTL escape mutations identified in 
Chapter 6.  
Methods 
Details of the test statistics for the each HLA allele and the overall test statistic across 
all HLA alleles are given in Table 8.1. The test statistic for clustering was defined as the 
number of associations that were within 12 amino acids of another association, with the 
same HLA allele. For each HLA allele, the test statistic was calculated from the original 
dataset and from each of 1000 randomised datasets that incorporated the entire 
modelling process. The P-value was calculated for each HLA allele as the proportion of 
randomised datasets with a test statistic greater than that for the original dataset. To 
calculate the overall significance for clustering across all HLA alleles, the test statistics 
for all HLA alleles were summed and compared to the randomised datasets as described 
above. 
Results 
There was significant clustering for HLA-B35 (P = 0.03) and HLA-B7 (P = 0.03). 
Several HLA alleles bordered on significance: HLA-A3 (P=0.10), HLA-B5 (P=0.07), 
HLA-B12 (P=0.07), HLA-B15 (P=0.08). Testing for clustering across all HLA alleles 
was significant (P=0.006; see Table 8.1). Results      
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Table 8.1. Clustering of HLA associations with polymorphism in HIV-1 RT. 
Clustering was defined as the maximum number of associations within a stretch of 12 amino acids. The 
P-value was generated by counting the number of the 1000 randomised datasets with a maximum number 
of associations clustered greater than that of the original, and dividing this number by 1000. 
HLA 
allele 
Positions where the 
HLA allele was 
associated with 
polymorphism 
Number 
of assoc-
iations 
Number of 
associations 
that cluster 
Number of the 1000 
randomised datasets with 
more associations that 
cluster than the original 
dataset  P-value 
A1  35, 75, 162, 215  4  0  1000  1 
A2  26, 32, 39, 69, 101, 
122, 169, 210 
8 3  122  0.122 
A3  28, 36, 38, 43, 101, 
215 
6 3  101  0.101 
A9  36, 65, 103, 115, 
142, 204, 219 
7 2  336  0.336 
A10 70,  135,  207  3  0  1000  1 
A11  53, 122, 166, 203  4  0  1000  1 
A19 178,  184  2  0  1000  1 
B5  38, 60, 135, 173, 
196, 211 
6 3  66  0.066 
B7  49, 118, 158, 162, 
165, 169, 178, 208, 
215 
9 5  32  0.032 
B8  32, 43, 69, 181, 200  5  0  1000  1 
B12  100, 102, 115, 118, 
123, 178, 203, 211 
8 4  67  0.067 
B14 43  0  0  1000  1 
B15  99, 169, 207, 211, 
214 
5 3  77  0.077 
B16 28,  122  2  0  1000  1 
B17 32,  214  2  0  1000  1 
B18  68, 135, 142, 173  4  0  1000  1 
B21 210  0  0  1000  1 
B22 200  0  0  1000  1 
B27 179  0  0  1000  1 
B35  69, 83, 121, 123, 177  5  4  28  0.028 
B37 123,  200  2  0  1000  1 
B40 69,  197,  207  3  2  262  0.262 
Total     29  6  0.006 
 
Discussion 
Alternative methods to those used in this thesis for determining statistically significant 
clusters have been described (see reference 927 and references therein). However, these 
are general methods and do not take into account the specific structure of our data: 
Clustering of escape mutations may not be limited to a single region because of the way Chapter 8 Clustering of putative escape mutations sites  146 
epitopes are distributed. Furthermore, more than one mutation can be induced by a 
single epitope.
3 Taking the smallest distance between any two associations, for 
example, would not capture the effect of a cluster of three associations; and using the 
smallest mean distance between three associations would potentially lose the effect if 
there were only two induced escape mutations within the one epitope. Moreover, within 
the region of HIV-1 analysed the occurrence of polymorphism was not uniform along 
the entire viral sequence. There were regions that had a lot of polymorphism and other 
regions that had little, probably reflecting different functional and structural constraints 
along the sequence (see Figure 5.2). Hence, using a simple definition of clustering 
would likely pick up a lot of false positive clustering due to the variable distribution of 
non-HLA associated polymorphism rather than that related particularly to the presence 
of epitopes. This would make it difficult to find a significant effect of specific HLA 
associated polymorphism clustering as other random associations would also tend to be 
clustered. 
The decision to use a stretch of 12 amino acids was based on the biological arguments 
given in the introduction. Since the actual epitope was not known in most cases, the 
maximum number of associations within a stretch of 12 amino acids was used to 
attempt to capture all the clustered mutations that could be being selected within an 
epitope. Using the actual number, rather than a binary covariate of, for example, two or 
more within 12 amino acids, reduced effect of randomised datasets having clustering by 
chance due to the non-uniform non-HLA associated polymorphism along the sequence. 
This definition also allowed the clustering across all HLA alleles to be summed in the 
actual dataset and compared to the randomised datasets to provide an overall P-value 
for clustering across all HLA alleles.  Discussion      
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Use of the standard definitions of clustering mentioned above failed to show significant 
HLA associated polymorphism clustering (data not shown). The biological 
understanding of epitopes and how the virus mutates in response to the recognition of 
these epitopes allowed a more appropriate definition to be made. Perhaps a more 
powerful and comprehensive definition of clustering could be postulated, including all 
P-values and odds ratios and allowing clustering in multiple epitopes. However, despite 
the small region of HIV-1 analysed and the use of broad serologically defined HLA 
alleles, the simple definition used in this study appears to be quite powerful.  
This study shows significant clustering of putative HLA-specific CTL escape 
mutations. This finding is all the more notable as the modelling of putative escape 
mutation in Chapter 6 adjusted for polymorphism at other positions to reduce the 
chance of detecting an association with a compensatory mutation secondary to the 
actual CTL escape mutation. This would suggest that the clustering seen is not due to 
compensatory mutations, but due to different individuals escaping the same epitope via 
mutation at different positions. The choice of mutation used to escape from a CTL 
epitope may depend on other host factors (for example, other HLA alleles present), 
other polymorphisms in the virus and stochastic processes. Escape from multiple 
epitopes may also partly explain these findings, but this is probably unlikely due to the 
relative large size of the genome compared to the size of HLA-restricted CTL epitopes. 
A final possibility is that different molecular subtypes of the broad HLA allele (for 
which the association with escape was attributed) may be able to present the same 
epitope, but escape using different polymorphisms. Experimental studies will be needed 
to determine the degree to which each of these factors are contributing to escape. 
  
Chapter 9 Putative escape mutation sites flanking 
known HLA-restricted CTL epitopes 
Introduction 
Intracellular HIV-1 proteins are degraded (cut) by the proteasome complex into short 
peptides.
14,15 These peptides are delivered into the endoplasmic reticulum (ER) via 
TAP-dependent transporters.
247,248 Inside the ER the peptides are trimmed to a length, 
usually between eight and 10 amino acids long and loaded on to HLA class Ia 
molecules. This peptide-HLA complex is then transported to the cell surface for 
presentation to CTLs. Most of the preferential selection of peptides occurs at the level 
of the HLA molecule. However, it is known that TAP complexes and, more so, the 
proteasome complex have some preferences for different peptides. 
The proteasome complex has three active sites for cleavage: after hydrophobic, basic 
and acidic residues. The presence of interferon-γ  (a soluble factor secreted by CTLs 
and T-helper cells upon activation) enhances the cleavage specificity after basic and 
hydrophobic residues and reduces it after acidic residues.
16-18 Several proteasome 
processed products have been determined using various techniques.
602,928-936 However, 
the rules for cleavage cutting are not well understood. One study suggests that only the 
amino acid on the C-termini side of the sequence is important for determining 
cleavage.
937 Another suggests that a number of consecutive amino acids influence the 
probability of where a protein will be cleaved.
938 Several neural network and statistical 
models have been created that predict human proteasome cleavage sites.  
There are fewer proteasome subunit alleles in humans compared to the number of HLA 
class Ia genes. However, the population frequencies of these alleles are high in all Chapter 9 Putative escape mutation sites flanking known HLA-restricted CTL 
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ethnic groups (up to 44 percent compared to the most common allele), and linkage 
disequilibrium with other HLA genes is similar between different ethnic groups.
907 
Since the proteasome can influence the amount of a particular peptide processed and 
ultimately presented at the cell surface in an HLA molecule, polymorphisms could be 
selected to increase the chance of a proteasome cut within an immunogenic CTL 
epitope (that is, a cut in the middle of an epitope so that it cannot be presented), or 
decrease the chance of a cut that would lead to the creation of an immunogenic 
epitope.
939 These polymorphisms would be HLA-specific and seen outside (flanking) an 
HLA-restricted epitope. This mechanism could give relief from HLA restricted 
selective pressures as it increases the scope of potential escape from the length of the 
epitope (around eight to 10 amino acids) to a larger area that includes residues outside 
of the epitope. Furthermore, this mechanism could allow escape from several epitopes 
that are mapped to the same region, and may be important and influence immunogenic 
sites with many overlapping epitopes. 
Escape through the proteasome has not been described in HIV-1. This type of escape is 
likely to be less effective than other forms of escape because mutation is unlikely to 
totally eliminate the processing of the peptide. However, it may be occurring within or 
flanking residues where escape by other mechanisms is not absolute or well tolerated. 
Our previous method for finding HLA associated polymorphism allowed us to detect 
putative CTL escape mutation that occurred outside of an epitope (see Chapter 6). We 
found putative CTL escape mutation associations at 52 positions using this method. We 
hypothesise that some of these positions, in particular those that are flanking 
corresponding known HLA-restricted CTL epitopes, represent escape through mutation 
that affects proteasome processing. In particular, the associations with HLA-A2 and 
polymorphism at position 26, HLA-A3 at 28, HLA-B8 at 32, HLA-A2 at 32, HLA-B5 Introduction      
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at 38, HLA-A2 at 101, HLA-A2 at 122, HLA-B7 at 169, HLA-A19 at 184, and HLA-
B40 at 167 all flanked known corresponding-HLA restricted CTL epitopes. We 
hypothesise that these HLA associated mutations and associations within 
corresponding-HLA restricted epitopes are near proteasome cutting sites. We also 
hypothesise that the virus has evolved to be able to tolerate mutation near the 
proteasome cleavage sites, allowing it another mechanism for escape if an epitope (with 
any HLA-restriction) is presented. 
Methods 
The neural network PAProC
940 was used to predict proteasome cleavage sites in the 
population consensus. This sequence was submitted online
941 and the results returned 
were collated with the polymorphism frequency prior to antiretroviral treatment and the 
HLA associations determined in Chapter 6.  
The pre-antiretroviral polymorphism frequencies were used as a measure of how 
tolerant the virus is to mutation at a particular residue. The predicted amounts of 
cleavage preference were compared to the tolerability of the residues on the C-termini 
side of this cleavage site using a Wilcoxon rank test (due to the non-normal distribution 
of the data). 
The number of predicted cleavage sites at our previously identified putative HLA 
escape mutation sites were compared using a Fisher’s exact test. 
Results 
The strength of predicted proteasome cleavage sites are shown in Table 9.1. There was 
no significant association between these and the tolerability of a mutation at a residue 
(P=0.6656, Wilcoxon; see Figure 9.1). Chapter 9 Putative escape mutation sites flanking known HLA-restricted CTL 
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There were several HLA 
associations from our previous 
analysis that flanked or were within 
corresponding HLA epitopes that 
were also on the C-termini side of 
the predicted proteasome cleavage 
site (see Table 9.1). For example, 
the association between HLA-A2 at 
position 26 flanked the HLA-A2 
restricted CTL epitope RT(33-41 LAI)
124,916 and the HLA-A3 association at position 28 
flanked the HLA-A3 epitope RT(33-43).
124,916 These were both at residues on the C-
termini of strongly predicted cleavage sites. Similarly, the following HLA alleles were 
associated with polymorphism, were within known corresponding HLA epitopes and 
were on the C-termini of strongly predicted cleavage sites: HLA-B5 and 135, B7 and 
162, and HLA-A2 and 210. However, there was no significant correlation between our 
putative escape mutation sites defined in Chapter 6 and the putative cleavage sites 
determined in this study (P=0.610; see Table 9.2). 
Table 9.1. Predicted proteasome cleavage sites. 
Weak, Medium and Strong indicate the predicted bias for increased cleavage behind the amino acid 
position. Positive and negative associations from our previous analysis, and known CTL epitopes are 
shown. 
Amino 
acid 
position 
Positive 
associations 
Negative 
associations  HLA epitope comment 
Cleavage 
prediction 
21      Strong 
22      Strong 
24      Strong 
26 A2   
Flanking HLA-A2 epitope [RT(33-41 
LAI)
124,916] Strong 
28  A3, B16    Flanking HLA-A3 epitope [RT(33-43)
124,916] Strong 
29      Weak 
35   A1    Weak 
36  A9 A3 Within  HLA-A3  epitope  [RT(33-43)
124,916] Weak 
37      Weak 
50      Strong 
55      Weak 
58      Medium 
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Figure 9.1. Predicted cleavage site verus polymorphism 
frequency in HIV-1 RT prior to antiretroviral treatment. Results      
 
 
153
Amino 
acid 
position 
Positive 
associations 
Negative 
associations  HLA epitope comment 
Cleavage 
prediction 
61      Strong 
63      Strong 
65 A9      Weak 
66      Medium 
71      Medium 
73      Medium 
77      Weak 
80      Strong 
88      Weak 
90      Strong 
99 B15      Medium 
100 B12      Strong 
102 B12      Strong 
103 A9      Weak 
107      Weak 
109      Weak 
113      Strong 
115  A9, B12    Within HLA-A9 epitope [RT(113-120 SF2)
516] Medium 
116      Strong 
118 B12  B7    Weak 
119      Medium 
124      Weak 
125      Weak 
131      Strong 
135 B18,  B5  A10 
Within HLA-B5 epitope [RT(128-135 
IIIB)
49,126,400,516,915,916] Strong 
137      Strong 
138      Strong 
143      Medium 
145      Strong 
153      Weak 
156      Strong 
159      Strong 
161      Strong 
162 A1,  B7   
Within two HLA-B7 epitopes [RT(156-164 
HXB2CG)
917 and RT(156-165 SF2)
126,918]  Strong 
163      Medium 
167      Strong 
168      Medium 
170      Weak 
172      Strong 
174      Strong 
180      Strong 
182      Strong 
183      Medium 
185      Strong 
187      Strong 
188      Weak 
191      Weak 
198      Strong 
205      Strong 
208   B7    Weak 
210  B21  A2  Within HLA-A2 epitope [RT(209-220 )
124] Strong 
216      Weak 
221      Medium 
223      Strong 
225      Strong 
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Table 9.2. The number of putative cleavage sites corresponding to putative CTL escape mutation sites. 
   
Putative CTL 
escape mutation site 
Not a putative CTL 
escape mutation site  Total 
Predicted cleavage site  15  52  67 
Not a predicted cleavage site  37  104  141 
Total 52  156  208 
 
 
Discussion 
The lack of correlation between residue tolerability to change and cleavage site 
prediction may be due to a number of reasons. Firstly, the proteasome cleavage site 
predictions are known to be fairly inaccurate.
940 Secondly, residues other than the 
residue on the C-termini side of the cleavage site may be important.
938,940,942 Thirdly, 
the possibly small reduction in epitope processing may not outweigh the reduction in 
viral fitness to result in a polymorphism. Fourthly, the trimming of epitopes within the 
ER
943 may offset the position of the polymorphism to the epitope.
940 Finally, escape 
from several epitopes via this mechanism may be occurring, but may not have had a 
large impact on the total variability of the virus in the population. 
The lack of correlation between residues at the C-termini of the predicted cleavage sites 
and the associations found in our previous analysis may also be explained by the 
arguments above. Furthermore, the associations we found previously that flanked 
corresponding HLA-restricted CTL epitopes may have been false or represented escape 
from other epitopes or compensatory mutations to other epitopes. These associations 
and those within corresponding HLA-restricted CTL epitopes could represent escape 
via other, possibly unknown, mechanisms. 
Despite the negative results, the correlation of two flanking HLA associations and 
several associations within CTL epitopes to predicted cleavage sites do provide some 
data that can be analysed further using ex vivo assays that allow proteasome processing 
and its influence on epitope presentation to be tested. This would provide evidence that Discussion      
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escape occurred through the proteasome in HIV-1. Combined with our results this 
would provide strong evidence that escape from the proteasome cleavage is evident at a 
population level.   
Chapter 10 Determining putative HLA-restricted CTL 
epitopes from the putative escape mutation sites and 
HLA binding motifs 
Introduction 
The peptides that an HLA molecule presents are determined by its peptide-binding 
groove. The differences in peptides presented by different HLA alleles are determined 
largely by the polymorphisms within this groove. Peptides that can be bound within an 
HLA molecule can be determined using three principle methods.
19 The first is by X-ray 
crystallographic analysis of the molecule. The second involves incubating radioactively 
labelled peptides with purified HLA molecules and determining which peptides bind. 
The final and most common method is by direct sequencing of peptides eluted from a 
given HLA molecule. Results from these methods show that all HLA alleles have 
preferences for particular amino acids along the length of the peptides they present. 
They also have different preferences for the length of peptides presented. Classical 
HLA class I molecules typically present an eight or nine amino acid long peptide with 
strong preference for particular amino acids at the second and final (terminal) amino 
acid position. However, these preferred amino acid positions vary between alleles and 
are referred to as anchor residues. X-ray analysis of HLA-peptide complexes reveals 
that these anchor residues fit in deep pockets within the peptide-binding groove (namely 
pockets A and F for positions two and terminal amino acids respectively). Other 
positions can also show some amino acid preference, but are, in general, less important 
in determining binding. Chapter 10 Determining putative HLA-restricted CTL epitopes from the putative 
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Knowledge of HLA-allele-specific peptides that can be bound in different HLA 
molecules has been used to describe HLA motifs. The HLA motif summarises the 
amino acid preferences at each position. This approach assumes that each amino acid 
does not influence the preference for other amino acids. See Figure 14.1, Panel C (page 
194) and Figure 14.2, Panel C (page 195) for examples of HLA motifs. Other HLA 
motifs can be seen online.
944 For the more rare alleles, motifs have not been defined. 
These HLA motifs are commonly used to screen sequences for potential HLA-specific 
epitopes. Epitopes that fit their specific motif well (usually with both anchor residues 
for eight or nine amino acid long peptides) may be tested in vitro for an HLA-restricted 
CTL response. It is likely that HIV-1 sequence that fits the motifs of the most common 
Caucasian HLA alleles (for example, HLA-A2, -A1, -A3, -B8, -B5, -B7, -B27, -B35 
and -B44) have been tested for a CTL response. However, as it has been shown that up 
to one third of the epitopes that result in a CTL response do not correspond to their 
motif at all anchor positions, and hence many epitopes are likely to have been missed 
(reviewed in reference 945). 
We previously found many HLA-specific putative CTL escape mutations that were not 
within or near known corresponding HLA epitopes. Use of published HLA motifs 
provides an independent biologically relevant way of validating our methods, and 
together they can offer a more powerful screening method to identify potential 
immunogenic epitopes. This combined method can also help identify epitopes 
previously missed because they did not “adequately” fit their motif, or because the 
peptide tested had already escaped. 
This study attempts to use HLA motif information to identify putative HLA-restricted 
CTL epitopes from the HLA-specific putative CTL escape mutations found in Chapter 
6. Furthermore, we attempt to find CTL epitopes that HIV-1 may have escaped at a Introduction      
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population level. We hypothesised previously that negative associations with 
polymorphism might represent epitopes that have already escaped in the population and 
consensus sequence. A polymorphism at a site with a negative HLA allele association 
that results in a sequence that better fits the corresponding HLA motif would support 
this hypothesis. 
Methods 
To estimate how well known HLA-restricted epitopes fit their described motif, each 
known epitope within the amino acids 20 to 227 of HIV-1 RT was compared to its 
corresponding published motif. HLA motifs were defined as in references 944 and 946. 
In cases where the motif or published epitope was defined more or less broadly, the 
motif with the greatest overlap with the epitope was used. For example, for epitopes 
described with the HLA-A2 specificity, the HLA-A*0201 motif was used; and for 
epitopes described with HLA-A*0301, the motif HLA-A3 was used as there is no HLA-
A*0301 motif defined. Due to the complexity of motif definitions, inconsistencies 
between the motif definitions and very limited data used to generate motifs for some 
HLA alleles, an epitope was considered to fit its corresponding motif if the epitope had 
the preferred amino acids at all of its defined anchor residues. 
For each significant putative positive HLA escape mutation position found in Chapter 6, 
the best epitope that included the position was determined. The best epitope was defined 
as the one that maximised the number of anchor residues, then auxiliary residues and 
then other preferred residues for the corresponding HLA motif. If this resulted in a 
number of epitopes, epitopes that overlapped the putative escape mutation position at an 
anchor position were chosen over other epitopes; and epitopes of nine amino acids long 
were chosen over those eight amino acids long, which were chosen over those 10 amino Chapter 10 Determining putative HLA-restricted CTL epitopes from the putative 
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acids long. From this list of best-fitting epitopes, the number and proportion of putative 
CTL mutation sites that fitted at all their anchor residues of their corresponding HLA 
motif were calculated. 
To get an indication as to how easily an HLA allele and position combination can be 
found within a good epitope predicted by its corresponding HLA motif, the above 
procedure was also conducted for all significant negative associations with 
polymorphism from Chapter 6. The significant negative associations were also used to 
predict possible epitopes that the virus would create if it mutated at the negative 
association amino acid position. For each negative association, every possible amino 
acid change at the corresponding amino acid position was made, and the best epitope(s) 
(based on the peptide-binding motif) that overlapped this amino acid position was 
determined. The number of negative associations where it was possible for an amino 
acid change (from consensus at the amino acid position) to create a putative epitope 
defined by the corresponding HLA motif at all anchor positions was calculated. 
Results 
Of the putative epitopes that best fitted around the positive HLA associations with 
polymorphism from Chapter 6, 46 percent had corresponding HLA motifs that fitted at 
all anchor positions (see Table 10.2). This was similar to the percentage of known 
HLA-restricted CTL restricted epitopes in this region of HIV-1 that fitted their 
corresponding motif at all anchor residues (44 percent; see Table 10.1). However, it was 
not was significantly different to the percentage of control (negative) associations that 
had a corresponding HLA epitope that fitted at all anchor positions (54 percent; see 
Table 10.3; P=0.325). Results      
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Seventy percent of the negative associations were at positions at which an amino 
polymorphism could create an epitope fitting the corresponding HLA motif at all anchor 
positions (see Table 10.4). 
Table 10.1. Known CTL epitopes in HIV-1 RT and how well they fit their corresponding HLA motifs. 
Columns one and two show the position of the mapped epitope in HIV-1 RT. Column three shows the 
HLA for which the epitope is restricted. Column four shows the HLA allele type or broad HLA allele 
(with a known motif) that best fits the known epitope. Column five shows the epitope and is colour coded 
to show how well it fits the motif: Bold characters indicate preferred amino acids, red characters indicate 
anchor amino acids, purple characters indicate auxiliary amino acids, blue characters indicate common 
amino acids, green characters represent other common amino acids, black characters are other residues 
with no known positive effect; known HLA-restricted epitopes that have not been mapped to their 
optimal length are shown in lowercase characters. The final column shows how many anchor and 
auxiliary positions each motif has and indicates how well the known epitope fits its motif. Twelve (44%) 
of known epitopes in this region of RT with known motifs fit their motif at all anchor positions. HLA-
A*6801 does not have a defined motif. 
Published Epitope 
Start End 
Published 
Restriction(s) Sequence 
Motif’s HLA 
restriction(s) Comments 
18 26  B8,
126,689,702, 
947-949  
B*0801.
916 
GPKVKQWPL  B*08  Has all 3 primary 
anchors 
33 43  A*0301.
124,916  ALVEICTEME  A3  Has 1 of 2 primary and 0 
of 3 auxiliary anchors 
33 41  A2.
124,  
A*0201.
916 
ALVEICTEM  A*0201  Has 1 of 2 primary and 0 
of 1 auxiliary anchors 
42 50  B51,
124 
B*5101.
916 
EKEGKISKI  B*5101  Has 1 of 2 primary 
anchors 
107 115  B35,
126,950 
B*3501.
916 
TVLDVGDAY  B35, B*3501  Has both primary 
anchors 
108 118  A2,
951,952 
A*0201.
626 
VLDVGDAYFSV  A*0201  Has 1 of 2 primary and 0 
of 1 auxiliary anchors 
113 120  A24.
516  DAYFSVPL  A24  Has 1 of 2 primary and 0 
of 1 auxiliary anchors 
113 120  B*5101.
516  DAYFSVPL  B*5101  Has both primary 
anchors 
118 127  B35,
400,513,923 
B*3501.
49,126, 
513,916 
VPLDKDFRKY  B35, B*3501  Has both primary 
anchors 
126 135  A2.
719  KYTAFTIPSI  A*0201  Has 0 of 2 primary and 1 
of 1 auxiliary anchors 
128 135  B51,
49,126,915 
B*5101.
916 
TAFTIPSI  B*5101  Has both primary 
anchors 
151 159  B*5101.
516  QGWKGSPAI  B*5101  Has both primary 
anchors 
156 164  B7.
953  SPAIFQSSM  B*07  Has 1 of 2 primary and 1 
of 1 auxiliary anchors 
156 164  B35,
126,513 
B*3501.
49,126 
SPAIFQSSM  B35, B*3501  Has both primary 
anchors 
156 165  B7.
126,917,918  SPAIFQSSMT  B*07  Has 1 of 2 primary and 1 
of 1 auxiliary anchors 
158 166  A3,
126,716,921, 
950  
A3.1,
915,940 
A*0301.
126,563,
916,921 
AIFQSSMTK  A3  Has 1 of 2 primary and 2 
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Published Epitope 
Start End 
Published 
Restriction(s) Sequence 
Motif’s HLA 
restriction(s) Comments 
158 166  A11,
126,283,295, 
541,954 
A*1101.
126,916,
921 
AIFQSSMTK  A*1101  Has all (1) primary and 
2 of 3 auxiliary anchors 
158 166  A33.
339  AIFQSSMTK  A*3303  Has 0 of 1 primary and 1 
of 1 auxiliary anchors 
158 166  A*6801.
126,921  AIFQSSMTK    Unknown motif 
175 183  B35,
49,126,283, 
310,339,442,513,563,
923,955,956 
B*3501.
49,916 
NPDIVIYQY  B35, B*3501 Has both primary 
anchors 
175 199  A11.
957  npdiviyqymddlyvgsdleigqhr Exact epitope unknown. May be one or 
more of the following: 
       NPDIVIYQY  A*1101  Has 0 of 1 primary and 2 
of 3 auxiliary anchors 
         DIVIYQYMD  A*1101  Has all (1) primary and 
2 of 3 auxiliary anchors 
           VIYQYMDD  A*1101  Has all (1) primary and 
2 of 3 auxiliary anchors 
                MDDLYVGSD  A*1101  Has all (1) primary and 
1 of 3 auxiliary anchors 
                       SDLEIGQHR A*1101  Has all (1) primary and 
1 of 3 auxiliary anchors 
179 187  A2,
124,310,838, 
956,958 
A*0201,
126,688,
837,916,959-962 
A*0202.
310 
VIYQYMDDL  A*0201  Has 1 of 2 primary and 0 
of 1 auxiliary anchors 
180 189  A*0201.
126,149  IYQYMDDLYV  A*0201  Has 1 or 2 primary and 0 
of 1 auxiliary anchors 
192 201  A3.
124  DLEIGQHRTK  A3  Has both primary 
anchors 
192 216  B60.
126,957  dleigqhrtkieelrqhllrwgftt Exact epitope unknown. May be one or 
more of the following: 
           GQHRTKIEEL  B*4001  Has 1 of 2 primary and 1 
of 1 auxiliary anchors 
                 IEELRQHLL  B*4001  Has both primary and 0 
of 1 auxiliary anchors 
                  EELRQHLLRW  B*4001  Has 1 of 2 primary and 1 
of 1 auxiliary anchor 
201 209  A2.
124  KIEELRQHL  A*0201  Has 1 of 2 primary and 0 
of 1 auxiliary anchor 
203 212  B44.
126,149  EELRQHLLRW  B*4402  Has 1 of 2 primary 
anchors 
209 220  A2.
124  LLRWGFTTPD  A*0201  Has 1 of 2 primary and 0 
of 1 auxiliary anchors 
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Table 10.2. Putative epitopes best fitting around the positive putative CTL escape mutation sites, based 
on their corresponding HLA motifs. 
Each positive HLA association with between residues 20 and 227 of HIV-1 RT is shown with its amino 
acid position, P-value and odds ratio in the first four columns. For each association, the HLA (sub)type 
with the best putative epitope, based on its motif, that includes the amino acid position with the 
significant association is shown. Colour codes are the same as in Table 10.1. Underlined characters 
indicate the amino acid position of the association. The final column indicates if the putative epitope fits 
at all anchor residues. Twenty seven (46%) associations (with known motifs) were within putative 
epitopes with the same (or subtype) HLA-restriction that had all their anchor residues. Note the number 
of anchor residues for each motif varies from one to three depending on the HLA allele; there is no 
known motif for HLA-A28, HLA-B18 and HLA-B21. N.A. means not applicable as a corresponding 
HLA motif is not known. 
HLA association with polymorphism 
HLA Position  P-value Odds  ratio 
Motif’s 
HLA 
restriction 
Epitope Fits  at   
all  
anchors 
A2 26  0.004  4.214  A*0201  PLTEEKIKAL  Yes 
A3 28  0.034  2.54  A3  PLTEEKIK  Yes 
B16 28  0.032  3.295  B*3801  LTEEKIKAL  Yes 
B8 32  0.023  3.416  B*08  LTEEKIKAL  No 
           EEKIKALVE  No 
B17 32  0.038  4.264  B*5701  KALVEICTE  No 
A9 36  0.002  7.918  A24  EKIKALVEI  No 
B5 38  0.009  5.389  B*5101  KALVEICTEM  Yes 
A2 39  0.001  4.823  A*0201  ALVEICTEM  No 
B8 43  <0.001 7.666  B*08  EKEGKISKI  No 
           TEMEKEGKI  No 
               MEKEGKISK  No 
B14 43  0.001  19.093  B14  EKEGKISKI  No 
B7 49  0.042  2.421  B*07  ISKIGPENP  No 
A11 53  <0.001  6.69  A*1101  KISKIGPEN  No 
B5 60  0.035  2.28  B*5101  GPENPYNTPV  Yes 
A9 65  0.024  3.063  A24  KKDSTKWRKL  No 
B18 68  0.008  4.875      Unknown Motif  N.A. 
A2 69  0.010  3.453  A*0201  KDSTKWRKL  No 
B35 69  0.027  3.974  B*3501  KDSTKWRKL  Yes 
B40 69  0.038  2.879  B40  FAIKKKDST  No 
A10 70  0.014  2.815  A*2601  TKWRKLVDF  Yes 
B15 99  0.006  3.802  B*1501  VQLGIPHPAG  No 
B12 100,   
102 
0.004, 
0.009 
3.042, 
2.742 
B*4402  GLKKKKSVT  No 
A3 101  0.044  2.437  A3  IPHPAGLKK  No 
A9 103  0.033  2.222  A24  KKKSVTVL  No 
A9 115  0.014  3.623  A24  YFSVPLDKDF  Yes 
B12 115  0.015  2.803  B*4402  VLDVGDAYF  Yes 
B12 118  0.045  2.68  B*4403  SVPLDKDF  Yes 
B35 121,   
123 
0.014,  
0.001 
3.998,  
2.861 
B*3501  VPLDKDFRKY  Yes 
B37 123  <0.001  11.453  B*3701  LDKDFRKYT  Yes 
B5 135  <0.001 16.74  B*5101  TAFTIPSI  Yes 
B18 135  0.002  3.793      Unknown Motif  N.A. 
B18 142  0.033  2.512      Unknown Motif  N.A. 
A9 142  0.029  1.965  A24  SINNETPGI  No 
B7 158,   
162,  
165 
0.001,  
<0.001,  
0.024 
4.46,  
10.041,  
2.398 
B*07  SPAIFQSSMT  No 
A1 162  0.028  1.813  A1  SSMTKILEP  No 
B7 162,   
165,  
169 
<0.001,  
0.024,  
<0.001 
10.041,  
2.398,  
12.575 
B*07  SSMTKILEPF  No 
A11 166  <0.001  4.357  A*1101  AIFQSSMTK  Yes 
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HLA association with polymorphism 
HLA Position  P-value Odds  ratio 
Motif’s 
HLA 
restriction 
Epitope Fits  at   
all  
anchors 
B5 173  0.016  3.692  B*5101  PFRKQNPDI  Yes 
           EPFRKQNPDI  Yes 
               PFRKQNPDIV  Yes 
B18 173  0.020  6.079    Unknown Motif  N.A. 
B35 177  <0.001  3.524  B*3501  NPDIVIYQY  Yes 
           EPFRKQNPDI  Yes 
           NPDIVIYQYM  Yes 
           PDIVIYQY  Yes 
               PDIVIYQYM  Yes 
A19 178  0.032  1.983  A*3001  KQNPDIVIY  Yes 
           NPDIVIYQY  Yes 
B27 179  0.034  2.663  B*2701  KQNPDIVIY  Yes 
         B*2702  FRKQNPDIVI  Yes 
B8 181  0.001  5.106  B*08  VIYQYMDDL  No 
B5 196  0.003  4.286  B*5101  IGQHRTKI  Yes 
B40 197  0.004  5.775  B40  LEIGQHRT  Yes 
B37 200  <0.001  19.158  B*3701  SDLEIGQHRT  No 
           LEIGQHRTKI  No 
           IGQHRTKI  No 
           EIGQHRTKI  No 
           QHRTKIEEL  No 
           LEIGQHRT  No 
A11 203  0.018  4.084  A*1101  EELRQHLLR  Yes 
B12 203,   
211 
0.001,  
<0.001 
5.571,  
4.539 
B*4402  EELRQHLLR  No 
A9 204  0.014  3.593  A24  HRTKIEEL  No 
B15 207,   
211,  
214 
0.003,  
0.003,  
0.005 
2.894,  
2.866,  
3.769 
B*1501  RQHLLRWGF  Yes 
B40 207  0.017  2.185  B*40012  IEELRQHLL  Yes 
B21 210  0.003  10.187      Unknown Motif  N.A. 
B17 214  0.007  3.458  B*5801  FTTPDKKHQ  No 
           RQHLLRWGF  No 
         B*5701  RQHLLRWGF  No 
               FTTPDKKHQ  No 
A3 215  0.030  2.351  A3  HLLRWGFTT  No 
           LLRWGFTTP  No 
               WGFTTPDKK  No 
A1 215  0.004  2.691  A1  FTTPDKKHQ  No 
B7 215  0.047  2.050  B*07  LLRWGFTTP  No 
A9 219  0.013  3.278  A24  KKHQKEPPF  No 
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Table 10.3. Putative epitopes best fitting around the negative putative CTL escape mutation sites, based 
on their corresponding HLA motifs. 
Each negative HLA association with residues between 20 and 227 of HIV-1 RT is shown with its amino 
acid position, P-value and odds ratio in the first four columns. For each association, the HLA (sub)type 
with the best putative epitope, based on its motif, that includes the amino acid position with the 
significant association is shown. Colour codes are the same as in Table 10.1. Underlined characters 
indicate the amino acid position of the association. The final column indicates if the putative epitope fits 
at all anchor residues. Thirteen (54%) associations (with known motifs) were within putative epitopes 
with the same (or subtype) HLA-restriction that had all their anchor residues. N.A. means not applicable 
as a corresponding HLA motif is not known. 
HLA association with polymorphism 
HLA Position  P-value Odds  ratio 
Motif’s 
HLA 
restriction  Epitope 
Fits at  
all  
anchors 
A2 32  0.017  0.271  A*0201  LTEEKIKAL  Yes 
A1 35  0.011  0.388  A1  LVEICTEME  No 
A3 36,   
38,  
43 
0.013,  
0.008,  
0.044 
0.042,  
0.073,  
0.236 
A3  LVEICTEMEK  Yes 
B8 69  0.001  0.054  B*08  STKWRKLVDF  Yes 
A1 75  0.006  0.032  A1  LVDFRELNK  No 
B35 83  0.018  0.278  B*3501  VDFRELNKR  No 
           ELNKRTQDF  No 
               KRTQDFWEV  No 
A2 101  0.013  0.290  A*0201  GLKKKKSV  Yes 
           GLKKKKSVTV  Yes 
B7 118  0.030  0.208  B*07  GDAYFSVPL  No 
A2 122  0.004  0.509  A*0201  PLDKDFRKY  No 
A11 122  0.002  0.394  A*1101  AYFSVPLDK  Yes 
B16 122  0.026  0.350  B*3801  DKDFRKYTAF  Yes 
B12 123  0.021  0.529  B*4402  PLDKDFRKY  Yes 
               KDFRKYTAF  Yes 
A10 135  0.039  0.417  A*2601  FTIPSINNE  No 
A2 169  0.014  0.288  A*0201  SMTKILEPF  No 
B7 178  0.002  0.301  B*0702  IVIYQYMDDL  Yes 
B12 178  0.036  0.483  B*4402  PDIVIYQY  Yes 
           QNPDIVIY  Yes 
               QNPDIVIYQY  Yes 
A19 184  0.016  0.329  A*3001  IYQYMDDL  Yes 
           VIYQYMDDL  Yes 
           IYQYMDDLY  Yes 
           NPDIVIYQYM  Yes 
           IVIYQYMDDL  Yes 
B8 200  0.041  0.536  B*08  QHRTKIEEL  Yes 
B22 200  0.041  0.257      Unknown Motif  N.A. 
A10 207  0.044  0.411  A*2601  ELRQHLLRW  No 
B7 208  0.022  0.167  B*07  IEELRQHLL  No 
A2 210  0.029  0.370  A*0201  ELRQHLLRW  No 
B5 211  0.039  0.488  B*5101  ELRQHLLRW  No 
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Table 10.4. Putative CTL epitopes best fitting the negative CTL escape mutation sites after puative 
escape, based on their corresponding HLA motifs. 
Each negative HLA association with residues between 20 and 227 of HIV-1 RT is shown with its amino 
acid position, P-value and odds ratio in the first four columns. For each association, the HLA (sub)type 
with the best escaped putative epitope, based on its motif, that includes the amino acid position with the 
significant association is shown. The wild-type epitope is shown in column six. The putative epitope(s) 
that would be created if mutation occurred (at the amino acid position) is shown in column seven. 
Column seven indicates if the putative escape epitope contains all anchor amino acids for the motif. 
Colour coding, bolding and underlining is as in Table 10.1. N.A. means not applicable as a corresponding 
HLA motif is not known. 
HLA association with 
polymorphism 
HLA Position  P-value 
Odds 
Ratio 
Motif’s 
HLA 
restriction Epitope 
Escape 
Epitope 
Escape into an 
epitope with 
all anchor 
residues 
A2 32  0.017 0.271  A*0201  PLTEEKIK P LTEEKIV  Yes 
          PLTEEKIL  Yes 
A1 35  0.011 0.388  A1  LTEEKIKALV LTEEKIKALY Yes 
               TEEKIKALV TEEKIKALY  Yes 
A3 36  0.013 0.042  A3  VEICTEMEK V MICTEMEK  Yes 
             VVICTEMEK  Yes 
                  VLICTEMEK  Yes 
A3 38  0.008 0.073  A3  ICTEMEKEGK IMTEMEKEGK Yes 
           ICTEMEKEGK IVTEMEKEGK Yes 
               ICTEMEKEGK ILTEMEKEGK Yes 
A3 43  0.044 0.236  A3  EKEGKISK E MEGKISK  Yes 
             EVEGKISK  Yes 
                  ELEGKISK  Yes 
B8 69  0.001 0.054  B*08  AIKKKDST AIKKKDSL  Yes 
             AIKKKDSM  Yes 
                  AIKKKDSF  Yes 
A1 75  0.006 0.032  A1  DSTKWRKLV D STKWRKLY  No 
           LVDFRELNK LSDFRELNK  No 
              LTDFRELNK  No 
B35 83  0.018  0.278  B*3501  VDFRELNKR  VDFRELNKI  Yes 
             VDFRELNKL  Yes 
             VDFRELNKM  Yes 
             VDFRELNKF  Yes 
                  VDFRELNKY  Yes 
A2 101  0.013 0.290  A*0201  LKKKKSVTV L MKKKSVTV  Yes 
                  LLKKKSVTV  Yes 
B7 118  0.030 0.208  B*07  SVPLDKDF S PPLDKDF  Yes 
            B*0702  DVGDAYFSV  DVGDAYFSL  Yes 
A2 122  0.004 0.509  A*0201  DAYFSVPLDK DAYFSVPLDL No 
             DAYFSVPLDV No 
           YFSVPLDK  YFSVPLDL  No 
                  YFSVPLDV  No 
A11 122  0.002  0.394  A*1101  VPLDKDFRK VPLDMDFRK  Yes 
             VPLDVDFRK  Yes 
             VPLDFDFRK  Yes 
             VPLDIDFRK  Yes 
             VPLDPDFRK  Yes 
           FSVPLDKDFR FSVPLDFDFR Yes 
             FSVPLDVDFR Yes 
             FSVPLDYDFR Yes 
             FSVPLDIDFR Yes 
                  FSVPLDLDFR Yes 
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HLA association with 
polymorphism 
HLA Position  P-value 
Odds 
Ratio 
Motif’s 
HLA 
restriction Epitope 
Escape 
Epitope 
Escape into an 
epitope with 
all anchor 
residues 
B16 122  0.026  0.350  B*3801  DKDFRKYTAF DHDFRKYTAF  Yes 
             DVDFRKYTAF  Yes 
             DMDFRKYTAF  Yes 
             DYDFRKYTAF  Yes 
             DWDFRKYTAF  Yes 
             DPDFRKYTAF  Yes 
             DFDFRKYTAF  Yes 
           YFSVPLDK  YFSVPLDL  Yes 
             YFSVPLDF  Yes 
           AYFSVPLDK  AYFSVPLDL  Yes 
                  AYFSVPLDF  Yes 
B12 123  0.021  0.529  B*4402  KDFRKYTAF K EFRKYTAF  Yes 
A10 135  0.039  0.417  A*2601  YTAFTIPSI Y TAFTIPSF  Yes 
             YTAFTIPSY  Yes 
A2 169  0.014 0.288  A*0201  SSMTKILE  SSMTKILL  No 
             SSMTKILV  No 
           FQSSMTKILE FQSSMTKILL  No 
             FQSSMTKILV  No 
B7 178  0.002 0.301  B*07  EPFRKQNPDI EPFRKQNPDF  Yes 
             EPFRKQNPDL  Yes 
B12 178  0.036  0.483  B*4402  QNPDIVIY Q NPDYVIY  Yes 
               QNPDIVIYQY QNPDYVIYQY  Yes 
A19 184  0.016  0.329  A*3001  NPDIVIYQYM NPDIVIYQYL  Yes 
         A*3303  DIVIYQYM D IVIYQYR  No 
            A*2902  DIVIYQYM  DIVIYQYY  No 
B8 200  0.041 0.536  B*08  HRTKIEEL HRKKIEEL  No 
             HRRKIEEL  No 
           GQHRTKIEEL GQHRRKIEEL  No 
                  GQHRKKIEEL  No 
B22 200  0.041  0.257     
Unknown 
motif  N.A. 
A10 207  0.044  0.411  A*2601  RQHLLRWGF R FHLLRWGF  Yes 
             RLHLLRWGF  Yes 
             RIHLLRWGF  Yes 
             RTHLLRWGF  Yes 
             RVHLLRWGF  Yes 
           RTKIEELRQ R TKIEELRF  Yes 
              RTKIEELRY  Yes 
B7 208  0.022 0.167  B*07  RQHLLRWGF RQRLLRWGF  No 
A2 210  0.029 0.370  A*0201 
No mutation changes the 
number of anchor or auxiliary 
anchor positions  No 
B5 211  0.039 0.488  B*5101  EELRQHLLR  EELRQHLLI  No 
          EELRQHLLV  No 
         EELRQHLLL  No 
         EELRQHLLM  No 
         EELRQHLLW  No 
        LRWGFTTPD  LGWGFTTPD  No 
          LPWGFTTPD  No 
          LAWGFTTPD  No 
          LFWGFTTPD  No 
          LWWGFTTPD  No 
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Discussion 
The most common method of identifying potential epitopes within a polypeptide utilises 
anchor-based motifs.
963 However, it has been shown that approximately one third of the 
defined immunodominant epitopes do not fit their corresponding motif (reviewed in 
reference 945). In the region of HIV-1 we analysed, we observed that about half of the 
known CTL epitopes did not fit their respective motif. Hence, even for HLA 
associations with polymorphisms that represent true escape mutations within a CTL 
recognised epitope, for only about 50 to 67 percent would we expect to find a putative 
epitope that matched its corresponding HLA motif at all anchor residues. Indeed, for 49 
percent of the positive putative escape mutation sites, we found putative epitopes that 
fitted their corresponding HLA motif at all positions. This finding suggests that HLA 
molecules are more promiscuous in the peptides for which they bind efficiently enough 
to induce a CTL response than suggested by their HLA motif. It could also reflect a 
virus that has evolved both in the human population and primordially to avoid stretches 
of amino acids that fit HLA/MHC well. This has some support, as there are similarities 
between the types of amino acids that can be bound in the anchor pockets between 
MHC molecules.
283 
We were able to find putative epitopes for 54 percent of the negative putative escape 
mutation sites. We would have expected to see a lot fewer epitopes fitting around 
negative associations, as we would presume that there is less chance that such epitopes 
are presented by the corresponding HLA molecule. This apparent paradox could be 
explained in two ways. The first explanation is that if these putative epitopes are real, 
then biologically either the epitope is being presented but there is negative pressure to 
escape, possibly because the mutated epitope has a higher efficacy or the next epitope in Discussion      
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the hierarchy has higher CTL efficacy. This may be the case for the HLA-A3 restricted 
CTL epitope RT(33-43)
124,916 which has been shown to present the consensus sequence 
and in which we found three negative HLA-A3 associations. The other explanation for 
the high proportion of putative epitopes which include the polymorphic sites with 
negative corresponding HLA associations could be a statistical problem. Using one 
association to find an epitope, based on the corresponding HLA motif, that could be 
plus or minus nine amino acids from the amino acid position, creates a stretch of 19 
amino acids in which there appears to be a high probability that an epitope fitting its 
motif well could be found purely by chance. This highlights a limitation of using HLA 
motifs as a screening procedure to help define epitopes. Our data would suggest that in 
a stretch of 19 amino acids, there is about a 50 percent chance that a potential epitope 
with a good fit for an HLA motif can be found. Furthermore, while it may be true that 
many of these putative epitopes can be presented, their immunogenicity is unknown. 
Nonetheless, our data combined with peptide-binding motifs may help to identify those 
epitopes that are more likely to be real and immunodominant. Improving the specificity 
of defining a putative epitope may require incorporation of a combination of the size of 
the P-value, strength of the odds ratio, clustering of associations, proteasome cutting 
around the amino acid position, as well as the use of HLA motif information, and 
finally, testing these putative epitopes in vitro or ex vivo. 
A large proportion of the negative associations were at positions where, if there was an 
amino acid change, the sequence would fit the corresponding HLA motif and an epitope 
would potentially be created. It is unknown whether finding these escaped or negative 
epitopes, “negitopes”, would be statistically more difficult by chance than finding 
regular epitopes. Finding negitopes requires the sequence to not already be a putative 
epitope, mutation to only occur at an anchor residue, and the other anchor residues to be 
fixed. However, mutation at the amino acid position can be to any of the 19 non-Chapter 10 Determining putative HLA-restricted CTL epitopes from the putative 
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consensus amino acids. Knowing what amino acids are and are not tolerated by the 
virus may help limit these 19 amino acids and provide more evidence for negitopes.  
Clearly, if epitopes and negitopes are to be used in combination with our previous study 
of putative CTL escape and non-escape, then further work needs to be done to identify 
which of the epitopes defined in this study are actually real. Motifs defined using neural 
networks and statistics based on ligands, proteasome cutting sequence preferences, TAP 
transporter amino acid sequence preferences and HLA binding preferences may 
improve the results. However, ultimately, creating the putative epitopes and negitopes 
and seeing if an individual responds to it ex vivo or seeing if an HLA molecule can bind 
to it in vitro would be required.  
Chapter 11 Adjustment for multiple comparisons 
Introduction 
Many of the studies on associations of genetic factors with HIV-1 infection and 
outcome are hampered by the problem of multiple comparisons and the associated risk 
of type I errors, producing erroneous results. For this reason many investigators are 
cautious about the interpretation of studies looking for associations using many 
explanatory variables and/or many models.
467 In other chapters we show statistical and 
independent biological justification for the associations we found between HIV-1 
polymorphism and HLA in Chapter 6. Here we present a method for identifying those 
associations that withstand statistical correction for the number of effective independent 
comparisons that were made. 
The issue of multiple comparisons was considered when we designed the method for 
identifying putative escape mutation sites. Several steps were performed prior to formal 
statistical testing to reduce the actual number of tests. These included removing 
covariates that had insufficient power to be significant in the final model, and using a 
multiple variable logistic regression model rather than several univariate models at each 
position (see Chapter 6). However, while these precautions probably went part way to 
reduce the number of covariates considered, and hence the number of false associations, 
the effective number of comparisons made is uncertain. 
The simplest and most conservative approach to correct for multiple tests conducted and 
covariates considered would be to multiply each P-value by the total number of 
covariates considered at each polymorphic position multiplied by the total number of 
positions examined (known as a Bonferroni correction). At each position, we Chapter 11 Adjustment for multiple comparisons  172 
considered 26 HLA alleles and 227 other positions as covariates. And we did this across 
208 positions. This would give us a correction factor of 48,464, and only P-values less 
than 1x10
-6 (that is, 0.05/48,464 rather than 0.05) would be considered significant after 
this correction. While this correction would leave a few of the associations we observed 
significant (namely, HLA-B5 at 135, HLA-B7 at 162, HLA-A11 at 166, HLA-B7 at 
169, HLA-B12 at 211) it is intuitively overly conservative because more common HLA 
alleles have a greater chance of turning up a false result and positions with little 
mutation are unlikely to produce a model with any significant covariates. In addition, 
this correction assumes all tests are independent, and this is clearly not true in our 
situation, where the test results would be correlated in a complex way. A more 
appropriate method that could be used for this study and future studies was therefore 
needed.  
The aim of this study is to define a method to estimate the effective number of multiple 
comparisons made in our analysis of HLA associated polymorphism Chapter 6 and to 
use this information to identify those associations that withstand correction. 
Methods 
The method described estimates the number of false positive associations, for each 
HLA covariate, that would be expected over the entire genome analysed (208 amino 
acids) using the same methods used to identify putative escape mutations described in 
Chapter 6. The expected number of false positives for each HLA covariate is then used 
to generate a correction factor for that HLA. P-values for each of the identified HLA 
association are then adjusted using this correction factor. Those P-values remaining less 
than 0.05 were considered significant after correction for multiple comparisons.  Methods      
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One thousand randomised datasets were created by randomly reassigning the HLA 
alleles amongst individuals. The actual combinations of HLA alleles observed within 
individuals, rather than individual alleles at each locus, were randomised to avoid HLA 
combinations that did not exist in the study group. This also allowed any associations 
(or linkage disequilibria) that exist between HLA alleles to be kept within the 
randomised datasets. For each of the randomised datasets, the previously described 
method for determining HLA associated polymorphisms, including all pre-selection 
criteria, was carried out for amino acid positions 20 to 227. For each HLA allele, the 
average number of significant positive and negative associations (inexact logistic P-
value <  0.05) across datasets was calculated. This number was divided by 40 [i.e. 
2(1/0.05); 1/0.05 was multiplied by 2 because negative and positive associations were 
considered separately] to estimate the effective number of independent tests carried out 
as a correction factor for multiple comparisons. Using a Bonferroni-type correction [i.e. 
Pc = 1-(1-P)
x, where Pc is the corrected P-value; P is the original, uncorrected P-value; 
and x is the effective number of comparisons; note, this correction is similar to the more 
commonly known correction factor of Pc = x.P but limits Pc to 1], the correction factor 
was used to calculate the P-values corrected for multiple comparisons for the 
associations found in Chapter 6.  
Only correction factors for the inexact P-values were calculated due to computer 
processor limitations. The number of models that would have been required to calculate 
correction factors for exact P-values would have been in the order of 208 (amino acid 
positions) multiplied by 1000 randomisations (to calculate exact P-values) multiplied by 
1000 randomisations (to calculate the correction factor). That is, 208 million. Chapter 11 Adjustment for multiple comparisons  174 
Positive and negative correction factors were considered separately because there was 
less power to detect negative associations than positive associations. See the discussion 
in this chapter and in Chapter 13. 
Results 
Correction factors 
ranged from 5.0 
(HLA-B37) to 92.2 
(HLA-B7) for 
positive associations 
and 0.8 (HLA-B38) to 
60.2 (HLA-A2) for 
negative associations 
(see Table 11.1). 
Correction factors 
correlated with the frequency of the allele in the cohort (see Figure 11.1). For positive 
associations, the correction factor plateaued at about 80 with an HLA allele frequency 
of 12 percent. For negative associations the correction factor increased fairly 
monotonically until an allele frequency of about 50 percent, at which point it had a 
similar correction factor to the positive associations. For all alleles the correction factor 
for positive associations was greater than for the negative associations. The correction 
factor for each HLA allele correlated strongly with the number of models for which 
each of the alleles were considered (P<0.0001, see Figure 11.2 and Table 11.1) but was 
less conservative (P<0.0001, sign test). 
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Figure 11.1. HLA correction factor versus HLA allele frequency. Results      
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The corrected P-values 
from the original 
modelling of the amino 
acids 20 through 227 are 
shown in Table A.4 (see 
Appendices, page 309) 
and in boxes in Figure 
6.3, Panel A and Panel 
B (see page 131). There 
were 12 associations that remained significant following this correction. Only one of 
these was for a negative association. 
Table 11.1. Multiple comparisons HLA correction factors for each HLA allele. 
The number of positions in HIV-1 between amino acids 20 and 227 that each HLA allele was considered 
(i.e. not eliminated from in the preselection process) is shown in column two. The mean number of 
significant negative and positive associations that were generated in the 1000 randomised datasets, which 
incorporated the entire preselection process is shown in column three. The correction factor, which is the 
estimated number of effective independent tests conducted for each allele, is shown in the final column. 
N.A. means not applicable and occurred when an HLA allele did not have any significant negative or 
positive association in any model. 
Negative/ 
positive 
HLA 
association 
Number of 
models the 
allele was 
considered 
Mean number 
of associations 
per randomised 
dataset 
Correction 
Factor  
A1  78 2.86  57.24 
negative   1.03  41.36 
positive   1.83  73.08 
A2  70 3.31  66.19 
negative   1.50  60.16 
positive   1.81  72.20 
A3  78 2.95  59.06 
negative   1.05  41.80 
positive   1.91  76.24 
A9  78 2.99  59.82 
negative   0.94  37.60 
positive   2.05  82.00 
A10  64 2.24  44.87 
negative   0.47  18.68 
positive   1.78  71.04 
A11  74 2.82  56.36 
negative   0.80  31.84 
positive   2.02  80.80 
A19  74 3.00  60.00 
negative   0.94  37.52 
positive   2.06  82.48 
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Figure 11.2. The correction factor versus the number of models for which 
an HLA allele was not eliminated. Chapter 11 Adjustment for multiple comparisons  176 
Negative/ 
positive 
HLA 
association 
Number of 
models the 
allele was 
considered 
Mean number 
of associations 
per randomised 
dataset 
Correction 
Factor  
A28  48 1.45  29.09 
negative   0.23  9.28 
positive   1.22  48.96 
A31  0 0.00  N.A. 
negative   0.00  N.A. 
positive   0.00  N.A. 
A36  0 0.00  N.A. 
negative   0.00  N.A. 
positive   0.00  N.A. 
B5  64 2.55  50.97 
negative   0.49  19.52 
positive   2.06  82.36 
B7  78 3.38  67.55 
negative   1.07  42.84 
positive   2.30  92.16 
B8  78 2.86  57.22 
negative   0.90  35.88 
positive   1.97  78.68 
B12  78 3.18  63.60 
negative   1.10  43.88 
positive   2.08  83.28 
B13  45 1.44  28.89 
negative   0.18  7.28 
positive   1.26  50.48 
B14  61 2.21  44.16 
negative   0.36  14.56 
positive   1.85  73.80 
B15  71 2.69  53.73 
negative   0.61  24.32 
positive   2.08  83.28 
B16  56 1.84  36.88 
negative   0.30  11.92 
positive   1.55  61.80 
B17  65 2.41  48.29 
negative   0.44  17.68 
positive   1.97  78.96 
B18  48 1.53  30.63 
negative   0.21  8.56 
positive   1.32  52.80 
B21  31 0.80  16.04 
negative   0.09  3.64 
positive   0.71  28.40 
B22  38 1.02  20.46 
negative   0.13  5.36 
positive   0.89  35.68 
B27  49 1.50  29.91 
negative   0.22  8.84 
positive   1.27  50.96 
B35  65 2.55  51.03 
negative   0.50  19.96 
positive   2.05  82.12 
B37  10 0.15  2.90 
negative   0.02  0.76 
positive   0.13  5.04 
B40  70 2.56  51.09 
negative   0.55  22.04 
positive   2.01  80.28 
      Results      
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Negative/ 
positive 
HLA 
association 
Number of 
models the 
allele was 
considered 
Mean number 
of associations 
per randomised 
dataset 
Correction 
Factor  
B41  3 0.00  N.A. 
negative   0.00  N.A. 
positive   0.00  N.A. 
B42  3 0.00  N.A. 
negative   0.00  N.A. 
positive   0.00  N.A. 
 
Discussion 
The results of our analysis verify that those alleles that are more common in the 
population are those that are more likely to have false-positive results, and hence 
require a larger correction factor. The correction factors were orders of magnitude less 
than the overall single factor of 48,464 suggested by the conservative Bonferroni 
correction. The main reduction came from the use of multiple variable, rather than 
single variable, modelling at each position. This effectively reduced the number of 
comparisons to the number of positions where the allele remained in the modelling 
process after the initial elimination steps (due to those HLA alleles and polymorphic 
sites with reasonable power and numbers to demonstrate an association; see column two 
of Table 7.2, page 141). The number of positions at which an HLA allele was not 
eliminated in the initial elimination steps was similar to its correction factors produced 
from this study. Further reduction may have come from leaving the associations that 
existed between HLA in individuals in the cohort (that is, by not breaking up HLA from 
individuals) and the associations that may occur between polymorphisms in the virus in 
individuals (by not randomising ‘other’ positions) in the randomisation process. This 
may have allowed some of the variability that exists between viral amino acid positions 
(for example, due to clade differences) to be reduced, effectively reducing the amount 
of mutation at each position, and hence the number of covariates with power to have a 
false positive association. In all cases, the correction factor for negative HLA Discussion  178 
associations was 
less than that for 
positive 
associations. This 
is because the 
power to detect a 
negative 
association is 
lower than the 
power to detect a 
positive 
association where HLA allele frequency is less than 50 percent (see Figure 11.3). As we 
have described in Figure 11.1, there was a plateauing of the positive correction factors 
at an HLA allele frequency of around 12 percent. The inverse can be seen in Figure 11.3 
where the frequency of polymorphism also plateaus for positive associations at around 
12 percent. Furthermore, the trends of the points in Figure 11.1 are inversed compared 
to the shape of the curves generated for HLA allele frequency and polymorphism 
frequency in Figure 11.3. This is true for both negative and positive associations. 
It is important to note that our correction for multiple comparisons will still be overly 
conservative in some cases because the extent of correction depends on the size of the 
gene region arbitrarily chosen for study. Such correction results in decreasing false 
associations (higher specificity) at the cost of losing true associations (lower 
sensitivity). Our methods provide a more robust and appropriate method for correcting 
for multiple observations. However, we conclude that independent biological validation 
rather than statistical means will best determine what corrections are optimal for 
sensitivity or specificity in detecting biologically important polymorphisms. 
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Figure 11.3. Minimum amount of polymorphism and HLA frequency required 
to detect an association. 
This graph was produced using a power of 30% and an odds ratios of 2 (positive 
association) and 0.5 (negative association).   
Chapter 12 Overall test of significance 
Introduction 
The traditional approach with multiple comparisons would be to firstly show a 
statistically significant overall test for association that incorporates all the data and 
covariates via the experiment-wise P-values. After a significant result, separate tests 
would be performed to determine what factors are influencing the association. Using 
this approach, we wanted to provide further statistical evidence that polymorphism in 
the region of HIV-1 RT analysed previously was associated with HLA. However, the 
size of a single statistical model that would be required to produce a result for 208 
positions by 26 alleles and 227 ‘other polymorphism’ covariates, plus all the potential 
interactions, was computationally prohibitive. In this chapter we present an alternative 
method using randomisation techniques. 
As mentioned in previous chapters, we propose that the polymorphism in HIV-1 is 
largely driven by HLA induced CTL escape mutations. Other arguments for genetic 
drift (random polymorphism),
109 founder effect (both in the individual and in clades)
26 
are also likely to also contribute to some extent. However, we hypothesise that even in a 
short region of HIV-1, in an HLA-diverse population and in 473 individuals, 
polymorphism can be seen to be associated with the individuals’ HLA. 
Methods 
The method presented here breaks the modelling of an overall HLA and polymorphism 
association into separate models for each position and later combines them using Chapter 12 Overall test of significance  180 
randomised datasets to generate an overall P-
value for all HLA associated polymorphism 
across all positions. 
The randomisation data sets generated from 
calculating the correction factors for multiple 
comparisons were used. First, the sum of test 
statistics across all positions for all significant 
alleles was calculated for each allele in the 
original dataset. This was repeated for each of 
the 1000 randomised datasets and compared to 
the number calculated from the original dataset. 
For each allele, the proportion of randomised 
datasets with a test statistic greater than the 
original dataset was calculated to give an 
overall P-value. This represented the probably 
that the allele was associated with 
polymorphism across the region of HIV-1 
analysed. The sum of test statistics across all 
positions and all alleles was also compared in a 
similar manner to produce an overall P-value 
for the association between all HLA alleles and polymorphism. 
Results 
For none of the 1000 random datasets was the sum of test statistics across all alleles and 
all positions greater than in the actual data, giving an overall P-value of <1/1000 or 
Table 12.1. Association between HLA and 
polymorphism in HIV-1 RT. 
The P-value for association between each 
allele and polymorphism across all 208 
amino acids was calculated by counting the 
number of the 1000 randomised datasets 
with a sum of test statistics greater than the 
original dataset, and dividing this number 
by 1000. The P-value across all HLA 
alleles and all positions was calculated in a 
similar manner using the sum of all test 
statistics for all HLA (see last row).  
HLA 
allele 
Sum of test 
statistics 
from 
original 
dataset  P-value 
A1  19.39  0.239 
A2  31.84  0.007 
A3  19.19  0.256 
A9  18.12  0.299 
A10  14.90  0.183 
A11  22.52  0.063 
A19  8.87  0.874 
A28  8.19  0.355 
A31  0.00  1.000 
A36  0.00  1.000 
B5  24.91  0.014 
B7  31.18  0.008 
B8  22.28  0.082 
B12  33.37  0.007 
B13  1.22  0.959 
B14  14.26  0.177 
B15  19.88  0.079 
B16  8.52  0.454 
B17  13.39  0.324 
B18  10.71  0.152 
B21  4.31  0.384 
B22  3.83  0.557 
B27  5.41  0.599 
B35  16.71  0.190 
B37  5.18  0.001 
B40  17.06  0.175 
B41  0.00  1.000 
B42  0.00  1.000 
TOTAL  375.22  <0.001 Results  
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<0.001 (see Table 12.1, final row). The individual alleles with significant amounts of 
mutation in this region of HIV-1 were HLA-A2 (P=0.007), HLA-B5 (P=0.014), HLA-
B7 (P=0.008), HLA-B12 (P=0.007) and HLA-B37 (P=0.001) (see Table 12.1). 
Discussion 
The overall significance of less than 0.001 from this study gives further strong statistical 
evidence that HLA does contribute to the polymorphism in HIV-1 at a population level. 
The individual alleles that are significant indicate those alleles that are contributing to 
the polymorphism. Four out of the five alleles found to be significantly associated with 
polymorphism in this region of HIV-1 were also significant at individual positions after 
correction for multiple comparisons in Chapter 11 The exception was HLA-A2, which 
was not significant at any position after correction for multiple comparisons; (see 
Chapter 11; Figure 6.3, page 131 and Table A.4, page 309). The most significant 
association was with the rare HLA allele HLA-B37 (allele frequency was 1.5 percent; 
see Table 3.2, page 99). This was the only allele with a significant association for which 
a corresponding HLA-restricted CTL epitope has not been mapped in this region of 
HIV-1 (see Figure 6.3). This allele also had the smallest correction factor from a 
previous analysis (see Chapter 11 and Table 11.1, page 175). Performing an analysis at 
each position in this region, and using the standard Bonferroni method to correct for 
multiple comparisons would have resulted in no significant association with HLA-B37, 
as 10 positions had enough power to show an association for HLA-B37 (see Table 7.2, 
page 141), and the smallest P-value for HLA-B37 was 0.009 at position 123 (see Table 
A.4, page 309). In contrast, the second strongest association with HLA-A2 – the most 
common allele in the cohort (see Table 3.2, page 99) and the allele with one of the 
largest correction factors (see Table 11.1) - was not associated with polymorphism at 
any single residue after correction for multiple comparisons, but was associated with Chapter 12 Overall test of significance  182 
polymorphism at eight positions prior to correction, one of which was within a known 
HLA-A2 restricted CTL epitope [P=0.017 at position 39, within RT(33-41, LAI);
124,916 
see Figure 6.3, page 131], and three of which clustered (P=0.12; see Chapter 8 and 
Table 8.1, page 145). Only by combining the effects of HLA-A2 over all positions were 
we able to show that HLA-A2 significantly contributed to polymorphism in HIV-1 RT 
after taking multiple comparisons into account. Other analyses performed in this thesis 
are able to indicate where each allele is acting and if the allele is contributing to 
increased or decreased polymorphism.  
These results support the biological significance of HLA-restricted epitopes that are 
mapped to this region of HIV-1. They also indicate which restriction of HLA epitopes 
to use to search for new epitopes in this region. The method could be applied to other 
regions, other genomes and other explanatory variables (for example, HLA class II 
alleles).  
Combining the effects of explanatory variables from multiple models in this way is an 
effective means of analysing sequences that would otherwise be computationally 
intensive. The individual models also give some indication of those alleles that are 
contributing to the significance. This method could also be useful where the number of 
individuals is too small to show significance or the region being analysed is too large to 
show significance after correction for multiple comparisons.   
Chapter 13 Population evolution of HIV-1 
Introduction 
There is strong evidence that the HLA-A and HLA-B restricted CTL immune response 
can induce mutations in HIV-1, both in humans (reviewed in reference 164),
1,12,13,46-
48,283,524,565,583,585,586,590 and in SIV
2,3 and SHIV
4 in rhesus macaques. Evolution of HIV-1 
is likely to have been influenced by these HLA restricted immune responses and may be 
evident in the amino acid sequences seen in HIV-1. Earlier it was noted that it is 
uncommon to see long stretches of amino acids that cannot tolerate a change, possibly 
because the immune system recognises the virus through stretches of eight to 12 amino 
acids through HLA class I restriction.
40,249 How the most common amino acid at a 
particular position in HIV-1 at the population level is determined may be evident by 
examining sites where there is a reduced chance of polymorphism associated with an 
HLA allele. These associations may indicate where epitopes have escaped HLA 
restricted CTL responses during passages through previous hosts or through more 
ancestral hosts (such as Chimpanzees) with a structurally similar HLA allele. 
Population escape from an epitope would only be expected to occur where the 
frequency of that allele in the population is high or the sum of frequencies of several 
alleles that commonly present that epitope is high. This type of population escape has 
been described for an HLA-A11 epitope in EBV in South East Asia where HLA-A11 is 
the most common HLA allele.
22-25,895 
It is likely that our definition of consensus sequence incorporates CTL escape that has 
occurred at the population level – where CTL escape mutations from common HLA 
alleles has been selected for in the population.
21 Standard methods for detecting HLA Chapter 13 Population evolution of HIV-1  184 
epitopes and escape could not easily detect these escaped epitopes. Our approach of 
detecting escape mutations is able to indicate the possible presence and position of these 
as negative associations. From the results in Chapter 6, there were 26 residues at which 
non-synonymous polymorphism was significantly associated with HLA alleles but with 
an OR<1, indicating a ‘negative’ association (see Figure 6.3, panel C, page 131). Unlike 
positive immune selection causing demonstrable escape to fixation in individuals over 
time, negative immune selection favours preservation of wild-type virus in vivo and so 
is more readily evident at the population level. For example, non-synonymous 
polymorphism at positions 101, 122, 169, 206 and 210 of HIV-1 RT was negatively 
associated with presence of HLA-A2 (OR<1, P<0.05 in all cases). This means that 
HLA-A2 individuals were significantly less likely to vary from the consensus at these 
sites compared with all non-HLA-A2 individuals in the cohort. HLA-A2 was the most 
common HLA allele analysed in our cohort and had five of the 25 (20 percent) negative 
associations compared with three of the 64 positive associations (5 percent). Similarly, 
individuals with the common HLA-B7 allele were significantly less likely to mutate at 
the HIV-1 RT positions 118, 178 and 208 compared with non-HLA-B7 individuals. 
That is, it appeared from our previous results that the more common HLA alleles were 
more likely to be associated with lack of polymorphism.  
We hypothesise that the more common the HLA allele, the more negative associations 
the allele will have, even after adjusting for the fact that associations are easier to find 
with more common alleles. 
Methods 
As the great majority of molecular subtypes of serologically defined HLA groups are 
likely to influence HIV-1 infection differently, only those broad serological HLA Methods      
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groups that had specificity at least as great as HLA-B5 (77 percent) for a single 
molecular subtype were considered in this analysis. These were HLA-A1, -A2, -A3, -
A11, -B5, -B7, -B8, -B17, -B18, -B27 and -B37 (see Table 3.2, page 99). For each of 
these alleles, the number of negative associations was calculated. The linear regression 
line of this versus the HLA allele frequency was calculated and the slope determined. 
Because the frequency of 
an allele affects the 
ability to find significant 
associations (see Figure 
11.3, page 178), the 
number of negative 
associations and the 
linear regression slope 
from the original data 
were compared to 1000 
randomised datasets that 
would have incorporated the same biases. The significance of the positive correlation 
between HLA allele frequency and number of significant negative associations was 
calculated by determining the proportion of the randomised datasets that had a steeper 
slope than the original dataset. Regression lines were forced to go through the origin to 
reflect the biology that for an allele that is not present in the population there will be no 
associations. Regressions without this restriction were also calculated. Similarly, to 
calculate the significance of the number of negative associations found for each HLA 
allele, the number from the original dataset was compared to that of the randomised 
datasets.  
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Figure 13.1. The number of negative associations versus HLA 
phenotypic frequency. 
Only HLA alleles with a molecular subtype greater than 77% were 
included. The regression line generated from this dataset and the 95% 
prediction interval of slopes generated from the 1000 randomised 
datasets are shown. Only six randomised datasets had a slope greater 
than the one generated from the actual data (P=0.006). Chapter 13 Population evolution of HIV-1  186 
For this analysis, only the non-exact P-values were used because exact P-values on the 
randomised datasets that incorporated the entire selection process could not be 
calculated with the resources available.  
Results 
The slope of the linear regression line of the number of negative associations versus the 
HLA allele frequency (in percentage) was 0.084 (data shown in Table 13.1). The mean 
of the slopes generated from the randomised datasets was 0.036 with a standard 
deviation of 0.014. Only six of the 1000 randomised datasets had a slope greater than 
the slope generated from the original dataset (P = 0.006). Figure 13.1 displays the data 
and slopes for the original dataset and the 95% prediction intervals generated from the 
slopes from the randomised datasets. The significance of the linear regression line that 
were not forced through zero was similar (P = 0.007).  
When considering the HLA alleles separately, only HLA-A2 and HLA-B5 had 
significantly more negative associations with P-values of 0.015 and 0.012 respectively 
(see Table 13.1). To check for the possible effect of HLA-A2 being an outlier, the 
slopes of the linear regression lines were recalculated after removing HLA-A2 from the 
original and randomised datasets. This resulted in a slope of 0.070 and a significant P-
value (P = 0.01) when compared to the slopes from the randomised datasets with HLA-
A2 removed.  Results    
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Table 13.1. The frequency and the number of negative associations found for each HLA allele. 
Only HLA alleles with their largest molecular subsplit greater than 77 percent were considered.  
HLA 
Number of 
negative 
associations 
HLA 
allele 
frequency 
(%) 
Average number of 
randomised datasets with 
more negative associations 
(P-value) 
A1 2  29.4  0.263 
A2 5  48.2  0.015 
A3 3  23.7  0.288 
A11 1  17.3  0.547 
B5 1  11.0  0.012 
B7 3  26.4  0.659 
B8 2  23.5  0.226 
B17 0  9.7  1.000 
B18 0  6.3  1.000 
B27 0  6.3  1.000 
B35 1  12.1  0.396 
B37 0  1.5  1.000 
 
Discussion 
After using permutation analyses to overcome the problem with the HLA allele 
frequency affecting the number of associations expected by chance, a significant 
positive association was observed between the number of negative associations and the 
HLA allele frequency. This remained significant after considering the possibility that 
the significance of this slope may have been determined by an outlier corresponding to 
HLA-A2. Aside from the power considerations mentioned, the observation of fewer 
negative associations than positive associations may have resulted from the fact that in 
order to see a negative association some positive selection (for example, by other HLA) 
or randomness (for example, genetic drift) would need to occur to see under-
representation of an HLA allele. Acknowledging the criticism of the small number of 
associations and small region of the genome analysed, more individuals and a larger, or 
different, region of the genome should be analysed in other studies.  
These results provide some statistical evidence (even after adjusting for the non-
conservative biases) for the intriguing possibility that the consensus or wild-type virus Chapter 13 Population evolution of HIV-1  188 
is partly adapted to the CTL responses that it is most likely to encounter (that is, those 
restricted to the most common or evolutionary conserved HLA alleles in the host 
population). Whether this adaptation occurred since arriving in humans or primordially 
in other primates requires further investigation. Since HIV-1 is estimated to have been 
transmitted from primates to humans around 1930,
879 it may have had enough exposure, 
and possibly some bottleneck effect while it was not epidemic, to be influenced by 
human MHC (HLA). It has been shown that weakly immunogenic variants of EBV 
appear to be selected by the predominant HLA type of a host population.
22-25,895 While 
the majority of polymorphisms between the different HIV-1 clades appears to be due to 
founder effects,
26 we speculate that HIV-1 population adaption to the common prevalent 
HLA alleles also contributes to some of the differences. This could explain why 
selection of escape mutations in CTL epitopes restricted to the common allele HLA-
A*0201 was not demonstrated in studies that have argued against the viral ‘escape 
hypothesis’
688,917 and even why surprisingly few HLA-A2 and HLA-A1 restricted 
epitopes have been mapped in HIV-1.
719 Furthermore, studies of HIV-1 exposed 
seronegative individuals suggest that CTL responses can alter viral infectivity and 
susceptibility to established primary HIV-1 infection.
310,339,406,433,442 The HLA class I 
alleles associated with natural HIV-1 resistance or susceptibility appear to differ 
between racially distinct populations.
303,310,339,433 To some extent this may reflect the 
varying relative frequencies of alleles in different populations and the degree to which a 
‘population-adapted’ consensus virus can adapt to the individual. It has also been 
observed that rare HLA alleles offer some protection from infection, however there is 
some debate as to whether this is because of an HLA response to the virus or an 
alloimmune reaction to the HLA particles of the transmitting host in the virion.
297,316-318 
Population adaptation can also be seen in the increasing frequency of transmitted drug Discussion      
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resistant strains in HIV-1 in populations where antiretroviral treatment is in common 
usage.
750,751  
These results may be able to explain why RNA viruses have been seen to evolve in vitro 
without any immune selection pressures.
964 While random mutations that do not affect 
the fitness of the virus may exist, these results would suggest that viruses that evolve 
and become more fit in the absence of immune pressures are evolving away from the 
constraints applied by population adaptation. In HIV-1 we would predict that viral 
polymorphisms away from the consensus sequence at the sites of negative associations 
for common HLA alleles may be more fit in vitro and we would expect to see these 
evolve in the absence of immune pressures. Another explanation is that the virus seen in 
vivo may have evolved to be less pathogenic to increase its infectivity of other hosts. 
While this appears to be the case for many viruses that co-exist for the life of their host, 
in HIV-1 this may not be the current case. The same is true for SIV in their unnatural 
hosts. Passage of SIV
888 and SHIV
889 in rhesus macaques sees a progressive increase in 
viral load. Furthermore, the less pathogenic HIV-2 is believed to have been introduced 
into the human population more recently than HIV-1.
469,879 Our data supports this 
apparent increase in pathogenicity, with the virus that is most likely to infect an 
individual already partially adapted to the HLA alleles it is most likely to encounter on 
infection of a new individual. This argues that co-existence of pathogens and hosts, as 
seen in HBV and in natural SIV infection, is influenced more by host evolution (for 
example, selection of MHC).   
Chapter 14 HLA molecular subtyping: improving the 
strength of associations and biological importance 
Introduction 
The analysis described previously to determine putative HLA escape mutations used 
broad serologically defined HLA alleles as covariates in the modelling. This was done 
since many of the individuals in the cohort did not have higher resolution typing 
available, some individuals had died without adequate storage of material to allow high 
resolution HLA typing, the expense of high resolution typing prevented it being 
undertaken as the initial typing, and we felt the effect of such typing on analysis was 
likely to be conservative and if anything, result in a reduced ability to detect significant 
associations. However, HLA class I subtypes, within a broader serologically defined 
allele, defined by high resolution DNA sequence based typing, commonly have amino 
acid sequence differences that influence epitope binding.
342 Such differences have 
probably arisen through selection because they bind different peptides
27,31,37 and have 
different effects on pathogens.
28-30,32-36,38-40 
In this study, we sought to examine the effect of molecular subtyping on some examples 
of serologically defined HLA associations with polymorphism found in the logistic 
regression models. We chose two examples of strongly associated HLA-specific 
polymorphism, associated with broad HLA alleles that have common subtypes with 
differences within known CTL epitopes and where the HLA restriction of the epitope at 
the molecular level is known. 
The HIV-1 RT polymorphism at position 135 (I135x, where I is the consensus amino 
acid isoleucine and x is any other amino acid) associated with presence of HLA-B5 was Chapter 14 HLA molecular subtyping: improving the strength of associations 
and biological importance 
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the strongest positive HLA association with a residue within a published epitope 
(OR=17, P <0.001; Figure 6.3, panels A and B, page 131). The epitope RT(128-135 
IIIB/SF2) is known to be restricted to HLA-B*5101 specifically (a molecular subtype of 
HLA-B5, see Table 3.2, page 99) and position 135 is one of its anchor sites.
516 Six of 
the other seven amino acids in the epitope are critical stability residues for the RT 
protein,
152 and are relatively invariant (see Figure 5.2, page 115 and Figure 6.3, Panel 
D, page 131).  
The polymorphic position 177, shown to be associated with HLA-B35 (OR=4, P 
<0.001; Figure 6.3, Panels A and B, page 131), is within a CTL epitope restricted to 
HLA-B*3501, RT(175-183 IIIB/LAI).
49,126,283,310,339,442,513,563,916,923,955,956 As the residue 
177 is at position three of the epitope, which is thought to have little effect on HLA-
binding, we postulate that this polymorphism is likely to have a greater affect on TCR 
interactions. 
Within out cohort, the main HLA-B5 subtypes are HLA-B*5101, HLA-B*5108, HLA-
B*5201 and HLA-B*5301. HLA-B*5101 is the most common subtype. HLA-B*5108 
and HLA-B*5201 only differ from HLA-B*5101 at two amino acid positions, and 
HLA-B*5301 varies at eight positions (see Figure 14.1, Panel A and reference 965). All 
differences are in the peptide-binding groove (see Figure 14.1, Panel B). Similarly, the 
main HLA-B35 subtypes in our cohort are HLA-B*3501, HLA-B*3502, HLA-B*3503 
and HLA-B*3504, with HLA-B*3501 the most common. HLA-B*3502, HLA-B*3503 
and HLA-B*3504 vary from HLA-B*3501 by three, one and two amino acids, 
respectively (see Figure 14.2, Panel A; and reference 965). As with the HLA-B5 
subtypes, these differences are in the peptide-binding groove (see Figure 14.2, Panel B).  
Differences in only one or a few amino acids in the peptide-binding groove of the HLA 
molecule have been shown to influence disease susceptibility and progression. For Introduction      
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example, in Behcet’s disease, HLA-B*5101 is associated with disease while the other 
HLA-B5 subtypes are not.
966 In HIV-1, HLA-B*3502, HLA-B*3503 and HLA-B*3504 
are associated with more rapid disease progression while HLA-B*3501 is not.
342 These 
differences are likely to be due to the different preferences in peptides the HLA 
molecules present. These preferences can be seen in the HLA binding motifs and are 
shown in Panel C of Figure 14.1 and Panel C of Figure 14.2 for HLA-B5 and HLA-
B35, respectively. While this information argues that finer resolution of HLA typing 
will result in stronger associations with escape polymorphisms, others have argued for 
the use of grouping of alleles into superfamilies based on similarities in peptides they 
can bind. The main rationale for the latter approach is to identify peptides for a vaccine 
that can stimulate an immune response in many individuals across many genetic 
backgrounds.
921  
In this chapter the molecular HLA subtypes of individuals with HLA-B5 and HLA-B35 
are determined and the effect in the strength of association with polymorphism at 
positions 135 and 177, respectively, is analysed. The subtypes are also used to analyse 
the effect on other positions that had (weaker) HLA-B5 and HLA-B35 associations with 
polymorphism described in Chapter 6. For HLA-B5 these positions were 38, 60, 173, 
196 and 211, and for HLA-B35 they were 69, 83, 121 and 123. Chapter 14 HLA molecular subtyping: improving the strength of associations 
and biological importance 
194 
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                                        1  1      1   1 1  1 
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HLA-B*5101 WDRNTQIFKTNTQTYRENLRIALRYYNQSEAGSHTWQTMYGCDVGPDGRLLRGHNQYAYD 
HLA-B*5108 ............................................................ 
HLA-B*5201 ...E...S.................................................... 
HLA-B*5301 ..................................II.R.....L..........D.S... 
 
 
1         1         1         1 1   1   1         11       1 
2         3         4         5 5   5   6         77       7 
012345678901234567890123456789012345678901234567890123456789 
 
HLA-B*5101 GKDYIALNEDLSSWTAADTAAQITQRKWEAAREAEQLRAYLEGLCVEWLRRHLENGKETL 
HLA-B*5108 ................................V...D....................... 
HLA-B*5201 ............................................................ 
HLA-B*5301 ................................V..................Y........ 
 
B. C. 
 
      HLA  Allele:  B*5101  B*5201  B*5301 
      Peptide 
      Position:  123456789  123456789  123456789 
      Preferred     A      V   QF L  II   P 
      Residues:    P      I    W V  VV 
        G 
 
      O t h e r   IWIGVNKTM  VMILFKKMM  S FEIY 
      preferred  LFLVTIQ L  LFAILNEFF  Y KIL 
      residues:  V MIGLR  IPPVTLQ  F NL 
       Y  FKAKE    GPDTY  M QQ 
       D  WEIQ     KK S     
           YDS      E  
           V          
           E          
           H            
           D            
           R           
       N        
 
Figure 14.1. HLA-B5 molecular subtypes. 
Panel A. HLA sequence of the HLA-B5 sequence subtypes, HLA-B*5108, HLA-B*5201 and HLA-
B*5301 aligned with HLA-B*5101. There are two amino acid differences between HLA-B*5101 and 
HLA-B*5108; two with HLA-B*5201 and eight with HLA-B*5301. Only the region with differences is 
shown. Panel B. Molecular diagram of the HLA peptide-binding region. Amino acid differences from 
HLA-B*5101 are shown: Yellow (positions 94, 95, 97, 103, 114, 116, 171) – differences with HLA-
B*5301; Blue (position 152) – HLA-B*5108 and HLA-B*5301; Cyan (position 156) - HLA-B*5108; and 
Purple (positions 63 and 67) - HLA-B*5201. Adapted from reference 255 using the software package 
RasMol.
159 Panel C. Motifs for HLA-B*5101, HLA-B*5201 and HLA-B*5301. Anchor residues are 
coloured red. Auxiliary anchors are coloured purple. Other residues are coloured blue. Preferred residues 
are in bold text. There is no published motif for HLA-B*5108. 
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1        11   1 1   1         1         1         1     1   1 
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HLA-B*3501 GCDLGPDGRLLRGHDQSAYDGKDYIALNEDLSSWTAADTAAQITQRKWEAARVAEQLRAYL 
HLA-B*3502 .........F....N.Y............................................ 
HLA-B*3503 ................F............................................ 
HLA-B*3508 ........................................................R.... 
 
B. C. 
 
     HLA  Allele:  HLA-B*3501    HLA-B*3503 
     Peptide 
     Position:  123456789   123456789 
     Preferred     P      Y    P      M 
     Residues:           F           L 
                   M 
                     L 
                   I 
 
     Other  MAIKDIVE   AMEVDY  F 
     preferred   VLDIQNQ     IGMNT 
     residues:   YFEVKEV     LNTGN 
         RVGTVQT     FDI 
         DMPELT     VKG 
          E GMK     H 
          T L 
          Y M 
          N 
 
Figure 14.2. HLA-B35 molecular subtypes. 
Panel A. HLA sequence of the HLA-B35 sequence subtypes HLA-B*3502, HLA-B*3503 and HLA-
B*3508 aligned with HLA-B*3501. There are three amino acid differences between HLA-B*3501 and 
HLA-B*3502; and one with HLA-B*3503 and HLA-B*3508. Only the region with differences is shown. 
Panel B. Molecular diagram of the HLA peptide-binding region. Amino acid differences from HLA-
B*3501 are shown: Yellow (positions 109 and 114) – HLA-B*3502; Purple (position 116) – HLA-
B*3502 and HLA-B*3503; and Cyan (position 156) – HLA-B*3508. Adapted from reference 255 using 
the software package RasMol.
159 Panel C. Motifs for HLA-B*3501 and HLA-B*3503. Anchor residues 
are coloured red. Other residues are coloured blue. Preferred residues are in bold text. There are no 
published motifs for HLA-B*3502 and HLA-B*3508. 
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Methods 
High resolution HLA typing was performed for all individuals with HLA-B5 and HLA-
B35 using the methods described previously (see Laboratory assay methods, page 102). 
For each position where an association was previously found for HLA-B5 and HLA-
B35, a univariate odds ratio was determined for the broad subtype, and the most 
common molecular subtype. These were then compared to see if there was an 
improvement in the association. That is, if the odds ratio increased for positive 
associations or decreased for negative associations. 
Results  
High resolution HLA typing was determined for 51 of the 52 HLA-B5 individuals and 
for 50 of the 57 HLA-B35 individuals. Individuals for whom typing was not determined 
had absence of or inadequate samples to perform the assay.  
The most common subtype for HLA-B5 was HLA-B*5101, present in 78 percent of 
HLA-B5 positive individuals. This was similar to the expected frequency of 77 percent, 
determined in the WABMRDB (see Table 3.2, page 99). For each of the polymorphic 
positions previously shown to be associated with HLA-B5, the number of individuals 
with and without the broad and molecular typing allele and with and without the 
polymorphism are shown in Table 14.1. The percentage of individuals with HLA-B5 
and a polymorphism at position 135 was 85 (44 out of 52). Considering only individuals 
with HLA-B*5101 this percentage increased to 98 (39 out of 40). The one individual 
with HLA-B*5101 who did not have a polymorphism at position 135 received potent 
antiretroviral treatment during acute infection. The odds ratio for the association at Results      
 
 
197
position 135 improved from 13 to 93 when considering the molecular subtype. For the 
other five positions, the odds ratio only improved at positions 60 and 211.  
Table 14.1. Change in strength of associations of polymorphic sites associated with HLA-B5 after 
considering the molecular subtypes. 
For all HLA-B5 associations, the univariate odds ratio was calculated for grouping into HLA-B5 and 
HLA-B*5101. Note, one HLA-B5 patient did not have sequenced based typing performed, and not all 
patients had HIV-1 sequence at all positions. 
Logistic 
model    Broad HLA typing  Sequenced based HLA typing 
Amino 
acid  
pos-
ition 
Odds 
ratio  P-value  
B5,  
mut-
ated 
B5, 
not 
mut-
ated
Not 
B5, 
mut-
ated
not 
B5, 
not 
mut-
ated
Odds 
ratio
B* 
5101, 
mut-
ated
B* 
5101, 
not 
mut-
ated
not 
B* 
5101, 
mut-
ated
not 
B* 
5101, 
not 
mut-
ated 
Odds 
ratio 
Odds 
ratio 
improved
38 5.39  0.009    8  36 21 351 3.71 6 30 23 357 3.10  No 
60  2.28 0.035   17 34 51 367 3.60 15 25 53 376  4.26  Yes 
135 16.74  <0.001   44  8 123 297 13.28 39 1 127 304 93.35 Yes 
173  6.08 0.020   14 38 50 370 2.47 9 31 54 377  1.75  No 
196 4.29  0.003    9  42 28 391 2.99 5 34 32 398 1.83  No 
211  0.49 0.039   26 25 272 140 0.54 19 20 278 145  0.50  Yes 
 
Of the 57 individuals identified as HLA-B35, seven had inadequate sample to perform 
high resolution typing and four were determined to not be HLA-B35. The individuals 
incorrectly classified by serology were not taken out of the broad HLA-B35 group to 
give an indication of the strength of association between using serological and sequence 
based typing. Of the individuals that were typed by sequencing, 33 were HLA-B*3501 
(66 percent) (see Table 14.2). This was similar to the expected frequency of 63 percent 
(see Table 3.2, page 99). For polymorphism at position 177, the odds ratio improved 
from 3 for HLA-B35 to 5 for HLA-B*3501. For three of the other four positions the 
odds ratio also improved. Note that for position 83 the odds ratio was negative in our 
original analysis, and the odds ratio improved (that is, became smaller) from 0.47 to 
0.41 when considering the molecular subtype. 
The individual sequence alignments, categorised by HLA subtype and amino acid at 
positions 135 and 177 are shown in Figure 14.3 and Figure 14.4 for HLA-B5 and HLA-
B35, respectively. For individuals with HLA-B*5101, one had the consensus amino Chapter 14 HLA molecular subtyping: improving the strength of associations 
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acid of an I (isoleucine) at position 135, 25 (62 percent) had a T (threonine), five (12 
percent) had a V (valine), one had an L (leucine), one had an M (methionine), one had 
an R (arginine) and the remaining six individuals (15%) had a mixed population. For 
individuals with HLA-B*3501, 14 (42 percent) had consensus amino acid of a D 
(aspartate), 15 (45 percent) had an E (glutamate) and four (12 percent) had a mixed 
population that included a glutamate. 
 
Table 14.2. Change in strength of associations of polymorphic sites associated with HLA-B35 after 
considering the molecular subtypes. 
For all HLA-B35 associations, the univariate odds ratio was calculated for grouping into HLA-B35 and 
HLA-B*3501. Note, seven HLA-B35 patients did not have sequenced based typing performed; not all 
patients had HIV-1 sequence at all positions; in four patients, HLA-B35 was not confirmed by 
sequencing; and 33 of the patients with HLA-B35 were found to be HLA-B*3501 by sequencing. 
Logistic 
model    Broad HLA typing  Sequenced based HLA typing 
Amino 
acid  
pos-
ition 
Odds  
ratio  P-value  
B35, 
mut-
ated 
B35, 
not 
mut-
ated 
not 
B35, 
mut-
ated 
not 
B35, 
not 
mut-
ated
Odds 
ratio
B* 
3501, 
mut-
ated
B* 
3501, 
not 
mut-
ated
not 
B* 
3501, 
mut-
ated
not 
B* 
3501, 
not 
mut-
ated
Odds 
ratio
Odds 
ratio 
improved 
69  3.97 0.027    8 48 32  383 1.99 6 27 33 399 2.69 Yes 
83  0.28 0.018    6 51 83  332 0.47 3 30 85 347 0.41 Yes 
121  4.00 0.014    7 49 15  400 3.81 4 29 16 415 3.58 No 
123  2.86 0.001   31 25  135  280 2.57 22 11 141 290 4.11 Yes 
177  3.52  <0.001   26 31 84  330 3.29 19 14 86 345 5.44 Yes 
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  B5 subtype  Amino acid at pos  Codon 
  (num pts)  135 (num pts)  135 
 
     Isoleucine (1)   1
1 ATA ..................................................................................Q...................P............    .    ......V...................A...R..D..............................I..........K................ 
      
         2 ACA  ........................................I.............................................................E............    T    ..............................R........................................E...K................ 
         3 ACA  .......KK......I................................G.....................................................AN...........    T    ..............................R..........E.................................................. 
         4 ACA  .....................L..................I............................................................YE............    T    .........................................E.............................E.M.K.. K............ 
         5 ACA  .... KM..K...K................................................................................E........E...........    T    ..........................C..R............L.....................I......E...K...K..N....... 
         6 ACA  .......K..........Y..............K..............G.. K.................................................Q............    T    .......................................KKE.................................K..L............. 
         7 ACA  .......R...........................T...Q.......N.......................................................E...........    T    ................................................................I..........K...N............ 
         8 ACA  ...........V.................R..........I..........................................................................    T    ..............................R...........M................................................. 
         9 ACA  R......KKK.....T...E.L..D...K..E........I......NN.R....M..................L......H................I...E............    T    ..............................R......A...E......................A...K..D..SK...Y..ER........ 
       10 ACA  .......K..............................................................................................E............    T    ............................................................................................ 
       11 ACA  ...............I...............................................K..................................I...E............    T    ...........................................I................E.....V.......WK......E......... 
  B*5101 (40)  Threonine (25)  12 ACA ..................  .A..........................N..R..............................................P.................    T    ..........................C..............................................PW.R..E..E......... 
       13 ACA  ...............................................................K...................................................    T    .............................I..................................I.............L.........K... 
       14 ACA  .........A.....TA..D........T...........I...R.........................................................EN...........    T    ..A...V......................IR.....KTK.........................A......E...K................ 
       15 ACA  ........................................I.........R...................I............N...................E...........    T    ......V..................................E.................................................. 
       16 ACA  ...............TK.W.D........R........................................................................ES...........    T    .....................................S...E.I.........................K.A...S................ 
       17 ACA  .......................................................................................................E...........    T    ..........................C................................................................. 
       18 ACA  .....................................K...................................................MN....N...................    T    ..........................C..........I.........N..N............................H............ 
       19 ACA  ...............L...................................................................................................    T    ..............................................................................L............. 
       20 ACA  .......K...........K.L..................I......N............................Q......................................    T    ................................................V...........E......D......WK...Y............ 
       21 ACA  ...............T..SK.K.E........T.KT...Q.........................................R...................HE............    T    .....................................LK..E........................V....N...K................ 
       22 ACA          ..........W.....................I..............................................................E...........    T    ............................................................................................ 
       23 ACA                                         ........................................E...................................    T    ............................................................E............................... 
B5 (52)       24 ACA                                      ..................................................................E............    T    ............................................................................................ 
       25 ACA                                      ...................................................................E...........    T    ..........................................M................. 
       26 ACA                                      .............DR...........................S...................I...E............    T    .....................................E..........................A......E......LI...Q...     
      
       27
2 GTA  ...............I.................K................................................Q................................    V    ..........................C................................................................. 
       28 GTA  ..R.....................................I.............................I...........Q................................    V    ......V... ............................K..............E.........A........................... 
     Valine (5)  29 GTA  ..................Y.....................I..........................................................................    V    ......V..................................................................................... 
       30 GTA  .............V.TA..E........T.................................................S......P................ES...........    V    ..A.................QQEKS....I.......T....M.....................A......D...K................ 
       31 GTA  ............R...........................I.......G.....................................................Q............    V    ..........................C...R...........LI...............................K................ 
      
     Leucine (1)  32 CTA             ....ID...................................................G..........................N......ES...........    L    ......................S..............SK..E............................KA...S................ 
      
     Methionine (1)  33 ATG .......K....................K.................................................S.......................E............    M    .......................................................................E.................... 
      
     Arginine (1)  34 AGG  ...............I...............................................................E.......................E...........    R    ............................................................E...A........................... 
      
       35 AYA  ...............................................................K..............................G....................   I/T   ...........................................................................S..L............. 
       36 ASA  ........K......I............K...........I......N.N....................................................EN...........   R/T   ............................................................E...R......E..WK................ 
       37 ASA  ......... .....TA..ED.......T...........I.............................................................E............   R/T   ..........................G..........T...E......................A......E...K................ 
     Mixed (6)  38 RSA  ............................ ...................................................................................... A/G/T/R ................................................................I......E.................... 
       39 RYA  ...............I........................I.....................................S.......................E............ A/T/I/V ......................G..................E......................A......E.................... 
       40 RYA  ...... ......... .Y...... ..... .... ...I........................................ ................... E... . ...... A/T/I/V ............ .............. .. ...... K.................. ......   ........K................ 
        
     Arginine (1)  41
3 AGA                                           .............................................................E............    R    .....................................A...E......................A......E...K...Y............ 
        
  B*5108 (1)   Isoleucine (1)  42 ATA  .....................L................................I.........................I......................E...........    .    ..........................................................................F....Y............ 
      
       43 ATA  ...............T..Y....E...........T...Q..............................................................ES...........    .    .....................................IK..EM............................A..KS................ 
       44 ATA  .......K...............................................................................................E...........    .    ..........................N...........H.....................E..........E.................... 
     Isoleucine (4)  45 ATA                                      ...........N..R.............................I...N..............................    .    ...........................................................................K.......Q...     
       46 ATA                                      ...............................................................................    .    ................................................................I.............L........     
 
  B*5201 (8)    47 ACA                    .................T...T.........................K.................................................    T    .....................................E..T..................................K................ 
     Threonine (3)  48 ACG  ..................W....................Q......................................S...ER...............................    T    ..........................Y................................................K................ 
       49 ACA  ...............T....D...................I.............................................................EN...........    T    .....................................SR..EVI................E..........A...S................ 
 
     Valine (1)  50 GTA  .......R...............................Q.............................................................YE............    V    ......V....................................I................E............................... 
        
  B*5301 (2)   Isoleucine (2)  51 ATA ........................................I......N.A................................................I...E............    .    ............................................................E.................L....Q........ 
  52 ATA                                      ..................V.......................G..........I............EN...........    .    .....................................T...E......................A.T....E..WK...Y............ 
Figure 14.3. Distribution of I135x in HIV-1 RT sequence in all HLA-B5 individuals. 
The most recent amino acid sequences of HIV-1 RT in all 52 individuals in the cohort with serologically defined HLA-B5 (individuals 1-52) were compared with the population 
consensus sequence. HIV-1 RT sequences are grouped according to the HLA-B subtype of the individual. In all sequences, a dot ( . ) indicates no difference from consensus. Amino 
acids different from consensus are shown. Where quasispecies with different amino acids were detected, the most common non-consensus amino acid is shown, except at position 
135 where all detected amino acids in a mixed viral population are shown. All but one of the forty individuals (98%) with the HLA-B*5101 subtype have a substitution of the 
consensus amino acid isoleucine (I) at position 135, most commonly with threonine (T). Positions shown to be associated with polymorphism are highlighted in vertical columns. 
1The sequence without I135x is that of the single HLA-B*5101 individual who had potent antiretroviral during acute HIV infection. 
2This individual was an HLA-B*5101/B*5201 
heterozygote but was counted only once in the HLA-B*5101 group. 
3This individual did not have molecular genotyping performed. H
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  B35 subtype  Amino acid at pos  Codon 
  (num pts)  177 (num pts)  177 
 
       1 GAC  ..N...YK..........W.........C..................................................D.....................HE.....................S..................R............S    .    M.......................V...........L....... 
       2 GAC  ...............................................................................................N.......E..........................................R..........    .    .................................................. 
       3 GAC  R..............................................N..R................................N...................E...........T.................RE.....S................    .    ......V..................................G........ 
       4 GAC  ....................................................G.........................S........................E....................................S.....R..........    .    .....................................N............ 
       5 GAC  ...............I.................G...K..M........AR............K......G..........Q..N.................ES...............M.............R...........A...........    .    .I................................................ 
       6 GAC                                      ......T...................................S..............................................................................    .    ......................A........................... 
     Aspartate (14)  7 GAC  .......A.......T.............E...K.....R...........................................T...K..................................V..................................    .    ......................A.V........G............K... 
       8 GAC                                      ...........A..............................G..........I............EN...........T.........................................    .    .................................G...........      
       9 GAC  .......K.................R............................................................................EK......................................C..............    .    M................................................. 
       10 GAC  .................K.....R................I......N.DR............................V.......................E.............................................D.......    .    .I........L.............V..K....FG...F..EQ.......N 
       11 GAC  ...............T.N........................................................................................................V..................................    .    ......................A.V....L...K................ 
       12 GAC  ..N...FKK..............................Q.....E.........................................................E...........T..........................C..............    .    M......G..............A..........K................ 
       13 GAC  .......K.............L.............T...Q........G.....V......................................................................................................    .    .................................K...Y............ 
       14 GAC  ...............I..............................................................S...............................................................C..............    .    ...................E.........E...K................ 
           
       15 GAA  ........................................I..............................................................E...........R......V..................................    E    .................................K................ 
       16 GAA  ......FKK......I.............E..................G...S.................................................AN...........T..............................R..........    E    .................................................. 
  B*3501 (33)   17 GAA  .F........E....T..*K...E..........T....................................................................S.........................................I.......TK..    E    M............................AN.KS..IN..EN.......L 
       18 GAA  ......YKG..............................Q...............................................................E......................................C..............    E    .............................E...K................ 
       19 GAA  .......................................................................................................E...........T.....................................Q...    E    .............................E...K................ 
       20 GAA  .....................L..................I............................................................YE......................................................    E    .............................E.......N............ 
       21 GAA  ...............I..........................V.....G......I.L.....................................FY.....PE...........................M..........T..............    E    ......V..........................K.......E........ 
     Glutamate (15)  22 GAA  .......R..............................................................I..............................HE.......................................C..........N...    E    ..............................................K... 
       23 GAA  .......K...VNKY..............................R..G......................................................E........................................I.R..........    E    .....C................A..............K..N......... 
       24 GAA  ..........E.......W............................................K..............S.......................P............R.........................................    E    ......................I........................... 
       25 GAA  .....................................................................................................YE............V..........................C..............    E    ......I................NK........K...P............ 
       26 GAA  ........K..........E.L..D......................N.D....V............................N..............I....E...........T..........................C...........R..    E    ...C..V...............A...G..E..WK...Y...R...T.... 
       27 GAG  R.........................................V....N.N.....I.L.....................................FY......E...........................M...............V.........    E    ......V.................V........K...V...Q........ 
       28 GAG                                          .........AR....................................................E......................................Y..............    E    .................................K.E.S...Q........ 
       29 GAG  .....................L..D.......................G.....V............................N..............I....E...........M..............................Q..........    E    ...C..V.........................FK...D............ 
                
       30 GAK  .I........................................P............................................................E....................S.....................R..........   D/E   ......V.................V......................... 
     Mixed (4)
 
  31 GAM  .................................................A.............................A*..R.......I...........E............T.....V..................................   D/E   M.....V..........................K................ 
B35 (57)       32 GAN  ..........E...........................................................................................E............T.........................................   D/E   .I..................Q........H......L............. 
       33 GRA  ........................................I......................K.HN....................................K................................................S.P..   G/E   ......................I......E................Q... 
                
  B*3502 (2)   Aspartate (2)  34 GAC  ...............................................N.NR...........................S.......................E............T..........................C..............    .    F.....V.....A................E.......F...E........ 
       35 GAC  ......................................................................I...........................................................................R..........    .    .................................K................ 
                 
       36 GAC  ........G....................E...G.....Q.....................................................................................................................    .    ......................I..........G..L.........D..S 
       37 GAC  .............................R.................................K...................R.........................................................PKKKK.NFKA......    .    ...........I...................................... 
       38 GAC  ........................A..............................E...D........................................*.E......................................................    .    .F..............................RSGKKA..EN........ 
     Aspartate (8)  39 GAC  .....................L......................R................................................................................................................    .    .....................................S............ 
  B*3503 (9)    40 GAC  .......R...............................Q.............................................................YE............V......V..................................    .    .I................E............................... 
       41 GAC  ...............L...................................................................................................T.........................................    .    ....................................L............. 
       42 GAC  .............................R.....................................................................................T.........................................    .    M................................................. 
       43 GAC  .....................L.......................E.N..R.G........S..P......PI.........                                    G....G.SS.....D......L.................    .    ......V...............A......HY.WK...Y...E........ 
                 
     Glutamate (1)  44 GAA  ........................................I......N...................................N...................E...........V......V...........E......................    E    ......V...........E...........N................... 
                 
     Aspartate (1)  45 GAT  ..........E........................T...Q...............................................................E.....................................................    .    .................................................. 
  B*3508 (2)              
     Mixed (1)
   46 RAS  ..........E............R..................................................................................................................................... D/E/K/N .................................Q................ 
                
     Aspartate
1 (2)  47 GAC  .I...Q.........I..*.................N..........................K.................Q....................Q...................M...............................P.S    .    L..................K............WK...Y............ 
       48 GAC  ..........E....E.............................................................................................................................................    .    .................................K................   
       49 GAA                                                       .V..........................E...................YE......................................................    E    ...C........A...................WQ...Y............ 
     Glutamate
1 (3) 50  GAA ....................................N.............................................RN..................EE.....................................................    E    ......................I........................... 
       51  GAR  .....................L..D......................N.A..................................N......I......I....E..........................................R..........    E    ..............................Y.WK...Y........D... 
 
     Mixed
1 (2)  52 GAM  ...............TA..E........T.....................................................Q..................YEE......................................C..........TK..   D/E   L.....................A......E...K............... 
       53 VAA                                       KN..................L..........................N............QF...P.........................................IN........T..  E/K/Q  ..............H.K.....N..GG.K...........NQ...EK... 
                         
       54 GAC  .......A.......I...K...........................................K.......................................E........................G............................    .    M............................E...K......... 
  not B35
2 (4)  Aspartate (4)  55 GAC  .......K....NKFKSV.D........T...........I....R........................................................EN..............A..........................I.......TK..    .    .....C................A.V....E... 
       56 GAC  .........A.....TA..D........T...........I...R.........................................................EN...........T..A...V......................IR.....KTK..    .    ......................A......E...K................ 
       57 GAC  .....Q.........K..Y.................N...............T.................F........................N.......E..................V..................................    .    M...........................I..FF..EL............. 
 
Figure 14.4. Distribution of D177x in HIV-1 RT sequence in all HLA-B35 individuals. 
Presentation of sequences is similar to Figure 14.3. Nineteen of the 33 individuals (58%) with the HLA-B*3501 subtype have a substitution of the consensus amino acid aspartate 
(D) at position 177, most commonly with glutamate (E). Positions shown to be associated with polymorphism are highlighted in vertical columns. 
1These seven individuals did not 
have molecular genotyping performed. 
2These four individuals were determined not to be HLA-B35 from HLA molecular subtyping. Discussion  
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Discussion 
We have shown that polymorphisms at anchor residues and at sites that affect TCR 
recognition are associated with different HLA subtypes. All HLA-B5 individuals, 
except one, who were determined to have HLA-B*5101 had a polymorphism at position 
135 of HIV-1 RT. The one individual with the HLA-B*5108 subtype and four of eight 
individuals with the HLA-B*5201 subtype did not have I135x, suggesting that these 
subtypes may not bind the RT(128-135 IIIB) epitope as well. Both subtypes differ from 
HLA-B*5101 by only two amino acids (HLA-B*5108 at positions 152 and 156, and 
HLA-B*5201 at positions 63 and 67 of the HLA amino acid sequence).
965 Notably, the 
single HLA-B*5101 individual who had the consensus amino acid at position 135 was 
an individual who had taken highly active antiretroviral therapy during acute HIV-1 
seroconversion. This individual had presented within days of virus transmission with 
plasma HIV RNA concentration (viral load) of 6.5 log copies/mL and a negative HIV 
antibody test. He had no symptoms of seroconversion illness. After antiretroviral 
treatment was started, viral load progressively decreased to undetectable levels over the 
next six months, and has remained undetectable on treatment for a further 18 months 
until the present time.  
Likewise, the majority of individuals with the HLA-B*3501 subtype of HLA-B35 had a 
polymorphism at 177 compared to none with the HLA-B*3502 subtype and 11 percent 
with the HLA-B*3503 subtype. HLA-B*3502 and HLA-B*3503 differ from HLA-
B*3501 by three and one amino acids, respectively. Of the four individuals that were 
mistyped as being HLA-B35 by serology all had the consensus amino acid at position 
177. This strongly suggests that the HLA-B*3501 molecule presents a more 
immunodominant epitope around position 177 of HIV-1 than other subtypes of HLA-
B35. This also appears to be the case for HLA-B*5101 at position 135 compared to Chapter 14 HLA molecular subtyping: improving the strength of associations 
and biological importance 
202 
other subtypes of HLA-B51. This is supported by the different peptide-binding 
properties of the different subtypes. HLA-B*5101 has two anchor sites at positions two 
and nine while HLA-B*5201 has two anchor sites at positions eight and nine as well as 
three auxiliary anchors at positions two, three and five. Furthermore, the amino acid 
preferences are different between these subtypes. The HLA-B35 subtypes appear to 
have more peptide-binding preferences in common, but do differ.
946  
While HLAs with similar peptide-binding grooves can bind the same peptides, the 
differences can change the dynamics of the amount of different peptides of HIV-1 
presented in HLA class I molecules on the cell’s surface.
946 This can, in-turn, change 
the immunodominance of the epitopes that are recognised by the immune system. 
Hence, while the HLA alleles within HLA superfamilies can present the same peptides 
they are unlikely to do so in natural disease in vivo. One HLA superfamily epitope has 
been described in this region of HIV-1 RT: RT(158-166), restricted to the HLA-A3 
superfamily which includes the HLA alleles HLA-A*0301, HLA-A*1101, HLA-
A*3101, HLA-A*3301 and HLA-A*6801.
126,921 In our previous analysis in Chapter 6 
we found an association with only one of these alleles within this epitope (A11 at 
position 166; P<0.001, OR=4.36), arguing that the efficacy or immunodominance of 
this epitope is different for the different alleles that can present it. This is argument is 
strengthed by the fact that there was more power to detect an association for HLA-A3 
than for HLA-A11 (see Table 3.2). Furthermore, the different subtypes may be in 
linkage with other polymorphic genes that influence the HLA class I pathway. This 
could be exacerbated as HLA superfamilies, but not HLA alleles, are distributed fairly 
evenly across all races. Superfamilies may also have limited use in vaccinations as a 
stronger response from better epitopes representing the common alleles in the 
population may be more effective to the population than epitopes that have a weaker 
response from marginally more individuals.  Discussion  
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These observations and our results support observations by others that one or a few 
amino acid differences can affect disease.
342,966 The use of molecular typing in the 
modelling of polymorphism, rather than grouping HLA with differences in their 
peptide-binding grooves, are likely to reduce the error and improve the results. The 
extra covariates in the models are unlikely to have a large affect on the modelling 
because most will be eliminated through lack of power. 
The HLA-B*5101 epitope surrounding position 135 has been described to present the 
epitope TAFTIPSI, where the final (and underlined) amino acid is position 135 of HIV-
1 RT. The most common variants to this epitope are TAFTIPST and TAFTIPSV as seen 
in our cohort and by others.
52 These two variants have been shown to necessitate a 
hundred-fold and ten-fold, respectively, increase in the peptide concentration required to 
sensitise target cells for 50 percent lysis (SD50) by CTLs in vitro.
400 In addition, these 
two peptides have smaller predicted half time of dissociation scores compared to the 
consensus peptide.
963  
These observations support the modelling of any polymorphism as outcome, rather than 
polymorphism from a specific amino acid. The amino acid that is selected to escape 
binding is more likely to be influenced by the fitness of the virus, rather than the HLA, 
because most amino acid changes within an epitope are likely to affect epitope 
processing or recognition to some degree. Differences between amino acids used to 
escape epitopes are likely to vary between individuals, and may be influenced by: 1) the 
immune competence or broadness of the TCR response to the epitope and the amino 
acid substitutions they can recognise; 2) amino acids substitutions that have similar 
effects on fitness; 3) the number of nucleotide polymorphisms required to produce the 
amino acid change; 4) polymorphisms at other positions; and 5) interactions with other 
HLA molecules.  Chapter 14 HLA molecular subtyping: improving the strength of associations 
and biological importance 
204 
Three of the five other HLA-B5 associations did not show an improvement in odds ratio 
when looking at subtypes. This may be because for epitopes around these positions, 
peptides may be presented with similar efficacy for the different HLA-B5 alleles. 
Alternatively, these may represent false positive associations, and may have been a 
result of our modelling. Our modelling of HLA and polymorphism included 
polymorphism at other sites as covariates. Because 98 percent of individuals with HLA-
B*5101 had a polymorphism at position 135, but only 78 percent of individuals with 
HLA-B5 were HLA-B*5101, polymorphism at position 135 may have been a better 
marker of HLA-B*5101 than HLA-B5. This argues for modelling without the 
explanatory variables representing polymorphism at other positions if HLA-broad 
alleles are to be used. Comparing these models with models including these covariates, 
however, is still useful for detecting secondary polymorphisms, as discussed in Chapter 
6. This does not appear to have been a problem for the associations with HLA-B35 with 
four of the five associations showing an improvement after only considering HLA-
B*3501. The extent of this problem with non-HLA-B5 covariates may not have been 
large as HLA-B*5101 appears to be the only HLA-allele of sufficient size with an 
epitope of this type in this region of HIV-1-RT. In fact, the modelling may have helped 
remove some of the variability introduced by the more rare subtypes from the broad 
HLA groups if they had characteristic polymorphisms in HIV-1 RT. 
We conclude that use of sequence based typing increases the ability to detect true 
associations with polymorphism.  
  
Chapter 15 Longitudinal analysis of putative escape 
mutation sites 
Introduction 
The genetic diversity of HIV-1 within individuals increases over the course of 
disease.
13,41-48 Some of this increase has been attributed to escape from HLA restricted 
CTL epitopes.
12,13,46-48,283,524,565,583,585,586,590 However, the amount of polymorphism due 
to selection and stochastic processes is subject to debate.
109,886 
The virus with which an individual is infected is likely to be different to the wild-type 
virus, possibility due to adaptation of the virus in its previous host. However, in the new 
host, the virus is likely to revert back to the more fit wild-type virus at sites of 
adaptation induced by the previous host.
48,141,165,601,690,745-749 Reversion to wild-type is 
less likely, however, if multiple compensatory or nucleotide changes are required; if the 
fitness of virus is similar to the fitness of the wild-type virus; or the viral load (and 
hence chance of mutation) is low. Parallels can be drawn between moving from one 
host to another (and one set of HLA to another) and the removal of antiretroviral drug 
pressure. This often sees reversion of the (drug resistant) virus to the virus more fit in 
the absence of the drug (that is, wild-type). However, this reversion depends on the 
number of mutations required to get back to the fitter virus and the viral load.
591-594 
Hence, the number of amino acid differences from the wild-type virus across a 
population is likely to be small at sites where there is no pressure. On the other hand, at 
sites where there is pressure (for example, through the new host’s HLA) there is likely 
to be an increase in mutation over time.  Chapter 15 Longitudinal analysis of putative escape mutation sites  206 
Individuals on antiretroviral therapy that reduces the viral load to undetectable levels 
have been shown to have a weakened CTL response due to the resulting lack of 
stimulating antigen.
428,531,568,720,819 Lack of CTL pressure could see the virus revert back 
to wild-type at sites where the virus had mutated to escape the CTL response. However, 
because the viral load is low, the chance of this is reduced. In addition, antiretroviral 
therapy could potentially interact with CTL by applying pressure at the same sites as 
CTL – either synergistically or antagonistically.
126 However, only two epitopes have 
been described that are influenced by antiretroviral drug induced mutations, and the 
effects of both appear limited.
837,838 
In the cohort to be analysed, the date of seroconversion was unknown for most 
individuals. Also, the assay for determining the viral load only started being used in 
1996 and the reliability of results from stored samples was uncertain. In addition, most 
individuals were treated with antiretroviral therapy, and sequence, viral loads and 
compliance information was not always obtained adequately for an ideal longitudinal 
analysis. However, most individuals did have more than one HIV-1 RT sequence. With 
this limited data, we made the testable hypothesis that the amount of mutation between 
serial sequence measurements at the positive putative HLA escape positions increases, 
while at negative putative HLA escape positions it decreases.  
Methods 
For each putative HLA escape polymorphism, the number of individuals with and 
without mutation, and with and without the HLA allele was calculated. This was done 
for each individual’s first and last sequence. This data was used to calculate the 
percentage of individuals with the HLA allele that had a mutation at the putative escape 
site for their first and last sequence. From this, the increase in individuals with the HLA Methods  
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and polymorphism at the position was calculated as a percentage. Similar calculations 
were performed at the same position for those without the HLA allele. The number of 
putative HLA escape sites for which the amount of polymorphism increased more in 
individuals with the corresponding allele compared to those without was calculated. 
Sign tests were then used to test for significance across all putative escape mutation 
associations. These were performed separately for positive and negative associations. 
Results 
For 61 of the 64 positive HLA-specific polymorphism associations, the percentage of 
individuals with the corresponding HLA and an amino acid polymorphism at the 
corresponding position increased between their first and last sequence (P<0.0001, sign 
test). Similarly, for 49 of the 64 positive HLA-specific polymorphism associations, the 
percentage of polymorphism increased in those individuals without the corresponding 
HLA allele (P<0.0001, sign test). For example, for the positive association found 
between HLA-A2 at position 26, 14 percent of individuals with HLA-A2 had a 
polymorphism at position 26 at their first sequence. This increased to 16 percent by 
their last sequence. In contrast, fewer individuals among the non-HLA-A2 had a 
polymorphism in their first sequence (11 percent) and this decreased (to 9 percent) by 
their last sequence. As was the case with this association, in 52 of the 64 positive 
associations, the increase was greater in those with the HLA allele associated with the 
polymorphism, compared with those without the allele (P<0.0001, sign test; see Table 
15.1 and Table A.2, page 303 of Appendices).  
For 10 of the 25 negative HLA-specific polymorphism associated positions, the 
percentage of individuals with the corresponding HLA allele and amino acid 
polymorphism decreased between their first and last sequence, however, this was not Chapter 15 Longitudinal analysis of putative escape mutation sites  208 
significant (P=0.86, sign test). Fewer positions had a decrease when considering 
individuals without the corresponding HLA-specificity (2 of the 25; P=1.00, sign test; 
see Table 15.1 and Table A.3, page 307 of Appendices). However, this lower number of 
associations with decreased polymorphism in individuals without the corresponding 
HLA allele compared with those with the corresponding HLA allele was significant 
(P=0.033, Fisher’s exact test). Furthermore, at 15 HLA allele/positions the decrease was 
greater in the HLA allele group compared to the non-HLA allele group, though this did 
not reach significance (P = 0.21, sign test; see Table 15.1 and Table A.3). 
Table 15.1. Summary of mutations that occurred over time at sites with HLA associated polymorphism in 
those individuals with and without the corresponding HLA allele. 
  n P-value (sign test) 
Positive Associations:    
HLA-specific polymorphisms  64   
HLA-specific polymorphisms that increased from first to last HIV-1 RT 
sequence 
 
61  2.37 x 10
-15 
Non-HLA-specific polymorphisms that increased from first to last HIV-1 
RT sequence  49  1.22 x 10
-5 
HLA-specific polymorphisms that increased more from first to last HIV-1 
RT sequences in those with the corresponding HLA allele compared 
with all others 
45 
  0.0008
 
Negative Associations:    
HLA-specific polymorphisms  25   
HLA-specific polymorphisms that decreased  
from first to last HIV-1 RT sequences  10  0.86 
Non-HLA-specific polymorphisms that decreased from first to last HIV-1 
RT sequences  2 1.00 
HLA-specific polymorphisms that decreased more from first to last HIV-1 
RT sequences in those with the corresponding HLA allele compared 
with all others 
 
15  0.21 
 
Discussion 
As described by others, we observe that polymorphism in general is increasing over 
time in HIV-1 disease.
13,41-48 This study is unique however, as we have been able to 
demonstrate that some of this is HLA specific. Previously, this had only been 
demonstrated in studies of a few individuals.
12,13,46-48,283,524,565,583,585,586,590 The fact that 
we found more polymorphism at the positive HLA associated sites in those with the Discussion  
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corresponding HLA alleles compared to those without, and similarly less at the negative 
HLA associated sites, suggests that CTL pressure induces polymorphism in addition to 
that from other pressures or stochastic processes. However, there still remains a large 
amount of polymorphism that we have not been able to account for. This could be 
because of the limitations of our previous study in defining putative HLA escape 
mutation positions (see discussion in Chapter 6) and other undefined pressures or 
random polymorphisms that occur after the bottleneck of viral strains seen in primary 
infection.
109,141,886 However, the existence of these other polymorphisms probably 
worked in our favour to help us define the negative associations in Chapter 6. Without 
differences in the infecting strain or bottleneck in primary infection, other pressures on 
the virus causing polymorphism or random polymorphism, we would not have been 
able to observe HLAs with reduced polymorphism.  
A methodological limitation with this study is that HLA-specific polymorphism would 
not be seen if CTL effects occur before the individuals’ first sequence. For the 
association seen between HLA-B5 at position 135, every individual except one with the 
suspected subtype (HLA-B*5101) that induced this polymorphism had done so by their 
first sequence. Consequently, we observed no extra individuals with HLA-B5 
developing a polymorphism by their last sequence. In other examples, it may be the 
case that the amount of polymorphism in the HLA group is decreasing if those 
individuals with an HLA subtype different from that inducing the polymorphism revert 
to the consensus sequence. The loss of CTLs seen late in infection
7,124,149,415-419,515,572-
582,588,589 or when individuals are on effective antiretroviral treatment
428,531,568,638,720,819-
823,913,914 may also reduce our ability to see an increase in HLA-associated 
polymorphism. The use of pre-treatment sequences or sequences from individuals 
where the viral load is at levels high enough to induce a CTL response, and sequences 
taken before the final stages of disease, would reduce this problem. These problems Chapter 15 Longitudinal analysis of putative escape mutation sites  210 
were also reasons why we chose polymorphism from the population consensus to find 
putative HLA escape mutations in Chapter 6. Comparing differences in polymorphisms 
between last sequence and first sequence, say, would not have detected an association 
with HLA-B*5101 and might even show it as a negative association. 
In summary, polymorphisms at putative CTL escape mutation sites are increasing 
overtime. In particular, it is increasing moreso in individuals with the HLA allele 
associated with polymorphism. Furthermore, reversion to wild-type is occurring 
preferentially at sites that have HLA associations with less polymorphism in those 
individuals with the corresponding HLA allele.   
Chapter 16 Putative escape mutations and viral load: 
clinical implications 
Introduction 
The strength of the CTL response after primary infection is inversely correlated with 
viral load
413-416 and more rapid disease progression in humans
130 and primates.
571 
During chronic infection CD8+ responses can develop and mature for many years,
572-574 
after which there is a progressive loss of CTLs and a rise in viral load as the individual 
progresses to AIDS.
7,415,417-419,515,575-582 Escape from CTL responses is likely to be 
occurring all the time from recognised epitopes
283 and has been documented in small 
cohorts (reviewed in reference 164),
12,13,47,48,283,524,565,585,586,590 even in patients with low 
viral loads.
46,583 Each escape is believed to give the virus a slight survival advantage and 
increased viral load.
583,584 
The great majority of studies on HIV-1 disease protection and progression have 
focussed on differences in the human (see Literature review, Table 2.3, page 42). Few 
studies have examined differences in the virus as a possible reason for differing rates of 
protection and progression. Those that have have shown that differences in the virus and 
interactions between the host and virus can explain a lot of the variability. A study of a 
cohort of haemophiliac individuals with slow progression that were infected with HIV-1 
by a single contaminated batch of blood discovered that the slow progression was due to 
a defective nef gene in the virus.
214-216 In other studies of a few individuals, mutation 
within a recognised epitope results in higher viral loads and increased disease 
progression.
12,13,49-51 One study of SIV in a family of five rhesus macaques showed the 
accumulation of mutations in 10 CTL epitopes and subsequent disease progression.
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Furthermore, some strains of SIV are more pathogenic than others, and HIV-2 and clade 
C of HIV-1 may be less pathogenic than other major strains of HIV-1.
468-475 However, 
in general genetic studies to date have not taken viral genotypic variation or host-viral 
interactions into account. In this study we sought to determine whether the presence of 
putative CTL escape mutations are associated with increased viral load.  
We previously identified four associations that were at anchor sites of known CTL 
epitopes restricted to the same corresponding HLA. These were HLA-A3 at positions 43 
(OR = 0.04) and 101 (OR = 2.4), HLA-B5 at position 135 (OR = 16.7), HLA-B7 at 
position 165 (OR = 2.4) and HLA-A11 at position 166 (OR = 4.4). All associations 
were at the terminal anchor positions of HLA corresponding CTL epitopes: RT(33-43), 
HLA-A*0301 restricted;
124,916 RT(93-101), HLA-A3 restricted;
916 RT(128-135), HLA-
B51
49,126,400,915 and HLA-B*5101
516,916 restricted; RT(156-165 SF2), HLA-B7 
restricted;
126,918 and RT(158-166 LAI), HLA-A11
126,283,295,541 and HLA-A*1101
126,921 
restricted. We also found 13 associations within, but not at anchor sites of known CTL 
epitopes with the same HLA restriction. These were HLA-A3 at positions 36 (OR = 
0.04) and 38 (OR = 0.07) within RT(33-43);
124,916 HLA-A2 at 39 (OR = 4.8) and within 
RT(33-41 LAI);
124,916 HLA-A9 at 115 (OR = 3.6) and within RT(113-120 SF2);
516 
HLA-B35 at 121 (OR = 4.0) and 123 (OR = 2.9), within RT(118-127 
SF2);
49,126,513,916,923 HLA-B7 at 158 (OR = 4.5) and 162 (OR = 10.0) within RT(156-164 
HXB2CG)
917 and RT(156-165 SF2);
126,918 HLA-B35 at 177 (OR = 3.5), within RT(175-
183 IIIB/LAI);
49,126,283,310,339,442,513,563,916,923,955,956 HLA-A19 at 178 (OR = 2.0), within 
RT(173-181 LAI);
916,967 HLA-B12 at 203 (OR = 5.6) and 211 (OR = 4.5), within 
RT(203-212);
126,149 and HLA-B40 at 207 (OR = 2.2), within RT(202-210 LAI).
916,968 
In this study we analyse the strongest of these associations with sufficient numbers of 
cases of pre-treatment viral load measurements that were 1) positive and at an anchor Introduction  
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site of a CTL epitope restricted to the same HLA; 2) positive and not at an anchor site 
of a CTL epitope restricted to the same HLA; and 3) negative within a CTL epitope. We 
hypothesise that those individuals with the corresponding HLA allele and a 
polymorphism at a position associated with more polymorphism in our previous 
analysis would have higher pre-treatment viral loads. Similarly, we hypothesise that 
individuals with the corresponding HLA allele and a polymorphism at a position 
associated with less polymorphism will have lower viral loads. 
We also attempt to show a correlation between the putative HLA escape mutations 
identified in Chapter 6 and pre-treatment viral load. Separate viral load analyses of each 
association may not produce a significant result because of lack of pre-treatment viral 
load measurements and because of polymorphisms at other positions induced by the 
factors other than HLA. However, if enough individuals have corresponding putative 
escape mutations and a viral load in the same direction, the combination in a single 
model may be able to show significance. This analysis would also allow for adjustment 
of any effect of HLA per se and other human genetic markers. 
Methods 
The analyses of polymorphism at specific sites for individuals with a particular HLA 
were performed only on those individuals with a pre-antiretroviral viral load. 
Individuals were categorised into those that had a polymorphism and those that did not 
in the sequence closest to starting antiretroviral treatment. The log of viral load, 
percentage of lymphocytes that were CD4 positive and CD4 count measurements prior 
to but closest to the sequencing, and prior to treatment, were used and tested for 
significance using a Wilcoxon rank test. A rank test was used because some individuals 
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used. The medians and inter-quartile ranges (IQR) were also determined for the two 
groups.  
The method for analysing the effect of all putative escape polymorphisms on viral load 
involved the following. As in the previous method, polymorphism at the putative escape 
mutation sites was taken from the sequence closest to the date of starting antiretroviral 
treatment, and the log of the pre-treatment viral load closest to the sequencing was used. 
Individuals that did not have a pre-treatment viral load, CCR5 ∆32 typing, had active 
AIDS or a viral load measurement during seroconversion were removed from the 
analysis. HLA/position combinations were restricted to those with at least four 
individuals representing the HLA allele versus non-HLA allele, with polymorphisms 
and without. This reduced the chance of creating an unstable model. HLA alleles where 
the greatest molecular subtype was not as high as that seen for HLA-B5 (that is, less 
than 77 percent) were not considered. These were removed to reduce some of the noise 
introduced by broad HLA groups that were not represented by a single allele. Cox 
models were used for this analysis because they could handle censoring of the viral 
load, which has an upper limit of detection in the assays used. 
As HLA and CCR5 ∆32 heterozygosity, and possibly polymorphisms per se influence 
viral load (as an increase in the number of different HIV-1 species is observed to 
increase as disease progresses
13,41-48), a Cox model was first fitted with all HLAs that 
had a molecular subtype split of at least 77 precent, CCR5 ∆32 heterozygosity, and the 
putative HLA escape positions that were to be considered. This model provided a 
baseline from which to compare a second Cox model that fitted the same covariates plus 
interaction terms representing the putative escape mutations (that is, a polymorphism 
and it’s positively associated HLA allele, or consensus amino acid and the negatively 
associated HLA allele). The change in the log likelihood (L2-L1) and degrees of freedom Methods  
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(df2 – df1) were calculated. The improvement in the second model, by adding the 
putative escape mutation covariates, was assessed using a chi square distribution (
2 χ ) 
with a value of two times the difference in the log likelihood values and degrees of 
freedom equal to the difference in the degrees of freedom for the two models: 
()
2
1 2 1 2 ~ 2 df df L L − − − χ . The resulting P-value represented the effect of the putative escape 
polymorphisms in those with the HLA, independent of the effect of the HLA and 
polymorphisms.  
Results 
The strongest positive 
association at an anchor 
residue of a known CTL 
epitope restricted to the 
same HLA that had 
sufficient numbers was 
HLA-A11 at position 166. 
The association between 
HLA-B5 and 
polymorphism at position 
135 that was studied in 
detail in previous chapters 
did not have enough cases 
as most individuals with 
HLA-B5 had mutated by 
their first sequence. There were 21 individuals with HLA-A11 who had a viral load 
Table 16.1. Association between viral load and a polymorphism at 
position 166 in individuals with HLA-A11. 
Individuals are grouped by those that had a polymorphism at position 
166 and those that did not.  
 
HLA-A11 Patients 
without a polymorphism 
at position 166 of HIV-1 
RT pre treatment 
HLA-A11 Patients with a 
polymorphism at position 
166 of HIV-1 RT pre 
treatment 
 
Pt
#
Viral load
(log, 
copies per 
mL) 
CD4 
% 
CD4 
count 
Pt 
#
Viral load 
(log, 
copies per 
mL) 
CD4
% 
CD4 
count 
  1 2.67 34 680 16  4.80  1 12
  2 3.79 27 621 17  4.73  24 624
  3 3.99 30 660 18  5.58  18 288
  4 3.81 30 780 19  5.78  7 91
  5 5.78 5 55        
  6 4.90 29 667        
  7 3.95 17 323        
  8 4.31 16 352        
  9 4.67 33 660        
  10 4.03 21 400        
  11 4.24 49 980        
  12 4.34 26 390        
  13 5.05 24 408        
  14 >6.00 9 171        
  15 4.53 16 224             
n  15 15 15   4  4 4
Median  4.31 26 408   5.54  12 190
IQR  3.97-4.78
16-
30
338-
664
 
4.78-5.63  6-20
71-
372
P-value 
(Wilcoxon)      
 
0.045 0.089 0.099
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measurement prior to the commencement of antiretroviral therapy. 16 of these had the 
consensus amino acid at position 166 of HIV-1 RT and five had a polymorphism at this 
position. One individual from each group had active AIDS at the time of the viral load 
measurement and was taken out of the analysis. Table 16.1 shows the viral load, CD4 
percentage and CD4 count data for each individual. The viral load was significantly 
higher in those individuals with HLA-A11 that had a polymorphism at position 166 
(n=4, 5.54 ± 0.46 log copies/mL) compared to those with HLA-A11 without a 
polymorphism (n=15, 4.31 ± 0.82 log copies/mL; P=0.045, Wilcoxon). The CD4 
percentage and count were lower in this group, but not significant (P = 0.089 and 0.099 
respectively, Wilcoxon). 
The strongest positive 
association not at an 
anchor residue of a 
known CTL epitope 
restricted to the same 
HLA that had sufficient 
numbers was HLA-B7 at 
position 162. Again, the 
association between 
HLA-B35 and 
polymorphism at position 
177 that was studied in 
detail in Chapter 14 did 
not have enough cases. 
There were 17 individuals 
with HLA-B7 who had the consensus amino acid at position 162, two of whom were 
Table 16.2. Association between viral load and a polymorphism at 
position 162 in individuals with HLA-B7. 
Patients are grouped by those that had a polymorphism at position 162 
and those that did not. 
 
HLA-B7 Patients without 
a polymorphism at 
position 162 of HIV-1 RT 
pre treatment 
HLA-B7 Patients with a 
polymorphism at position 
162 of HIV-1 RT pre 
treatment 
 
Pt 
# 
Viral load
(log, 
copies per 
mL) 
CD4
% 
CD4 
count 
Pt 
#
Viral load
(log, 
copies per 
mL) 
CD4 
% 
CD4 
count 
  1 4.57 29 841 16 3.99 30  660 
  2 4.02 19 247 17 3.11 43  1032 
  3 4.57 18 162 18 5.21 14  280 
  4 5.50 4 124 19 2.67 43  645 
  5 3.83 13 286 20 4.80 35  420 
  6 3.64 26 624 21 5.61 23  391 
  7 4.31 16 352 22 5.50 13  247 
  8 >6.00 13 208 23 4.67 33  660 
  9 2.67 21 315 24 5.86 32  736 
  10 5.23 12 552 25 4.92 17  646 
  11 4.96 34 748 26 >6.00 4  24 
  12 4.57 35 735 27 >6.00 13  325 
  13 4.64 30 600 28 5.32 27  648 
  14 3.51 39 429 29 3.50 28  1232 
  15 4.76 11 176 30 >6.00 12  204 
          31 5.50 21  315 
             32 >6.00 9  171 
n  15 15 15   17 17  17 
Median  4.57 19 352   5.32 23  420 
IQR  3.93-4.86
13-
29
227-
612   4.67-5.86 13-32 
280-
660 
P-value  
(Wilcoxon)    
 
  0.046 0.638 0.504 Results  
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excluded because of active AIDS at 
the time of their viral load 
measurement. There were 21 
individuals in the group with a 
polymorphism at position 162, with 
three removed because of active 
AIDS and one because of 
seroconversion. The values for each 
individual and statistics are shown 
in Table 16.2. The results for HLA-
B7 and polymorphism at position 
162 were similar to that for HLA-
A11 and 166. The viral load was 
higher in the HLA-B7 individuals 
with a polymorphism at position 
162 (n=17, 5.41 ± 1.04 log 
copies/mL) compared to the HLA-
B7 individuals with a consensus 
amino acid (n=15, 4.57 ± 0.83 log 
copies/mL;  P=0.046, Wilcoxon). 
There was no significant difference 
in the CD4 percentage and CD4 
count (P = 0.638 and 0.504, 
respectively, Wilcoxon), although the trend was the same as before. 
The negative association analysed was HLA-A3 at position 43. While the difference in 
viral loads between the two groups was not significant (P=0.119, Wilcoxon), the trend 
Table 16.3. Association between viral load and a 
polymorphism at position 43 in individuals with HLA-A3. 
Patients are grouped by those that had a polymorphism at 
position 43 and those that did not.  
HLA-A3 Patients 
without a polymorphism 
at position 43 of HIV-1 
RT pre treatment   
HLA-A3 Patients with a 
polymorphism at 
position 43 of HIV-1 RT 
pre treatment 
Pt 
#
Viral load
(log, 
copies per 
mL) 
CD4
% 
CD4 
count  
Pt 
# 
Viral load 
(log, 
copies per 
mL) 
CD4
% 
CD4 
count 
1 >6.00 5 25  38  4.90  31 837
2 3.99 30 660  39  4.54  36 864
3 3.86 32 800  40  4.03  19 646
4 >6.00 22 286  41  4.11  21 378
5 4.02 19 247  42  4.59  1 5
6 4.57 18 162         
7 4.84 25 675         
8 >6.00 14 336         
9 5.50 27 432         
10 2.67 49 833         
11 4.69 22 638         
12 5.47 14 210         
13 5.50 13 247         
14 >6.00 13 208         
15 5.86 32 736         
16 2.67 21 315         
17 4.42 33 627         
18 5.23 12 552         
19 4.57 35 735         
20 5.49 24 552         
21 5.32 27 648         
22 4.40 25 325         
23 >6.00 12 204         
24 >6.00 24 24         
25 5.58 18 288         
26 4.77 21 462         
27 4.53 18 360         
28 4.25 22 594         
29 4.51 16 256         
30 >6.00 10 120         
31 4.58 30 447         
32 5.83 7 42         
33 5.50 10 150         
34 4.47 21 252         
35 5.82 11 143         
36 5.70 24 456         
37 5.32 20 360         
n  37 37 37    5  5 5
Median 5.32 21 336    4.54  21 646
IQR
4.51-
5.82
14-
25
210-
594   
4.11- 
4.59 
19-
31
378-
837
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was consistent with our hypothesis that those with a polymorphism would have lower 
viral loads. The CD4 percentage and CD4 count between these two groups was not 
significant (P=0.726, 0.214, respectively; see Table 16.3). 
Of the 25 negative and 64 positive putative HLA escape positions identified in Chapter 
6, only six negative and nine positive remained after removing those broad HLA 
groupings with too few cases and those that had as their greatest molecular subtype an 
allele that represented less than 77 percent of the broad HLA group (see Table A.5). 
These 15 putative HLA escape mutation sites were analysed in the overall modelling of 
viral load. The numbers vary slightly between Table A.5, and Table 16.1, Table 16.2 
and Table 16.3 because individuals without CCR5 ∆32 typing were removed in Table 
A.5. 
The model of viral load with HLA, position, CCR5 ∆32 polymorphism and 
HLA/position polymorphism covariates had a log likelihood of –31.3615 with 39 
degrees of freedom (P = 0.3058). The same model without the HLA/position 
polymorphism covariates had a log likelihood of –13.4855 with 24 degrees of freedom 
(P = 0.009). The improvement in the model after including the HLA/position 
polymorphism covariates was calculated as -2(L2-L1) = -2(-31.3615-(-13.4855)) = 
35.752, P = 0.002 (see Table 16.4). Risk ratios greater than one from these models 
indicate a decreased (compared to the average) and risk ratios less than one indicate an 
increased viral load. For the first model, the covariate representing CCR5 ∆32 
heterozygosity was the only significant covariate with a risk ratio greater than one, 
indicating a reduced viral load. The only borderline significant HLA association was 
HLA-B27, also with an odds ratio greater than one. For the second model, four of the 
six negative putative HLA escape positions had risk ratio greater than one – indicating 
if an individual with that HLA type had a polymorphism at that position their viral load Results  
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would be reduced. Of the nine positive putative HLA escape positions, four had an risk 
ratio less than one. These were for HLA-A11 and 166, HLA-B5 and 60, HLA-B7 and 
162, and HLA-B17 and 214. 
Table 16.4. Comprehensive viral load model. 
Only broad HLA groups that had a molecular split that represented at least 77 percent of the group were 
considered. Only HLA/position combinations with at least four cases in each of the four classes were 
considered. Improvement in model after including HLA/position interaction terms was -2(-31.3615-(-
13.4855)) = 35.752, P =  0.002. 
 
Model without HLA/position 
interaction terms   
Model with HLA/position interaction 
terms 
Log Likelihood  -13.4855       -31.3615   
Degrees of freedom  24       39   
Model P-value 0.3058       0.009   
  Variable  P-value 
Risk 
Ratio   Variable  P-value
Risk 
Ratio
  A1 0.3701 0.749  A1    0.0120 0.224
  A11 0.5744 1.226  A2    0.0983 0.483
  A2 0.7009 0.895  A3    0.0197 0.389
  A3 0.1855 0.659  A11    0.0715 2.809
  B5 0.8701 1.068  B5    0.5757 1.513
  B7 0.8620 0.941  B7    0.3491 1.863
  B8 0.8117 0.918  B8    0.1726 2.062
  B17 0.1047 1.969  B17    0.0009 5.743
  B18 0.9265 0.959  B18    0.9156 0.944
  B27 0.0688 2.431  B27    0.1599 2.119
  B35 0.8225 1.089  B35    0.9245 1.046
  B37 0.5971 1.938  B37    0.1398 0.118
  CCR5 ∆ 32   0.0203 2.178  CCR5 ∆ 32  0.0590 2.036
  Polymorphism at 26  0.2904 0.654  Polymorphism at 26  0.2128 0.405
  Polymorphism at 35  0.8698 1.046  Polymorphism at 35  0.6643 0.847
  Polymorphism at 49  0.1725 1.814  Polymorphism at 49  0.1074 0.317
  Polymorphism at 60  0.3587 1.402  Polymorphism at 60  0.2889 1.595
  Polymorphism at 122 0.6508 0.882  Polymorphism at 122  0.0363 0.294
  Polymorphism at 162 0.6209 0.855  Polymorphism at 162  0.9241 1.046
  Polymorphism at 166 0.4556 1.286  Polymorphism at 166  0.0715 2.224
  Polymorphism at 200 0.4812 0.826  Polymorphism at 200  0.8200 1.091
  Polymorphism at 211 0.2975 1.329  Polymorphism at 211  0.6176 0.845
  Polymorphism at 214 0.0793 0.434  Polymorphism at 214  0.4173 0.585
  Polymorphism at 215 0.4049 1.422  Polymorphism at 215  0.0403 0.17
       Negative putative HLA escape sites: 
          A1 and polymorphism at 35  0.3544 1.967
          A2 and polymorphism at 122  0.0028 9.171
          A11 and polymorphism at 122  0.6861 0.631
          A1 and polymorphism at 162  0.0142 6.148
          B5 and polymorphism at 211  0.9122 1.125
          B8 and polymorphism at 200  0.0402 0.143
       Positive putative HLA escape sites: 
          A1 and polymorphism at 215  0.1908 3.172
          A2 and polymorphism at 26  0.4269 2.159
          A3 and polymorphism at 215  0.0183 17.34
          A11 and polymorphism at 166  0.1380 0.234
          B5 and polymorphism at 60  0.9436 0.924
          B7 and polymorphism at 49  0.0250 10.49
          B7 and polymorphism at 162  0.1306 0.295
          B7 and polymorphism at 215  0.5201 2.097
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Discussion 
While no HLA covariate was significant in the Cox model of viral load without 
interactions, the directions of the associations were in most cases consistent with the 
literature. HLA-A11,
315 HLA-B5,
330,331 HLA-B17,
319,330,331 HLA-B27
319,330-332 and 
CCR5  ∆32 heterozygosity
108,362-376 have been associated with decreased disease 
progression, and in the model were associated with reduced viral load. Similarly, HLA-
B8, which is associated with more rapid disease progression
313,315,319-329 was associated 
with increased viral load. Only two covariates disagreed with the literature – HLA-
B35
298,315,319,323,329-331,333-338,340,341 and HLA-B37,
319 both of which have both been 
associated with more rapid disease progression. The disagreement with HLA-B35 may 
be explained through the observations that the majority of HLA-B35 individuals in our 
cohort have the HLA-B*3501 molecular subtype (see Figure 14.4), and HLA-B*3510 is 
not associated with rapid disease progression.
342 Another explanation may come from 
the observation that in the WAHIVCS (from which the study group of patients for this 
thesis were taken), the effect of HLA-B35 and rapid disease progression appears to 
occur late in disease.
466 Since the majority of individuals in this study were more likely 
to have not been in late infection (because the samples used were taken prior to 
antiretroviral treatment and the majority of individuals in the cohort start treatment prior 
to late disease), the effect of HLA-B35 may not be apparent. 
The presence in individuals of putative CTL escape mutations significantly correlated 
with the viral load. This was more significant than viral polymorphisms and HLA 
alleles per se. This is surprising given the small region of the HIV-1 genome 
considered, and the large number of HLA alleles associated with disease progression. 
Also unexpected was that the negative putative HLA escape polymorphism sites Discussion 
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appeared to contribute more to explaining the variability in viral load than the positive 
putative associations. This implies that the more adapted the founding virus in the host 
is, the higher the viral load. This has also been seen in SIV where rhesus macaques were 
infected with clones representing virus found in early, intermediate and late-stage 
infection.
969 
These results do not only add to the body of evidence that argue that escape from HLA-
restricted CTL responses leads to disease progression,
12,13,49-51 but also support our 
previous results of identifying putative CTL escape mutations using biological and 
independent data. These results highlight the importance of the interactions between the 
host genetics and viral genetics in influencing disease progression. To date, only a 
handful of studies have shown this,
12,13,49-51,214-216 and none have shown this occurring at 
a population level.  
These results have several clinical implications. Antiretroviral treatment during primary 
infection has been shown to protect individuals from subsequent disease progression, 
even after ceasing treatment, and favour long-term non-progression.
344,426,429,827,834 The 
majority of this effect has been attributed to the preservation of the most effective CD4+ 
T-helper cells by reducing the chance of clonal deletion of the most effective T-helper 
cells that are activated during primary infection.
426,427,638,835,836 Studies showing CTL 
escape in individuals with HIV-1
47,48,524 and in the majority of rhesus macaques infected 
with SIV
561 during seroconversion suggest that the preservation of these responses, 
which by the definition of immunodominance must be highly effective at HIV-1 killing, 
also reduce the chance of subsequent progression.  
CTL escape mutations can be likened to antiretroviral drug resistance mutations, where 
each different HLA allele in an individual is equivalent to a different drug. Because 
most individuals cannot naturally suppress viral load to levels that reduce viral load to Chapter 16 Putative escape mutations and viral load: clinical implications  222 
substantially prevent CTL escape for the life of an individual, drug therapy to assist the 
CTL in controlling the virus seems advisable based on these results. This would reduce 
the chance of further escape and further adaptation of the virus to the individual’s HLA 
restricted immune responses. Hence, these results would argue for antiretroviral 
treatment early in infection, as CTL escape is likely to be occurring throughout 
infection.
7,20,124,415,420,562,565,570 The earlier antiretroviral treatment is started the greater 
the preservation of effective CTL responses. These results would also argue against 
structured treatment interruptions (reviewed in reference 843)
263,844-857 in chronically 
infected individuals and potentially explain the more favourable responses seen to 
ceasing treatment where HAART has been started during acute 
infection.
344,426,429,638,827,834  
These results suggest, to some degree, why some individuals do better on treatment than 
others. Virus that has fully adapted to an individual’s immune system may have viral 
loads close to the levels seen at the peak of viremia in primary infection. This is seen in 
natural infection prior to HIV-1 related death. After primary infection, the immune 
responses reduce the viral load (of around two to three logs from around 10-100 
million
970 to 10-100 thousand
971 copies/mL). Having an immune system that can make 
effective responses against the virus may mean the effectiveness of antiretroviral 
therapy has to be only four logs rather than seven logs. In some individuals on 
treatment, a CTL response may not be needed to aid suppression of the virus and indeed 
CTL responses may wane with effective antiretroviral treatment, reducing viral antigen. 
However, individuals that do not fully respond to treatment (because of compliance 
problems, drug resistance mutations, drug absorption or for other reasons) may have a 
viral load at levels that CTL can detect and provide support for reduction and prevention 
of both drug resistance mutations and CTL escape. In these individuals, the more Discussion 
  
223
adapted the virus is to the CTL immune response, the higher the viral load would be and 
the faster the rate of progression. 
Remarkably the presence of just one mutation in individuals with HLA-A11 and HLA-
B7 was able to predict viral load. The phenomenon of immunodominance likely 
contributed to the significance and magnitude of this finding as the epitopes for which 
the virus in these individuals escaped was likely to be within a hierarchy of epitopes. 
Escape from the particular epitopes examined most likely divided individuals into those 
that were at this point in the hierarchy and those that were not. That is, a polymorphism 
at these positions also marked other escape mutations in other epitopes elsewhere in the 
genome. Hence, the effect on viral load of a mutation at this position in these 
individuals may be less than we found. Polymorphisms may also be merely marking 
progression rather than influencing it as individuals who have been infected for a long 
time or who have higher viral loads have more chance for escape or just random 
polymorphism. Others have shown that the diversity of the virus increases through the 
course of infection
13,41-48 and in the previous chapter we also saw that non-HLA-
associated polymorphisms appear to increase over time. This may be a problem in the 
models restricted to individuals with a specific HLA allele, and testing for an 
association between viral load and polymorphism as in Table 16.1, Table 16.2 and 
Table 16.3. However, our overall model of viral load adjusted for the independent 
effects of HLA and polymorphism, leaving the interaction term of HLA and 
polymorphism to show the true effect.  
Interestingly, both the model of HLA-A3 at position 43 and the covariates in the overall 
model of viral load that corresponded to negative associations with polymorphism from 
our study in Chapter 6 suggest that individuals that have a polymorphism at these sites 
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strain of HIV-1 being able to elicit a strong CTL response towards this non-consensus 
epitope and hence having lower viral loads. The fact that the putative epitope that these 
negative associations mark is escaped at a population level suggests that they are able to 
elicit a strong CTL response. This is the case for an EBV epitope restricted to the most 
common local HLA class Ia allele that has escaped at the population level.
22-25,895 These 
negative associations could also mark places where two HLA responses are applying 
pressure at the same amino acid position. Escape from one could result in the creation 
of an epitope recognised by another HLA. This type of antagonism has been seen in 
drug resistance mutations that create a new recognised CTL epitope.
837,838 It is 
interesting to note that the negative association with HLA-A3 and position 43, as well 
as two other negative HLA-A3 associations (see Figure 6.3, panels A and C; and Table 
A.4), are within an HLA-A3 restricted CTL epitope. For some reason, despite the fact 
that the consensus epitope has been shown to elicit a CTL response the virus still 
appears to prefer the consensus sequence in individuals with HLA-A3. The simplest 
explanation is that while the consensus epitope can be recognised by CTL the mutated 
epitope may be recognised with greater efficacy. Another explanation is that escape 
from this epitope may result in the recognition of a more effective CTL epitope 
elsewhere in the genome.  
These results and other studies of this nature could indicate the importance of each 
epitope and the effect of an escape mutation on viral load. These could be used to 
monitor an individual’s disease progression in a similar way to that in which drug 
resistance mutations are monitored during antiretroviral treatment. The strength of 
association can give some indication of immunodominance and the effect on viral 
fitness of the polymorphism. However, models of the entire genome and of molecular 
subtypes would be needed to give a better indication of the actual effects of single 
polymorphisms. Unfortunately, the large number of covariates this would produce for Discussion 
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the comprehensive viral load method presented here would require a large pre-treatment 
population. A different approach that estimates the degree to which an individual’s virus 
has adapted to the individual’s HLA may be more practical. Individuals with virus that 
is more adapted to their HLA - either more polymorphism at positive putative CTL 
escape sites and less at negative putative CTL escape sites – would be expected to have 
higher loads, and those with less adapted virus would have lower viral loads. 
Individuals could be grouped into, say, quartiles of how well the virus is adapted to the 
individual’s HLA and a test for differences in viral loads between these groups could be 
performed. 
In conclusion, the presence of viral polymorphisms in combination with their positively 
associated HLA alleles or consensus amino acids with their negatively associated HLA 
alleles is significantly associated with viral load. Furthermore, these predictors explain 
the viral load variability better than the HLA alleles or viral polymorphisms per se. 
  
Chapter 17 General discussion 
The HIV-1 RT sequence is relatively conserved among isolates.
905 We observed this in 
our population consensus sequence that was almost identical to the first ever sequenced 
HIV-1 genome (HXB2CG-RT
54). However, even in our stable, geographically isolated 
population of HIV-1 infected persons, there was sequence diversity. Our findings 
suggest that this diversity is the net result of at least two competing evolutionary 
pressures selecting for or against change at each amino acid. Foremost is the need to 
maintain functional integrity of the virus. Within the bounds of this fundamental 
constraint, a strong predictor of viral polymorphism appears to be host HLA. 
We showed a significant overall association between HLA and polymorphism in HIV-1 
RT. Other analyses identified the positions at which HLA alleles were associated with 
polymorphisms. These associations occurred at sites that were within or proximate to 
published CTL epitopes, and correlated with the HLA alleles to which these epitopes 
are known to be restricted. This correlation was highly significant, and gives both 
support for our method for determining putative escape mutation sites and an indication 
of how immunodominant or effective each of the known CTL epitopes are in vivo. By 
implication, those HLA associations not within known CTL epitopes may mark, as yet, 
unknown CTL epitopes. The observation of significant clustering of HLA allele 
associations is also indicative of escape from CTL epitopes restricted to those HLA 
alleles. 
The detailed features of specific examples, such as HLA-B*5101 associated I135x, 
were highly suggestive of CTL escape mutation affecting HLA-peptide-binding. 
Polymorphisms at non-primary anchor residues of CTL epitopes, such as HLA-B*3501 
associated D177x, HLA-B7 associated S162x and others may confer a survival Chapter 17 General discussion  228 
advantage to the virus by disrupting T-cell receptor-peptide recognition,
689 epitope 
processing from precursor protein
566 or by inducing antagonistic CTL 
responses.
608,689,701 In both these examples the odds ratio of the HLA allele and 
polymorphism improved when considering the molecular subtype – even though there 
are only a few amino acid differences between the subtypes. This argues against the use 
of superfamilies in natural infection and supports the use of modelling polymorphism 
with HLA alleles defined to their molecular level.  
The HLA-specific polymorphisms at residues flanking CTL epitopes, and possibly 
others at sites near predicted proteasome cleavage sites may indicate viral escape by 
disruption of proteasome peptide cleavage. This form of escape has been particularly 
difficult to identify by standard techniques that only use the epitope peptide to measure 
CTL responses and has never been described in HIV-1.
5 However, these techniques 
could be used in combination with our results to identify the importance of this escape 
in HIV-1.  
HLA-specific polymorphisms increased over time, were associated with secondary 
changes at other positions and were predictive of viral load at a population level. The 
effect of single residue changes on viral load is especially striking given that there may 
be a polyclonal immune response against epitopes in other HIV-1 genes and other 
independent influences on viral load such as CCR5 polymorphism (reviewed in 
reference 467). Taken together, these data suggest that the HLA-specific 
polymorphisms we identified in HIV-1 RT represent the net effects of in vivo CTL 
escape mutations in individuals. We propose that the HLA associations that are very 
strong (with high ORs), are clustered with other associations of the same HLA or 
remain significant after correction for multiple comparisons are those most likely to 
represent viral escape mutations from CTL epitopes that are yet to be defined. Use of Chapter 17 General discussion 
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HLA motifs may also provide further support, but our results would suggest that the 
above indications are more important. 
CTL escape mutation has been well characterised in individuals with HLA-B8 (most 
commonly),
46,48,702 HLA-B44,
47 HLA-B27,
12 HLA-A11
200 and HLA-A3,
590 who may 
have been more escape-prone because of narrow range and oligoclonal CTL responses. 
Our data suggests that CTL escape mutation is common and widespread, and is selected 
by responses restricted to a much wider range of HLA alleles than has been studied in 
individual cases. Though many HLA-specific polymorphisms increased over time in 
this study, some were present in first pre-treatment HIV-1 RT sequence and could 
reflect viral founder effects, or have been variants selected at transmission or during the 
early CTL response of acute infection. The single HLA-B*5101 patient without I135x 
was distinguished by use of potent antiretroviral treatment in acute infection whilst 
highly viremic. This patient presented in the first days of infection with no symptoms, 
suggesting he had not yet mounted a CTL response. Presumably the immune selection 
pressure was reduced or eliminated, arguing that I135x is selected during the acute CTL 
response, rather than selected at transmission or in chronic infection in HLA-B*5101 
individuals. Protection from CTL escape variants may contribute to the effect of 
antiretroviral treatment in acute HIV infection leading to stronger chronic inhibitory 
CTL responses which, to date, has been largely attributed to preservation of HIV-1-
specific CD4 T-cell help.
426,427,638,835  
HLA alleles were also associated with lack of polymorphism at certain residues, 
including at residues without functional constraint and these associations contributed 
independently in a comprehensive model of viral load. Unlike positive immune 
selection causing demonstrable escape over time in individuals, negative immune 
selection favours preservation of wild-type virus in vivo and so could only be evident at Chapter 17 General discussion  230 
a population level. It is possible that consensus or wild-type virus is primordially 
adapted to the CTL responses that have most often been encountered (that is, those 
restricted to the most common or evolutionary conserved HLA alleles in the host 
population). It has been shown that weakly immunogenic variants of EBV appear to be 
selected by the predominant HLA types of a host population.
22-25,895 While the majority 
of differences between the HIV-1 clades are probably due to founder effects
922, our data 
suggests that some are due to the common prevalent HLA alleles in the host 
population.
20,21 It is interesting to note that few HLA-A1 and HLA-A2 restricted 
epitopes have been mapped to HIV-1
719 and studies that have argued against the 
importance of escape have analysed HLA-A*0201.
688,917 However, in the region of 
HIV-1 RT we analysed, the second strongest association with polymorphism was with 
HLA-A2 and the majority of the HLA-A2 associations with polymorphism at single 
amino acid positions were negative. Furthermore, studies of HIV-1 exposed 
seronegative individuals suggest that CTL responses can alter viral infectivity and 
susceptibility to established primary HIV-1 infection.
310,339,406,433,442 The HLA class I 
alleles associated with natural HIV-1 resistance or susceptibility appear to differ 
between racially distinct populations.
303,310,339,433 To some extent this may reflect 
differences in the HLA alleles that are common in different populations and the degree 
to which a ‘population-adapted’ consensus virus can adapt to the individual. 
The generation of chance associations as a result of comparisons made with multiple 
covariates and at multiple residues is a potential limitation to our analyses. However, 
power calculations and other screening procedures can considerably restrict the number 
of alleles and positions that are examined and reduce the likelihood of such 
associations. The degree to which P-values generated within multivariate logistic 
regression models are corrected will depend on the size of the gene(s) and hence the 
number of polymorphic sites that has been arbitrarily chosen for study. With such Chapter 17 General discussion 
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correction, the approach will lose power to detect associations in direct proportion to the 
size of the genome region selected, decreasing false positive associations (higher 
specificity) but at the cost of losing true positive associations (lower sensitivity). Our 
analyses of HIV-1 RT provided a gradation of P-values uncorrected for multiple 
comparisons, reflecting a gradation in strength of associations. We have concluded that 
independent biological validation, rather than statistical means, will best determine what 
P-value cut-offs are optimal for either sensitivity or specificity. If correction is to be 
made (for high specificity) the randomisation procedure we have undertaken allows the 
number of effective independent comparisons in the entire analysis to be estimated.  
In terms of the known associations between certain HLA alleles and HIV-1 disease 
progression, we have suggested and provide some evidence that HLA allele frequencies 
influence adaptation of wild-type HIV-1 at a population level. However, in vivo 
evolution also occurs within individuals of diverse HLA. Our analysis of viral load 
shows that the presence of HLA alleles with their corresponding HLA allele associated 
viral polymorphisms (or consensus, as appropriate) is more predictive of viral load than 
the HLA alleles alone. It has also been suggested that it is the breadth of CTL responses 
that determines the risk of viral escape and hence clinical progression.
562 Narrow 
monospecific responses directed against a single epitope, as seen in HLA-B*5701 long 
term non-progressors, can be protective
345 but they may also increase risk of viral 
escape in other individuals with HLA alleles shown to be associated with more rapid 
progression, such as HLA-B8.
48 Increasing heterozygosity of the HLA class Ia loci, 
which would predict broader polyclonal responses, has been shown to be associated 
with slower progression to AIDS.
349,350 Successful viral CTL escape mutation depends 
on having low functional barriers to mutation at the appropriate residues, so it may be 
the balance struck between the breadth of host epitope-specific CTL responses and viral 
functional constraint at those epitopes that is important. Hence narrow CTL responses Chapter 17 General discussion  232 
could be protective if directed against conserved epitopes,
12,345 but not protective or 
harmful if directed against epitopes susceptible to variation.
46,48,689,701,819 The ability to 
map both the range of putative epitopes and the observed polymorphism of the epitope 
in a population for many HLA alleles at once is thus potentially very useful. 
Future directions 
The cellular immune response is recognised to be an important correlate of protective 
immunity in HIV-1 infection and immune escape mutation is potentially critical to the 
immunopathogenesis of HIV-1 disease. However, elucidating the extent and overall 
importance of HIV-1 escape in populations of individuals with diverse HLA alleles has 
been has been problematic as it has largely relied on labour-intensive laboratory assays 
of antigen-specific CTL responses in individual cases. Hence, the primary CTL escape 
mutations associated with many different HLA alleles, the risk factors for escape, 
compensatory changes, effects on viral replication rate (viral load) and interactions with 
other selection pressures such as antiretroviral drugs are not well characterised. The 
novel approaches presented in this thesis avoids many of the problems associated with 
these standard experimental studies and reveals new insights into viral evolution by 
considering immune escape at a population level. Future studies based on these methods 
may substantially elucidate the issues identified here. The detection of HLA-specific 
polymorphisms may lead to the identification of many new HLA class I-restricted CTL 
epitopes in HIV-1. The impact of immune escape on viral set-point (as a known close 
correlate of chronic viral load and pathogenicity) could be determined for a wide range 
of HLA genotypes. This information could potentially allow clinicians to anticipate the 
clinical course of infection, response to antiretroviral drugs, optimal antiretroviral drugs 
and response to structured treatment interruptions in individuals given their HLA 
genotype, and plan their management accordingly. Future directions   
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We have highlighted those HLA allele associations with P-values that withstand 
rigorous correction for multiple comparisons, shown those with high ORs, identified 
HLA alleles with significant amounts of clustering and identified putative epitopes that 
these associations may be representing. It is hoped that this information will be the 
starting point for those using these results to map new epitopes in HIV-1 RT. However, 
the broader implications of these results for clinical management or vaccination cannot 
be confirmed without similar data on the remainder of the HIV-1 genome. As other 
HIV-1 genes are more polymorphic (for example, env) and hence may provide greater 
power to detect selection effects, or are regulatory (for example, nef and tat), they may 
have greater impact on viral load. To these ends, collaborations with groups proficient 
in identifying CTL and T-helper epitopes through Elispot and tetramer assays; and an 
international collaboration to pool data and provide the EpiPop program to participating 
centres have been initiated. The later collaboration is likely to be required to show 
significant associations after adjusting for multiple comparisons, or for analysing rare 
HLA alleles or positions that do not have large amounts of polymorphism. The aim of 
these efforts will involve characterisation of HLA associated polymorphism throughout 
the entire viral genome across different host and viral populations to determine the 
extent of escape, and identifying which of the most likely or interesting associations 
represent escape from actual epitopes. 
Methods implemented that extend those presented in this thesis to the entire HIV-1 
genome will have to consider the phenomenon of insertions and deletions, and 
premature stop codons in sequences which are common in some HIV-1 proteins. It is 
possible that at least some of these types of changes are selected by host immune 
responses to disrupt epitope processing.
712 These methods may also have to devise an 
appropriate definition for considering an association significant due to the large number 
of models that will be generated. This could incorporate a P-value correction or score Chapter 17 General discussion  234 
that takes into account multiple comparisons, HLA allele association clustering, odds 
ratios, and biological data such as associations with viral load and known corresponding 
epitopes. Grouping HLA alleles based on polymorphisms in the binding groove rather 
than alleles defined by serology or sequencing may be more relevant and may also be 
considered.
972-974 
It seems likely the overall influence on viral control will be quantitative. Therefore, 
some quantitative score of viral adaptation across the entire viral genome to the host 
could be devised. Individuals with virus that is more adapted to their HLA – more 
polymorphism at their HLA-corresponding positive putative CTL escape sites and less 
at their HLA-corresponding negative putative CTL escape sites – would be expected to 
have higher viral loads and those with less adapted virus would have lower viral loads, 
as has been shown for HIV-1 RT. These models could provide information on the 
incremental survival advantage that each polymorphism in the hierarchy of CTL escape 
mutations provides to the virus. This information may indicate how CTL escape and 
disease progression can be avoided. Furthermore, it would be valuable in the clinical 
management of individuals and the design of clinical studies. As with drug resistance 
mutation tests, testing for critical polymorphisms based on a patient’s HLA may 
ultimately influence patient care decisions. This information could help clinicians 
individualise antiretroviral treatment strategies. For example, in individuals with 
evidence of early in vivo escape mutation at critical sites, early antiretroviral treatment 
to prevent further loss of CTL responses and viral adaptation may be advantageous.  
Similarly individuals with chronic infection and evolving in vivo escape would be 
unlikely to achieve enhancement of HIV-1-specific CTL responses during structured 
treatment interruptions. On the other hand, treatment might arguably be delayed in an 
individual with an HLA profile which is associated with one (or more) immune 
dominant epitopes which occur within sites with strong functional or structural Future directions   
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constraints to mutation and in whom such mutations have not been detected. In 
therapeutic vaccine studies, information on the important sites of viral escape in an 
individual could be used to monitor how effectively vaccines delay the emergence of 
CTL escape mutations and in preventative vaccine studies could help determine which 
CTL responses are most effective to prevent infection.  
The methods developed in this thesis are not limited to HLA-A and HLA-B. The 
importance of other HLA class I genes in HIV-1 disease are not known. For example, 
HLA-C could be important because, unlike HLA-A and HLA-B, it is not downregulated 
by HIV-1. Furthermore, the importance of class II escape in HIV-1 disease progression 
is not known. Indeed, escape from CD4 T-helper escape is still to be determined in vivo 
for HIV-1. These methods, especially if they predict viral load, could provide evidence 
for the importance of class II escape in HIV-1, and may direct which class II alleles and 
HIV-1 peptides should be examined in experimental systems. Other polymorphic 
factors could also be analysed in a similar manner to determine if they are applying 
pressure to residues in HIV-1. For example, the extent of escape from the polymorphic 
proteins that make up the TAP and proteasome complexes, and the effect of 
polymorphisms in chemokine receptors on polymorphism on residues in the envelope 
glycoproteins could be determined. If applied to virus that had been exposed to drugs, 
these sequence analyses can incorporate appropriate covariates to identify or confirm 
drug resistance sites in vivo. To date, knowledge of positive drug resistance sites is 
fairly well known from in vitro and in vivo data on the proteins they target. However, in 
vivo information about new drugs targeting other proteins and compensatory mutations 
outside of the proteins targeted (for example, pol/gag protease cleavage sites) are still to 
be fully elucidated. Furthermore, knowledge of potentially important pressures exerted 
by drugs to resist polymorphism (indicated by a negative association in our method) is 
lacking. Such knowledge could be used to optimise potentially synergistic interactions Chapter 17 General discussion  236 
between antiretroviral drugs and HLA-restricted CTL responses, or to avoid potentially 
harmful drug or drug/HLA combinations. This information could help explain part of 
the variability in responses to antiretroviral drugs seen between patients. 
The large diversity in HIV-1 is well known and is recognised as a problem for vaccine 
design. Gaschen et al
21 suggest the use of an imputed clade B ancestor or consensus 
virus would reduce the problem of viral diversity by approximately half. However, the 
HLA alleles present in an individual critically influence the CTL response to a vaccine 
and less attention has been given to the influence of HLA diversity of a population to 
the response to a vaccine. The interaction between viral and HLA diversity and pre-
antiretroviral treatment viral load in a population can be used as a model to determine 
how to design a vaccine to optimise CTL responses in that population.  
The most common (and arguably most effective) responses used by individuals with 
different HLA alleles can be identified in conjunction with other tests to determine the 
actual immunodominant epitopes. In addition, these studies could identify the epitopes 
with the greatest effect on viral load, those which are more prone to escape and those 
that can be used in individuals with different HLA alleles. Preventative or therapeutic 
vaccines could then be designed to target epitopes with the greatest HLA allele 
efficacies, those that have a high genetic barrier to change and/or those that are shared 
across several HLA alleles. Ultimately, knowledge of HLA subtypes in a population, 
and the population of viral subtypes to which individuals are likely to be exposed could 
be used in conjunction with the knowledge gained from identifying these epitopes to 
create a host and virus population specific vaccine. That is, a vaccine based on the 
prevalent HLA types, HLA responses, and the viral variants that individuals are most 
likely to be exposed to.  Future directions   
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Finally, these methods are not limited to HIV-1. Such approaches could be used to 
examine host immune responses and drug effects on other pathogens, such as hepatitis 
B and hepatitis C. Similar studies to those suggested in this section could also be 
undertaken to design preventive and therapeutic vaccines, to monitor disease in 
individuals, monitor viral adaptation at a population level, and to individualise 
treatment based on knowledge of the HLA-restricted immune responses and autologous 
viral sequence. 
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Table A.1. HLA alleles remaining after each step of the modelling process. 
Initially the alleles HLA-A1, -A2, -A3, -A9, -A10, -A11, -A19, -A28, -A31, -A36, -B5, -B7, -B8, -B12, -
B13, -B14, -B15, -B16, -B17, -B18, -B21, -B22, -B27, -B35, -B37, -B40, -B41, -B42, -B55, -B56, -B58, 
-B60 and -B61 were considered. 
HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons
20 27 402A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B14, B15, 
B16, B17, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, B7, B8, 
B12 
     
 
21 10 402          
22 23 402A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B17, 
B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B17, B40 
A2, A3, B17  A2, A3, B17     
 
23 9 402          
24 5 402          
25 33 402A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40
A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B40 
   A1  
 
26 47 402A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B15, 
B17, B35, B40
A2, A10  A2, A10  A2  A2 
 
27 82 402A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40
A9 A9     
 
28 39 403A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B22, B27, 
B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B5, B7, B8, 
B12, B16, 
B35, B40 
A3, B16, B40  A3, B16, B40  A3, B16, B40  A3, 
B16 
 
29 14 404          
30 30 404A1, A2, A3, 
A9, A10, A11, 
A1, A2, A3, 
A9, A11, A19, 
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HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40 
B7, B8, B12, 
B35 
31 2 406          
32 21 406A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B15, 
B17, B35, B40 
A1, A2, A3, 
A11, B7, B8, 
B12, B17 
A2, B8, B17  A2, B8, B17  A2, B8, B17  A2, B8, 
B17 
 
33 17 406A1, A3, A9, 
A11, A19, B7, 
B8, B12 
A1, B7, B12         
 
34 7 406          
35 116 406A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
B37, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B22, B27, 
B35, B40 
A1  A1 A1 A1 
 
36 25 407A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B16, 
B17, B35, B40 
A1, A2, A3, 
A9, A19, B5, 
B7, B8, B12, 
B40 
A1, A3, A9, 
B5, B12 
A1, A3, A9, B5, 
B12 
A3, A9  A3, A9 
 
37 7 407          
38 28 416A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B14, B15, 
B16, B17, 
B18, B27, 
B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B5, B7, B8, 
B12, B17, B35
A3, B5, B7, 
B12 
A3, B5, B7, B12  A3, B5  A3, B5 
 
39 54 416A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B17, 
B27, B35, B40
A1, A2, A3, 
B14, B15 
A1, A2, A3, B14, 
B15 
A2 A2 
 
40 14 416          
41 76 416A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40
A10, A19, 
A28, B7, B15, 
B17, B18 
A10, A19, A28, 
B7, B15, B17, 
B18 
A19, B18   
 
42 5 416          
43 39 416A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
A1, A2, A3, 
A9, A11, A19, 
A28, B5, B7, 
B8, B12, B14, 
B15, B35, B40
A3, B8, B14  A3, B8, B14  A3, B8, B14  A3, B8, 
B14 
B8,B14 Tables  
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HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons
B15, B16, 
B17, B18, 
B22, B27, 
B35, B40 
44 23 417A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B17, 
B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12 
     
 
45 4 417          
46 5 417          
47 0 418          
48 33 418A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40
A1, A2, A3, 
A9, A11, A19, 
B5, B7, B8, 
B12 
A1, B5  A1, B5     
 
49 39 418A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B22, B27, 
B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B5, B7, B8, 
B12, B15, 
B35, B40 
B5, B7, B8  B5, B7, B8  B7  B7 
 
50 4 418          
51 4 418          
52 3 418          
53 15 418A1, A3, A9, 
A11, B7, B8, 
B12 
A1, A11, B12  A11  A11  A11  A11 
 
54 2 418          
55 15 418A1, A3, A9, 
B7, B8, B12 
A1, B12  B12  B12     
 
56 18 456A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B15, B40 
A1, A2, A19, 
B7, B8, B12 
     
 
57 7 462          
58 5 465          
59 41 468A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B22, B27, 
B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B5, B7, B8, 
B12, B15, 
B16, B35, B40
A2, B12, B16  A2, B12, B16     
 
60 67 469A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B14, B15, 
B16, B17, 
B18, B21, 
B35, B40 
A9, A10, B5, 
B16, B21 
A9, A10, B5, 
B16, B21 
B5 B5 
 
61 2 470          Appendices  294 
HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons 
62 14 471          
63 0 472          
64 16 472A1, A3, A9, 
A11, A19, B7, 
B8, B12 
A1,  A3       
 
65 15 472A1, A3, A9, 
B7, B8, B12 
A9 A9 A9  A9  A9 
 
66 6 472          
67 69 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B14, B15, 
B16, B17, 
B18, B22, 
B35, B40 
B14, B17  B14, B17  B14   
 
68 38 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B22, B27, 
B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B14, B15, 
B17, B18, 
B27, B35, B40
B18, B27  B18, B27  B18  B18 
 
69 40 471A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B22, B27, 
B35, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, B7, B8, 
B12, B15, 
B35, B40 
A1, A2, B8, 
B35, B40 
A1, A2, B8, B35, 
B40 
A2, B8, B35, B40A2, B8, 
B35, 
B40 
B8 
70 86 471A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B22, B27, 
B35, B40 
A10, B35  A10, B35  A10  A10 
 
71 2 472          
72 26 471A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B16, 
B17, B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B17 
A9, B17  A9, B17     
 
73 4 472          
74 21 472A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B15, 
B17, B35, B40 
A1, A2, A3, 
A11, B7, B8, 
B12 
A2 A2     
 
75 18 472A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B15, B40 
A1, A2, A3, 
A19, B7, B12 
A1, A2, B12  A1, A2, B12  A1  A1 
 
76 2 472          
77 9 472          
78 4 472          
79 11 471          Tables  
 
  
295
HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons
80 3 472          
81 2 472          
82 6 472          
83 90 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40
A10, B5, B8, 
B12, B15, 
B27, B40 
A10, B5, B8, 
B12, B15, B27, 
B40 
B5, B35  B35 
 
84 5 472          
85 8 472          
86 6 472          
87 0 472          
88 2 472          
89 4 472          
90 23 472A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B17, 
B35, B40 
A1, A2, A3, 
A9, A11, B7, 
B8, B12 
     
 
91 3 472          
92 2 472          
93 1 471          
94 1 471          
95 2 471          
96 5 471          
97 1 472          
98 55 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B14, B15, 
B17, B27, 
B35, B40 
A1 A1     
 
99 26 472A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B16, 
B17, B35, B40
A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B15 
B15  B15 B15 B15 
 
100 26 472A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B16, 
B17, B35, B40
A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12 
B12  B12 B12 B12 
 
101 26 472A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B16, 
B17, B35, B40
A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12 
A2, A3, A11  A2, A3, A11  A2, A3  A2, A3
 
102 37 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
A1, A2, A3, 
A9, A11, A19, 
B5, B7, B8, 
B12, B15, B40
A1, B12, B15  A1, B12, B15  B12  B12 
 Appendices  296 
HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons 
B15, B16, 
B17, B18, 
B27, B35, B40 
103 58 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B14, B15, 
B17, B22, 
B35, B40 
A9, A28, B17, 
B22 
A9, A28, B17, 
B22 
A9, B17  A9 
 
104 35 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, B7, B8, 
B12, B14, 
B15, B40 
B8, B14  B8, B14     
 
105 3 472          
106 8 472          
107 10 472          
108 5 472          
109 8 472          
110 4 472          
111 10 472          
112 0 472          
113 2 472          
114 9 472          
115 18 472A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B15, B40 
A1, A2, A9, 
A19, B7, B12 
A9, B12  A9, B12  A9, B12  A9, 
B12 
 
116 4 472          
117 17 472A1, A3, A9, 
A11, A19, B7, 
B8, B12 
A1, A3, A9, 
B7, B12 
A3 A3     
 
118 32 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B15, B40 
A11, B12  A11, B12  B7, B12  B7, 
B12 
 
119 0 472          
120 2 472          
121 22 472A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B17, 
B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B35 
B35  B35 B35 B35 
 
122 195 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A11, A19, 
A28, B5, B16, 
B40 
A1, A2, A3, A11, 
A19, A28, B5, 
B16, B40 
A1, A2, A11, 
B16 
A2, 
A11, 
B16 
 Tables  
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HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons
B37, B40, 
B41, B60 
123 166 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
B37, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
B37, B40 
A1, A11, A28, 
B12, B35, B37
A1, A11, A28, 
B12, B35, B37 
A28, B12, B35, 
B37 
B12, 
B35, 
B37 
B37 
124 0 472          
125 3 472          
126 6 472          
127 3 472          
128 0 472          
129 7 472          
130 0 472          
131 6 472          
132 0 472          
133 0 472          
134 4 472          
135 167 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
B37, B40, 
B41, B60 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A10, B5, B12, 
B17, B18, B40
A10, B5, B12, 
B17, B18, B40 
A10, B5, B18  A10, 
B5, 
B18 
B5 
136 6 472          
137 5 472          
138 24 472A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B17, 
B35, B40 
A1, A2, A3, 
A9, A19, B7, 
B8, B12, B40 
B8  B8 B8  
 
139 7 472          
140 0 472          
141 2 472          
142 74 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B14, B15, 
B16, B17, 
B18, B27, 
B35, B40 
A9, B15, B18, 
B40 
A9, B15, B18, 
B40 
A9, B18, B40  A9, 
B18 
 
143 1 473          
144 3 473          
145 3 473          
146 2 473          
147 2 473          
148 2 473          
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HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons 
150 1 473          
151 7 473          
152 2 473          
153 4 473          
154 5 473          
155 0 473          
156 1 473          
157 1 473          
158 21 473A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B15, 
B17, B35, B40 
A1, A2, A3, 
A9, A19, B7, 
B8, B12, B40 
B7  B7 B7 B7 
 
159 5 473          
160 12 472          
161 1 472          
162 138 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
B37, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A3, A10, 
B7, B14, B16, 
B17, B35 
A1, A3, A10, B7, 
B14, B16, B17, 
B35 
A1, B7  A1, B7  B7 
163 5 472          
164 7 472          
165 30 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B5, B7, B8, 
B12, B35, B40
B7  B7 B7 B7 
 
166 67 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40
A2, A3, A11, 
B16, B40 
A2, A3, A11, 
B16, B40 
A2, A11, B40  A11  A11 
167 6 472          
168 1 472          
169 25 472A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B16, 
B17, B35, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, B7, B8, 
B12, B15 
A2, B7, B12, 
B15 
A2, B7, B12, B15A2, B7, B15  A2, B7, 
B15 
B7 
170 1 472          
171 3 472          
172 7 472          
173 65 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B13, 
B14, B15, 
B16, B17, 
A1, A2, A19, 
B5, B12, B18 
A1, A2, A19, B5, 
B12, B18 
B5, B18  B5, 
B18 
 Tables  
 
  
299
HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons
B17, B18, 
B21, B22, 
B27, B35, B40
B18, B35, B40
174 56 472A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B13, 
B14, B15, 
B16, B17, 
B35, B40 
A2, A19, B12, 
B14 
A2, A19, B12, 
B14 
  
 
175 3 471          
176 5 471          
177 110 471A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
B37, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A10, 
A11, B12, B35
A1, A2, A10, 
A11, B12, B35 
B12, B35  B35 
 
178 79 471A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40
A2, A10, A19, 
B7, B12, B14 
A2, A10, A19, 
B7, B12, B14 
A19, B7, B12  A19, 
B7, 
B12 
 
179 44 471A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A11, A19, 
B5, B7, B8, 
B12, B15, 
B17, B27, 
B35, B40 
B27  B27 B27 B27 
 
180 3 471          
181 19 471A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B15, B35, B40
A1, A2, A3, 
A9, B7, B8, 
B12 
B8  B8 B8 B8 
 
182 5 471          
183 9 471          
184 72 471A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B14, B15, 
B16, B17, 
B18, B27, 
B35, B40 
A19, B5, B7  A19, B5, B7  A19, B5, B7  A19 
 
185 6 471          
186 1 471          
187 3 471          
188 3 471          
189 4 471          
190 11 471          Appendices  300 
HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons 
191 4 471          
192 11 471          
193 1 471          
194 5 471          
195 6 471          
196 37 470A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B27, B35, B40 
A1, A2, A3, 
A9, A11, A19, 
B5, B7, B8, 
B12, B15, B40
B5  B5 B5 B5   
197 18 470A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B15, B40 
A1, A2, A9, 
B7, B12, B40 
B40  B40 B40 B40  B40 
198 3 470          
199 3 469          
200 150 468A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
B37, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
B37, B40 
A1, A11, A28, 
B7, B8, B13, 
B14, B22, 
B27, B37 
A1, A11, A28, 
B7, B8, B13, 
B14, B22, B27, 
B37 
A11, B8, B22, 
B37 
B8, 
B22, 
B37 
 
201 5 468          
202 45 468A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B15, 
B35, B40 
     
 
203 17 468A1, A3, A9, 
A11, A19, B7, 
B8, B12 
A1, A11, B12  A11, B12  A11, B12  A11, B12  A11, 
B12 
 
204 15 468A1, A3, A9, 
B7, B8, B12 
A9, B7, B12  A9  A9  A9  A9 
 
205 10 467          
206 10 467          
207 165 467A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
B37, B40, 
B41, B60 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A10, A19, 
B12, B14, 
B15, B35, B40
A10, A19, B12, 
B14, B15, B35, 
B40 
A10, B15, B40  A10, 
B15, 
B40 
 
208 22 466A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B15, 
B17, B35, B40 
A1, A2, A3, 
A9, B7, B8, 
B12 
B7  B7 B7 B7 
 
209 6 464          
210 67 464A1, A2, A3,  A1, A2, A3,  A1, A2, A11,  A1, A2, A11,  A2, B21  A2,  B21 Tables  
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HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B14, B15, 
B16, B17, 
B21, B27, 
B35, B40 
A28, B8, B16, 
B17, B21 
A28, B8, B16, 
B17, B21 
B21 
211 298 463A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
B37, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
B5, B12, B15, 
B35 
B5, B12, B15, 
B35 
B5, B12, B15  B5, 
B12, 
B15 
B12 
212 10 462          
213 18 462A1, A2, A3, 
A9, A11, A19, 
B7, B8, B12, 
B15, B40 
A1, A2, A9, 
B7, B8, B12 
B8 B8     
 
214 53 462A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B14, B15, 
B17, B35, B40
A10, B15, B17A10, B15, B17  B15, B17  B15, 
B17 
 
215 136 462A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, 
B37, B40 
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A3, A10, 
A11, A28, B7, 
B15, B16, B17
A1, A3, A10, 
A11, A28, B7, 
B15, B16, B17 
A1, A3, B7  A1, A3, 
B7 
 
216 3 461          
217 2 461          
218 25 461A1, A2, A3, 
A9, A10, A11, 
A19, B5, B7, 
B8, B12, B14, 
B15, B16, 
B17, B35, B40
A1, A2, A3, 
A9, A19, B7, 
B8, B12, B35 
A2, B8  A2, B8     
 
219 70 461A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B18, 
B21, B22, 
B27, B35, B40
A1, A2, A3, 
A9, A10, A11, 
A19, A28, B5, 
B7, B8, B12, 
B13, B14, 
B15, B16, 
B17, B27, 
B35, B40 
A9, A11, B17  A9, A11, B17  A9  A9 
 
220 3 459          
221 5 458          
222 9 453          
223 8 437          
224 28 436A1, A2, A3, 
A9, A10, A11, 
A1, A2, A3, 
A9, A10, A11, 
A11 A11     
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HLA alleles remaining after each step of the modelling 
Amino 
acid 
pos-
ition 
Number 
of 
patients 
with 
mut-
ation 
Number 
of 
patients 
with 
sequence 
Step 1. Power 
for an odds 
ratio of 2 or 
0.5 < 30%. 
Step 2. Less 
than 5 in a 
box for 
expected and 
actual 
numbers 
Step 3. 
Univariate 
(Fisher's 
exact) P-value 
greater than 
0.1 
Step 4. Forward 
Selection if/to 
number of 
covariates ≤ 
10% of number 
of patients 
Step 5. 
Backwards 
Elimination, 
removing 
covariates, 
iteratively, with 
P-values greater 
than 0.1 
Step 6. 
Exact  
P-value 
greater 
than 
0.05 
P-value 
greater than 
0.05 after 
adjusting for 
multiple 
comparisons 
A19, A28, B5, 
B7, B8, B12, 
B14, B15, 
B16, B17, 
B18, B27, 
B35, B40 
A19, B7, B8, 
B12, B35 
225 4 435          
226 3 433          
227 10 427          
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Table A.2. Relative increase over time of polymorphism in the positive associations.  
For each of the 64 positive associations, the number of patients with and without the allele at each position is shown for the patients’ first sequence and last sequence. The 
percentage by which the mutation increased between first and last sequence is shown (P=2.37 x 10
-15, 61 ~ sign test(64)). The cases where the change in mutation for those with 
the HLA allele was greater than those without it is also shown (P=0.0008, 45 ~ sign test (64)). 
Association  First sequence  Last sequence 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Percentage of 
individuals with HLA 
and mutation 
Amino 
acid  
position 
HLA 
allele  P-value 
Odds 
ratio 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
First 
sequence 
Last 
sequence 
Percentage 
increase in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence 
Increase in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence 
Percentage 
increase in 
individuals 
without HLA 
allele and 
mutation 
between first 
and last 
sequence 
Greater 
increase in 
individuals 
with the 
HLA than 
those without 
26 A2  0.004 4.21  166  27  190 21  162 30  192 18  14  16  12 YES  -14 YES 
28 A3  0.034 2.54  81  14  284 27 82 13  283 25  15  14  -7  NO  -7  NO 
28 B16  0.032 3.30  28  4  337 37 23  7  342 31  13  23  87 YES  -16 YES 
32 B8  0.023 2.87  85  9  307  8 84  9  301 12  10  10  1 YES  51  NO 
32 B17  0.038 3.18  40  3  352 14 39  5  346 16  7  11  63 YES  16 YES 
36 A9  0.002 7.92  78  10  307 15 77 11  305 14  11  13  10 YES  -6 YES 
38 B5  0.009 5.39  39  6  353 19 36  8  351 21  13  18  36 YES  11 YES 
39 A2  0.001 4.82  173  27  196 21  168 32  194 22  14  16  19 YES  5 YES 
43 B8  <0.001 7.67  82  14  299 22 79 17  298 22  15  18  21 YES  0 YES 
43 B14  0.001 19.09 32  3  349 33 29  6  348 33  9  17  100 YES  0 YES 
49 B7  0.042 2.42  102  10  280 25 97 15  282 24  9  13  50 YES  -4 YES 
53 A11  <0.001 6.69  65  5  341 6  62 9  340 7  7  13  77  YES  17  YES 
60 B5  0.035 2.28  37  15  378 39 34 17  367 51  29  33  16 YES  30  NO 
65 A9  0.024 3.06  96  2  369 6  91 7  365 9  2  7  250  YES  50  YES 
68 B18  0.008 4.88  26  4  414 29 25  5  409 33  13  17  25 YES  14 YES 
69 B40  0.038 2.88  60  3  386 23 54  9  377 31  5  14  200 YES  35 YES 
69 A2  0.010 3.45  214  14  232 12  202 25  229 15  6  11  79 YES  25 YES A
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Association  First sequence  Last sequence 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Percentage of 
individuals with HLA 
and mutation 
Amino 
acid  
position 
HLA 
allele  P-value 
Odds 
ratio 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
First 
sequence 
Last 
sequence 
Percentage 
increase in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence 
Increase in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence 
Percentage 
increase in 
individuals 
without HLA 
allele and 
mutation 
between first 
and last 
sequence 
Greater 
increase in 
individuals 
with the 
HLA than 
those without 
69 B35  0.027 3.97  52  5  394 21 48  8  383 32  9  14  63 YES  52 YES 
70 A10  0.014 2.81  32  17  356 67 33 16  351 71  35  33  -6  NO  6  NO 
99 B15  0.006 3.80  55  7  370 41 54  8  392 18  11  13  14 YES  -56 YES 
100 B12  0.004 3.04  115  13  321 24  114 13  332 13  10  10  1 YES  -46 YES 
101 A3  0.044 2.44  101  11  351 10 99 13  346 14  10  12  18 YES  40  NO 
102 B12  0.009 2.74  115  13  326 19  112 15  323 22  10  12  16 YES  16 YES 
103 A9  0.033 2.22  89  9  354 21 81 17  332 42  9  17  89 YES  101  NO 
115 B12  0.015 2.80  124  4  342 3  118 9  336 9  3  7  127  YES  200  NO 
115 A9  0.014 3.62  95  3  371  4 91  7  363 11  3  7  133 YES  176  NO 
118 B12  0.045 2.68  121  7  332 13  114 13  326 19  5  10  87 YES  46 YES 
121 B35  0.014 4.00  51  6  403 13 50  7  400 15  11  12  17 YES  16 YES 
123 B35  0.001 2.86  28  29  287  129 26 31  280  135  51  54  7 YES  5 YES 
123 B37  <0.001 11.45  3  4  312  154 2 5  304  161  57  71  25  YES  5  YES 
135 B18  0.002 3.79  13  17  297  146 14 16  291  151  57  53  -6  NO  4  NO 
135 B5  <0.001 16.74  8 44  302  119  8  44  297  123  85  85  0  YES  4  NO 
142 A9  0.029 1.97  81  17  325 50 77 21  320 54  17  21  24 YES  8 YES 
142 B18  0.033 2.51  21  9  385 58 21  9  376 66  30  30  0 YES  14  NO 
158 B7  0.001 4.46  116  9  340  8  115 10  337 11  7  8  11 YES  38  NO 
162 A1  0.028 1.81  94  45  240 94 92 47  242 91  32  34  4 YES  -3 YES 
162 B7  <0.001 10.04 53  72  281 67 51 73  283 65  58  59  2 YES  -3 YES 
165 B7  0.024 2.40  113  12  328 20  109 15  333 15  10  12  26 YES  -25 YES 
166 A11  <0.001 4.36  59  23  351 40 57 25  348 42  28  30  9 YES  5 YES 3
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Association  First sequence  Last sequence 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Percentage of 
individuals with HLA 
and mutation 
Amino 
acid  
position 
HLA 
allele  P-value 
Odds 
ratio 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
First 
sequence 
Last 
sequence 
Percentage 
increase in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence 
Increase in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence 
Percentage 
increase in 
individuals 
without HLA 
allele and 
mutation 
between first 
and last 
sequence 
Greater 
increase in 
individuals 
with the 
HLA than 
those without 
169 B15  0.002 9.65  57  5  394 17 56  6  391 19  8  10  20 YES  12 YES 
169 B7  <0.001 12.57  113  12  338 10  107 17  340  8  10  14  43 YES  -20 YES 
173 B5  0.016 3.69  39  13  373 48 38 14  370 50  25  27  8 YES  4 YES 
173 B18  0.020 6.08  23  7  389 54 22  8  386 56  23  27  14 YES  4 YES 
177 B35  <0.001 3.52  33  24  333 83 31 26  330 84  42  46  8 YES  2 YES 
178 A19  0.032 1.98  72  20  327 54 66 26  295 84  22  28  30 YES  56  NO 
179 B27  0.034 2.66  25  5  412 31 23  7  404 37  17  23  40 YES  20 YES 
181 B8  0.001 5.11  110 1  358  4  102  9  350 10  1  8  800 YES  151 YES 
196 B5  0.003 4.29  43  8  396 24 42  9  391 28  16  18  13 YES  17  NO 
197 B40  0.004 5.77  55  5  398 10 55  8  397 10  8  13  52 YES  0 YES 
200 B37  <0.001 19.16  2  5  315  148 1 6  316  148  71  86  20  YES  0  YES 
203 A11  0.018 4.08  76  5  381  8 75  6  376 11  6  7  20 YES  38  NO 
203 B12  0.001 5.57  121 6  336  7  117 10  334  7  5  8  67 YES  1 YES 
204 A9  0.014 3.59  94  4  365 7  92 6  361 9  4  6  50  YES  29  YES 
207 B40  0.017 2.19  38  25  280  127 34 29  268  136  40  46  16 YES  8 YES 
207 B15  0.003 2.89  30  31  288  121 28 33  274  132  51  54  6 YES  10  NO 
210 B21  0.003 10.19 12  5  390 63 11  6  385 62  29  35  20 YES  0 YES 
211 B15  0.003 2.87  16  45  165  243 15 45  148  255  74  75  2 YES  6  NO 
211 B12  <0.001 4.54  34  93 147 195  24 103 139 197  73  81  11  YES  3  YES 
214 B17  0.007 3.46  36  9  385 39 35 10  374 43  20  22  11 YES  12  NO 
214 B15  0.005 3.77  51  10  370 38 48 11  361 42  16  19  14 YES  12 YES 
215 B7  0.047 2.05  87  38  264 80 73 49  253 87  30  40  32 YES  10 YES A
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Association  First sequence  Last sequence 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Percentage of 
individuals with HLA 
and mutation 
Amino 
acid  
position 
HLA 
allele  P-value 
Odds 
ratio 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
First 
sequence 
Last 
sequence 
Percentage 
increase in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence 
Increase in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence 
Percentage 
increase in 
individuals 
without HLA 
allele and 
mutation 
between first 
and last 
sequence 
Greater 
increase in 
individuals 
with the 
HLA than 
those without 
215 A3  0.030 2.35  80  32  271 86 68 41  257 96  29  38  32 YES  13 YES 
215 A1  0.004 2.69  91  47  260 71 84 52  241 85  34  38  12 YES  22  NO 
219 A9  0.013 3.28  82  16  333 38 74 23  316 48  16  24  45 YES  29 YES 
TOTAL                            61    45 
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Table A.3. Relative decrease over time of polymorphism in the negative associations.  
For each of the 25 negative associations, the number of patients with and without the allele at each position is shown for the patients’ first sequence and last sequence. The 
percentage by which the mutation decreased between first and last sequence is shown (P=0.79, 11 ~ sign test(25)). The cases where the decrease in mutation for those with the 
HLA allele was greater than those without it is also shown (P=0.21, 15 ~ sign test (25)). 
Association  First sequence  Last sequence 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Percentage of 
individuals with HLA 
and mutation 
Amino 
acid  
position 
HLA 
allele  P-value 
Odds 
ratio 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
First 
sequence 
Last 
sequence 
Percentage 
decrease in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence 
Decrease in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence  
Percentage 
decrease in 
individuals 
without HLA 
allele and 
mutation 
between first 
and last 
sequence 
Larger  
decrease in 
individuals 
with the 
HLA than 
those without 
32  A2  0.017 0.3  193 3  199  14  191  4  194  17  2  2  -25 NO  -19 NO 
35  A1  0.011  0.4 97 23  192  98  116  3  266  22  19  3  669  YES  335  YES 
36  A3  0.013  0.0  91  4  294 21 93  2  289 23  4  2  100 YES  -10 YES 
38  A3  0.008  0.1  94  4  298 21 97  2  290 27  4  2  104 YES  -22 YES 
43  A3  0.044  0.2  92  6  289 30 94  5  283 34  6  5  22 YES  -12 YES 
69  B8  0.001  0.1  106 5  340 21  107  3  324 37  5  3  64 YES  -43 YES 
75  A1  0.006 0.0  138 0  323  11  137  1  316  18  0  1  -100 NO  -100 NO 
83  B35  0.018  0.3  50  7  339 76 51  6  332 83  12  11  16 YES  -8 YES 
101 A2  0.013  0.3  221  7  231  14  220  7  225  20  3  3  0  NO  -30  YES 
118  B7  0.030 0.2  124 1  329  19  120  5  319  28  1  4  -80 NO  -32 NO 
122  B16  0.026  0.3  28 8  270  167 30  6  247  189  22  17  33 YES  -12 YES 
122  A11  0.002  0.4 58 24  240  151  55  27  222  168  29  33  -12  NO  -11  NO 
122  A2  0.004  0.5  154  74 144 101 149  78 128 117  32  34  -6  NO  -14  YES 
123  B12  0.021  0.5 98 30  217  128  93  34  213  132  23  27  -12  NO  -3  NO 
135  A10  0.039  0.4 39 10  271  153  38  11  267  156  20  22  -9  NO  -2  NO 
169  A2  0.014 0.3  223 5  228  17  221  7  226  18  2  3  -29 NO  -6 NO 
178  B7  0.002  0.3  116  9  283 65 31 26  330 84  7  46  -84  NO  -8  NO A
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Association  First sequence  Last sequence 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Number 
individuals 
with HLA 
allele 
Number 
individuals 
without HLA 
allele 
Percentage of 
individuals with HLA 
and mutation 
Amino 
acid  
position 
HLA 
allele  P-value 
Odds 
ratio 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
No 
mut- 
ation 
Mut- 
ation 
First 
sequence 
Last 
sequence 
Percentage 
decrease in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence 
Decrease in 
individuals 
with HLA 
allele and 
mutation 
between first 
and last 
sequence  
Percentage 
decrease in 
individuals 
without HLA 
allele and 
mutation 
between first 
and last 
sequence 
Larger  
decrease in 
individuals 
with the 
HLA than 
those without 
178  B12  0.036  0.5  114  14  285 60  109 18  252 92  11  14  -23  NO  -35 YES 
184  A19  0.016  0.3  91  1  377  4 85  7  313 66  1  8  -86  NO  -94 YES 
200  B22  0.041  0.3  16 4  301  149 17  3  300  148  20  15  33 YES  0 YES 
200  B8  0.041  0.5 89 22  228  131  87  23  230  128  20  21  -5  NO  2  NO 
207  A10 0.044 0.4  42 6  276  146  40  8  262  157  13  17  -25 NO  -7 NO 
208  B7  0.022  0.2  120 5  329 16  120  2  323 21  4  2  144 YES  -24 YES 
210  A2  0.029  0.4  201  26  201 42  200 25  196 43  11  11  3 YES  -4 YES 
211  B5  0.039  0.5 25 26  156  262  25  26  140  272  51  51  0  NO  -5  YES 
TOTAL                     10    15 
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Table A.4. Inexact, exact and corrected P-values, and odds ratio for each association with an exact P-
value less than 0.05. 
Amino 
acid 
position 
HLA 
allele 
Inexact 
 P-value 
Exact 
P-value 
Odds 
ratio 
Correction 
Factor 
Corrected  
P-value 
26 A2  0.0103  0.004  4.21  72.20  0.528 
28 A3  0.0443  0.034  2.54  76.24  0.968 
28 B16  0.0429  0.032  3.30  61.80  0.934 
32 A2  0.0237  0.017  0.27  60.16  0.764 
32 B8  0.0330  0.023  2.87  78.68  0.928 
32 B17  0.0511  0.038  3.18  78.96  0.984 
35 A1  0.0076  0.011  0.39  41.36  0.271 
36 A3  0.0260  0.013  0.04  41.80  0.668 
36 A9  0.0059  0.002  7.92  82.00  0.384 
38 A3  0.0125  0.008  0.07  41.80  0.409 
38 B5  0.0130  0.009  5.39  82.36  0.659 
39 A2  0.0015  0.001  4.82  72.20  0.105 
43 A3  0.0475  0.044  0.24  41.80  0.869 
43 B8  0.0003  <0.001  7.67  78.68  0.021 
43 B14  0.0002  0.001  19.09  73.80  0.016 
49 B7  0.0346  0.042  2.42  92.16  0.961 
53 A11  0.0011  <0.001  6.69  80.80  0.084 
60 B5  0.0435  0.035  2.28  82.36  0.974 
65 A9  0.0331  0.024  3.06  82.00  0.937 
68 B18  0.0126  0.008  4.88  52.80  0.487 
69 B8  0.0009  0.001  0.05  35.88  0.032 
69 B40  0.0689  0.038  2.88  80.28  0.997 
69 A2  0.0096  0.010  3.45  72.20  0.501 
69 B35  0.0258  0.027  3.97  82.12  0.883 
70 A10  0.0198  0.014  2.81  71.04  0.758 
75 A1  0.0082  0.006  0.03  41.36  0.288 
83 B35  0.0155  0.018  0.28  19.96  0.268 
99 B15  0.0066  0.006  3.80  83.28  0.423 
100 B12  0.0066  0.004  3.04  83.28  0.424 
101 A2  0.0226  0.013  0.29  60.16  0.747 
101 A3  0.0511  0.044  2.44  76.24  0.982 
102 B12  0.0117  0.009  2.74  83.28  0.625 
103 A9  0.0340  0.033  2.22  82.00  0.941 
115 B12  0.0612  0.015  2.80  83.28  0.995 
115 A9  0.0248  0.014  3.62  82.00  0.872 
118 B7  0.0251  0.030  0.21  42.84  0.664 
118 B12  0.0604  0.045  2.68  83.28  0.994 
121 B35  0.0160  0.014  4.00  82.12  0.733 
122 B16  0.0380  0.026  0.35  11.92  0.369 
122 A11  0.0031  0.002  0.39  31.84  0.095 
122 A2  0.0035  0.004  0.51  60.16  0.191 
123 B12  0.0223  0.021  0.53  43.88  0.628 
123 B35  0.0029  0.001  2.86  82.12  0.215 
123 B37  0.0087  <0.001  11.45  5.04  0.043 
135 A10  0.0430  0.039  0.42  18.68  0.560 
135 B18  0.0028  0.002  3.79  52.80  0.139 
135 B5  1x10
-10 <0.001  16.74  82.36  <0.001 
142 A9  0.0323  0.029  1.97  82.00  0.932 
142 B18  0.0429  0.033  2.51  52.80  0.901 Appendices  310 
Amino 
acid 
position 
HLA 
allele 
Inexact 
 P-value 
Exact 
P-value 
Odds 
ratio 
Correction 
Factor 
Corrected  
P-value 
158 B7  0.0031  0.001  4.46  92.16  0.249 
162 A1  0.0263  0.028  1.81  73.08  0.858 
162 B7  <1x10
-10 <0.001  10.04  92.16  <0.001 
165 B7  0.0292  0.024  2.40  92.16  0.935 
166 A11  2x10
-5 <0.001  4.36  80.80  0.002 
169 A2  0.0175  0.014  0.29  60.16  0.654 
169 B15  0.0008  0.002  9.65  83.28  0.066 
169 B7  5x10
-6 <0.001  12.57  92.16  <0.001 
173 B5  0.0217  0.016  3.69  82.36  0.836 
173 B18  0.0170  0.020  6.08  52.80  0.596 
177 B35  0.0006  <0.001  3.52  82.12  0.051 
178 B7  0.0021  0.002  0.30  42.84  0.087 
178 B12  0.0373  0.036  0.48  43.88  0.812 
178 A19  0.0410  0.032  1.98  82.48  0.968 
179 B27  0.0615  0.034  2.66  50.96  0.961 
181 B8  0.0093  0.001  5.11  78.68  0.522 
184 A19  0.0190  0.016  0.33  37.52  0.514 
196 B5  0.0013  0.003  4.29  82.36  0.104 
197 B40  0.0004  0.004  5.77  80.28  0.032 
200 B22  0.0416  0.041  0.26  5.36  0.203 
200 B8  0.0364  0.041  0.54  35.88  0.736 
200 B37  0.0126  <0.001  19.16  5.04  0.062 
203 A11  0.0184  0.018  4.08  80.80  0.777 
203 B12  0.0023  0.001  5.57  83.28  0.177 
204 A9  0.0271  0.014  3.59  82.00  0.895 
207 A10  0.0544  0.044  0.41  18.68  0.648 
207 B40  0.0231  0.017  2.19  80.28  0.847 
207 B15  0.0014  0.003  2.89  83.28  0.111 
208 B7  0.0489  0.022  0.17  42.84  0.883 
210 A2  0.0181  0.029  0.37  60.16  0.666 
210 B21  0.0019  0.003  10.19  28.40  0.053 
211 B5  0.0459  0.039  0.49  19.52  0.600 
211 B15  0.0044  0.003  2.87  83.28  0.305 
211 B12  2x10
-7 <0.001  4.54  83.28  <0.001 
214 B17  0.0096  0.007  3.46  78.96  0.532 
214 B15  0.0036  0.005  3.77  83.28  0.257 
215 B7  0.0505  0.047  2.05  92.16  0.992 
215 A3  0.0246  0.030  2.35  76.24  0.850 
215 A1  0.0041  0.004  2.69  73.08  0.259 
219 A9  0.0164  0.013  3.28  82.00  0.742 
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Table A.5. Associations considered and eliminated from the comprehensive viral load model.  
Those putative HLA escape positions with a broad HLA allele whose greatest molecular subtype split 
was less than 77 percent or where the number of individuals with and without the HLA, with and without 
polymorphism was less than four were removed from the analysis of viral load. Putative HLA escape 
positions that were removed from the subsequent viral load model are shown in the final column. The 
reason for removal is indicated by shading. 
  Association  with HLA  without HLA 
 
Amino 
acid 
position HLA 
Exact  
P-value 
Odds 
ratio 
Greatest 
molecular 
subtype split 
greater than 77%
without 
poly-
morphism 
with poly-
morphism  
without 
poly-
morphism 
with poly-
morphism 
Include in 
model 
Negative associations: 
  32 A2  0.017 0.271  Yes  50 1 57  2 No 
  35 A1  0.011 0.388  Yes  26 14 25  13  Yes 
  36 A3  0.013 0.042  Yes  27 3 79 8  No 
  38 A3  0.008 0.073  Yes  29 1 80 7  No 
  43 A3  0.044 0.236  Yes  27 3 81 6  No 
  69  B8 0.001  0.054 Yes  35 0 84  1 No 
  75 A1  0.006 0.032  Yes  39 0 75  2 No 
  83 B35  0.018 0.278  No  1 0 74 19  No 
  101 A2  0.013  0.29  Yes  63 2 55 4  No 
  118 B7  0.03 0.208  Yes  35 0 84  2 No 
  122 A2  0.004 0.509  Yes  36 22 41  27  Yes 
  122 A11  0.002  0.394  Yes  15 5 62  44  Yes 
  122 B16  0.026  0.35  No 9 2 62 39  No 
  123 B12  0.021 0.529  No 18 12 55  41  No 
  135 A10  0.039  0.417  No 11 4 68  43  No 
  169 A2  0.014 0.288  Yes  65 0 54 5  No 
  178  B7 0.002  0.301 Yes  33 2 70 16  No 
  178 B12  0.036 0.483  No 25 3 69 15  No 
  184 A19  0.016  0.329  No 20 1 84  2 No 
  200  B8 0.041  0.536 Yes  24 6 61  36  Yes 
  200 B22  0.041 0.257  No  1 2 74 34  No 
  207 A10  0.044  0.411  No 13 2 58 40  No 
  208  B7 0.022  0.167 Yes  34 1 85  1 No 
  210 A2  0.029  0.37  Yes  53 3 62 5  No 
  211  B5 0.039  0.488 Yes  8 7 33  62  Yes 
Positive associations: 
  26 A2  0.004 4.214  Yes  46 8 60  5  Yes 
  28 A3  0.034  2.54  Yes  24 3 80 7  No 
  28 B16  0.032 3.295  No 8 2 93 8  No 
  32  B8 0.023  3.416 Yes  24 3 84  1 No 
  32 B17  0.038 4.264  Yes  18 0 91  3 No 
  36 A9  0.002 7.918  No 21 7 86  7  No 
  38  B5 0.009  5.389 Yes  15 3 90 5  No 
  39 A2  0.001 4.823  Yes  48 3 54 5  No 
  43 B8  <0.001 7.666  Yes  25 4 89  3 Yes 
  43 B14  0.001 19.09  No 9 0 96 7  No 
  49  B7 0.042  2.421 Yes  20 4 75  11  Yes 
  53 A11  <0.001  6.69  Yes  21 1 92  0 No 
  60  B5 0.035  2.28 Yes  10 5 80  15  Yes 
  65 A9  0.024 3.063  No 29 0 85  1 No 
  68 B18  0.008 4.876  Yes  7 2 95 6  No Appendices  312 
  Association  with HLA  without HLA 
 
Amino 
acid 
position HLA 
Exact  
P-value 
Odds 
ratio 
Greatest 
molecular 
subtype split 
greater than 77% 
without 
poly-
morphism 
with poly-
morphism  
without 
poly-
morphism
with poly-
morphism 
Include in 
model 
  69 A2  0.01 3.453 Yes  64 15 8 1 No 
  69 B35  0.027 3.974 No  1 09 3 0 No 
  69 B40  0.038 2.879 No 21 19 0 1 No 
  70 A10  0.014  2.815 No 15 09 4 4  N o  
  99 B15  0.006 3.802 No 36 18 6 5  N o  
  100 B12  0.004 3.042 No 28 08 1 3 No 
  101 A3  0.044 2.437 Yes  29 18 1 6  N o  
  102 B12  0.009 2.742 No 26 4 74 10  No 
  103 A9  0.033 2.222 No 27 27 9 7  N o  
  115 A9  0.014 3.623 No 27 28 5 1 No 
  115 B12  0.015 2.803 No 27 18 2 2 No 
  118 B12  0.045 2.685 No 26 08 2 2 No 
  121 B35  0.014 3.998 No  1 08 9 4  N o  
  123 B35  0.001 2.861 No  0 1 57 36 No 
  123 B37  <0.001 11.45 Yes  0 1 63 46 No 
  135 B5  <0.001 16.74 Yes  21 86 62 9  N o  
  135 B18  0.002 3.794 Yes  2 7 65 36 No 
  142 A9  0.029 1.965 No 23 7 84 12  No 
  142 B18  0.033 2.512 Yes  8 1 88 13 No 
  158 B7  0.001  4.46 Yes  33 28 4 2 No 
  162 A1  0.028 1.813 Yes  24 14 62 25  Yes 
  162 B7  <0.001 10.04 Yes  11 18 76 21  Yes 
  165 B7  0.024 2.398 Yes  34 17 9 7  N o  
  166 A11  <0.001  4.357 Yes  14 4 79 13  Yes 
  169 B7  <0.001 12.57 Yes  27 28 3 3 No 
  169 B15  0.002 9.649 No 34 4 86 2 No 
  173 B5  0.016 3.692 Yes  12 3 95 11 No 
  173 B18  0.02 6.079 Yes  6 39 2 9  N o  
  177 B35  <0.001 3.524 No  0 1 74 19 No 
  178 A19  0.032  1.983 No 18 8 85 10  No 
  179 B27  0.034 2.663 Yes  7 29 7 6  N o  
  181 B8  0.001 5.106 Yes  35 08 5 0 No 
  196 B5  0.003 4.286 Yes  18 29 2 3 No 
  197 B40  0.004 5.775 No 19 38 9 2 No 
  200 B37  <0.001 19.16 Yes  0 1 75 34 No 
  203 A11  0.018  4.084 Yes  22 09 2 0 No 
  203 B12  0.001 5.571 No 28 08 4 0 No 
  204 A9  0.014 3.593 No 29 08 6 0 No 
  207 B15  0.003 2.894 No 22 16 57 31  No 
  207 B40  0.017 2.185 No 13 8 66 39  No 
  210 B21  0.003 10.19 No 4 1 100 6 No 
  211 B12  <0.001 4.539 No 5 25 37 47  No 
  211 B15  0.003 2.866 No 15 22 29 59  No 
  214 B15  0.005 3.769 No 33 4 82 9  No 
  214 B17  0.007 3.458 Yes  12 4 87 7  Yes 
  215 A1  0.004 2.691 Yes  31 8 78 6  Yes 
  215 A3  0.03 2.351 Yes  19 4 78 9  Yes 
  215 B7  0.047  3.28 Yes  20 4 77 9  Yes 
  219 A9  0.013 3.278 No 27 28 5 1 No EpiPop user manual   
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EpiPop user manual 
Written by Corey Moore. 1 June 2001. 
Overview 
EpiPop is a custom built program to explore relationships between nucleotide amino or 
amino acid sequences and other covariates – in particular HLA and drugs. The program 
can also be automated to multiple large batch jobs over many machines. The current 
installation of the program is connected to the WA HIV Cohort database which contains 
daily downloads of patients’ HIV sequences, HLA and other covariates. 
Opening Form 
Figure A.1 shows the opening screen of EpiPop. It is kept simple to allow the user to 
easily explore relationships. This form offers 3 types of models, all in HIV-RT;  
1)  Outcome: Amino acid change from the population consensus for a patient’s last 
sequence. 
Covariates: The patient’s HLA-A, HLA-B, mutations away from the population 
consensus at all other residues. 
2)  Outcome: Amino acid change from the patient’s first sequence for a patient’s 
last sequence. 
Covariates: The patient’s HLA-A, HLA-B, mutations away from the patient’s 
first sequence at all other residues. 
3)  Outcome: Amino acid change from the patient’s first sequence for all other 
sequences from a patient. 
Covariates: The patient’s HLA-A, HLA-B, time of exposure to each NRTI and 
NNRTI drugs, mutations away from the patient’s first sequence at all other 
residues. 
To create a model, the user clicks on an amino acid in the graph. For example, clicking 
on amino acid 135 with the first option selected produces the model in Figure A.6. 
More options can be selected by clicking on the “More Options” button. These options 
are shown in Figure A.2 and allow the user to choose the following: 
1)  Outcome: Mutation at first, last or all sequences compared to population 
consensus or a patient’s first sequence.  
2)  Covariates: Drugs (NRTIs and NNRTIs); HLA-A and HLA-B; HLA-C; HLA-
DR; HLA-DR51, 52, 53; mutation at other residues.  
3)  Test: Univariate using a Fisher’s exact test; Multivariate using a logistic 
regression (with a generalised linear equation adjustment if a patient has more 
than one sequence in the model); Permutation analysis – based on the logistic 
regression. Appendices  314 
Click on the “Advanced” button from either form shown in Figure A.1 and Figure A.2 
opens the form shown in Figure A.3. This form allows the user to modify all aspects of 
data input; modelling and presentation. The following sections will describe these 
options. 
 
 
Figure A.1. The standard opening form of EpiPop. 
 
Figure A.2. The standard form with advanced options. EpiPop user manual   
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Data Source 
The program can use data from saved datasets, kept in the files MAIN_RT?.XDB, 
MAIN_PR?.XDB, DR5X?.XDB, GROUPQ?.XDB, HLASEQ?.XDB, where ? is the 
number of the dataset, or blank if the first dataset. The datasets are can be selected from 
the “Dataset” box (“15/2/2000”, “11/10/2000”, etc.). These datasets were created from 
an ODBC link to the WA HIV database, using the SQL statement shown in the “HIV 
WA Cohort Database Table and Query Definitions” section below. This SQL can be 
changed to correspond with the options selected in the “ODBC” box. The data from the 
SQL is displayed in the dataset view within this box. The “Adequate Drug History” 
check box, when checked removes patients without good longitudinal drug data. The 
“Known Rx Start Date” excludes patients without a known starting antiretroviral 
therapy date. The “Pre Rx ODBC” check box only selects sequences prior to a patient’s 
antiretroviral therapy start date. The “CTL paper pts” check box selects patients used in 
the CTL paper. The “Protein” box (below) determines which sequences (either RT or 
protease) are selected. Changing this option automatically changes the graph, dataset 
and ODBC SQL. The “SQL” Box with the options “Original” and “Patch 1” allows an 
old version of the SQL statement to be used to allow old results to be reproduced. The 
“Save Data” button saves the current data to a new set of .XDB dataset files. Clicking 
on the “ODBC” check box allows the data from the cohort database to be used in 
analyses, instead of from the saved datasets. 
 
Figure A.3. The Advanced form. Appendices  316 
Consensus 
The “Consensus” box allows the user to choose and change the sequence that is used to 
compare the patients’ sequences. The population consensus sequence can be calculated 
(using sequence selection options on the form) from either the amino acid sequences 
(“Nuc & AA Consensus”) or from the nucleotide sequences (“Nuc (& AA) 
Consensus”). These usually give the same sequence. Alternatively, the reference 
sequence stored in the program can be used by selecting the “Use Reference Sequence” 
radio box. The nucleotide and amino acid sequences can also be edited directly. When 
the “Use Own Consensus” check box is checked, the analyses compare a patient’s 
sequence to the patient’s first sequence. These consensus sequences can be restricted to 
only include sequences prior to NRTI, NNRTI, PI or selected drugs (see the “Include 
Drugs” box). They can further be restricted to include only those first sequences that 
have the amino acids selected in the list box (top right of the “User Own Consensus” 
box). The dropdown list box, to the left of this list box, allows the user to add any 
amino acid, or groups of amino acids (for example, all polar amino acids). Changing 
between the population and own consensus automatically changes the graph, dataset 
and ODBC SQL. 
Other Data Options 
The options below the “Consensus” box, allow the analysis of: only sequences prior to 
NRTI, NNRTI, PI or selected drugs (see the “Include Drugs” box); patients’, first, last 
or all sequences; the reverse transcriptase (RT) or protease protein; sequences with a 
nucleotide frame shift of 0, 1 or 2 nucleotides; and a selected number of sequences. The 
“Population Residue Summary” shows the table of data used to create the graph 
(below). This includes the percentage of synonymous, nonsynonymous and 
nonconservative mutation, known information, consensus amino acid, and distribution 
of each amino acid for each position (see Figure A.4).  
Graph 
The “Graph Options” box allows the user to select what is displayed in the graph. 
“Known Epitopes” displays all known epitopes for the selected protein. The bars which 
are plotted can be changed to show percentage of nonsynonymous mutation (“NS %”), 
percentage of synonymous mutation (“S%”), percentage of nonsynonymous and 
synonymous mutation (“NS and S (%)”), number of patients with nonsynonymous and 
synonymous mutation (“NS and S (total)”), the ratio of nonsynonymous to synonymous 
mutation (“NS / S”) and an adjusted amount of nonsynonymous and synonymous 
mutation, based on the number of codons which can encode the consensus amino acid 
(“NS%, S% Adjusted”). The “Show Legend” check box turns the graph’s legend on and 
off. The “Display Nonconservative” check box splits the nonsynonymous mutations 
into conservative and nonconservative bars. When the “Display NS and NC Only” 
check box is checked off, for each amino acid, the bars in the graph are separated 
further in the following way: Where the amino acid is within a known epitope, mutation 
from patients with the corresponding HLA is separated; Likewise, where the amino acid 
is a known drug resistance mutation side, mutation from patients on the corresponding EpiPop user manual   
 
  
317
drug is separated. The “Max Y Axis” allows the Y Axis to be changed. Clicking inside 
the graph with the left mouse button and dragging the mouse to form a box, and then 
releasing the left mouse button can also change the axes. The “Graph Title” edit box 
allows the name of the graph title to be edited. 
 
The “Enlarge” button below the graph hides the options and makes the graph the size of 
the form. The “Copy” button copies the graph into the Windows’ clipboard. The “Print” 
button opens a print dialog box. The “Save” button saves the current graph to a .GRP 
file. The “Load” button loads a .GRP file and replaces the current graph. The “Recalc” 
button calculates the amount of mutation from the currently selected sequences for the 
selected protein and consensus sequence. This uses the same data as for any analyses 
done. The “Update” button updates the graph with the new display options. When the 
consensus sequence or protein is changed the graph is automatically changed. The files 
RTWT.GRP, PRWT.GRP, RTOC.GRP and PROC.GRP are loaded when the population 
consensus and the RT protein, the population consensus and the protease protein, the 
own consensus and RT protein, and the own consensus and protease protein are 
selected, respectively.  
The right side of the form in figure 3 contains the options for selecting which covariates 
to analyse, the outcome, the parameters of the tests, and buttons which open multiple 
site analysis forms. 
 
Figure A.4. The Population Residues Summary form. Appendices  318 
Covariates 
Drugs 
To include drugs in the analyses, turn the “Include Drugs” check box on and then select 
the individual drugs. If this is checked, only sequences with adequate drug history are 
used. The drug groups (NRTI, NNRTI and PI) can also be selected as covariates. To 
only include the time a patient was exposed to a drugs between sequences (or 
consensus) select the “Recent Drugs Only” check box.  If this is not checked, the 
covariate is the time between the sequence and the date the patient first started that 
drug. The “Total Cumulative Time” check box is the total cumulative time on a drug. 
This is different to checking off the “Recent Drugs Only” check box if the patient 
stopped the drug before the sequence date. The “Intervals for LR” allows time on drugs 
to be converted to a binary value, days, weeks, months or years. If the time on a drug (in 
days) is less than the “Min Drug Time”, the drug value is set to 0. The “Add Drug 
Intercept” check box allows and binary drug value to be included with a drug time value 
(if it is not a binary value).  
HLA 
To include patients’ HLA as covariates check on the “Include HLA” check box. HLA-
A; HLA-B; HLA-C; HLA-DR; HLA-DR51,52,53; and Bw can be used as covariates. 
Depending on the HLA type, different resolutions of typing can be selected – “Seq”: 
sequencing typing to 4 digits (for example, B5101, B5102, B5103, B5201, B5301, etc.); 
“Fine”: fine serology typing (for example, B51, B52, B53); “Brd”: serology typing its to 
smallest denominator (for example, B5); “Spr”: Super HLA families (A2, A3, B7 and 
B44). The “Use” check box specifies which HLA to include in the analysis. The “Rstrt” 
check box specifies to restrict sequences to those patients who have typing done to the 
selected resolution. If this check box is not selected and the “Use” check box is, and the 
patient doesn’t have the appropriate HLA and resolution, then the covariate is set to 0 
for that patient. The “BG” check box, when checked, makes a best guess at what the 
HLA type is where it is defined in the dataset at a lower resolution than what is 
specified. For example, if the HLA-B “BG” check box is checked and the HLA-B 
“Seq” radiobox is selected, and a patient’s best HLA-B typing is B5, then the program 
assumes the patient has B5101 – the most common B5 subtype. 
The “HLA Class I AAs” and “HLA Class II AAs” check boxes allow the amino acids of 
the HLA molecules to be included as covariates. The “HLA Class I AAs” box uses 
HLA sequences determined from the patients HLA-A, HLA-B and HLA-C typing. If 
the “BG” check boxes are not selected, then only patients typed to 4 digits by 
sequencing are used. To add HLA sequence amino acid and amino acid positions select 
the pocket, or individual position/AA from the drop down list and select “Add>>”.  The 
“HLA Class II AAs” box is similar, but only uses the patient’s HLA-DR typing.  EpiPop user manual   
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Other covariates 
To include mutations away from consensus as covariates, select the “Include Positions” 
check box. To exclude ambiguous amino acids (for example, AYA is a mixed 
population of ACA (threonine) or ATT (isoleucine)), check the “Exclude Ambiguous 
AAs”. To include the time (in days) since a patient seroconverted, selected the “Time 
Since Seroconversion” check box. Patients without a seronegative and seropositive date 
are excluded. To include the time (in days) since a patient was first sequenced, check 
the “Time Since 1
st Sequence”. To include a patient’s viral load, or a viral load cut-off, 
choose from the options in the “Viral Load” drop down box. 
Outcome  
Four different types of mutation can be specified. The first is a change in a patient’s 
codon from consensus while coding for the same amino acid (“Synonymous Mutation 
Only”). Second, a mutation that causes a nonsynonymous mutation (“Nonsynonymous 
Mutation”). Third, a mutation that causes a nonconservative mutation 
(“Nonconservative mutation”). The fourth option is to select the amino acids, or group 
of amino acids that determines if the outcome is 1.  
“Censor At Mutation” removes all subsequent sequences from a patient after one has 
mutated.  “Use Ambiguous AAs” specifies how much ambiguity away from the 
consensus amino acid is required to set the outcome as 1. 
Tests 
To produce a logistic regression model select the “Logistic” check box. To make it a 
multiple variable logistic regression check “Multivariate”. Select “Extend” to apply a 
generalised estimator equation adjust multiple sequences per patient.  Check “Intercept” 
to add an intercept to the logistic regression model. Check “Adjust pvalues for mult 
comp” to adjust the pvalue results for the number of covariates in the initial model. Set 
the minimum number of patients or sequences required to be included in the initial 
model, change the drop down list in the “Minimum Cases” box. To remove covariates 
with a univariate (Fisher’s exact test) pvalue with a specified cut-off, check the 
“Remove if univar US” check box and set the “Sig pValue” drop down listbox. 
“Forward Selection” check box allows the user to specify the ratio of number of 
sequences to number of covariates required in the initial model. If the number of 
sequences to the number of covariates ratio is greater than that specified, forward 
selection is performed to choose the initial model. To perform backwards elimination to 
a specified pvalue, check the “Remove Largest P-value” and set the pvalue in the “Sig 
pValue” drop down list box. The convergence options for the logistic regression can be 
changed in the “Convergence Options” box.  The default options are the same as those 
used by SAS. The univariate test can be changed between a Fisher’s exact test and a 
McNemars univariate test. 
To run a model on a single residue using the selected options, click on the residue in the 
graph. This will open the “Single Residue Analysis Form” (see below). The status of the 
modelling will be shown in the progress and status bars on the bottom of the form. Appendices  320 
Other Buttons 
The “Mult Ana Form” opens the “Multiple Sites Analysis” form (see below). The 
“ABOUT” button displays version, memory, copyright, and contact information. The 
“Load Options” button allows saved options for this and other forms to be loaded. The 
“Save Options” button allows the currently selected options to be saved to a .OPT file. 
The “Graph Form” button opens the “Results Display Form” (see below). The “Exit” 
button closes EpiPop and saves the current settings to the Windows’ registry. 
Single Residue Analysis Form 
When a residue is clicked on in the graph on the “Advanced Form”, a model, using the 
selected options is created and displayed in this form (see Figure A.5). The residue 
selected is displayed in the “Position” text box. The population consensus amino acid, 
and corresponding amino acid group, for this position is displayed in the “Consensus 
AA” textbox. “% Synonymous Mutation”, “% Nonsynonymous Mutation” and “% 
Nonconservative Mutation” show the percentage of individuals who have a 
synonymous, conservative and nonconservative mutation at this position, respectively. 
Known information about this site is shown in the “Known Information” textbox. 
Buttons 
The “Print Sites” button prints the “Model Results Grid” (see below). The “Print AAs” 
button prints the amino acid distribution from the “Model Results Grid”. The “Print 
HLA Estimates” prints the “HLA Estimates” grid (see below). The “Print UMRN 
Estimates” prints the “UMRN Estimates Grid” (see below). The “Load” button loads a 
previously saved model (.SIT file). The “Save” button saves the model to a .SIT file. 
The “Close” button closes the form. EpiPop user manual   
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Residue Summary Grid 
The grid on the left of the form shows the distribution of amino acid usage in the cohort. 
The “AA” column shows the amino acid and corresponding amino acid group. The 
“Num (%)” column displays the number and percentage of individuals with the amino 
acid. 
Model Results Grid 
The second grid from the left displays the results from the modelling. The “HLA” 
column displays the covariate name. The “Other” displays the number of individuals 
without the covariate who did not mutate, where mutation is defined by the “Mutation 
Type” box in the “Advanced Form”. “Non Syn” displays the number of individuals with 
the covariate who did not mutate. “~HLA Other” displays the number of individuals 
who do not have the covariate and who did mutate. “~HLA Non Syn” displays the 
number of individuals who do not have the covariate and mutated. “LR P-value”, “LR 
OR”, “LR Coeff”, “LR StdErr” and “LR OR CI” display the P-values, odds ratio, 
coefficient, standard error and confidence interval for each covariate in the logistic 
regression model. “F P-value” and “F P-value*” display the P-value and correct P-value 
(adjusted for the total number of covariates) of the univariate test performed on each 
covariate, respectively. “RR” displays the univariate relative risk for each covariate. 
The final 21 columns of this form show the distribution of amino acids (including the 
 
Figure A.5. The Single Residue Analysis form. Appendices  322 
stop codon) from sequences from patients with the covariate. This is also displayed in 
the graph below the five grids. 
Patient Data Grid 
The third grid from the left displays some of the patient data. “UMRN” is the unique 
identifier for the individual. “VISIT_D” is the data of the individual’s sequence. “N” is 
the codon (nucleotide sequence) at the amino acid position selected. “A1”, “A2”, “B1”, 
“B2”, “C1”, “C2”, “DR1” and “DR2” are the HLA of the individual, grouped by the 
options specified in the “HLA Grouping” box in the “Advanced Form”. 
HLA Estimates Grid 
When HLA amino acids are used as covariates (see the “HLA Class I AAs” and “HLA 
Class II AAs” check boxes in the “Advanced Form”), this grid displays a probability, 
based on the coefficients of these covariates, that an HLA allele is associated with 
mutation. The “HLA” column distances the HLA allele, and the “Probability” column 
displays the estimated probability. 
Patient Estimates Grid 
The final grid displays the estimated probability, for each individual, that a virus has 
mutated. The “UMRN” column displays the individual’s unique identifier. The “Mut” 
column displays a 0 if the patient mutated and a 1 if he did not. The “Probability” 
column displays the estimated probability based on the coefficients of each covariate 
from the model that the patient has. “HLA Used” displays the number of the 
individual’s HLA that were used in creating the estimate. “HLA Actual” displays the 
number of HLA that the individual has. 
Multiple Residues and Permutation Analysis Form 
This form allows multiple sites to be analysed using a permutation method (see Figure 
A.6).  
 
Range 
The “Range” box specifies the start (“From” textbox) and end (“To” textbox) residue to 
analyse. The “Test Stat/P-value” specifies the test statistic (and P-value) used to define 
the starting model for the permutation analyses.  EpiPop user manual   
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Other Options 
The “Number of Randomisations” textbox specifies the number of permutations to 
perform. The “Minimum # swap possibilities” specifies the minimum number of 
patients required with a certain number of sequences. If there is not the minimum 
number of patients with a certain number of sequences, then some of the patients’ 
sequences are removed. This option is only effective when doing permutations on data 
with multiple sequences per patient. The reason for the limit is that a patient’s 
sequences can only be randomised to another patient with the same number of 
sequences. “Calculate univariate (Fisher’s) stats performs Fisher’s exact tests and 
univariate relative risks for each covariate. “Save Options (Bitmap)” saves a bitmap 
(.BMP ) file of the “Advanced Form” to keep a record of the options used to create the 
results. Similarly, the “Save Options (OPT File)” saves an options (.OPT) file to keep a 
record of the options used to create the results. The “Rand Vars Individually” check 
box, when checked, randomises one covariate at a time while preserving the other 
covariates, and at the end of the permutations, calculates the exact P-value for that 
covariate, then continues to the next covariate. Without this check box checked, all 
covariates are randomised to another patient at the same time. The “Reset after ___ 
mins” check box and text box restarts the computer and program after the specified 
number of minutes. This feature was added to clear memory leaks within the program. 
Buttons 
The “Save & Calculate” button asks for a filename (.RND file) to save the results to, 
and then performs the permutations. The “Calculate” button performs the permutations 
without saving the results to a file. The “Load” button loads a previously saved results 
(.RND) file. The “Save” button saves the results to a (.RND) file. The “Append” button 
saves the results to the end of a (.RND) results file. The “END” button stops a currently 
running permutation analysis. The “Close” button closes the form. Progress of the 
permutation analysis is shown in the two progress bars at the bottom of the form and on 
the 3 status bars on the lower right of the form. The bottom progress and status bar 
show the status of the individual covariate analyses (if “Rand Vars Individually” was 
selected. The status and status bar above this shows the number of permutations done. 
The final status bar shows the residue being analysed. 
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Results 
The results are displayed in the grid. The “Site” column displays the residue position. 
The “HLA” column displays the covariate name. The third column shows the status of 
the permutation of the covariate. The “Actual”, “Coeff” and “Std Err” columns show 
the test statistic, coefficient and standard error of each covariate for the starting model, 
respectively. The “Est” column displays the exact P-value calculated from the 
permutations. This is calculated, for each covariate, by where, within the permutation 
test-statistics, the test-statistic from the initial model lies. The “1% cut-off” and “5% 
cut-off” display the test statistics from the permutation analyses at the one and five 
percent level, respectively. The “OR” and “OR Conf” columns displays the odds ratio 
and confidence interval from the starting model. The remaining columns display the 
results from the permutation analyses, where every second column is the coefficient and 
standard error from the permutated models. 
Results Display Form 
This form displays results stored from analyses in the CUTOFFS table of the HIV 
database (see Figure A.7). Results are shown in order of odds ratio, and are separated 
into negative (odds ratio < 1) and positive (odds ratio > 1) boxes. These are displayed in 
green below the known epitopes, which are displayed in a red box at the top of the 
graph. The protein displayed, and marks for each residue (such as known drug sites, 
functional information etc.), are specified in the advanced form. 
Models 
The “Models” box allows up to five different sets of analyses to be displayed on the 
graph. To select a set of models, select from one of the drop down list boxes.  To 
 
Figure A.7. The Results Display form. EpiPop user manual   
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convert the odds ratios of the drug covariates to an odds ratio per month, or year, etc, 
change the “Convert Drug ORs by” drop down list box. To change the P-value cut-off 
of covariates that are shown, change the “P-value cut-off” text box. 
Display 
The “Display” box allows the user to change what and how the models’ results are 
displayed. The “From” and “To” text boxes specify the residues to be shown. When the 
“Positive Associations” check box is checked, positive associations are shown (odds 
ratio > 1). Likewise when the “Negative Associations” check box is checked, negative 
associations are shown (odds ratio < 1).  Similarly the “HLA-A”, “HLA-B’, “HLA-C”, 
“HLA-DR”, “HLA-DR51,52,53”, “Drugs” and “Positions” check boxes allow the user 
to show and hide these covariates. The “Corresponding Epitopes” check box, when 
checked, shows the known epitopes, for the protein, from those types of HLA that have 
been selected to be displayed. The “All Epitopes” check box shows all known epitopes 
for the protein. These epitopes are shown in red at the top of the graph.  When “2 lines” 
check box, the covariate name, and odds ratio result are displayed on two lines instead 
of one. The “Min OR” and “Max OR” text boxes specify the minimum and maximum 
odds ratio results displayed, respectively. Covariates with odds ratios smaller or greater 
than these values are given a “<” or “>” sign in front of the minimum or maximum 
value. For example, if the “Max OR” is 100, and a covariates odds ratio is 200, “>100” 
is displayed on the graph. 
Graph Options 
The “Graph Options” box specifies how the graph presents the graph. When “Show 
Legend” check box is checked, the legend to the bars in the graph is shown. The 
“Horizontal Line” and “Vertical Lines” check boxes turns on and off the horizontal and 
vertical lines in the graph. The “Graph Width” text box specifies how many pixels wide 
the graph is. If the graph is wider than the form, a horizontal scroll bar appears at the 
bottom of the form to allow the rest of the form to be viewed.  “Max Right Y Axis” and 
“Max Left Y Axis” sets the maximum value of these axes. The font sizes of the items in 
the graph can be changed by editing the “Label Font Size”, “Axis Font Size”, “Epitope 
Font Size” and “Font Size” text boxes. 
Auto Print 
The “Auto Print” box allows the graph to be printed to segments. The “Start” text box 
specifies the starting amino acid, the “End” text box specifies the end amino acid, and 
the “Step” check box specifies how many amino acids are shown per page. When the 
“Print” button is pressed the graph is printed. 
Print Options 
The “Print Options” box allows the user to print in portrait of landscape by selecting the 
turning the “LandScape” button off and on, respectively. When the “Print Cover” check Appendices  326 
box is turned on, a cover page is printed out before the graph, showing the date and 
models being shown. 
Buttons 
The “Print” button prints the current graph to the printer on to one page, and prints a 
cover page if the “Print Cover” check box is turned on. The “Copy” button copies the 
current graph to the clipboard. The “Update” button refreshes the graph with any 
changes made to the options that affect the graph. The “Close” button closes the 
“Results Display Form”. 
HIV WA Cohort Database Table and Query Definitions 
The following is a list of tables accessed by EpiPop using the ODBC link to the HIV 
WA Cohort database. 
SEQUENCE Table 
This table contains the patient sequences, drug exposure times between sequences and 
the closest viral load measurement to the sequence. 
UMRN Text  Patient unique identifier 
PROTEIN Text 
“RT” indicates reverse transcriptase 
“PRO ” indicates protease 
SEQUENCE 
Long 
Text Protein  sequence 
VISIT_D  Date  Date the patient sample was taken 
START  Integer  Start position of the sequence 
DONTUSE  Boolean  Indicates a sequence not to use 
ANA  Boolean  Indicates a sequence is okay to analyse 
AZT  Integer  Days of exposure of zidovudine 
3TC  Integer  Days of exposure of lamivudine  
DDI  Integer  Days of exposure of didanosine 
DDC  Integer  Days of exposure of zalcitabine 
D4T  Integer  Days of exposure of stavudine 
1592  Integer  Days of exposure of abacavir 
LOV  Integer  Days of exposure of lovuride 
EFAV  Integer  Days of exposure of efavirenz 
NEV  Integer  Days of exposure of nevirapine 
DEL  Integer  Days of exposure of delavirdine 
SAQ  Integer  Days of exposure of saquinavir 
IND  Integer  Days of exposure of indinavir 
RIT  Integer  Days of exposure of ritonavir 
NEL  Integer  Days of exposure of nelfinavir 
VLOAD  Float  Viral load closest to the sequence date 
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HIV_PROG Table 
This table contains the date of seronegative and seropositive HIV antibody tests and the 
date of seroconversion, if known. 
Variable Type  Comment 
UMRN Text  Patient  unique  identifier 
SERNEG_D  Date  Date of last seronegative HIV Ab test 
SERPOS_D  Date  Date of first seronegative HIV Ab test 
SERCON_D  Date  Date of seroconversion 
AZTDATE  Date  This is the date a patient first started antiretroviral therapy 
      
HLA_PHENOTYPE Table 
This table contains the HLA information. 
Variable Type  Comment 
UMRN Text  Patient  unique  identifier 
A1  Text  HLA-A result 1 by serology 
A2  Text  HLA-A result 2 by serology 
ASTAR_1  Text  HLA-A result 1 by sequencing 
ASTAR_2  Text   HLA-A result 2 by sequencing 
B1  Text  HLA-B result 1 by serology 
B2  Text  HLA-B result 2 by serology 
BSTAR_1  Text  HLA-B result 1 by sequencing 
BSTAR_2  Text  HLA-B result 2 by sequencing 
C1  Text  HLA-C result 1 by serology 
C2  Text  HLA-C result 2 by serology 
CSTAR_1  Text  HLA-C result 1 by sequencing 
CSTAR_2  Text  HLA-C result 2 by sequencing 
DR1  Text  HLA-DR result 1 by serology 
DR2  Text  HLA-DR result 2 by serology 
DRB11  Text  HLA-DR result 1 by sequencing 
DRB12  Text  HLA-DR result 2 by sequencing 
CUTOFFS Table 
This table stores the results from the permutation analyses. This table is accessed to 
display the results in the “Results Display Form”. 
 
Variable Type  Comment 
AA_POS  Integer  Amino acid position number 
HLA Text  Covariate  name 
STATUS Text 
“Yes” = used in permutation analysis 
“Skipped” = not used  
ACTUAL  Float  Test statistic from the stating model 
COEFF  Float  Coefficient from the stating model 
STDERR  Float  Standard error from the stating model 
EST Float  Exact  P-value from the permutations 
CUTOFF1  Float  1% test stat cut-off from the permutation 
CUTOFF5  Float  5% test stat cut-off from the permutation 
OR  Float  Odds ratio from the stating model 
ORCI  Float  Confidence interval from the starting model 
PROTEIN  Text  Name of the model 
DATE  Date  Date the model was imported 
NUM  Integer  Unique number for the record Appendices  328 
HLA_GROUPS Table 
This table contains the definitions of the different HLA groupings (sequence, fine 
(serology), broad (serology) and supergroups). It also contains the number of patients 
with each allele defined by sequencing. This is used to determine the HLA to use when 
the “Best Guess” check boxes are checked. 
Variable Type  Comment 
LOCUS  Text  HLA locus (“A”, “B”, “C”, “DR”) 
SEQ  Text  HLA allele defined by sequencing 
FINE  Text  HLA allele defined by serology 
BROAD  Text  The lowest common denominator of the HLA allele defined by serology. 
SUPER  Text  The HLA supergroup the allele belongs to 
NUM  Integer  The number of patients from which have the allele defined by sequencing 
HIV_UMRN Table 
This table is used to merge records from patients with multiple “unique” identifiers. 
Variable Type  Comment 
UMRN  Text  Actual unique identifier 
UMRN2  Text  Another identifier belonging to the same patient 
DRUGDATES Table 
This table contains the date patients started the different antiretroviral drugs. 
Variable Type  Comment 
UMRN Text  Patient  unique  identifier 
AZT_D  Date  Date of starting zidovudine 
3TC_D  Date  Date of starting lamivudine  
DDI_D  Date  Date of starting didanosine 
DDC_D  Date  Date of starting zalcitabine 
D4T_D  Date  Date of starting stavudine 
1592_D  Date  Date of starting abacavir 
LOV_D  Date  Date of starting lovuride 
NEV_D  Date  Date of starting nevirapine 
DEL_D  Date  Date of starting delavirdine 
EFAV_D Date Date  of starting efavirenz 
SAQ_D  Date  Date of starting saquinavir 
IND_D  Date  Date of starting indinavir 
RIT_D  Date  Date of starting ritonavir 
NEL_D  Date  Date of starting nelfinavir 
HLA_SEQ Table 
This table contains the HLA sequences. This table is used when using the “HLA Class I 
AAs” and “HLA Class II AAs” check boxes. 
Variable Type  Comment 
HLA  Text  HLA allele name 
SEQUENCE Text  HLA  sequence 
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SELECT A.UMRN AS UMRN, SEQUENCE.VISIT_D, SEQUENCE.SEQUENCE, SEQUENCE.PROTEIN, 
       SEQUENCE.START, SEQUENCE.VLOAD, HLA_PHENOTYPE.A1, HLA_PHENOTYPE.A2,  
       HLA_PHENOTYPE.B1, HLA_PHENOTYPE.B2, HLA_PHENOTYPE.C1, HLA_PHENOTYPE.C2, 
       HLA_PHENOTYPE.DR1, HLA_PHENOTYPE.DR2, HLA_PHENOTYPE.A_STAR1, 
       HLA_PHENOTYPE.A_STAR2,HLA_PHENOTYPE.B_STAR1,HLA_PHENOTYPE.B_STAR2,  
       HLA_PHENOTYPE.C_STAR1, HLA_PHENOTYPE.C_STAR2, HLA_PHENOTYPE.DRB11, 
       HLA_PHENOTYPE.DRB12,HLA_PHENOTYPE.DRB31,HLA_PHENOTYPE.DRB32, 
       HLA_PHENOTYPE.DRB41,HLA_PHENOTYPE.DRB42,HLA_PHENOTYPE.DRB51, 
       HLA_PHENOTYPE.DRB52, 
       SEQUENCE.AZT, SEQUENCE.[3TC], SEQUENCE.DDI, SEQUENCE.DDC, SEQUENCE.D4T,  
       SEQUENCE.Efav, SEQUENCE.[1592], SEQUENCE.NEV, SEQUENCE.LOV, SEQUENCE.DEL,  
       SEQUENCE.SAQ, SEQUENCE.IND, SEQUENCE.RIT, SEQUENCE.NEL, DRUGDATES.AZT_D,  
       DRUGDATES.DDI_D, DRUGDATES.DDC_D, DRUGDATES.D4T_D, DRUGDATES.LOV_D,  
       DRUGDATES.EFAV_D, DRUGDATES.NEV_D, DRUGDATES.DEL_D, DRUGDATES.SAQ_D,  
       DRUGDATES.IND_D, DRUGDATES.RIT_D, DRUGDATES.NEL_D, DRUGDATES.[3TC_D],   
       DRUGDATES.[1592_D], HIV_PROG.SERPOS_D, HIV_PROG.SERNEG_D, HIV_PROG.SERCON_D, 
       SEQUENCE.ANA  
FROM ((((SEQUENCE INNER JOIN HIV_UMRN AS A ON SEQUENCE.UMRN = A.UMRN2) INNER JOIN  
     DRUGDATES ON A.UMRN = DRUGDATES.UMRN) LEFT JOIN HLA_PHENOTYPE ON  
     A.UMRN = HLA_PHENOTYPE.UMRN) INNER JOIN HIV_PROG ON A.UMRN = HIV_PROG.UMRN) 
WHERE (DONTUSE=FALSE)AND(SEQUENCE <> ‘’)AND((not isnull(HLA_PHENOTYPE.A1))OR 
      (not isnull(HLA_PHENOTYPE.A2))or(not isnull(HLA_PHENOTYPE.A_STAR1))OR 
      (not isnull(HLA_PHENOTYPE.A_STAR2)))AND 
      ((not isnull(HLA_PHENOTYPE.B1))OR(not isnull(HLA_PHENOTYPE.B2))or 
      (not isnull(HLA_PHENOTYPE.B_STAR1))OR(not isnull(HLA_PHENOTYPE.B_STAR2)))AND  
      ((DRUGDATES.AZT_D>=VISIT_D)OR(ISNULL(DRUGDATES.AZT_D)))AND 
      ((DRUGDATES.[3TC_D]>=VISIT_D)OR(ISNULL(DRUGDATES.[3TC_D])))AND 
      ((DRUGDATES.DDI_D>=VISIT_D)OR(ISNULL(DRUGDATES.DDI_D)))AND 
      ((DRUGDATES.DDC_D>=VISIT_D)OR(ISNULL(DRUGDATES.DDC_D)))AND 
      ((DRUGDATES.D4T_D>=VISIT_D)OR(ISNULL(DRUGDATES.D4T_D)))AND 
      ((DRUGDATES.[1592_D]>=VISIT_D)OR(ISNULL(DRUGDATES.[1592_D])))AND 
      ((DRUGDATES.LOV_D>=VISIT_D)OR(ISNULL(DRUGDATES.LOV_D)))AND 
      ((DRUGDATES.NEV_D>=VISIT_D)OR(ISNULL(DRUGDATES.NEV_D)))AND 
      ((DRUGDATES.DEL_D>=VISIT_D)OR(ISNULL(DRUGDATES.DEL_D)))AND 
      ((DRUGDATES.EFAV_D>=VISIT_D)OR(ISNULL(DRUGDATES.EFAV_D)))AND 
      ((DRUGDATES.SAQ_D>=VISIT_D)OR(ISNULL(DRUGDATES.SAQ_D)))AND 
      ((DRUGDATES.IND_D>=VISIT_D)OR(ISNULL(DRUGDATES.IND_D)))AND 
      ((DRUGDATES.RIT_D>=VISIT_D)OR(ISNULL(DRUGDATES.RIT_D)))AND 
      ((DRUGDATES.NEL_D>=VISIT_D)OR(ISNULL(DRUGDATES.NEL_D)))AND 
      ((ART_DATE>=VISIT_D)OR(ISNULL(ART_DATE)))AND 
      ((AZTDATE>=VISIT_D)OR(ISNULL(AZTDATE)))AND 
      ((NOT ISNULL(AZTDATE))OR 
      ((ANA=TRUE)AND((HIV_PROG.CLINIC='RPH')OR(HIV_PROG.CLINIC='RPH*')OR 
      (HIV_PROG.CLINIC='PP-MF')OR(HIV_PROG.CLINIC='PP-SM')OR 
      (HIV_PROG.CLINIC='PP-MF/RPH')OR(HIV_PROG.CLINIC='PP-SM/RPH')OR 
      (HIV_PROG.CLINIC='RPH/SM-PP')OR(HIV_PROG.CLINIC='SM-PP'))))AND 
      (PROTEIN = 'RT') 
ORDER BY A.UMRN, SEQUENCE.VISIT_D 
Command Line Operation 
There are a number of command line options that can be used to run analyses 
automatically, in the background, over multiple machines and running multiple jobs.  
Command Line Options 
Command    Effect 
MINIMISE  Hides the application and shows a little icon in the bottom 
right hand corner of the screen. Right clicking on this icon 
brings up options to show the program and to change the 
way the program uses system resources  
DON’TYIELD  Doesn’t give any resources back to Windows. 
PAUSE  Loads the current or new job and waits. 
ADVANCED  Shows the “Advanced Form” Appendices  330 
RESETAFTEREACHAA  Restarts the computer and program after completing 
analysis of each residue. 
BACKGROUND  Runs the program at Windows’ ‘background’ priority 
NORMAL  Runs the program at Windows’ ‘normal’ priority 
FOREGROUND  Runs the program at Windows’ ‘foreground’ priority 
MAX  Runs the program at Windows’ ‘maximum’ priority 
RESTART  Restarts the program when/if the program runs out of 
memory. 
DISTRIBUTED  Runs the current job for this computer, outputs the results 
to a server, and starts a new job, from the server when 
finished. When the program starts, it checks in the 
subdirectory with the same name as the current machine’s 
C drive label for an incomplete job (.RND) file. If one 
exists, it then loads the options (.OPT) file with the same 
name, and continues running this job. If a job doesn’t 
exist, the program looks in the JOBS\1 through to 
JOBS\20 and JOBS subdirectories for new jobs (.OPT 
files). The first job it finds it moves to the subdirectory 
with the same name as the current machine’s C drive 
label. The job is then run. Once the job is complete it is 
renamed to a .DNE file. 
FIX  This option checks all .DNE files in the subdirectories for 
correct starting model and correct number of 
permutations. If a job has an error it is recorded in a .TXT 
file with the same name as the .DNE file. Once all jobs 
have been checked, all jobs with incorrect models are 
rerun and appended to the end of the .DNE file. Once a 
.DNE file has no errors it is renamed to a .FNL file and a 
new  .SHT file is created that contains only those 
covariates that were permutated. This file can then be 
imported into the CUTOFFS table and displayed in the 
program. This is repeated until there are no more .DNE 
files. WA HIV Cohort Study database user manual   
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WA HIV Cohort Study database user manual 
Written by Corey Moore. September 9, 1996. 
Introduction 
This is the database management system (DBMS) for the Western Australian (WA) 
HIV Cohort Study. It takes data from a number of sources (immunology, pharmacy, 
microbiology, biochemistry, haematology, and computer services), and combines them 
together (through the DBMS), to produce a number of reports that are used for the 
management of HIV infected patients. These reports target the clinician-patient 
interaction, during which critical treatment decisions are taken. Hence, the system is 
patient centred; in that it focuses on how this information can be best used in helping 
clinicians better treat their HIV patients.  
The system was written in Microsoft (MS) Access version 7.0, and allows easy access 
to the data (without patient identifiers) for analysis, and is password encrypted (using 
the MS Access password encryption feature) for security and confidentiality reasons. 
An overall view of the system can be seen in Figure A.8. 
 
 
This manual describes the following: 
1.  How to import data from the various sources into the DBMS.  
2.  How the system handles this information. 
3.  How to edit and maintain this information. 
4.  How to make queries on the data. 
 
Figure A.8. Schematic diagram of flow of information from the various departments to the system. 
Note that the reports are the interface between the patient data, and the clinician-patient. Appendices  332 
5.  How to produce the reports prior to clinic visits. 
The system was designed to minimise the need to directly deal with the MS Access 
DBMS and with the knowledge that the data required in HIV treatment is constantly 
changing. Hence it was designed, where possible, to handle new information. New 
drugs, drug interactions, patients, complications, and trials, can be handled. Also, the 
data from the different departments is kept in separate tables and is only combined in 
the final VISITS table, so any change in, for example, the microbiology data will not 
effect how the rest of the system works. The biggest problems are expected to occur 
where there are changes in the import data formats. This is inevitable, and this user 
manual goes into some detail about how the data is taken from the initial reports, and is 
“filtered” and  “refined” though the system, into the final reports that are produced. 
Throughout the system, the following conventions apply: 
1.  To close a form, select the Close button at the bottom right corner of the form. 
To exit the system (and MS Access), select the EXIT button at the bottom right corner 
of the Main Form. 
Importing Data 
There are two methods to import data. The first is to import the data by using the 
AutoUpdate procedure which imports and updates all the new external data 
automatically. To start this procedure, click on the Auto Update button in the Main 
Form. The procedure works by looking in the directories specified for each type of data 
(see the Defaults section), and reads in each new file (which exists in the directory) by 
using the data type’s import procedure. Once the data is imported, the system is then 
updated, using the update procedures. To see the import and update procedures the 
automatic process calls, read the second method.  
The second method allows the user to import and update (either new, or old) data, one 
file, and one file type at a time. It essentially, breaks down the automatic method into its 
separate procedures. To import and update data in this method, select the Import and 
Update button in the Main Form. This will open the Import and Update form (see 
Figure A.9). This form is broken into the different types of data sources, which are 
described below. 
For all the import and update buttons, there is an option to either Import All data (that 
is, overwrite any existing data that may already exist in the system from either previous 
imports/updates or manual entry of data), or only Import New Data. The best option in 
most cases is to only import new data. This will save a lot of time, and will mean that 
any manually entered data, will not be overwritten. However, there may be some (rare) 
circumstances where the old data may want to be read in again. These may be if some 
data has been lost due to a system crash, or if some data that was imported data in the 
past is found to be corrupt. 
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Note, that each time an import or an update procedure is run, an entry is placed in the 
AUDIT table which saves the filename, file type, date and time of the action. This table 
is used in future imports, when deciding which files have been imported in the past. It 
can also be used to verify that an import or update actually took place. 
 
 
 
Figure A.9. The Import and Update form. 
 
Figure A.10 The Filename form. Appendices  334 
Pharmacy Data 
The Import Pharmacy Data button calls the procedure ImportPharmacy, which reads the 
text delimited .DAT file that is automatically transferred to the Novell server each 
weekday, and inserts it into the PHARMACY table. Note that the pharmacy files that 
are transferred to the Novell server are given a name corresponding to the date they 
were created (for example, CI101096.DAT refers to the pharmacy data from the 
10/10/96).  
After pressing the Import Pharmacy Data button, the system then asks for the pharmacy 
files you wish to import (see Figure A.10). It looks for these files in the directory 
specified in the Defaults form (see the Defaults section). Select the files you wish to 
import and then select the OK button. To select more than 1 file, hold down the Ctrl 
key, while selecting the files. Note, when importing with the “Display files that have 
not been imported before” option selected, only files that have not already been 
imported in the past are displayed. 
Once the data has been imported into the PHARMACY table, it needs to be filtered into 
the DRUGS table. This is done by selecting the “Update Pharmacy Data” button, which 
calls the UpdateFromPharamacy procedure. This reads the records in the PHARMACY 
table that belong to HIV patients, and which contain drugs that are in the drugs list of 
the system, into the DRUGS table. Note, that if a new drug is in the pharmacy data, but 
is not in the drugs list (i.e., it is not known by the system), then it is ignored. This stage 
also calculates the strengths of the drugs, the number of times per day and week they 
are taken, and the cease date of each prescription (the cease date is calculated by adding 
the number of capsules/tablets divided by the number taken per day to the start date. An 
extra ~14 days is also added to the cease date to allow for varied compliance to 
clinician’s directions by patients. This 14 days can be changed in the Defaults form -- 
see the Defaults section). 
Once the data is in the DRUGS table, it needs to be inserted into the VISITS table. This 
is done by selecting the “Update Drug Data” button, which calls the UpdateFromDrugs 
procedure. This takes the drugs in the DRUGS table, and for every drug that the patient 
is on, and which appears on either of the Patient Visit or Opportunistic Infections report, 
updates it. For example, every AZT drug in the DRUGS table (for a particular patient 
and visit date) is used to update the AZT_DOSE field in the VISITS table.  
The Update Pharmacy Data and Update Drug Data procedures are separated, so that any 
manually entered drugs can also be updated into the VISITS table. 
 
Microbiology Data 
No microbiology data import or update procedures have been implemented, because the 
structure of the data has not been finalised. WA HIV Cohort Study database user manual   
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Immunology Data 
No immunology import or update procedures have been implemented, because the 
method of data transfer has not been finalised. 
Core Laboratory Data 
The Import Core Lab Data button calls the procedure ImportCoreLabs, which reads the 
ASCII reports that core laboratories produce, and inserts it into the CORELABS table. 
Note, that the core lab reports contain date information in the format dd/mm. That is, 
the dates do not contain any year information. Hence the user is asked to enter the year 
the data comes from when reading the file.  
It is anticipated that the data that core labs produce for this system will come in a set of 
three files, each time the download is done -- one file for each of the three wards the 
comes from (IDU, immunology, and 10A). The names of these files, will be similar to 
the pharmacy files, with the prefix ID, IM, or 10 prefixed to the date the file was 
created. For example, a core laboratory file produced from the immunology ward on 
September 10, 1996, will have a filename: ID101096.  
After pressing the Import Core Labs Data button, the system displays a list of core 
laboratory files, and asks the user to select the files to import (see Figure A.10). It looks 
for these files in the directory specified in the Defaults form (see the Defaults section). 
Select the files you wish to import and then select the OK button. To select more than 
one file, hold down the Ctrl key, while selecting the files. Note, when importing with 
the “Display files that have not been imported before” option selected, only files that 
have not already been imported in the past are displayed. 
Once the core laboratory data has been imported into the CORELABS table, it needs to 
be filtered into the VISITS table. This is done by selecting the “Update Core Labs Data” 
button, which calls the UpdateFromCoreLabs procedure. This reads the records in the 
CORELABS table that belong to HIV patients, and either inserts a new record into the 
VISITS table, or updates a record in the VISITS table (if one already exists in the 
VISITS table, that is within the Core Laboratories days allowance (see the Defaults 
section)).  
 
Sequence Data 
There are two methods by which sequences can be read into the system. The first is by 
using a work list file (from immunology) that contains information such as the UMRN, 
sequence date, and lab number; and the second is by directly reading ASCII reports that 
are generated from the immunology system. It is anticipated that the first method will 
be the only method used for importing sequences. The second method was written so 
that older sequences that didn’t exist in the worklist file format could be imported. Both 
methods are described below. 
To import a sequence using a worklist file, select the “Use Worklist File” check box 
(the default), and then select the Import Sequence Data button. This will call the Appendices  336 
ImportSequences procedure. The system will then display the list of work list files 
which can be read (see Figure A.10). It is believed that their will only be the one 
worklist file (WORKLIST.SAV), that will be periodically updated by immunology. 
After this file is selected, the system reads the worklist file, for the lab number of the 
sequence, and then looks for the actual sequence, which is stored in another file, which 
has a filename the same as the lab number stored in the worklist file. For example, if the 
worklist file says that there is a sequence with a lab number of Q96112935Z, then the 
system will look for the actual sequence in a file named Q96012934Z.SEQ. From 
experience with use of the worklist file, it is likely that there will be a number of 
sequences referred to, which do not exist. Sequences which encounter errors such as 
this, are recorded in the table WORKLISTERRORS. The data read from these files are 
inserted into the SEQUENCE table.  
To import a sequence using an ASCII report, deselect the “Use Worklist File” check 
box, and then select the Import Sequence Data button. This will call the 
ImportSequenceReport procedure. The system then displays a list of ASCII report 
filenames (see Figure A.10). Once these have been selected, the system will attempt to 
read these reports. Note, that experience has shown that many of these reports have 
inconsistencies, and to get some of them to import correctly, may require some manual 
editing of the file. One common problem is where two sequences are stored in the one 
report. To correct this problem, open a report that is known to work, and edit the 
problem report to be in a similar format to the working report. The data read from the 
ASCII reports are inserted into the SEQUENCE table.  
Once the sequence data has been imported into the SEQUENCE table, it needs to be 
filtered into the VISITS table. This is done by selecting the “Update Sequence Data” 
button. This calls the UpdateMutations procedure, which reads the records in the 
SEQUENCE table, and either inserts a new record into the VISITS table, or updates a 
record in the VISITS table (if one already exists in the VISITS table, that is within the 
Sequence days allowance (see the Defaults section)).  
 
Costs Data 
The costs data is used as an estimate of the costs of drugs, in-patient days, X-rays, and 
tests spent on HIV patients. 
Currently, the format of the data files from computing services has not been finalised, 
and no import procedure has been implemented. 
To update the cost data once it is in the COSTS table, select the “Update Costs Data” 
button. This will call the UpdateCosts procedure, which reads the records in the COSTS 
table, and either inserts a new record into the VISITS table, or updates a record in the 
VISITS table (if one already exists in the VISITS table, that is within the Costs days 
allowance (see the Defaults section)).  
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Defaults 
To change the defaults in the system, select the Defaults button from the Main Form 
(see Figure A.20). The Defaults form will then appear (see Figure A.11).  
This form contains the directories where the system looks when it imports new data, the 
types of the files imported, the number of days allowance given to each type of data, 
and today’s date and time. 
The “number of days allowance” fields refers to the number of days that the data is 
allowed to differ to the patient’s visits. For example, if, when importing pharmacy data, 
a record with a date of 10/10/96 is found, and the closest patient visit date (stored in the 
VISITS table) to this is the 08/10/96, and the number of days allowance is greater than 
2 days, then this pharmacy data will be entered in the same record as the patient’s visit. 
If, on the other hand, no patient visit exists, or the number of days allowance is less than 
2 days, a new visit record will be inserted, containing only the pharmacy data. 
Today’s date is used when deciding which drugs the patient is currently on when the 
system generates a patient profile report. Any drugs that have a cease date before 
today’s date, will not be displayed. Today’s date is also used to calculate the age of a 
patient. This is required when calculating the patient’s creatinine clearance, and is 
displayed in the Opportunistic Infections report. Finally, today’s date, along with 
today’s time is used when updating the AUDIT form, and when printing the date and 
time at the bottom of the reports. 
The “Number of days added to the cease date of a prescription”, is the number days 
added to the cease date of the prescriptions automatically read in from pharmacy. Note, 
that these cease dates will most probably be updated manually later when the clinician 
gives a more accurate cease date by writing in the Corrections section of the Patient 
Profile report. 
 
 
Figure A.11. The Defaults form. Appendices  338 
 
Entering and Editing Data 
To edit a patient’s data, select the type of data you wish to edit, by selecting one of the 
edit buttons in the Main Form (see Figure A.20). There are four edit forms: Edit Profile 
(Profiles), Edit Visits (Visits), Edit Drugs (Drugs), and Edit Trials and Complications 
(Comps/Trials). To select a specific patient to edit, see the Selecting Patients section. 
Note that some of the fields in the forms are automatically updated, when the reports are 
generated, or when new data is read in. Note, in most cases, you can update a field that 
is automatically updated, but must realise that it may be overwritten if an import is 
carried out with the “Update All (Overwrite)” option selected, in the future (see the 
Importing Data section). 
To move through the fields in the forms, either use the mouse to select the fields, or 
press the TAB key. Also, note that many fields have drop down lists (these can be 
identified by those fields that have the down arrow icon to the right of their field). In 
most cases, the value that appears in the field, must be selected from the list. The drop 
down lists also have descriptions of each of the field values. This is useful for coded 
fields such as RISK_FAC. 
To move to other forms for this patient, simply click on the appropriate button on the 
button of the form. 
Editing the Patient Profile 
Most of the data in this form (see Figure A.12) needs to be manually entered. Most of 
this data entry occurs when a new patient is added to the cohort. However, there is some 
data which needs to be updated as the disease progresses in the patient.  
 
Adding a new patient 
New patients can only be added by clicking on the New Patient button in the Patient 
Profile Form.  
Once a patient is added in this method, the patient can be selected in other forms the 
same way as other patients are (see the Selecting Patients section for information on 
selecting patients).  
Adding a contact 
To add a contact for a patient, select the contact’s UMRN from the UMRN list box in 
the contacts section of the Patient Profile form. Then click on the “<<< Add Contact” 
button. The contact’s UMRN will then appear in the CONTACTS list. This list contains 
a list of all known contacts the patient has or had.  
To remove a contact, select the contact’s UMRN in the list, and press the Remove 
Contact button. WA HIV Cohort Study database user manual   
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Note that more than three contacts can be added for each patient, however, only three 
contacts currently appear on the Patient Report. 
Edit Race 
To add a new type of race, click on the Edit Race button (at the top of the Edit Patient 
Profile form). This displays the Edit Race form. To add a race, type in a Race Code, and 
description, and select the Add button. To remove a race, select the race from the list, 
and press the Delete button. Note, removing a race may leave many patients with race 
codes that do not exist anymore. To edit a race, delete the race, then add a new one with 
the same Race Code. 
Edit GP 
To add a new GP, click on the Edit GP button (at the top of the Edit Patient Profile 
form). This displays the Edit GP form. To add a new doctor, type in the GP Code, First 
Name, and Surname of the doctor, and then press the Add button. To remove a GP, 
select the GP from the list, and press the Delete button. Note, removing a GP may leave 
many patients with GP codes that do not exist anymore. To edit a GP, delete the GP, 
then add a new one with the same GP Code. 
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Editing the Patient Visit Data 
Most of the data in this form (see Figure A.13) are automatically updated when either a 
Patient Visit Report or an Opportunistic Infection Report is generated, or when an 
Update is requested in the Import and Update form. However the data can still be 
manually entered. 
 
 
Editing Patient Drug Data 
The drug data is automatically updated from the pharmacy data, when the Update 
Pharmacy button is pressed in the Import And Update form (see the Importing Data 
section).   
Any data that is updated in this form may be overwritten if the “Update All 
(Overwrite)” option button is selected when the “Update Pharmacy” button is pressed in 
the Import And Update form. 
Where this form (see Figure A.14) will be used most often is in changing a patient’s 
cease date or drug directions. 
 
 
Figure A.13. The Edit (patient) Visits form. Appendices  342 
 
Adding a new type of drug 
To add a new type of drug to the database or a new name for an existing drug, select the 
Edit Drug Names button. This will open the Edit Drug Names form (see Figure A.15). 
Enter the name of the new drug code, and the name of the drug and select the Add 
button. From now on, whenever the system updates the pharmacy data, it will look in 
this list, and try and match the drug names with the pharmacy data.  
For drugs with more than one drug (for example, trimethoprim and sulphamethoxazole), 
the Drug Code should begin with a “&” (for example, &TRIMSULP). This is so, the 
system looks for trimethoprim and sulphamethoxazole, before it looks trimethoprim or 
sulphamethoxazole, when updating the drug data. 
Note, that it is possible to enter more than one name for the same drug. To enter a new 
name for a drug that is already in the list, use the same Drug Code. After the system 
asks if you wish to add a new drug name for a drug that already exists, it will ask if you 
want to make the drug you entered the default drug. The default drug name is the drug 
name that is displayed on the Patient Profile Report when the patient is on this drug. For 
example, the system considers the two names “trimethoprim and sulphamethoxazole” 
and “cotrimoxazole” the same drug, because they share the same drug code. However, 
“cortimoxazole” is the default drug, and hence, this is the drug name that is displayed 
on the Patient Profile Report when the patient is on this drug. 
 
 
Figure A.14. The Edit (patient) Drugs form. WA HIV Cohort Study database user manual   
 
  
343
 
From this form, it is also possible to change the drug code of a drug. To do so, select the 
Change Drug Code button. This will open the Change Drug Code form (see Figure 
A.16). Select the old drug code, enter the new drug code, and press the Change button. 
This will update all drug codes with the old code in the DRUGS and DRUGNAME 
tables to the new drug code. 
 
 
Editing Patient Complications  
Patient complications are entered in the Complications and Trials form (see Figure 
A.17). Note that all complications for a patient must be manually entered. To open this 
form, select the Comps/Trials button in the Main Form. 
To enter a new complication, select the last field in the Complications dataset, and type 
in the visit date (VISIT_D), and the complication code (COMPCODE). Note that the 
 
Figure A.15. The Edit Drug Names form. 
 
Figure A.16. The Change Drug Code form. Appendices  344 
complication code can be selected from the list of current complications, by selecting 
the COMPCODE field, and clicking on the down arrow on the right of the field.  
To edit an old complication, simply select the complication you wish to edit, and 
change the data directly. The system will remember the changes. 
To add a new type of complication to the system, select the “Edit Complication Types” 
button. This will open the Edit Complication Types form. To add the new complication 
type, type in a new complication code, group and description, and select the Add button. 
It is also possible to edit existing complication in this form. To do so, select the 
complication to edit from the list, click on the Edit button, edit the data, and then press 
the Add button.  
 
 
Editing Patient Trials 
The patient trials are entered in the Complications and Trials (see Figure A.17) form. 
Note that some complications are automatically entered when the system is updating the 
drug data and encounters a drug name (or strength) that contains the words 
“PLACEBO”, “STUDY”, or “TRIAL”. However, it is anticipated that most trials will 
be entered manually, or at least edited after they are automatically added. 
To enter a new trial, select the last field in the Trials dataset, and type in the start date 
(START_D), end date (END_D), and trial code (TRIACODE) of the trial. Note that the 
trial code can be selected from the list of current trials, by selecting the TRIACODE 
field, and clicking on the down arrow on the right of the field.  
To edit an old trial, simply select the complication you wish to edit, and change the data 
directly. The system will remember the changes. 
To add a new type of trial to the system, select the Edit Trial Types button. This will 
open the Edit Trial Types form. To add the new trial type, type in a new trial code, and 
description, and select the Add button. It is also possible to edit existing trials in this 
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form. To do so, select the trial to edit from the list, click on the Edit button, edit the 
data, and then press the Add button.  
 
Drug Interactions 
To edit the current drug interactions in the system, select the Drug Interactions button in 
the Main Form (see Figure A.20). This will open the Edit Drug Interactions form (see 
Figure A.18). 
To add a new drug interaction, select the drug codes of the two drugs in the “Drug Code 
1”, and “Drug Code 2” text boxes, by selecting them from the drop down list (to 
activate the drop down list, click on the down arrow button on the right of the field). 
Then type in the description of the interaction, and select the Add button. Once this 
interaction is in the system, any patient who is on these two drugs will have the 
interaction description appearing in the “Potential Drug Interactions” section of the 
Patient Profile Report when the report is generated. 
To edit an existing drug interaction, select the interaction from the list, select the Edit 
button, edit description, and then select the Add button.  
Note, that you can also search for an interaction. To search, enter the information you 
wish to search on (Drug code(s), or interaction description), and press the Search 
button. A list of interactions that contains the information you entered will then be 
displayed in the list. To reset this list, press the Reset button. 
To add a new drug, select the “Add New Drug” button, and read the “Adding a new 
type of drug” section in the “Edit Patient Drug Data” section. 
 
Figure A.18. The Edit Drug Interactions form. Appendices  346 
Running a Query 
To run a general query, select the Query button in the Main Form. This will invoke the 
MS Access query wizard (see Figure A.19).  
For further help on running a query, see the MS Access User Manual, or press F1, for 
on-line help. 
Selecting Patients 
Main Form 
There are 2 ways you can select a patient in the Main Form. If you know the patient’s 
UMRN, you can either directly type it into the “Select Patients” text box (this is the first 
control highlighted when the form is opened, at the top right hand corner of the form), 
or select it from the list of UMRNs by clicking on the down arrow button to the right of 
the text box with the mouse. To add this patient to the Select Patients list (below), either 
press Enter, or click on the Add button. The UMRN and name of the patient will then 
appear in the Select Patients list. 
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If you are unsure of the patient’s UMRN, but know the patient’s name, or other 
information, you can use the Search form to search for a patient’s UMRN. The Search 
form (see Figure A.21) can be opened by clicking on the Search button, which is 
located underneath the Select Patients text box. When this form is open, simply enter 
everything you know about the patient, and then select the Search button (or press 
Enter). In the list box below will be the short list of patients that satisfy the conditions 
you typed in. To select a patient from the list, either, double click on the patient, or click 
on the patient, and press the Select button. The patient’s UMRN and Name will then 
appear in the Select Patients List in the Main Form. To close the search form, select the 
Close button. 
 
 
Figure A.20. The Main Form for the system. Appendices  348 
 
Editing Forms 
To select a patient from the edit forms, either type in the UMRN of the patient in the 
Select UMRN list box, or select the UMRN from the list displayed when the down 
arrow button to the right of the list box is pressed. Another way to select a patient, is to 
go to the Main Form, select the patient there, and then click on the appropriate edit 
button.  
Printing Reports 
Before printing a report, you need to select the patients you wish to print. See the 
Selecting Patients section for instructions on how to select patients. 
To print all the patients selected (listed in the Select Patients List), click on the Selected 
Patients option button (note, this is the default). To print only the patient which is 
currently selected in the Select Patients List, click on the Single Patient option button.  
To print the Patient Report, the Patient Report check box (in the Report Type(s)) frame, 
must be selected. To turn it on (or off), simply click on it. Similarly, select the Visit 
Report, and Opportunistic Infections Report, if desired. Note, the default is that all 
reports are selected.  
To print the reports selected for the patients selected, click on the Print button.  
To preview the reports (see Figure A.22) on the screen (before they are printed), click 
on the Preview button. Note, that MS Access, only allows one report of each type to be 
previewed at any one time. Hence, only the reports for the first patient are displayed. 
 
Figure A.21. The patient Search form (with the Main Form to show that selecting the Select button 
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Note, when the report is displayed on the screen, you can print it by clicking on the 
Print icon, in the toolbar, or by selecting print from the File menu. 
 
 
Examples of the printed profile, visit and opportunistic infection reports are shown in 
Figure A.23, Figure A.24 and Figure A.25, respecitively. 
 
 
Figure A.22. An example preview of all three patient reports. Appendices  350 
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Figure A.24. Patient Visit Report. 
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 from a contracting to an expanding phase. Al-
though inflation does not address the cosmic
singularity problem directly, it does rely implic-
itly on the opposite assumption: that the big
bang is the beginning of time and that the
universe emerges in a rapidly expanding state.
Inflating regions with high potential energy ex-
pand more rapidly and dominate the universe. If
there is a preexisting contracting phase, then the
high–potential energy regions collapse and dis-
appear before the expansion phase begins.
String theory or, more generally, quantum grav-
ity can play an important role in settling the
nature of the singularity and, thereby, distin-
guishing between the two assumptions.
The cyclic model is a complete model of
cosmic history, whereas inflation is only a
theory of cosmic history following an as-
sumed initial creation event. Hence, the cy-
clic model has more explanatory and predic-
tive power. For example, we have already
emphasized how the cyclic model leads nat-
urally to the prediction of quintessence and
cosmic acceleration, explaining them as es-
sential elements of an eternally repeating uni-
verse. The cyclic model is also inflexible with
regard to its prediction of no long-wavelength
gravitational waves.
Inflationary cosmology offers no informa-
tion about the cosmological constant prob-
lem. The cyclic model provides a fascinating
new twist. Historically, the problem is as-
sumed to mean that one must explain why the
vacuum energy of the ground state is zero. In
the cyclic model, the vacuum energy of the
true ground state is not zero. It is negative and
its magnitude is large, as is apparent from
Fig. 1. However, we have shown that the
universe does not reach the true ground state.
Instead, it hovers above the ground state from
cycle to cycle, bouncing from one side of the
potential well to the other but spending most
time on the positive-energy side.
Reviewing the overall scenario and its im-
plications, what is most remarkable is that the
cyclic model can differ so much from the stan-
dard picture in terms of the origin of space and
time and the sequence of cosmic events that
lead to our current universe. Yet, the model
requires no more assumptions or tunings (and
by some measures less) to match the current
observations. It appears that we now have two
disparate possibilities: a universe with a definite
beginning and a universe that is made and
remade forever. The ultimate arbiter will be
nature. Measurements of gravitational waves
and the properties of dark energy (11) can
provide decisive ways to discriminate between
the two pictures observationally.
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Evidence of HIV-1 Adaptation
to HLA-Restricted Immune
Responses at a Population Level
Corey B. Moore,1 Mina John,1,2 Ian R. James,1
Frank T. Christiansen,2,3 Campbell S. Witt,1,2 Simon A. Mallal1,2*
Antigen-speciÞc T cell immunity is HLA-restricted. Human immunodeÞciency
virusÐtype 1 (HIV-1) mutations that allow escape from host immune responses
may therefore be HLA alleleÐspeciÞc. We analyzed HIV-1 reverse transcriptase
sequences from a large HLA-diverse population of HIV-1Ðinfected individuals.
Polymorphisms in HIV-1 were most evident at sites of least functional or
structural constraint and frequently were associated with particular host
HLA class I alleles. Absence of polymorphism was also HLA alleleÐspeciÞc.
At a population level, the degree of HLA-associated selection in viral se-
quencewaspredictiveofviralload.Theseresultssupportafundamentalrole
forHLA-restrictedimmuneresponsesindrivingandshapingHIV-1evolution
in vivo.
Selection of viral mutations associated with
loss of antiviral cytotoxic T lymphocyte
(CTL) responses has been described in hu-
mans with acute and chronic HIV-1 infection
(1), macaques infected with simian immuno-
deficiency virus (SIV) (2, 3), and rhesus
monkeys challenged with simian-human im-
munodeficiency virus (SHIV) after vaccina-
tion (4). However, the full extent and im-
portance of CTL escape mutation to HIV-1
evolution remains to be established. CTL es-
cape mutations occur at critical sites within
HLA-restricted CTL epitopes where an
amino acid substitution may abrogate
epitope-HLA binding, reduce T cell receptor
recognition, or generate antagonistic CTL re-
sponses (1). Mutations that affect proteosome
cleavage sites flanking CTL epitopes may
also disrupt cellular processing of the epitope
(5). The capacity of the virus to mutate at any
amino acid residue is constrained, however,
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residue to virus survival (6).
We hypothesized that, as CTL epitopes
are HLA-restricted, CTL escape mutations
selected within an individual host would be
characteristic for specific HLA class I alleles
across an HLA-diverse host population. We
speculated that such polymorphisms would
be particularly evident in viral genes encod-
ing internal proteins such as HIV-1 reverse
transcriptase (RT), which is highly expressed
in virions (7) and immunogenic in the early
response to HIV-1 (8, 9). Therefore, we ex-
amined the relationship between HIV-1 RT
sequence polymorphisms, known functional
constraint, and HLA genotypes in 473 partic-
ipants of the Western Australian (WA) HIV
Cohort Study (10–13).
We first determined the population con-
sensus sequence for HIV-1 RT by assigning
the most common amino acid for each posi-
tion between positions 20 and 227 of all first
pretreatment sequences pooled from the co-
hort. The consensus sequence matched the
clade B reference sequence HIV-1 HXB2 at
all positions in HIV-1 RT except residues 122
(lysine instead of glutamate) and 214 (phe-
nylalanine instead of leucine) (14). The per-
centages of individuals with an amino acid in
their own first pretreatment HIV-1 RT se-
quence different from that of consensus se-
quence were calculated for each amino acid
residue. This rate of polymorphism at single
residues varied from 0% to 60% and corre-
lated with the level of known functional con-
straint at each site (6, 15).
We then analyzed the most recent HIV-1
RT sequences obtained from all individuals.
We considered single amino acid residues
one at a time and the polymorphism of each
HIV-1 residue across the host population. We
conducted a multivariate analysis with logis-
tic regression for each residue to assess the
statistical significance of association(s) be-
tween the presence of a polymorphism (de-
fined as any substitution of the consensus
amino acid) and the HLA-A and HLA-B
alleles of the population. A P value and esti-
mated odds ratio (OR) for each HLA allele-
polymorphism association were generated.
We incorporated initial power calculations to
limit analyses to only those HLA alleles and
viral polymorphisms that were sufficiently
prevalent to have associations between them
detected. We applied a further selection pro-
cedure based on forward selection and back-
ward elimination. We used randomization
tests to determine the “exact” significance
levels for associations and designed a cus-
tomized software program, Epipop, to carry
out these analyses (15, 16). This process was
repeated for every residue from position 20 to
227 of HIV-1 RT, giving a residue-specific
view of the independent selection effects of
HLA on HIV-1 RT in vivo and at a popula-
tion level.
We plotted all the statistically significant
HLA-polymorphism associations on a map of
HIV-1 RT in relation to polymorphism rate,
previously reported functional characteristics
of residues (6), and published CTL epitopes
(17) (Fig. 1). There were 64 significant pos-
itive associations between polymorphisms
and HLA alleles (OR . 1, P , 0.05 in all
cases) (Fig. 1B, fig 51B). Polymorphisms
associated with the same HLA allele ap-
peared to cluster along the sequence. For
example, HLA-B7 was associated with poly-
morphism at positions 158, 162, 165, and
169, which are all within or flanking the
known HLA-B7–restricted CTL epitope
RT(156–165). There was also apparent clus-
tering of associations for HLA-B12, HLA-
B35, HLA-B18, and HLA-B15. Fifteen
Fig. 1. Map of polymorphism
rate and HLA associations at
amino acid positions 94 to
215 of HIV-1 RT. Residues
with little power to detect
HLA associations are shaded.
(A) Published CTL epitopes
are shown as black lines with
their known HLA restriction
to the level of broad serolog-
ical genotype, except the
HLA-B*5101Ð and HLA-
B*3501Ðrestricted epitopes
examined in further detail in
the study. HLA restrictions
of epitopes are marked in
red if there is a correspond-
ing HLA-speciÞc polymor-
phism within the epitope. (B)
HLA alleles signiÞcantly as-
sociated with speciÞc poly-
morphisms and ORs for the
association. HLA-speciÞc
polymorphisms within pub-
lished CTL epitopes restrict-
ed to the same HLA allele
are red. All other associa-
tions are black and may in-
dicate the location of puta-
tive CTL epitopes. Boxed
associations are those that
remain statistically signiÞ-
cant after correction for to-
tal number of residues ex-
amined across the entire
gene region. (C) Negative
HLA associations with ORs
of residue not varying from
consensus. (D) Percentages
of individuals with a viral amino acid different from that of consensus sequence at each position. Known functional characteristics of residues (6) are
marked as stability (S), functional (F), catalytic (C), and external (E).
R ESEARCH A RTICLES
24 MAY 2002 VOL 296 SCIENCE www.sciencemag.org 1440HLA-specific polymorphisms were at posi-
tions within known CTL epitopes, and the
HLA allele association matched the known
HLA restriction of the epitope. For example,
the amino acid at position 162 resides within
a known HLA-B7–restricted CTL epitope
RT(156–165) and the odds of polymorphism
at this site were significantly increased in
those individuals with HLA-B7 (OR 5 10, P
, 0.001). Four polymorphisms (at positions
101, 135, 165, and 166) were at primary
anchor positions within corresponding CTL
epitopes (HLA-A3–, HLA-B51/HLA-
B*5101–, HLA-B7–, and HLA-A11–restrict-
ed, respectively) where mutation could abro-
gate binding to the HLA molecule. The
remaining 11 associations were at nonpri-
mary anchor positions of CTL epitopes. The
number of HLA-specific polymorphisms ob-
served within known CTL epitopes with cor-
responding HLA restriction was significantly
greater than that expected if significant pos-
itive associations occurred randomly across
residues (15 versus 4.27, P , 0.001). Fur-
thermore, an excess of associations over that
expected was observed for 10 of the 11 HLA
specificities with CTL epitopes in this seg-
ment of HIV-1 RT (15). Six HLA allele–
specific polymorphisms were not within but
flanked CTL epitopes, including the predict-
ed proteosome cleavage sites at positions 26
and 28 flanking HLA-A2– and HLA-A3–
restricted CTL epitopes (18) [see fig. S1
(15)].
To take account of the multiple compari-
sons used in the statistical process over the
entire HIV-1 RT protein, we applied Bonfer-
roni-type corrections based on randomization
tests. Following this highly stringent correc-
tion, 12 associations remained statistically
significant (P , 0.05). Overall, the finding of
HLA associations, taking all positions and
multiple comparisons into account, was sta-
tistically significant (P , 0.001). We propose
that those HLA-associated polymorphisms
that were not within published corresponding
CTL epitopes may indicate where previously
unknown, untested epitopes are located. This
is particularly likely for those HLA associa-
tions that are strong (with high OR), are
clustered, or remain statistically significant
after correction for multiple comparisons. It
is important to note that our statistical correc-
tion for the number of residues examined will
be overly conservative in some cases, be-
cause the degree of correction depends on the
size of the gene region arbitrarily chosen for
study. Such correction results in decreasing
false associations (higher specificity) at the
cost of losing true associations (lower sensi-
tivity). Our gradation of P values uncorrected
for multiple comparisons reflects a gradation
in strength of statistical evidence for associ-
ations. We conclude that independent biolog-
ical validation rather than statistical means
will best determine what P value cutoffs are
optimal for sensitivity or specificity.
We further characterized two strong ex-
amples of HLA-specific polymorphism,
I135x (substitution of consensus isoleucine at
position 135) and D177x (substitution of as-
partate). These were associated with HLA-B5
and HLA-B35, respectively, in the multivar-
iate models (Fig. 1B). However, these broad
serologically defined HLA alleles both have
subtypes with distinct epitope binding motifs.
We performed high-resolution DNA se-
quence-based typing on all individuals with
HLA-B5 or HLA-B35 and reexamined the
associations between their HLA subtypes and
viral polymorphisms (Tables 1 and 2). Posi-
tion 135 is the anchor position of the HLA-
B*5101-restricted epitope RT(128–135 IIIB)
(17). Six of the other seven amino acids in
the epitope are critical stability residues (6)
and were relatively invariant (Fig. 1D). All
but 1 of the 40 (98%) individuals in the
cohort with HLA-B*5101 had I135x, com-
pared with 127 of the 431 (29%) without
HLA-B*5101 (P , 0.0001; Fisher’s exact
test) (Table 1). For the predominant substi-
tution observed, I135T [see fig. S2 (15)], the
predicted half-time of dissociation score for
the mutant epitope (TAFTIPST) is 11 com-
pared with 440 for the consensus sequence
(TAFTIPSI), which indicates that binding to
HLA-B*5101 in vivo would be abrogated
(19). I135T has also been shown to necessi-
tate a 100-fold increase in the peptide con-
centration required to sensitize target cells for
50% lysis by CTLs in vitro (20). Notably, the
one subject with HLA-B*5101 and consensus
sequence at position 135 had taken highly
active antiretroviral therapy only days after
exposure to HIV. He was asymptomatic,
highly viremic, and seronegative at the time
of starting treatment, which may have de-
creased viral replication before selection of
I135x by the acute CTL response. This sug-
gests that I135x is characteristically selected
during the acute HLA-B*5101–restricted
CTL response instead of at transmission or in
chronic infection and that protection from
viral escape could contribute to the effect of
therapy in acute HIV infection, leading to
stronger chronic inhibitory CTL responses.
Similarly, D177x is within the epitope
RT(175–183) known to bind HLA-B*3501
and contain a binding motif distinct from that
of other HLA-B35 subtypes (21). After high-
resolution HLA typing, D177x was associat-
ed with HLA-B*3501 specifically and not
with other HLA-B35 subtypes (Table 2). As-
sociations with other HLA-B35-associated
polymorphisms in HIV-1 RT, I69x, D121x,
and D123x were all strengthened by consid-
ering molecular subtypes of HLA-B35.
In addition to positive HLA associations,
we detected 25 negative HLA associations
[Fig. 1C, fig. S1C (15)]. For example, poly-
morphism at positions 32, 101, 122, 169, and
210 was negatively associated with HLA-A2
(OR , 1, P , 0.05 in all cases). This means
that HLA-A2 individuals were significantly
less likely to vary from the consensus at these
sites compared with all non–HLA-A2 indi-
viduals. HLA-A2 is the most common
HLA-A allele in our cohort and it had 5 of the
25 negative associations (compared with 3 of
the 64 positive associations). There appeared
to be a predominance of common HLA
alleles with negative associations. Unlike
positive selection pressure, which causes de-
monstrable escape over time in individuals,
negative selection pressure favors preserva-
tion of wild-type virus in vivo and therefore
could be made evident only at a population
Table 1. Distribution of the presence of I135x in HIV-1 RT within individuals with HLA-B5, HLA-B*5101
subtype, and nonÐHLA-B5. High-resolution HLA genotyping strengthens the I135x-HLA allele association.
One HLA-B5 individual did not have sufÞcient DNA sample for high-resolution HLA typing.
HLA type Present (n) Absent (n) Odds ratio P value
HLA-B5 44 8
NonÐHLA-B5 123 297 13 ,0.0001
HLA-B*5101 39 1
NonÐHLA-B*5101 127 304 93 ,0.0001
Table 2. Distribution of the presence of D177x within individuals with HLA-B35, HLA-B*3501 subtype,
and nonÐHLA-B35. High-resolution HLA genotyping strengthens the D177x-HLA allele association. Seven
individuals with HLA-B35 by serology did not have DNA available for high-resolution HLA typing; in
another four, HLA-B35 was not conÞrmed by sequencing.
HLA type Present (n) Absent (n) Odds ratio P value
HLA-B35 26 31
NonÐHLA-B35 84 330 3.3 ,0.0001
HLA-B*3501 19 14
NonÐHLA-B*3501 86 345 5.4 ,0.0001
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that consensus or wild-type virus is adapted
to the CTL responses that it has most often
encountered during primordial evolution (that
is, those CTL responses restricted to the most
common or evolutionarily conserved HLA
alleles in the host population). It is possible
that the consensus HIV-1 sequence in our
study population has been selected by the
host population’s predominant HLA types, as
has been shown for weakly immunogenic
variants of Epstein-Barr virus in other host
populations (22, 23). We speculate that this
could explain the apparent lack of HIV-1
escape from HLA-A*0201–restricted re-
sponses in studies that have argued against an
important role for CTL escape (24, 25), and
might even explain why surprisingly few
HLA-A2– and HLA-A1–restricted epitopes
have been mapped in HIV-1 (26). Primordial
viral adaptation to predominant HLA types
may account, at least in part, for HIV-1 clade
differences. Furthermore, studies of HIV-1–
exposed seronegative individuals suggest that
CTL responses can alter viral infectivity and
susceptibility to established primary HIV-1
infection (27–31). The HLA class I alleles
associated with natural HIV-1 resistance or
susceptibility appear to differ between racial-
ly distinct populations (27–29, 32). To some
extent, this may reflect differences in the
HLA alleles that are common in different
populations and the degree to which a popu-
lation-adapted wild-type virus can adapt to
the individual.
We sought to determine whether HLA-spe-
cific polymorphisms were associated with in-
creased plasma HIV RNA levels (viral load)
(33). We examined single polymorphisms with
sufficient subject numbers for comparison.
HLA-A11–associated K166x is at the anchor
position of HLA-A11 epitope RT(158–166
LAI). In HLA-A11 individuals (n 5 19), the
median pretreatment viral load was 5.54 60.46
log copies per ml (cps/ml) of plasma (median 6
SD) in those with K166x (n 5 4) compared
with 4.31 6 0.82 log cps/ml in those without
K166x (n 5 15; P 5 0.045, Wilcoxon test). A
second putative CTL escape mutation within a
CTL epitope (but not at a primary anchor po-
sition) showed a similar effect. The median
pretreatment viral load in HLA-B7 individuals
with S162x (n 5 18) was significantly higher
(5.41 6 1.04 log cps/ml) than in those without
S162x (n 5 15, 4.57 6 0.83 log cps/ml; P 5
0.046, Wilcoxon test ). A global analysis of
factors influencing viral load at a population
level showed that the presence of viral poly-
morphisms in combination with their positively
associated HLA alleles or consensus amino ac-
ids with their negatively associated HLA alleles
was a significantly better predictor of pretreat-
ment viral load than HLA alleles or viral poly-
morphisms alone (P , 0.004) (15). This sug-
gested that the amount of HLA-associated
selection in an individual, as defined by our
analyses, explained the viral load variability
in the population better than HLA alleles.
This study encompasses demographic,
clinical, and laboratory data collected over
2210 person-years of observation. Our find-
ings support a model of HIV-1 evolution in
vivo in which CTL escape mutations are
selected within functional limits within indi-
viduals, and this selection during viral pas-
sage through a population determines the
wild-type or consensus viral sequence. Thus,
the HLA alleles present in a population may
explain in large part both the polymorphism
(viral adaptation to individuals) and the con-
sensus (primordial adaptation) of HIV-1 se-
quences in that population. Our data suggest
that CTL escape mutation is common and
widespread and selected by responses re-
stricted to a much wider array of HLA alleles
than have been studied to date.
These results are especially notable, con-
sidering the factors that reduce the likelihood
of observing significant associations in such
analyses. First, the power to detect associa-
tions is not constant for all combinations of
HLA allele and viral residue. Large numbers
of individuals would be needed to observe
any polymorphism at residues under CTL
pressure but with strong functional constraint
or any associations with HLA alleles that are
rare. The use of formal power calculations
identifies those HLA associations that cannot
be excluded until larger data sets are exam-
ined. Second, as suggested by the enhance-
ment of associations between HLA-B5 and
I135x and between HLA-B35 and D177x by
high-resolution HLA typing, the molecular
subtype of an HLA allele better predicts its
binding properties in vivo. Other alleles with
multiple splits of similar frequency (HLA-
A10 or HLA-A19) may have had associations
that we did not detect because only broad
alleles were considered. Furthermore, molec-
ular splits that have opposing effects at the
same viral residue would negate any associ-
ation with the broad allele. Lastly, published
epitopes are more likely to be in conserved
regions, because studies tend to use laborato-
ry reference strains as target antigens and
conserved regions are more likely to generate
measurable CTL responses in vivo (34). This
approach, in contrast, preferentially detects
putative CTL epitopes in polymorphic re-
gions and, thus, may be complementary to
standard epitope mapping.
Application of this method to other HIV-1
genes in larger populations with more com-
plete high-resolution HLA genotyping is
needed. To that end, an international collab-
oration to pool data and provide the Epipop
program to participating centers has been ini-
tiated. This approach could be used to screen
or prioritize standard testing of candidate
epitopes in all HIV-1 proteins. In the HIV
envelope, effects associated with antibody
responses to HIV, CCR5 and CXCR4 geno-
type, and any other polymorphisms of genes
encoding products that target envelope pro-
teins could also be considered. Future analy-
ses of HIV-1 RT and other antiretroviral drug
targets should adjust for drug selection ef-
fects to examine the interactions between
drug resistance mutations and putative CTL
escape mutations. If CTL responses and an-
tiretroviral drugs compete at sites within viral
sequence (35), a greater or lesser tendency to
drug resistance and response may be observed
depending on HLA genotype. Individualiza-
tion of antiretroviral therapy conceivably
could be improved if synergistic or antago-
nistic interactions between immune pressure
and drug pressure were better understood.
Ultimately, it may be possible to generalize
these approaches to examine host immune
effects on hepatitis B, hepatitis C, and other
chronic human pathogens.
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Magneto-Opto-Electronic
Bistability in a Phenalenyl-
Based Neutral Radical
M. E. Itkis, X. Chi, A. W. Cordes, R. C. Haddon*
A new organic molecular conductor, based on a spiro-biphenalenyl neutral
radical, simultaneously exhibits bistability in three physical channels: electrical,
optical, and magnetic. In the paramagnetic state, the unpaired electrons are
located in the exterior phenalenyl units of the dimer, whereas in the diamag-
netic state the electrons migrate to the interior phenalenyl units and spin pair
as a p-dimer. Against all expectations, the conductivity increases by two orders
of magnitude in the diamagnetic state, and the band gap decreases. This type
of multifunctional material has the potential to be used as the basis for new
types of electronic devices, where multiple physical channels are used for
writing, reading, and transferring information.
The processing of information is based on the
ability to control and retrieve changes in a
particular physical property of a material,
such as the electrical, magnetic, or optical
response. Usually, at the level of the basic
unit, one of these physical channels is used.
When two different physical channels of the
material are simultaneously involved, a new
breadth of applications and even new fields
of research often appear, such as optoelec-
tronics, magnetooptics, and spintronics (1),
which, as Das Sarma (2) noted, “is a seamless
integration of electronic, optoelectronic and
magnetoelectronic multifunctionality on a
single device.... ” W e n o w report that a
phenalenyl-based neutral radical organic con-
ductor exhibits bistability just above room
temperature so that one state is paramagnetic,
insulating, and infrared (IR) transparent.
These properties reverse in the other state to
produce a material that is diamagnetic, con-
ducting, and IR opaque.
By definition, neutral organic radical mole-
cules contain an unpaired electron just as in a
classical (mono)atomic metal, and they are
promising basic units for the construction of an
intrinsic molecular metal or superconductor (3).
The basic molecular building block on which
we report consists of two phenalenyl ring sys-
tems, spiro-conjugated through a boron atom
(Fig. 1), so that the two halves of the molecule
are orthogonal to one another. This nonplanar
unit prevents the formation of a one-dimension-
al structural chain (4, 5), thus obviating the
occurrence of a Peierls transition to an insulating
ground state (6).
A variety of alkyl (CnH2n 1 1) groups can be
attached to the nitrogen atoms to modify the
crystal packing; the first phenalenyl-based neu-
tral radical to be crystallized [1, with a hexyl
group (n 5 6) attached to nitrogen] is a reso-
nance-stabilized carbon-based free radical (7).
The existence of the monomeric, neutral carbon-
based free radical 1 in the crystalline state is
unprecedented; all prior structures have re-
quired steric hindrance to inhibit dimerization
(4, 5, 8, 9). Furthermore, the hexyl radical 1
shows the highest conductivity of any neutral
organic molecular solid, despite the fact that
all intermolecular contacts are outside of the
van der Waals spacing (7).
Changing the alkyl group from hexyl 1 to
butyl 2 or ethyl 3 leads to a crystal structure
containing p-dimers as the basic building block
(Fig. 1) (10). In the high-temperature limit [3,
temperature (T) . 350 K], the interplanar dis-
tance within the p-dimer is about 3.3 Å and the
interaction is sufficiently weak that the electron
spins remain unpaired. The dimerization to a
diamagnetic state occurs at a structural phase
transition when T decreases below 320 K and
Center for Nanoscale Science and Engineering, De-
partments of Chemistry and Chemical & Environmen-
tal Engineering, University of California, Riverside, CA
92521Ð0403, USA.
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Fig. 1. (A) Molecular structure of neutral radicals. (B) X-ray crystal structure of ethyl radical 3,
showing the intra-dimer distance, d, indicated by the double-headed arrow. d increases from ;3.2
to ;3.3  as the spins unpair and the compound becomes paramagnetic.
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code began to unfold in the
early 1960s, it might have
been tempting to speculate
that some of the 64 possible
codons encoded the many rare
amino acids found in proteins.
However, it became clear that
20 is the correct number of
amino acids, and that the
great majority of nonstandard
amino acids are created by
chemical modifications of
standard amino acids after
translation. In 1986 came the
surprise discovery that the
nonstandard amino acid se-
lenocysteine is directly speci-
fied by the genetic code and is
not created by posttranslation-
al modification (5, 6). Seleno-
cysteine is now joined by
pyrrolysine, and together these two amino
acids demonstrate that the genetic code can
be expanded by redefining the meaning of a
stop codon.
This redefinition requires subversion of
the standard pathway for activating amino
acids in readiness for protein synthesis. In-
stead of a tRNA being charged with the new
amino acid, it receives a standard amino
acid that is then enzymatically modified
while still attached to the tRNA. This pro-
cess is similar to the way in which some or-
ganisms modify the standard amino acids,
aspartic acid and glutamic acid, while they
are attached to tRNAs, in order to obtain as-
paragine and glutamine (7). In the case of
selenocysteine, a selenocysteinyl tRNA is
first charged with serine, which is then en-
zymatically modified to form selenocys-
teine. Similarly, pyrrolysine is likely to be
produced by modifying a lysine residue at-
tached to a special lysyl tRNA. The tRNAs
involved in the production of selenocysteine
and pyrrolysine are distinct from those de-
coding the standard amino acids, serine and
lysine, but they differ from each other in
certain features, for example, the pyrroly-
sine tRNA has a “special” anticodon arm. 
In certain specialized niches, such as the
mitochondrion, the meaning of a subset of
codons is reassigned from that of the “univer-
sal” genetic code wherever these codons oc-
cur in all mRNAs. For example, in the
starfish, the codons UGA and AGR specify
Trp and Ser, respectively, when in mitochon-
drial mRNA, but Stop and Arg when in nu-
clear mRNA. In a few organisms with small
genomes, rarely used codons are permanently
reassigned (8). However, in organisms where
UGA specifies selenocysteine, only a subset
of UGA codons do so; the great majority
specify the standard meaning: “stop transla-
tion.” Special signals in mRNA help to repro-
gram the readout by distinguishing those
codons whose meaning is to be changed.
These signals can be close to the UGA
codon, as in bacteria, or distant, as in the 3′ -
untranslated region of eukaryotic mRNAs.
Recoding UGA as selenocysteine is not
fully efficient because there is direct com-
petition from standard reading of UGA stop
codons, even those that are specially
“tagged.” The slow-to-decode property of
“stop codons” may be the reason for usurping
them during the decoding of standard amino
acids. The goal in recoding UGA is to spec-
ify selenocysteine, the “special” 21st amino
acid. However, there are other cases of re-
coding where a standard amino acid is
specified by a “stop codon.” Here the im-
portant feature is that readthrough of the
stop codon permits continued decoding of a
downstream sequence producing one pro-
tein from two separated open reading
frames (9). 
For pyrrolysine, like selenocysteine, the
critical feature is specification of an addi-
tional amino acid. But whether specifica-
tion of pyrrolysine is due to “permanent”
reassignment of UAG or to recoding of a
subset of UAG codons is not yet clear (see
the figure). Does “UAG” mean “pyrroly-
sine” wherever it occurs in these organisms,
or are there signals in specific mRNAs that
redefine UAG codons one at a time? 
Natural selection has successfully led to
a code that specifies more than the 20 stan-
dard amino acids. Meanwhile, human ef-
forts to achieve the same goal are actively
under way, particularly by Schultz and his
colleagues (10). The challenges are
formidable, but striking progress is being
made. The goal is to engineer the direct en-
coding of additional amino acids at will. It is
by no means certain, however, that all of the
future excitement in this area will come
from these manipulations alone. As pyrroly-
sine illustrates, nature may yet surprise us
with more directly encoded amino acids. 
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of stop codons
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?
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When stop means go.There are two ways in which the stop codon
UAG could be redefined to specify the 22nd amino acid, pyrroly-
sine. In the first (top), special signals in mRNAs tag a subset of stop
codons that are to have their meaning redefined. In the second
(bottom),a codon is redefined regardless of the mRNA involved.
T
he reasons for the poor control of
HIV infection by the mammalian im-
mune system are gradually being un-
raveled. The ability of certain HIV pro-
teins to mutate and thus to elude immune
detection is increasingly seen as crucial.
On page 1439 of this issue, Moore et al.
(1) provide new evidence for critical in-
volvement of HLA proteins of the human
histocompatibility complex in shaping
variations in HIV proteins and possibly
evolution of the virus itself. 
During both the acute and chronic
phases of HIV infection, production of cy-
totoxic T lymphocytes (CTLs) by the host
immune system exerts a strong inhibitory
effect on HIV growth and replication.
Therefore, it is not surprising that there is
strong selective pressure for survival of
HIV mutants that escape the CTL re-
sponse (2–7). Although escape from the
host antibody response is well accepted
(8), escape from CTL responses has until
recently been more controversial. Objec-
tions to the idea have centered around
whether a CTL response against several
HIV epitopes could be undermined by es-
cape of only one epitope. With the host
immune system trying to control a swarm
of rapidly replicating viruses, a viral vari-
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ant that is slightly less well controlled be-
cause it carries a mutation in one of sever-
al crucial epitopes would still have a com-
petitive edge. Often the host immune re-
sponse has an unfortunate tendency to fo-
cus on a small number of “immunodomi-
nant” HIV epitopes, sometimes only one,
making viral escape even easier. 
Mutation in an epitope can have a num-
ber of consequences (2). If mutation af-
fects the ability of HLA molecules ex-
pressed by CTLs to bind to the viral pro-
tein, then the epitope may simply become
invisible to CTLs. In other cases, mutation
may alter the interaction of the T cell re-
ceptor with the viral protein, resulting in
altered recognition. This could be dealt
with by the immune system selecting new,
more specific T cell clones—but in prac-
tice that does not always happen (3). This
phenomenon, “original antigenic sin,”
could reflect the fact that a lower stringen-
cy of antigenic stimulation is required for
maintaining established CTL populations
than for generating new ones. A failure to
make primary CTL responses to new epi-
topes is accentuated by HIV-mediated
damage to T helper cells, dendritic cells,
and the architecture of the lymphoid sys-
tem. Also, in some cases, HIV variants
might antagonize the original T cell re-
sponse (4, 5). If viral escape impairs im-
mune control of HIV , then an increase in
the number of viruses would be expected
and indeed has been observed (6, 7).
Striking evidence that the ability of
HIV to dodge the CTL response is impor-
tant in determining the outcome of infec-
tion has come from studies in macaques
infected with cloned simian immunodefi-
ciency virus (SIV) (9, 10). Viral escape
occurred rapidly at several different epi-
topes, all selected in response to pressure
exerted by CTLs. Similar data from HIV-
infected humans are beginning to accumu-
late (7), although it is not clear how
widespread this process is. Moore et al.
(1) make a timely contribution to this dis-
cussion by suggesting that HIV evasion of
the CTL response is both common and im-
portant. They assessed amino acid se-
quence heterogeneity of the HIV pol pro-
tein in viral isolates from a large cohort of
patients infected with HIV-1. The authors
then analyzed the sequences according to
the HLA type of the donor. They identi-
fied areas of variability in pol that were
HLA class I dependent. Some of these ar-
eas map to known epitopes that engage the
HLA molecules expressed by T cells; oth-
ers do not, and may represent previously
unidentified epitopes. Although the au-
thors do not test whether these mutations
impair CTL responses, this does seem
likely.
Intriguingly, some areas of HIV pol
were less variable in patients with particu-
lar HLA types. The reason for this is not
clear. One possibility is that these areas
are epitope regions where common HLA
types have already selected a series of “op-
timized” mutations by passage through
many infected individuals of the same
HLA type. Overall, this study supports the
idea that immune escape is common in
HIV-infected persons and may be an inte-
gral part of the pathogenic process, and al-
so that it is patchy, depending largely on
the epitope (see the figure).
If this view is correct, there should be
regions of HIV proteins that for structural
or functional reasons are harder to mutate
without compromising virus survival. One
might predict that persons with HLA types
that select such epitopes might fare better
when it comes to fighting infection. This
seems to be the case for HLA B27 (11),
which recognizes an immunodominant
epitope in a conserved part of the p24 viral
capsid protein. Immune escape requires at
least two mutations in this region of p24
(12). HLA B57 also is associated with
longer survival of HIV patients (13) and
selects an epitope in this highly conserved
region.
If an HLA type is common in the com-
munity, there is a good chance that an es-
cape mutant virus could be transferred to
persons of the same HLA type (14). This
implies that people carrying common
HLA types might do worse when infected
with HIV , and that those with rare types
might do better (frequency-dependent se-
lection). Given that different populations
have markedly different frequencies of
HLA types, such selection could con-
tribute to the generation of locally distinct
viruses, although probably not the major
clades, which diverged quite early in the
history of HIV in central equatorial Africa
(15).
The fact that HIV is an astounding es-
cape artist has now been confirmed at a
population level. This is worrying news
for long-term immune control of HIV in-
fection and for vaccine development.
There have been clear warning signs that
although CTL-inducing vaccines can offer
some control of SIV infection in macaque
models, such control can be undermined
by these processes (16). HIV vaccines will
have to match the relevant circulating
virus, but must also elicit very broad re-
sponses to multiple epitopes in order to
stay one step ahead of HIV variation. 
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HLA to the rescue? HLA molecules on the surface of CTLs direct the CTL response to specific epi-
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pressure on the virus.Viral variant epitopes that escape these CTLs by failing to bind to HLA or to
interact with T cell receptors have an advantage in vivo. (Left) Other responses are less effective
and are not associated with obvious escape. (Right) If an effective CTL response is directed against
an epitope region that is constrained functionally or structurally, there may be no selection or slow
selection because a mosaic of mutations is required for escape to occur.List of relevant publications 
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DEFYING DEATH —
HIV MUTATION TO EVADE
CYTOTOXIC T LYMPHOCYTES
YTOTOXIC T lymphocytes control viral infec-
tions by lysing infected cells and secreting soluble
factors (cytokines) that enhance antiviral immunity
and suppress infection. The importance of antiviral
killer cells in controlling acute infection with human
immunodeficiency virus (HIV) and the related sim-
ian immunodeficiency virus (SIV) in macaque mon-
keys has clearly been demonstrated: resolution of the
first wave of viremia coincides with the development of
HIV-specific cytotoxic T lymphocytes, and macaques
depleted of killer cells control SIV poorly. Some virus-
es, especially herpesviruses, hepatitis viruses, and im-
munodeficiency viruses, have devised clever strategies
to outwit killer cells and thereby persist for the life of
the host.
Although HIV induces a very strong cytotoxic-
T-lymphocyte response, in which up to 1 in 10 circu-
lating T lymphocytes is specific for the virus, the in-
fection is not controlled in most untreated patients.
This fact is particularly surprising because there are
many more HIV-specific killer cells than cells infected
with actively replicating HIV, except perhaps in the
final stages of AIDS. Moreover, most in vitro assays
of killer-cell function cannot distinguish between pa-
tients whose infection is controlled without antiviral
drugs (long-term nonprogression) and those, treated
or not, who have progressive disease.
How does HIV outwit cytotoxic T lymphocytes?
Two ways have been described, and others are likely.
Killer cells recognize short viral peptides (called epi-
topes) presented to them by HLA class I molecules
on infected cells. The nef protein of HIV causes the
infected cell to down-regulate the HLA molecules that
present viral peptides to cytotoxic T lymphocytes. The
importance of this mechanism is unclear, since tens of
thousands to hundreds of thousands of HLA mole-
cules remain on the surface of HIV-infected cells, and
it takes only a few peptide-laden HLA molecules to
trigger a T lymphocyte. The second type of evasive
action is mutation of viral sequences that specify im-
munogenic epitopes. By changing only a single amino
acid in an epitope the virus can easily escape surveil-
lance by the immune system. Moreover, cells express-
ing such altered peptides can even block the lysis of
cells infected with unmutated virus.1
C
Figure 1. Evolution and Mutation of the Human Immunodefi-
ciency Virus (HIV).
HIV most likely arose from the chimpanzee simian immunode-
ficiency virus (SIV). After many cycles of viral replication in its
human host, it evolved to a consensus virus with mutations in
genes  that  encode  dominant  immunogenic  peptides.  These
mutations hinder the presentation of such peptides to cytotoxic
T lymphocytes (CTLs) by the most prevalent HLA molecules in
the population. As this consensus virus continues to multiply,
selective pressures engendered by the immune system of the
new host force the emergence of viruses with escape muta-
tions that enable infected cells to avoid being recognized by cy-
totoxic T lymphocytes.
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The high mutation rate of HIV is due to its rapid
replication kinetics and low-fidelity reverse transcrip-
tase. In the relatively short time that the virus has
been a human pathogen, it has evolved into distinct
clades, which are prevalent in different regions of the
world. Even within an infected host, viral mutation
gives rise to numerous distinct viral subspecies, whose
diversity increases with the duration of infection. Un-
til recently, it was uncertain whether immune pressures
select for mutations that allow the virus to escape from
cytotoxic T lymphocytes (so-called escape mutations)
or whether the evasion is simply incidental to the high
rate of mutations. Clear evidence of immune selection
was recently found in SIV-infected macaques: escape
mutations in epitopes recognized by cytotoxic T lym-
phocytes, but not in adjoining regions of the SIV tat
gene, developed within four weeks after infection with
a highly pathogenic viral strain.2 However, since this
strain in macaques replicates much more rapidly than
does HIV in humans, it is uncertain whether these
results can be extrapolated to humans.
A recent study now provides clear evidence of es-
cape mutations in HIV.3 Using automated DNA se-
quencing and sophisticated statistical tools, Moore
et al. examined the incidence of sequence polymor-
phisms in the HIV reverse transcriptase gene in 473
HIV-infected persons. Certain polymorphisms were
associated with particular HLA class I alleles, and in
some cases they clustered around known sequences
for epitopes recognized by cytotoxic T lymphocytes
and their flanking regions involved in processing an-
tigenic peptides (Fig. 1). One viral epitope was mutat-
ed in all but one of the HIV-infected subjects whose
T lymphocytes could recognize it. In that one instruc-
tive case, treatment with antiretroviral therapy was be-
gun within days after exposure to HIV. This finding
suggests that early treatment may limit escape muta-
tions by blocking viral replication. 
Moore et al. also found indirect evidence that HIV
has evolved within humans to avoid recognition by
T lymphocytes in the context of the most prevalent
HLA class I allele, HLA-A2. Infected HLA-A2–pos-
itive subjects were less likely than subjects without this
allele to harbor HIV with escape mutations. This idea
was previously advanced by the finding that the most
prevalent HLA class I alleles worldwide (HLA-A1, A2,
and A3) rarely present the dominant epitopes in HIV
envelope protein to cytotoxic T lymphocytes.4
When a dominant epitope in HIV mutates in a way
that allows it to evade recognition by cytotoxic T lym-
phocytes, a population of T lymphocytes that recog-
nizes subdominant, type-specific epitopes arises. Since
these T lymphocytes recognize infected targets poor-
ly and are often generated after the function of CD4
helper T lymphocytes has been compromised, their
ability to control the infection may be impaired. In-
deed, during chronic infection most HIV-specific CD8
T lymphocytes are incapable of lysing HIV-infected
cells when tested directly ex vivo.5
HIV is an evolving pathogen that has only recently
(on an evolutionary scale) infected humans. Mutations
that enable the virus to evade immune surveillance oc-
cur along with other adaptive mutations that make
HIV less easily defeated by the human host. Not all
these mutations are necessarily harmful to the host.
For example, AIDS does not develop in the presumed
original host, the chimpanzee. However, the ability to
evade recognition by cytotoxic T lymphocytes is likely
to cause harm by rendering the host’s immune system
unable to control the infection. Indeed, Moore et al.
found that subjects harboring HIV with escape muta-
tions had a level of viremia that was about a log high-
er than that of patients who were infected with HIV
that lacked such mutations.3 These findings suggest
that an important clinical benefit of early treatment
of HIV infection is to limit escape mutations, which
occur only when the virus has a chance to replicate.
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